
<html lang="en"     class="pb-page"  data-request-id="212a8b6b-cc4b-4fb4-b741-927275da8fcb"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-12;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.9b01625"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Promiscuity of in Vitro Secondary Pharmacology Assays and Implications for Lead Optimization Strategies" /></meta><meta name="dc.Creator" content="Dean G.  Brown" /></meta><meta name="dc.Creator" content="Graham F.  Smith" /></meta><meta name="dc.Creator" content="Heike J.  Wobst" /></meta><meta name="dc.Description" content="We conducted an analysis on screening data generated from 1445 compounds against a panel of 130 enzymes, ion channels, and receptors to assess secondary pharmacological risks. Hit rates of these ta..." /></meta><meta name="Description" content="We conducted an analysis on screening data generated from 1445 compounds against a panel of 130 enzymes, ion channels, and receptors to assess secondary pharmacological risks. Hit rates of these ta..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 12, 2019" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01625" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01625" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01625" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01625" /></link>
        
    
    

<title>Promiscuity of in Vitro Secondary Pharmacology Assays and Implications for Lead Optimization Strategies | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01625" /></meta><meta property="og:title" content="Promiscuity of in Vitro Secondary Pharmacology Assays and Implications for Lead Optimization Strategies" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0027.jpeg" /></meta><meta property="og:description" content="We conducted an analysis on screening data generated from 1445 compounds against a panel of 130 enzymes, ion channels, and receptors to assess secondary pharmacological risks. Hit rates of these targets as well as physicochemical properties for those hits were evaluated. A majority of targets yielded hits with higher clogP, molecular weight, and more basic character than inactive compounds. Although most targets favored lipophilic hits, the average clogP of hits at a given target did not correlate with its hit rate. Furthermore, a matched pair analysis was completed to determine structural changes that impacted off-target activities. A correlation of binding assays used in this analysis illustrated that some pharmacologically related binding assays are highly correlative and may be substituted for a smaller set of surrogate assays." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01625"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01625">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01625&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01625&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01625&amp;href=/doi/10.1021/acs.jmedchem.9b01625" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 6251-6275</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00874" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.9b00917" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Promiscuity of in Vitro Secondary Pharmacology Assays and Implications for Lead Optimization Strategies</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Dean G. Brown</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dean G. Brown</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Hit Discovery, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><span class="conrtib-corresp"><strong>*</strong>D.G.B.: phone, +1-484-639-4153; e-mail, <a href="/cdn-cgi/l/email-protection#e98d8c8887c78b9b869e87a9889a9d9b88938c878c8a88c78a8684"><span class="__cf_email__" data-cfemail="d9bdbcb8b7f7bbabb6aeb799b8aaadabb8a3bcb7bcbab8f7bab6b4">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dean+G.++Brown">Dean G. Brown</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7130-3928" title="Orcid link">http://orcid.org/0000-0002-7130-3928</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Graham F. Smith</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Graham F. Smith</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Data Science and Artificial Intelligence, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Graham+F.++Smith">Graham F. Smith</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0393-3650" title="Orcid link">http://orcid.org/0000-0003-0393-3650</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Heike J. Wobst</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Heike J. Wobst</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Waltham, Massachusetts 02451, United States</div></div><span class="conrtib-corresp"><strong>*</strong>H.J.W.: phone, +1-617-892-1824; e-mail, <a href="/cdn-cgi/l/email-protection#7a321f13111f542d1518090e3a1b00141f0f081554191517"><span class="__cf_email__" data-cfemail="bef6dbd7d5db90e9d1dccdcafedfc4d0dbcbccd190ddd1d3">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Heike+J.++Wobst">Heike J. Wobst</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01625&amp;href=/doi/10.1021%2Facs.jmedchem.9b01625" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 6251–6275</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 12, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 September 2019</li><li><span class="item_label"><b>Published</b> online</span>12 November 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 June 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01625" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01625</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6251%26pageCount%3D25%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDean%2BG.%2BBrown%252C%2BGraham%2BF.%2BSmith%252C%2BHeike%2BJ.%2BWobst%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D12%26contentID%3Dacs.jmedchem.9b01625%26title%3DPromiscuity%2Bof%2Bin%2BVitro%2BSecondary%2BPharmacology%2BAssays%2Band%2BImplications%2Bfor%2BLead%2BOptimization%2BStrategies%26numPages%3D25%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6275%26publicationDate%3DJune%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01625"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3545</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">4</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01625" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Promiscuity of in Vitro Secondary Pharmacology Assays and Implications for Lead Optimization Strategies&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Dean&quot;,&quot;last_name&quot;:&quot;G. Brown&quot;},{&quot;first_name&quot;:&quot;Graham&quot;,&quot;last_name&quot;:&quot;F. Smith&quot;},{&quot;first_name&quot;:&quot;Heike&quot;,&quot;last_name&quot;:&quot;J. Wobst&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;12&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;6251-6275&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01625&quot;},&quot;abstract&quot;:&quot;We conducted an analysis on screening data generated from 1445 compounds against a panel of 130 enzymes, ion channels, and receptors to assess secondary pharmacological risks. Hit rates of these targets as well as physicochemical properties for those hits were evaluated. A majority of targets yielded hits with higher clogP, molecular weight, and more basic character than inactive compounds. Although most targets favored lipophilic hits, the average clogP of hits at a given target did not correlate with its hit rate. Furthermore, a matched pair analysis was completed to determine structural changes that impacted off-target activities. A correlation of binding assays used in this analysis illustrated that some pharmacologically related binding assays are highly correlative and may be substituted for a smaller set of surrogate assays.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01625&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01625" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01625&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01625" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01625&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01625" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01625&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01625&amp;href=/doi/10.1021/acs.jmedchem.9b01625" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01625" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01625" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01625&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01625%26sid%3Dliteratum%253Aachs%26pmid%3D31714773%26genre%3Darticle%26aulast%3DBrown%26date%3D2020%26atitle%3DPromiscuity%2Bof%2Bin%2BVitro%2BSecondary%2BPharmacology%2BAssays%2Band%2BImplications%2Bfor%2BLead%2BOptimization%2BStrategies%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D12%26spage%3D6251%26epage%3D6275%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292588" title="Partition coefficient">Partition coefficient</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/jmcmar.2020.63.issue-12/20200625/jmcmar.2020.63.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0027.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We conducted an analysis on screening data generated from 1445 compounds against a panel of 130 enzymes, ion channels, and receptors to assess secondary pharmacological risks. Hit rates of these targets as well as physicochemical properties for those hits were evaluated. A majority of targets yielded hits with higher clogP, molecular weight, and more basic character than inactive compounds. Although most targets favored lipophilic hits, the average clogP of hits at a given target did not correlate with its hit rate. Furthermore, a matched pair analysis was completed to determine structural changes that impacted off-target activities. A correlation of binding assays used in this analysis illustrated that some pharmacologically related binding assays are highly correlative and may be substituted for a smaller set of surrogate assays.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar/63/12"><issue-title>Drug Metabolism and Toxicology</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30250" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30250" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Unexpected toxicological findings during clinical development can lead to significant delays, increased development costs, and potentially the complete abandonment of a clinical candidate. These risks can be mitigated by using a variety of predictive safety and toxicology models during early stage drug discovery<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> such as in silico safety models,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> in vitro safety screens,<a onclick="showRef(event, 'ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5">(3−5)</a> and integrated cellular models of toxicology to assess specific target organ toxicity.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> These models can be incorporated into a typical drug discovery cascade to help prioritize lead chemical series and identify key potential in vivo safety issues. Potential liabilities identified in these models require further study to understand the severity of the toxic effects and determine whether they can be designed out in the lead optimization campaign. Furthermore, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines require the inclusion of secondary pharmacology data in investigational new drug (IND) documentation. Researchers at AstraZeneca, GlaxoSmithKline (GSK), Pfizer, and Novartis proposed a standard set of safety pharmacology assays deemed suitable for preclinical safety assessment that have been used in this capacity.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Hits identified in these safety pharmacology assays may require close monitoring of the safety issue in preclinical in vivo toxicology models or elimination of the activity in a medicinal chemistry campaign. Elimination of off-target pharmacology is often accomplished using two fundamental strategies. In the first strategy, structural modifications are introduced to the lead series to reduce binding to undesired targets while maintaining on-target potency. This focused approach requires background knowledge of the undesired targets, such as a published crystal structure or previous structure–activity relationship (SAR) data. The second approach is to reduce lipophilicity in the chemical series, which does not require the same significant background knowledge of structure or SAR for the undesired pharmacology. The link between lipophilicity and off-target activity has been described previously in the literature. For example, Tarcsay and Keseru have reported on the correlation between lipophilicity and promiscuity in off-target screening panels, demonstrating that 67% of the compounds with a calculated log <i>P</i> (clogP) > 4 are also active at more than five targets at a 30 μM screening concentration.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Furthermore, an analysis by a team at Pfizer based on safety data from 245 preclinical compounds demonstrated that less polar, hydrophobic compounds carried a greater risk of eliciting toxicological effects in vivo.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Compounds with high clogP (>3) and low polar surface area (PSA < 75 Å<sup>2</sup>) were 6 times more likely to be toxic in vivo than compounds with clogP < 3 and PSA > 75 Å<sup>2</sup>. Finally, a review by Warring et al. demonstrated that compounds that reached phase II clinical trials were less hydrophobic than compounds that failed phase I trials due to safety findings (clogP = 3.8 for phase I failures vs 3.1 for phase I successes and clogD (7.4) = 2.7 for phase I failures vs 2.1 for phase I successes).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> In addition to an increased risk for polypharmacology, highly lipophilic compounds can also accumulate in a nonspecific manner and may act as detergents, thus providing the potential for other non-target-mediated toxicological effects.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> However, reducing the hydrophobicity of lead compounds can pose significant challenges. If the potency of the target is driven by hydrophobic interactions, significant optimization may be required to identify hydrophilic substituents that maintain the desired pharmacology while diminishing off-target activity.</div><div class="NLM_p last">With these considerations in mind, we conducted an analysis of the routine off-target screening panels used in AstraZeneca drug discovery programs. We sought to determine which targets were most frequently hit, what physicochemical properties characterized hits at these targets, and what strategies were deployed to circumvent potential liabilities.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Methods</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31115" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31115" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">An analysis was completed on 130 off-target screens referred to as the discovery screening panel (DSP). A set of 1445 diverse compounds (referred to as the DSP set) was screened against the majority or all 130 DSP targets. These compounds comprised 332 AstraZeneca drug discovery programs across a range of disease areas (e.g., oncology, cardiovascular, neuroscience, respiratory, and infection) and targets (e.g., kinases, G-protein-coupled receptors (GPCRS), enzymes, and ion channels). The off-target screens were either run at Eurofins<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> or screened internally at AstraZeneca and are summarized within the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01625/suppl_file/jm9b01625_si_001.pdf" class="ext-link">Supporting Information</a>. The majority of assays in the DSP panel were either binding (42%) or cell-based functional (42%) assays, with a smaller portion being biochemical/enzymatic assays (16%) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>a). Target class distribution of the panel is illustrated in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b. GPCRs constituted the largest target class (68%), followed by ion channels (11%), kinases (11%), and others (10%). It should be noted that only a small number of kinase targets are included in the DSP panel as kinase panel profiling is run separately on a set of >200 kinases.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) DSP panel assay types categorized as binding, cell-based, or biochemical/enzymatic assay. (b) DSP panel target class distribution.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56377" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56377" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In order to understand the nature of compounds that are submitted to the DSP panel, we compared the physicochemical properties of the full set of 1445 compounds to a random set of 100 000 compounds from the AstraZeneca collection. These results are shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>. In general, compounds submitted to the DSP panel are on average more basic (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a), possess a higher molecular weight (MW) (Δ = 89 kDa, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>c), and have a higher PSA (Δ = 26 Å<sup>2</sup>, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>d) compared to random AstraZeneca screening compounds but do not differ in either average clogP or clogD (7.4) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b).<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> As would be expected, these optimized compounds possess physicochemical properties similar to known oral drugs, unlike the physicochemical property profiles of the random compounds used as the comparison set in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Comparison of ion class distribution in the DSP versus random (Rand) set. (b) Average lipophilicity in DSP set for clogP or clogD (7.4). (c) Average molecular weight for DSP set versus random set. (d) Average PSA for DSP set versus random set. DSP = 1445 compounds tested in the panel; Rand = 100K random compounds from the AstraZeneca screening collection. Error bars denote the standard deviation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Average molecular volume in DSP set vs random set. (b) Average rotatable bonds DSP set vs random set. (c) Average number of H-bond donors in DSP set vs random set. (d) Average number of H-bond acceptors DSP set vs random set. DSP = 1445 compounds tested in the panel; Rand = 100K random compounds from the AstraZeneca screening collection.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We speculate that these differences most likely arise because compounds submitted to the DSP panel are typically more highly optimized for potency and drug metabolism and pharmacokinetics (DMPK) profiles in their respective drug discovery programs than a randomly selected compound in the AstraZeneca library. In general, there are no defined criteria for submission of a compound to the DSP panel, but typically a project team will often wait until they have an optimized and potent compound that meets many of their internal milestone criteria, which may differ from project to project. In the optimization process MW and PSA are typically added to improve potency, solubility, or off-target pharmacology, whereas lipophilicity is not typically increased for the reasons highlighted above. These findings are consistent with a previous publication on hits-to-clinical candidates which showed that although MW and PSA increased from initial hits to clinical candidates, lipophilicity did not significantly change.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> We also found that the average molecular volume (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a), number of rotatable bonds (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>b), and the number of H-bond acceptors (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>c) and donors (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>d) were higher for compounds submitted to the DSP panel compared to the random set. This reinforces the hypothesis that the difference in physicochemical properties of most compounds submitted to DSP panel compared to random compounds is a direct result of chemistry optimization campaigns.</div><div id="sec4" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Most Frequently Active Binding Assays</h3><div class="NLM_p">The binding assays used in this analysis are shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> (<i>n</i> = 54), along with the frequency of compounds binding to each target with IC<sub>50</sub> < 10 μM or IC<sub>50</sub> < 2 μM (defined as “hit rate”). The target with the highest hit rate was the adenosine transporter (AT), with 38% of compounds tested in this assay (550/1445 compounds) demonstrating IC<sub>50</sub> < 10 μM and 17% of compounds with IC<sub>50</sub> < 2 μM (251/1445). Hits in this assay could potentially increase the half-life of adenosine and cause vasodilation and inflammation as well as inhibit platelet function.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> However, a signal in the AT assay is just an initial warning flag since the compound may bind to the transporter but not have a functional effect. To understand whether adenosine transport is affected, the hit compound should be tested in a cellular uptake assay to confirm the effect.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Most frequent targets (binding assays) in the DSP panel of assays. Where the species is not indicated, the assay was run using the human recombinant protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another notable frequent off-target hit in the binding assays was 5-hydroxytryptamine receptor 2B (5-HT2B) with a 27% hit rate for IC<sub>50</sub> < 10 μM and 14% for IC<sub>50</sub> < 2 μM. Agonists at this receptor have been linked to an increased risk for cardiac valvular fibrosis and will be discussed later. However, in spite of the high hit rate in the binding assay, follow-up functional assays demonstrated that the vast majority of the actives in the 5-HT2B assay were antagonists. Of the actives in the 5-HT2B binding assay 87% proved to be functional antagonists, 12.9% had no functional response, and only 0.1% were functional agonists. This is in line with Whitebread et al., who reported that most 5-HT2B binders are not functional agonists, which is the primary safety concern at this target.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">Muscarinic acetylcholine receptors were also frequent hitters in the secondary pharmacology binding assays. Muscarinic acetylcholine receptor 1 (M1) agonists have been under development for neuroscience indications and although generally well tolerated, have dose-limiting side effects that may in part be due to muscarinic selectivity.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Muscarinic acetylcholine receptor 2 (M2) agonism is associated with gastrointestinal issues as well as excessive salivation and sweating.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> Muscarinic antagonists are clinically tolerated compounds approved for chronic airway diseases and overactive bladder syndrome.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19,20)</a> However, as some muscarinic compounds cause cardiovascular side effects such as elevated heart rate,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> muscarinic off-target activity should be avoided. The muscarinic receptors M1 and M2 were found to be promiscuous targets in binding assays (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), with 25.3% and 25.4% of compounds tested demonstrating IC<sub>50</sub> < 10 μM against M1 and M2, respectively. The majority (65%) of the M2-binding compounds were functional antagonists, 23% had no functional response, and only 12% were functional agonists. M1 functional agonism assays were not included in the DSP panel. Muscarinic acetylcholine receptor 5 (M5) was also part of this panel but demonstrated a slightly lower hit rate compared to M1 or M2 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, 12.5% with IC<sub>50</sub> < 10 μM).</div><div class="NLM_p">The DSP panel also includes four subtypes of the adrenergic receptor (α1A, α1B, α2A, α2C). Of these, α1A, α1B, α2C demonstrated hit rates with IC<sub>50</sub> < 10 μM of >20% while α2A had a hit rate of 8.9% (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). While there are approved adrenergic agonists and antagonists, they do affect cardiovascular function, blood pressure, and arrythmia.<a onclick="showRef(event, 'ref21 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23 ref24">(21−24)</a> Thus, these targets are included in early safety panels in order to minimize any undesired adrenergic and potential cardiovascular activity.</div><div class="NLM_p">The AstraZeneca DSP panel also includes two L-type calcium channel binding assays (CaV) to test for binding to the diltiazem site (CaV-DIL) and to the verapamil site (CaV-VER). Verapamil and diltiazem can cause cardiovascular effects such as bradycardia and atrioventricular block.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Both sites demonstrated high hit rates in the binding assays (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, hit rate = 22.1% for DIL site and 12.9% for the VER site, IC<sub>50</sub> < 10 μM). Furthermore, there was significant overlap between hits at the two sites, as evidenced by the fact that >90% of compounds with an IC<sub>50</sub> < 10 μM at the VER site also bound to the DIL site.</div><div class="NLM_p">Several neurotransmitter transporters were included in the panel, including dopamine, serotonin, and norepinephrine. All of these binding assays demonstrated hit rates of >10%, with the dopamine transporter (DAT) and norepinephrine transporter (NET) being slightly more promiscuous than the serotonin transporter (SET) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, hit rate = 18% for DAT and NET and hit rate = 10% for SET, IC<sub>50</sub> < 10 μM). DAT is an important target to monitor for safety pharmacology as inhibition can lead to psychostimulation and addiction similar to the effects of known drugs of abuse such as cocaine and methamphetamine.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Dopamine receptors were also found to be promiscuous targets in this panel (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, hit rate = 13% for D1, 10% for D2, and 16% for D3, IC<sub>50</sub> < 10 μM). For functional activity, D3 and D2 agonist modes were tested and demonstrated hit rates of 4.0% and 3.6%, respectively (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). D1 was tested in both agonist and antagonist modes and showed low hit rates of 1.6% for antagonist and 0.3% for agonist mode (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, IC<sub>50</sub> < 10 μM). From a safety perspective, D3 agonists may have the potential for abuse liability and should thus be avoided.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Also, several marketed dopamine agonists have been linked to fibrotic cardiac valvulopathy, which is the reason D2 agonism is included in this panel.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> However, it should be noted that D2 partial agonists such as aripiprazole do not show this effect, thus offering a more tolerable safety profile.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Most frequent targets (cell-based assays) in the DSP panel of assays. Dark (light) green color denotes functional antagonists at <10 μM (<2 μM), dark (light) red denotes functional agonist at <10 μM (<2 μM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A number of targets demonstrated low hit rates (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), such as NMDA agonist binding site (NMDA AGO, hit rate = 0.3%, IC<sub>50</sub> < 10 μM), endothelin A (EtA, hit rate = 0.3%, IC<sub>50</sub> < 10 μM), bradykinin receptor 2 (BK2, hit rate = 0.1%, IC<sub>50</sub> < 10 μM), and NMDA PCP site (NMDA PCP, hit rate = 0.1%, IC<sub>50</sub> < 10 μM). In the γ-aminobutyric acid receptor B (GABAB) binding assay, none of the compounds in the panel were identified with IC<sub>50</sub> < 10 μM.</div><div class="NLM_p">In general, targets with high hit rates in cell-based functional assays (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) also had high hit rates in the corresponding binding assays (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). However, there are a few exceptions to this observation. For example, while BK2 had a high functional hit rate for antagonists in the cellular assay (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, hit rate = 13%, IC<sub>50</sub> < 10 μM), the hit rate in the binding assay was comparatively low (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, hit rate = 0.1%, IC<sub>50</sub> < 10 μM). In both antagonist and binding assays bradykinin is used as a ligand (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01625/suppl_file/jm9b01625_si_001.pdf" class="ext-link">Supporting Information</a>). One possible explanation for this observation is that the BK2 functional assay is potentially more sensitive than the binding assay. Another possibility is that the functionally active antagonists in this assay are actually assay artifacts, for example, fluorescent quenchers, aggregation-based inhibitors, or pan-assay interference compounds (PAINS).<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> However, if this were the case, the same compounds would be expected to show up in all assays with the same technology (e.g., calcium fluorophore assays) regardless of the target, which was not our observation.</div><div class="NLM_p">Enzymatic assays used in the panel are included in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> along with their associated hit rates. The targets with the highest hit rates were kinases (i.e., top six targets in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), which is not surprising given that the majority of compounds tested are from kinase programs (∼20% of compounds tested in the panel). Non-kinase frequent hitters include thromboxane A2 (TXA2, hit rate = 5.3%, IC<sub>50</sub> < 2 μM), phosphodiesterase subtype 6 (PDE6, hit rate = 3.1%, IC<sub>50</sub> < 2 μM), and acetylcholine esterase (ACHE, hit rate = 2.9%, IC<sub>50</sub> < 2 μM).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Hit rates for biochemical/enzymatic assays in the DSP panel of assays.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Physicochemical Profiles of Compounds against Polypharmacological Targets</h3><div class="NLM_p">The analyses in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> led us to conclude that molecules submitted to the DSP panel had unique and different properties compared to random compounds taken from the AstraZeneca screening collection. We next wanted to compare the physicochemical properties of the hits from the targets in the DSP panel to those of inactive compounds from the same set. For this, we compared the physicochemical properties (clogP, clogD (7.4), MW, and ion class) of hit compounds in each assay (defined as IC<sub>50</sub> < 10 μM) to those of inactive compounds (defined as IC<sub>50</sub> > 100 μM). The physicochemical property analysis was restricted to those assays that had at least 30 actives with IC<sub>50</sub> < 10 μM to ensure sufficient data for comparative analysis. This analysis was categorized into binding assays, cell-based assays, and enzyme/biochemical assays in order to simplify the interpretation. We found that in 41/45 binding assays active compounds (IC<sub>50</sub> < 10 μM) had a significantly higher average clogP compared to inactive compounds (>100 μM) (data and statistics can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01625/suppl_file/jm9b01625_si_001.pdf" class="ext-link">Supporting Information, Table S1</a>). In addition, in 32/45 binding assays active compounds had a significantly higher average clogD (7.4) compared to inactive compounds (data and statistics can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01625/suppl_file/jm9b01625_si_001.pdf" class="ext-link">Supporting Information, Table S2</a>).</div><div class="NLM_p">The same analysis of lipophilicity was conducted on hits from the 29 cell-based functional assays<named-content content-type="anchor" rid="fig7" type="simple"></named-content> (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>) that had at least 30 actives with IC<sub>50</sub> < 10 μM. The cell-based functional assays also demonstrated a preference for lipophilic compounds, with 28/29 assays having a significantly higher average clogP compared to inactive compounds (data and statistics can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01625/suppl_file/jm9b01625_si_001.pdf" class="ext-link">Supporting Information, Table S3</a>) and 18/29 assays with a significantly higher average clogD (7.4) compared to inactive compounds (data and statistics can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01625/suppl_file/jm9b01625_si_001.pdf" class="ext-link">Supporting Information, Table S4</a>).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Average clogP and clogD (7.4) of hits (IC<sub>50</sub> < 10 μM) vs inactives (IC<sub>50</sub> > 100 μM) in functional biochemical/enzymatic assays. <i>N</i> = 45 assays with at least 30 actives against that target with IC<sub>50</sub> < 10 μM. ∗ = statistical significance as determined by <i>t</i> tests performed and corrected for multiple comparisons using the Holm–Sidak method (<i>p</i> < 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Average clogP and clogD (7.4) of hits (IC<sub>50</sub> < 10 μM) vs inactives (IC<sub>50</sub> > 100 μM) in functional biochemical/enzymatic assays. <i>N</i> = 29 assays with at least 30 actives against that target with IC<sub>50</sub> < 10 μM. ∗ = statistical significance as determined by <i>t</i> tests performed and corrected for multiple comparisons using the Holm–Sidak method (<i>p</i> < 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Finally, in the biochemical/enzymatic assays (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>), a significant difference in average lipophilicity was also observed between actives and inactives for 11/19 and 10/19 for clogP and clogD (7.4), respectively (data and statistics can be found in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b01625/suppl_file/jm9b01625_si_001.pdf" class="ext-link">Supporting Information, Tables S4 and S5</a>). The most prominent examples were non-kinase enzymes TXA2, cyclooxygenase-1 (COX1), and PDE6. Notably, kinase targets had less average lipophilicity difference between actives and inactives compared to non-kinase targets. There were also a few examples of kinase targets where no separation was observed between clogP of actives and inactives such as mitogen-activated protein kinase kinase kinase 7 (MAP3K7), Rho-associated protein kinase 2 (ROCK2), Rho-associated protein kinase 1 (ROCK1), and glycogen synthase kinase 3β (GSK3β). This observation may not be unexpected since adenosine triphosphate (ATP)-site kinase inhibitors are typically adorned with specific hydrophilic substituents that mimic ATP, a highly charged molecule.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Average clogP and clogD (7.4) of actives (IC<sub>50</sub> < 10 μM) vs inactives (IC<sub>50</sub> > 100 μM) in functional biochemical/enzymatic assays. <i>N</i> = 19 assays with at least 30 actives against that target with IC<sub>50</sub> < 10 μM. ∗ = statistical significance as determined by <i>t</i> tests performed and corrected for multiple comparisons using the Holm–Sidak method (<i>p</i> < 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In addition to lipophilicity, the MW distribution of actives compared to inactives was performed for the set of 45 binding assays with at least 30 actives of <10 μM (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). The targets which selected for the highest average MW hits were δ opioid receptor 2 (DOP2), melanin receptor 2 (MR2), nicotinic α7 acetylcholine receptor (NAchA7), and glucocorticoid receptor (GR), which were also among the targets with the highest lipophilic hits as well (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). For the 29 functional assays used in the analysis, the targets that most preferred higher molecular weight hits were D3 agonist, 5-hydroxytryptamine receptor 7 (5-HT7) antagonist, EtA agonist, α1B agonist, α1B antagonist, and somatostatin subtype 4 (SST4) agonist assays (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a> illustrates the MW analysis for the biochemical/enzymatic assays. Out of the five targets with the greatest MW difference between actives and inactives, three were non-kinase targets (TXA2, PDE6, and COX1).</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Average MW of hits (IC<sub>50</sub> < 10 μM) vs inactives (IC<sub>50</sub> > 100 μM) in functional cell-based assays. <i>N</i> = 45 assays which had at least 30 actives against that target <10 μM. ∗ = statistical significance as determined by <i>t</i> tests performed and corrected for multiple comparisons using the Holm–Sidak method (<i>p</i> < 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Average MW of hits (IC<sub>50</sub> < 10 μM) vs inactives (IC<sub>50</sub> > 100 μM) in functional cell-based assays. <i>N</i> = 29 assays which had at least 30 actives against that target <10 μM. ∗ = statistical significance as determined by <i>t</i> tests performed and corrected for multiple comparisons using the Holm–Sidak method (<i>p</i> < 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Average MW of hits (IC<sub>50</sub> < 10 μM) vs inactives (IC<sub>50</sub> > 100 μM) in biochemical/enzymatic assays. <i>N</i> = 19 assays which had at least 30 actives against that target < 10 μM. * = statistical significance as determined by <i>t</i> tests performed and corrected for multiple comparisons using the Holm−Sidak method (<i>p</i> < 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The ion class distribution of hits was categorized as basic, acidic, neutral, or zwitterionic and analyzed across all targets that had at least 30 hits with IC<sub>50</sub> < 10 μM. <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a> illustrates this analysis for the binding assays and is ranked by percent of compounds in the basic ion class category. Among the top hits were M5, nicotinic α4 acetylcholine receptor (NAchA4), β-1 adrenergic receptor (β1), CAV-L VER, 5-hydroxytryptamine 1b (5-HT1B), M1, and 5-hydroxytryptamine (5-HT3), while those with very limited numbers of basic hits were MR2, γ-aminobutyric acid receptor, <i>tert</i>-butyl bicyclophosphorothionate site (GABA TPBS), peroxisome proliferative-activated receptor γ (PPARγ), and retinoic acid receptor α (RARα). RARα demonstrated the highest number of acidic hits of any assay in the panel, probably owing to the acid nature of the endogenous ligand, retinoic acid. These compounds were also compared to all 1445 compounds screened (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, and <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a> labeled as “All cpds”) to understand how each target selects for particular ion classes relative to the proportion of all compounds in the screen. For functional assays (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>), the most basic distribution of hits was found for M2, α2C, 5-hydroxytrypamine receptor 4 (5-HT4) (antagonist forms of the assays), D2 agonist, and SST4 (agonist form of the assays) while the least basic distribution was found for histamine receptor 2 (H2) (antagonist form of the assays), cannabinoid receptor type 1 (CB1), and D3 (agonist form of the assays). For the biochemical/enzyme targets (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>), insulin receptor kinase (INSR), tropomyosin receptor kinase A (TRKA), and tyrosine-protein kinase CSK (Src) were among the targets with the highest proportion of basic hits, and the non-kinase targets COX2, PDE6, and TXA2 possessed the lowest proportion of basic hits.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Distribution of compound ion class in binding assays. <i>N</i> = 45 assays with at least 30 actives against that target <10 μM. All cpds = the proportion ion class of all 1445 compounds screened in the DSP panel.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Distribution of compound ion class in cellular/functional assays. <i>N</i> = 29 assays with at least 30 actives against that target <10 μM. All cpds = the proportion ion class of all 1445 screened in the DSP panel.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Distribution of compound ion class in biochemical/enzymatic assays. <i>N</i> = 19 assays with at least 30 actives against that target <10 μM. All cpds = the proportion ion class of all 1445 compounds screened in the DSP panel.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The assays that identified hits with the highest average clogD (7.4) were CB1, angiotension II AT1 (Ang2 AT1), GABA TPBS, and MR2, while those with highest clogP were MR2, DOP2, GR, and PPARγ. However, these are not among the assays with the highest hit rates, which were AT Gpig, M2, M1, CAV-L DIL, α2C, neurokinin-1 receptor (NK1), α1B, α1A, and mitochondrial translocator protein 18 kDa (TSPO). This led us to investigate correlations between the physicochemical properties of hits and the hit rates in the DSP panel assays. <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a> illustrates that neither clogP, clogD (7.4), MW, or ion class correlated with the hit rates found in the DSP panel assays. This may suggest that although many targets select for lipophilic and higher MW compounds, these properties by themselves do not dictate hit rate. The hit rate at a given target is likely dictated by, among other things, the protein topology, the size, shape, and the charge of a ligand binding pocket. Furthermore, although many of these targets preferentially bind to hydrophobic compounds, hydrophobic compounds cannot be predicted to be promiscuous simply based on their calculated or measured lipophilicities.</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Correlation plots between physicochemical properties of hits (IC<sub>50</sub> < 10 μM) and hits rates for (a) Avg. clogP, (b) Avg. clogD (7.4), (c) Avg. MW, and (d) percent basic ion class.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Correlation between Binding Assays</h3><div class="NLM_p">Assays in the DSP panel were selected for safety reasons to establish pharmacokinetic/pharmacodynamic (PK/PD) safety margins and not necessarily for biological diversity. For example, there are multiple subtypes of serotonergic, muscarinic, and adrenergic receptors in this panel, each one selected for a specific toxicological risk. We sought to identify if any of the assays held a strong correlation to one another and whether certain targets could serve as surrogate markers to indicate a wider promiscuity issue. In this analysis we used the 36 binding assays that had at least 30 hits with IC<sub>50</sub> < 2 μM (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>) and correlated each of these assays to one another. The analysis was also completed for the same set of targets with IC<sub>50</sub> < 10 μM (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>) in order to provide context between a low and high screening concentration. For example, actives at 5-HT2B were strongly correlated to most of the other 5-HT receptors as well as D1, D2, α2A, NET, H1, and SST4, suggesting that 5-HT2B could be a surrogate indicator for these other off-targets. This is consistent with a previously published paper by Peters et al.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Other potential surrogate binding assays for biogenic amine receptors could be α2C and M2. Designing new molecules with reduced activity at one target could thus decrease the likelihood of binding at correlated targets. Smaller panels for assessing off-target screens have been suggested by others and potentially offer a more cost-effective risk assessment compared to larger screens.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a></div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Binding assays (<i>N</i> = 36) having at least 30 hits with IC<sub>50</sub> < 2 μM. Colors denote % of hits common between two assays: dark red >75%, red = 50–74%, orange = 25–49%, yellow = 5–24%, green <5%. As the number and identity of hits differ between assays, the matrix of pairwise comparisons is not symmetrical. For example, there were 37 hits at M5, 31 of which overlap at M1 (31/37 = 83% overlap relative to M5 = dark red), while there were 175 hits at M1, which results in only an 18% overlap (31/175) relative to M1 = yellow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Binding assays (<i>n</i> = 36) having at least 30 hits with IC<sub>50</sub> < 10 μM. Colors denote % of hits common between two assays: dark red >75%, red = 50–74%, orange = 25–49%, yellow = 5–24%, green <5%. As the number and identity of hits differ between assays, the matrix of pairwise comparisons is not symmetrical.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec7" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Matched Pair Analysis</h3><div class="NLM_p">For all compounds, a matched-pair analysis was conducted to identify the smallest structural change between two compounds that also affected off-target activity. <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> summarizes these findings by illustrating the starting fragment, the new fragment that was introduced, the resulting change in clogP, and the change in activity in assays for which they could both be compared. If neither compound had activity at a target, they were excluded from the analysis. As expected, for most pairs with structural changes that resulted in a decrease in clogP, there was also a subsequent improvement in the off-target secondary pharmacological profile. For example, the change from isopropyl to tetrahydropyran (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, entry 1) resulted in a decrease in activity for ∼40% (dark green and light green combined for >0.5 log difference improvement) of the assays in which this pair was examined, with ΔclogP of −1.32. We found no examples of a matched pair that decreased activity in every assay. Rather, in all cases of these matched pair examples at least some examples either remained unchanged or increased activity at certain targets. For example, in entry 1, a small fraction of assays (∼5%) showed an increase in activity for this matched pair of fragments. In <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, entry 2, the change from phenyl to pyridine resulted in a change of >0.5 log units across 13 of 24 assays, but activity in a small portion of assays either remained neutral or increased. However, while the addition of a pyridine moiety may reduce compound activity at some of the off-target panels listed above, it may also introduce cytochrome P450 inhibition by binding to the heme moiety.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> As a cytochrome P450 assay was not included in the panel, the effects of the pyridine moiety could not be ascertained.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Matched Pair Analysis Resulting in Most Prominent Changes in Off-Target Pharmacology</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0021.gif" alt="" id="gr21" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0022.gif" alt="" id="GRAPHIC-d7e931-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0023.gif" alt="" id="GRAPHIC-d7e932-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0024.gif" alt="" id="GRAPHIC-d7e933-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0025.gif" alt="" id="GRAPHIC-d7e934-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0026.gif" alt="" id="GRAPHIC-d7e935-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last"><i>N</i> = number of off-target assays in which the starting fragment and ending fragment resulted in a change in potency. Color codes are defined by the following: dark green = change in pXC<sub>50</sub> between a compound that contains the starting fragment and a compound that contains the ending fragment in a particular assay decreasing pXC<sub>50</sub> by  >1 log unit; light green = decrease between 1 and 0.5; yellow = decrease between 0.5 and 0; pink = increase between 0 and 0.5; red = increase between 0.5 and 1; dark red = increase > 1.</p></div></div><div></div></div><div class="NLM_p"><a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> entries 10 and 16 highlight two examples where p<i>K</i><sub>a</sub> most likely plays an important role in mitigating off-target liabilities. In these examples, <i>N</i>,<i>N</i>-dimethlyazetidine-3-amine (ΔclogP = −0.13 and +0.36, respectively) led to reduced activity against ∼30–45% of targets (dark green and light green segments) and increased activity at only ∼10–15% targets (dark red and light red segments). We speculate that the improvement in off-target promiscuity for entries 10 and 16 may be due to a reduced basicity of the <i>N</i>,<i>N</i>-dimethlyazetidine-3-amine fragment relative to the starting fragment (<i>N</i>,<i>N</i>-dimethylethane-1,2-diamine). By use of the p<i>K</i><sub>a</sub> calculation tool in ACD Labs software (version 2015), the <i>N</i>,<i>N</i>-dimethlyazetidine-3-amine fragment (when attached to an aromatic ring, thus rendering the attachment amine as a weakly basic aniline) is ∼0.5 unit less basic than the <i>N</i>,<i>N</i>-dimethylethane-1,2-diamine. The same is true for entry 16, where the calculated p<i>K</i><sub>a</sub> for <i>N</i>,<i>N</i>-dimethlyazetidine-3-amine is ∼0.5 unit less than for <i>N</i>,<i>N</i>-dimethylpyrrolidine-3-amine. In some instances, a new fragment improved the off-target profile despite an increase in clogP from the initial fragment. For example, the addition of a methyl group on the pyrazole ring (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, entry 4) led to an improvement in activity at a majority of the off-target panels. We speculate that perhaps the methyl group may either cause a significant conformational change or perhaps block interactions of the pyrazole nitrogen with certain off-target receptors. The simple addition of a methyl group, if properly aligned into a hydrophobic pocket, may increase potency ∼10-fold,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> suggesting that in most cases this would generally increase off-target activity where such steric bulk could be accommodated. However, Jorgensen et al. surveyed more than 2100 cases of methyl group addition in medicinal chemistry applications and determined that it was just as likely to increase as it was to decrease potency.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Entries 4 and 36 in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> seem consistent with this analysis.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Most Frequent Off-Targets with Decreased Activity in Matched-Pair Analysis</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">entry</th><th class="colsep0 rowsep0" align="center">assay</th><th class="colsep0 rowsep0" align="center" char=".">frequency<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">assay hit rate (IC<sub>50</sub> < 10 μM)</th><th class="colsep0 rowsep0" align="center" char=".">average clogP (hits, IC<sub>50</sub> < 10 μM)</th><th class="colsep0 rowsep0" align="center" char=".">average clogD (7.4) (hits, IC<sub>50</sub> < 10 μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">5-HT2B (Bind)</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">26.9</td><td class="colsep0 rowsep0" align="char" char=".">3.62</td><td class="colsep0 rowsep0" align="char" char=".">2.69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">5-HT1D Rat (Bind)</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">10.1</td><td class="colsep0 rowsep0" align="char" char=".">4.33</td><td class="colsep0 rowsep0" align="char" char=".">2.54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">M1 (Antag)</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">31.2</td><td class="colsep0 rowsep0" align="char" char=".">3.74</td><td class="colsep0 rowsep0" align="char" char=".">2.69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">Ang2 AT1 (Antag)</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">9.8</td><td class="colsep0 rowsep0" align="char" char=".">4.75</td><td class="colsep0 rowsep0" align="char" char=".">2.92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">NK1 (Antag)</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">11.4</td><td class="colsep0 rowsep0" align="char" char=".">4.59</td><td class="colsep0 rowsep0" align="char" char=".">2.92</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">α1A (Antag)</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">18.8</td><td class="colsep0 rowsep0" align="char" char=".">4.18</td><td class="colsep0 rowsep0" align="char" char=".">2.81</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">5-HT4 (Bind)</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">12.6</td><td class="colsep0 rowsep0" align="char" char=".">3.61</td><td class="colsep0 rowsep0" align="char" char=".">2.35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">EGFR (Biochem)</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">11.5</td><td class="colsep0 rowsep0" align="char" char=".">3.65</td><td class="colsep0 rowsep0" align="char" char=".">2.69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">DAT (Bind)</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">18.8</td><td class="colsep0 rowsep0" align="char" char=".">4.13</td><td class="colsep0 rowsep0" align="char" char=".">2.53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">SST4 (Bind)</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">10.7</td><td class="colsep0 rowsep0" align="char" char=".">4.55</td><td class="colsep0 rowsep0" align="char" char=".">2.82</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">5-HT2B (Antag)</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">23.0</td><td class="colsep0 rowsep0" align="char" char=".">4.00</td><td class="colsep0 rowsep0" align="char" char=".">2.78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">cKIT (Biochem)</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">19.4</td><td class="colsep0 rowsep0" align="char" char=".">3.52</td><td class="colsep0 rowsep0" align="char" char=".">2.52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">Src (Biochem)</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">19.0</td><td class="colsep0 rowsep0" align="char" char=".">3.60</td><td class="colsep0 rowsep0" align="char" char=".">2.46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">OPRk1 (Antag)</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="char" char=".">4.32</td><td class="colsep0 rowsep0" align="char" char=".">2.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">H1 (Antag)</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">12.0</td><td class="colsep0 rowsep0" align="char" char=".">4.48</td><td class="colsep0 rowsep0" align="char" char=".">2.87</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">D1 (Bind)</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">13.0</td><td class="colsep0 rowsep0" align="char" char=".">4.56</td><td class="colsep0 rowsep0" align="char" char=".">2.70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">17</td><td class="colsep0 rowsep0" align="left">M2 (Bind)</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">24.5</td><td class="colsep0 rowsep0" align="char" char=".">3.52</td><td class="colsep0 rowsep0" align="char" char=".">2.33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">18</td><td class="colsep0 rowsep0" align="left">α1B (Antag)</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">9.3</td><td class="colsep0 rowsep0" align="char" char=".">4.62</td><td class="colsep0 rowsep0" align="char" char=".">2.49</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">BK2 (Antag)</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">13.7</td><td class="colsep0 rowsep0" align="char" char=".">4.31</td><td class="colsep0 rowsep0" align="char" char=".">2.97</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">ALK4 (Biochem)</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">9.1</td><td class="colsep0 rowsep0" align="char" char=".">3.68</td><td class="colsep0 rowsep0" align="char" char=".">2.53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">AT Gpig (Bind)</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">38</td><td class="colsep0 rowsep0" align="char" char=".">3.55</td><td class="colsep0 rowsep0" align="char" char=".">2.86</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Out of 38 molecular examples with <0.5 log change. Bind = binding assay. Antag = antagonist mode in a functional assay. Biochem = biochemical/enzymatic assay.</p></div></div></div><div class="NLM_p">Fluorine is an element commonly introduced into drug discovery optimization programs to mitigate clearance and ADME related issues.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Furthermore, substitution of fluorine near a basic amine can result in a significant decrease in p<i>K</i><sub>a</sub>,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> which may result in decreased off-target activity. However, fluorine incorporation can lead to either an increase or decrease in off-target activity (see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, entries 17 and 30), and the effect cannot be reliably predicted <i>a priori</i>.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><div class="NLM_p">The data underlying <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> were further analyzed to understand which off-target activities were the most likely to be reduced with the changes detailed in the matched pair analysis. Activity at the following receptors was reduced in 13 out of the 38 examples in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>: 5-HT2B, 5-hydroxytryptamine receptor 1D (5-HT1D), M1 followed by a number of receptors with 12, 11, and 10 examples (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_p">Since these structural changes can also increase activity at some targets, the same analysis was conducted to identify those targets that demonstrated an increase in potency with the changes in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. The frequency of these occurrences was much lower than that observed for <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>, with the top hit being the AT receptor with 6/38 matched pair examples resulting in increased potency (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). This was followed by 5-HT2C (antagonist, cell-based assay), A1 (binding assay), KDR and SET (enzyme assay).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Most Frequent Off-Targets Increased in Matched-Pair Analysis</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">entry</th><th class="colsep0 rowsep0" align="center">assay</th><th class="colsep0 rowsep0" align="center">frequency</th><th class="colsep0 rowsep0" align="center">assay hit rate (IC<sub>50</sub> < 10 μM)</th><th class="colsep0 rowsep0" align="center">average clogP (hits, IC<sub>50</sub> < 10 μM)</th><th class="colsep0 rowsep0" align="center">average clogD (7.4) (hits, IC<sub>50</sub> < 10 μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">AT Gpig (Bind)</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">38</td><td class="colsep0 rowsep0" align="left">3.55</td><td class="colsep0 rowsep0" align="left">2.86</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">5-HT2C (Antag)</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">10.1</td><td class="colsep0 rowsep0" align="left">4.48</td><td class="colsep0 rowsep0" align="left">2.78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">A1 (Bind)</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">14.3</td><td class="colsep0 rowsep0" align="left">3.36</td><td class="colsep0 rowsep0" align="left">2.70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">KDR (Biochem)</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">3.45</td><td class="colsep0 rowsep0" align="left">2.52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">SET (Bind)</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">10.8</td><td class="colsep0 rowsep0" align="left">3.77</td><td class="colsep0 rowsep0" align="left">2.32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">α1B (Bind)</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">3.97</td><td class="colsep0 rowsep0" align="left">2.46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">D1 (Antag)</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">5.07 (<i>n</i> = 25)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">2.93 (<i>n</i> = 25)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">NAchA1 (Bind)</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">7.5</td><td class="colsep0 rowsep0" align="left">3.80</td><td class="colsep0 rowsep0" align="left">2.19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">INSR (Biochem)</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">16.1</td><td class="colsep0 rowsep0" align="left">3.64</td><td class="colsep0 rowsep0" align="left">2.29</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">AurKA (Biochem)</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">8.7</td><td class="colsep0 rowsep0" align="left">2.94</td><td class="colsep0 rowsep0" align="left">2.48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">TSPO (Bind)</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">19.1</td><td class="colsep0 rowsep0" align="left">4.06</td><td class="colsep0 rowsep0" align="left">3.10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">These data were not included in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>–<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a> since only 25 data points were available, and the threshold used was 30 data points. Bind = binding assay. Antag = antagonist mode in a functional assay. Biochem = biochemical/enzymatic assay. Data analyzed for matched pairs with >0.5 log change.</p></div></div></div></div><div id="sec8" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Clinical Candidates</h3><div class="NLM_p">Finally, we examined nine clinical candidates from AstraZeneca that have successfully completed a phase I clinical trial (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). These compounds cover multiple therapy areas including oncology, infection, and respiratory diseases. The majority of successful phase I compounds have relatively few off-target activities (entries 4–9, <6 targets below 10 μM), but several clinical candidates (entries 1–3, ≥15 targets below 10 μM, ≥12 targets below 2 μM) have multiple activities at off-target receptors. This was consistent with a published report by Jalencas and Mestres that showed marketed drugs hit an average of five other targets (IC<sub>50</sub> < 10 μM).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Clinical Candidates Successful in Phase I</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">entry</th><th class="colsep0 rowsep0" align="center" char=".">% targets with IC<sub>50</sub> < 10 μM</th><th class="colsep0 rowsep0" align="center" char=".">% targets with IC<sub>50</sub> < 2 μM</th><th class="colsep0 rowsep0" align="center">indication</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">33</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="left">oncology</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="char" char=".">29</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="left">oncology</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="left">renal</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="left">neuroscience</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="left">respiratory</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">infection</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">oncology</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="left">oncology</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="left">respiratory</td></tr></tbody></table></div></div></div></div><div id="sec9" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_67527" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_67527" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec9_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Off-Target Pharmacology, Frequent Hitters, Role of Physicochemical Properties</h3><div class="NLM_p">An early observation from this study was that compounds submitted to the DSP panel possessed higher MW, higher PSA, more rotatable bonds, and more H-bond donors compared to random compounds in the AstraZeneca compound collection. This is by virtue that these are advanced compounds in their respective drug discovery programs, optimized for potency and ADME from the initial hit. On average, however, the lipophilicity of DSP compounds did not differ from random compounds, which may be explained by a deliberate focus on maintaining or lowering the lipophilicity of the original starting points and not adding unnecessary hydrophobicity during the optimization campaign. Many of the assays exhibited high hit rates (e.g., 53/130 have hit rates of >10% as defined by IC<sub>50</sub> < 10 μM). An analysis of the hits from these targets demonstrated that most targets favor lipophilic compounds (80/93 targets for clogP) when compared to compounds inactive in those assays. However, the hit rate of a target did not correlate with the average hydrophobicity of hits found at that target.</div><div class="NLM_p">Several seminal papers have been written about off-target pharmacology, promiscuity, and applications to drug design. For example, Leeson and Springthorpe examined patented compounds from 2000 to 2006 that show the trend of increasing hydrophobicity and molecular weight in spite of the acceptance of the “rule-of-five” and other guidelines published in that era.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> These authors posit that simply lowering lipophilicity of the lead compounds would result in an improvement in attrition rates for clinical drug development. In general, reduction of lipophilicity is a common and useful strategy to mitigate off-target liabilities as well as to limit low solubility and high clearance. However, some highly lipophilic compounds have been approved as drugs and thus serve as counterpoints to this notion (e.g., venetoclax and ceritinib, both approved for oncology indications, have clogP = 10.4 and 6.5, respectively). These types of compounds are exceptions, however, and often have very potent target affinities allowing for low clinical doses, thus presumably avoiding weaker off-target and nonspecific effects.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Highly lipophilic compounds may require significant formulation to overcome solubility issues and also may necessitate more significant effort to understand the pharmacokinetics/pharmacodynamics needed to accurate model human dose projections.</div><div class="NLM_p">In addition to hydrophobicity, basicity has been linked to promiscuity as well. Peters et al. have demonstrated that amines with p<i>K</i><sub>a</sub> (B) > 6 appeared to be the most important determination of promiscuity, especially in panels with large number of biogenic amine targets, such as GPCRs and ion channels.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> However, more recently, Lee et al. have published on the role of amine promiscuity and toxicological findings as categorized by primary, secondary, and tertiary amines. This work illustrated that primary amines are less promiscuous than secondary or tertiary amines based on an analysis of 938 basic compounds tested on 100 targets.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><div class="NLM_p last">Finally, the notion of molecular complexity has been described in the literature by Leach and Hann as a model to describe molecular interactions and the probability of single or multiple binding events.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> In this model, a less complex molecule (e.g., a fragment) has a higher probability of binding to a given target than a more complex molecule due to higher chances for mismatches with the ligand pocket. Hann and Leach report attempts by others to validate this hypothesis in the context of promiscuity using molecular weight and heavy atom count. The results are equivocal, with some examples illustrating higher molecular weight or heavy atom count compounds resulting in less promiscuity,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> while other examples demonstrate the opposite result.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The authors conclude that the complexity model as initially described may benefit from relaxation of the matching rules, along with consideration of binding interactions driven primarily by lipophilicity as examples.</div></div><div id="sec9_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Functional Activities in the Off-Target Panel</h3><div class="NLM_p">It is a commonly held perception that it is easier to find antagonists than agonists, since an agonist must not only bind but must also have the right molecular interactions to activate a particular target. Our analysis seems to support this perception. The average hit rate for agonist-based functional assays was 0.9% compared to 1.6% for antagonists at the IC<sub>50</sub> < 2 μM threshold and 2.5% for agonists compared to 8.7% for antagonists at the IC<sub>50</sub> < 10 μM threshold. However, there were exceptions to this trend. For example, MR2 and CB1 antagonist assays both showed lower antagonist hit rates relative to their agonist counterpart screens. Caution must be taken not to overinterpret these comparisons, since cell-based functional assays encompass a variety of cell backgrounds and assays types, which may also influence individual hit rates.</div><div class="NLM_p last">Our analysis yielded only four targets, α1A, 5-HT1B, ghrelin receptor (Ghre), and EtA, that allowed us to directly compare the physicochemical property profiles of antagonists versus agonists. This was due to the fact that not every target was screened for both agonist and antagonist functional activities, and for several targets where both agonist and antagonist assays were available, one or both hit rates were too low to calculate the average physicochemical properties. Of the four targets with a sufficient number of hits, all demonstrated small differences in properties (i.e., α1A antagonist clogP = 4.58 vs agonist = 4.18, 5-HT1B antagonist clogP = 4.43 vs 3.45, Ghre antagonist clogP = 4.11 vs 3.73, EtA antagonist clogP = 4.45 vs 5.04). Morphy has previously published an analysis of target class and ligand physicochemical properties against their respective functional activities<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> and found that for GPCRs and ion channels, agonists had lower MW and lower clogP than their respective antagonists. No change was observed for nuclear hormone receptors. These examples highlight potential opportunities for the medicinal chemist. If, for example, a functional activity at a receptor is undesired, one can use the physicochemical property profile of that activity, along with data and structures from known ligands, to help design away from the undesired effect on a target-by-target basis.</div></div><div id="sec9_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Literature Examples of Reducing Serious Off-Target Pharmacology: hERG</h3><div class="NLM_p last">Perhaps one of the best-studied off-targets is human ether-a-go-go-related gene (hERG), a subunit of the cardiac K<sup>+</sup> channel K<sub>v</sub>11.1. The pharmacophore has been well established,<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> and models are available to mitigate activity against hERG<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> (such as lipophilicity-adjusted hERG potency). As a general risk reduction strategy, a 30-fold margin between free <i>C</i><sub>max</sub> of a compound and its IC<sub>50</sub> against hERG is targeted.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Studies have shown that as little as 10% hERG inhibition can cause QT prolongation of ∼20 ms in human, highlighting the significant safety issue for even weak hERG blockers.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> It should be pointed out that the hERG assay was included in the list of assays in this paper for comparative purposes (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) but is much more widely used as a stand-alone assay than the DSP full panel profiling. Because of the serious and well-known nature of this issue, most teams will screen early for hERG liability but only submit compounds to the larger DSP panel when the series advances and there is a need to know the wider toxicology risks. However, many of the key learnings that evolved from the hERG discovery can be generally applied to other off-targets, for example the importance of keeping lipophilicty and p<i>K</i><sub>a</sub> low. Since hERG has been well described in many previous publications, we will not go into details in this review. Rather, we will focus on other case studies of significant toxicology issues which were later addressed by molecular changes in a new molecule.</div></div><div id="sec9_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Literature Examples of Reducing Serious Off-Target Pharmacology: Beyond hERG</h3><div class="NLM_p">The serotonin-releasing agent fenfluramine <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>), which was approved as an appetite suppressant, was withdrawn from markets in 1999 after it was found to cause an increased risk for cardiac valvular fibrosis. This effect was driven by potent agonism of its active metabolite norfenfluramine <b>2</b> at the 5-HT2B receptor,<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> which is expressed in heart valve. The circulating plasma concentrations of norfenfluramine were shown to be higher than fenfluramine itself in both humans and preclinical species. However, the extent to which fenfluramine was metabolized to norfenfluramine varied across species (rat ≫ dog ≫ mouse = man).<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a> While regulatory guidance does not require wide profiling of major metabolites, increasingly submissions will now include these studies in order to avoid metabolite-related adverse findings in the clinic. A similar drug, benfluorex <b>3</b>, was also withdrawn from the market based on the same propensity to form <b>2</b>.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> A next generation serotonergic weight loss drug was approved in 2012 (lorcaserin <b>4</b>)<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> which is a selective 5-HT2C agonist devoid of 5-HT1A agonism (which can cause hallucinations) and 5-HT2B agonism (which can cause cardiovascular effects). Lorcaserin shares structural similarity to <b>1</b> and <b>2</b>, but importantly because of ring constraints and the inability to dealkylate, it provides critical 5-HT selectivity and is thus a safer weight-loss drug.</div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Example target classes and compounds where off-target pharmacology was addressed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Off-target activity of 5-HT2B is also thought to be involved in the cardiac liability of some marketed dopamine agonists, which are approved for the symptomatic treatment of motor symptoms in Parkinson’s disease.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> There are two major classes of dopamine agonists, ergot alkaloids, illustrated by pergolide <b>5</b> (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>), and non-ergot alkaloids, illustrated by ropinirole <b>6</b>. Careful monitoring of patients treated with dopamine agonists is required due to potentially harmful cardiovascular side effects, and some dopamine agonists (e.g., pergolide <b>5</b>) have been withdrawn from U.S. and European markets due to unfavorable safety profiles.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> The cardiovascular liabilities of <b>5</b> are also thought to be working through the 5-HT2B receptor (similar to fenfluramine).<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Non-ergot alkaloid dopamine agonists (e.g., ropinirole <b>6</b>) appear to offer a more tolerable profile.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p">Another example of significant safety risks that were mitigated by compounds with reduced off-target pharmacology can be seen in the aminosteroid class of muscular blocking agents. Rapacuronium <b>7</b> is a nondepolarizing muscular blocking agent (NMBA) of the aminosteroid class. Rapacuronium and other aminosteroid NMBAs are antagonists of nicotinic cholinergic receptors (nAChRs) and inhibit signal transmission at the neuromuscular junction. NMBAs are used to induce paralysis during anesthesia to allow intubation. In 2001, rapacuronium <b>7</b> was withdrawn from markets shortly after approval after an increased incidence of intubation-induced bronchospasm was observed, which was linked to several deaths.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Rapacuronium <b>7</b> is the only aminosteroid withdrawn for this reason; the structurally related pancuronium <b>8</b>, rocuronium <b>9</b>, and vecuronium <b>10</b> are still marketed to date and have not been associated with increased risk of bronchospasm in vivo.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> The polypharmacology driving this serious adverse effect is thought to result from rapacuronium’s preferential binding to M2 over M3 muscarinic receptors. Veruconium binds to both M2 and M3 receptors but not at clinically relevant concentrations, while pancuronium antagonizes both receptors at plasma concentrations reached in the clinic.<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63,64)</a> In contrast, rapacuronium binds to the M2 receptor with a 15-fold greater affinity than to the M3 receptor, and while the IC<sub>50</sub> for the M2 receptor lies within the concentration range reached in human plasma, the IC<sub>50</sub> for the M3 receptor does not.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></div><div class="NLM_p">Telithromycin <b>11</b> (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) is the first and thus far only approved macrolide antibiotic of the ketolide class. However, telithromycin is associated with a number of serious adverse effects (“Ketek effects”) such as syncope, blurry vision, exacerbation of myasthenia gravis, severe liver injury, and liver failure.<a onclick="showRef(event, 'ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref65 ref66">(65,66)</a> Subsequently, approval was withdrawn for indications other than community-acquired bacterial pneumonia (CABP). Today, telithromycin is no longer manufactured. Compared to older macrolides such as erythromycin and clarithromycin, telithromycin has a side chain that forms a second binding site for the bacterial ribosome. This side chain contains a pyridine moiety that could interact with nAChRs and cause off-target activities that could explain some adverse effects of telithromycin. In a study, Bertrand et al. compared the activity of telithromycin <b>11</b> to solithromycin <b>12</b>, an as of yet not approved ketolide with the pyridine moiety replaced, as well as the non-ketolide macrolides azithromycin and clarithromycin, at several nAChRs.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> In in vitro experiments, telithromycin <b>11</b> was found to inhibit α7 and α3β4 nAChRs at concentrations reached in the clinic, with a lower IC<sub>50</sub> than the approved clarithromycin as well as <b>12</b>. Enhanced blockade of these receptors, which are expressed on the ciliary ganglion, could explain the adverse effects of telithromycin on visual acuity.<a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67,68)</a> Knockout of the α7 subunit has been shown to reduce visual acuity in a mouse model.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Example target classes and compounds where off-target pharmacology was addressed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">There is no codified rule to determine what potency of a compound against off-targets and the number of off-targets hit is “permissible” for a development candidate. Rather, many factors must be considered such as free drug exposure, target occupancy, and organ concentration (e.g., central nervous system (CNS) penetration if these are CNS targets). Dose-to-man predictions to determine the free drug concentration required to achieve efficacy can be used to understand the risk of any particular off-target. A recent example is the P2Y12 antagonist ticagrelor <b>13</b> (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>), which had been reported to inhibit adenosine uptake using in vitro models.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> However, through ex vivo and more extensive in vitro studies, van den Berg et al. demonstrated that while ticagrelor inhibits the adenosine transporter in a dose-dependent manner plasma concentrations in clinical practice are too low to cause any increase in adenosine levels.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> This is significant since it highlights that in some cases early signals from in vitro safety screens may necessitate extensive clinical studies to mitigate the findings.</div></div><div id="sec9_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> When Polypharmacology Is Also Part of the Efficacy of a Drug</h3><div class="NLM_p">Polypharmacology is one of the root causes for adverse events. However, it can also be the basis for a drug’s efficacy. This is perhaps most notable in psychiatric disease indications. Drugs approved for the treatment of depression, anxiety, and psychosis all bind to multiple targets at clinically relevant concentrations, and it is this breadth of target engagement that underlies their efficaciousness.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> More recently, a string of promiscuous kinase inhibitors have made their way to market for multiple cancer indications. One such example of beneficial polypharmacology in a cancer medication is crizotinib <b>14</b> (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>). Crizotinib <b>14</b> was originally developed as an inhibitor of the receptor tyrosine kinase c-Met (also known as hepatocyte growth factor receptor or HGFR)<a onclick="showRef(event, 'ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref73 ref74">(73,74)</a> but was approved based on its off-target activity. Crizotinib <b>14</b> inhibits c-Met with an IC<sub>50</sub> of 11 nM and HGF-stimulated NCI-H441 lung carcinoma cell migration and invasion with similar nanomolar potencies.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> In a panel of >120 kinases <b>14</b> was described as selective against 90% of targets<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> but was also shown to inhibit anaplastic lymphoma receptor tyrosine kinase (ALK) equipotently to c-Met.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> While <b>14</b> was under development, a paper demonstrated that genetic rearrangements result in a fusion protein of echinoderm microtubule-associated protein-like 4 (EML4) and ALK. This fusion oncogene was found in ∼7% of patients with non-small-cell lung cancer (NSCLC),<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> suggesting that ALK may be a therapeutic target for the treatment of a subset of NSCLC. Further studies in over 600 cancer cell lines showed that inhibition of ALK suppresses growth in cell lines derived from NSCLC, lymphomas, and neuroblastomas and characterized by genomic alterations related to ALK.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Crizotinib <b>14</b> was approved in 2011 for the treatment of ALK-positive NSCLC. Subsequently, its activity against another receptor tyrosine kinase, proto-oncogene tyrosine-protein kinase (ROS1),<a onclick="showRef(event, 'ref78 ref79'); return false;" href="javascript:void(0);" class="ref ref78 ref79">(78,79)</a> led to further approval in patients with NSCLC characterized by genomic rearrangements of ROS1.<a onclick="showRef(event, 'ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref80 ref81">(80,81)</a> More recently, a study of >1400 small molecules demonstrated that <b>14</b> may possess immunomodulatory activity that could augment immune-oncology-based therapies.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> In this study, <b>14</b> was shown to enhance interactions of T-cells with monocytes and cancer cells by upregulating major histocompatibility complexes I and II. This upregulation was the result of inhibition of the receptor tyrosine kinase macrophage-stimulating protein receptor (MSTR1), a close homolog of c-Met, which is also inhibited by crizotinib with an IC<sub>50</sub> of ∼200 nM in cell-based assays.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></div><div class="NLM_p last">Many marketed drugs have nonselective off-targets profiles, and thus one may argue that the industry at large is too conservative when deciding on acceptable or unacceptable off-target pharmacology while also using an ever-increasing menu of available secondary screening options. There are many historical examples where a certain drug was approved which would not be developed today due to preclinical identification of off-target promiscuity identified preclinically. However, general rules cannot be applied to this issue. Many factors such as morbidity of disease, availability of viable treatment options, and potential patient populations all must be considered. Ultimately, regulatory bodies decide on an acceptable risk-benefit profile on a disease-by-disease basis.</div></div><div id="sec9_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Limitations of Secondary Pharmacology Panels and Emerging Models</h3><div class="NLM_p">The binding, functional, and biochemical assays analyzed in this paper are only a part of the suite of in vitro safety assays available to a project team. For purposes of simplicity, we did not include other safety screens used at AstraZeneca, such as large kinase panels, ion channels outside of hERG, or cytochrome P450s in this analysis. Although these assays enable the interrogation of a significant number of different safety issues, there are still inherent limitations to these models. Perhaps the most obvious limitation is that these models are selected for specific targets or pathways of known toxicity and will not detect unknown mechanisms. Cytotoxicity models (e.g., THP-1 cells) can be used as unbiased approaches to detect preliminary toxicological signals. More complex tissue-relevant models and microphysiological systems are also rapidly developing and may become more widely employed in the future to more accurately predict clinical safety issues.<a onclick="showRef(event, 'ref83 ref84'); return false;" href="javascript:void(0);" class="ref ref83 ref84">(83,84)</a> We recently reported an example from a BRD4 program (AZD5153) that demonstrated gut toxicity signals during dog preclinical toxicology studies, raising significant concerns for clinical testing.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> On the basis of this result, minigut organoid models were employed and demonstrated that dog organoid models were more sensitive to AZD5153 than human organoid models; thus human toxicity was less of a liability than would have been predicted by using only the dog in vivo result. In silico predictive models are also gaining acceptance as surrogates to large off-target pharmacology panels. With the large amount of screening data now routinely collected in these types of screens, the data can be utilized to predict potential adverse drug reactions. A good example of these models was reported by Lounkine et al. who utilized 2D structural similarity matching of compounds to known ligands of important safety targets.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Using this method, they were able to accurately predict safety issues for more than half of the test compounds de novo. Importantly, they also identified inhibition of COX-1 enzyme as a novel safety concern of chlorotrianisene (a nonsteroidal estrogen).<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> In addition to ligand-based methods, structure-based predictive methods have also been recently reported and show promising potential, with the caveat that protein structures of the off-target proteins need to be available.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a></div><div class="NLM_p last">A second limitation of the secondary pharmacology panels is that only a specific pharmacology is interrogated for a given assay (e.g., binding, antagonism, agonism, biochemical activity). Other mechanisms that may potentiate these targets will likely be missed, such as positive and negative allosteric modulators (which would require screening against the native ligand), degraders (e.g., proteolysis targeting chimeras (PROTACS), or compounds that modulate target expression at the DNA/RNA level. Third, toxic metabolites will not be detected in these screens, since typically only the parent compound is tested. The examples of fenfluramine <b>1</b> and benfluorex <b>3</b> illustrate this and demonstrate why it is becoming a more common practice to profile off-target liabilities of any major metabolites for regulatory filing submissions. Finally, off-target panels also have their own propensity for false positives, which must be taken into consideration. Several strategies can be used to mitigate this risk, such as screening hits in an orthogonal assay with a different assay technology or screening in a functional assay if the initial hit was in a binding assay.</div></div><div id="sec9_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Improvements in Clinical Safety-Related Attrition</h3><div class="NLM_p last">An analysis conducted to assess the fate of the AstraZeneca pipeline from 2005 to 2010 determined that more than 62% of phase I failures were due to safety-related issues. Of these failures, approximately half (∼40%) were categorized as inability to detect a safety signal in preclinical screens, whereas the remainder was a failure to appropriately assess early safety signals.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> These results underscore the need for both continued development of new predictive models as well as clearly defined mitigation strategies to circumvent in vivo safety issues when early in vitro signals are detected. A follow-up report on the assessment of the pipeline from 2012 to 2016 demonstrated that attrition due to safety concerns in phase I trials decreased to less than 10% in the 2012–2016 time frame compared to 62% in 2005–2010.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> This has largely been attributed to an improvement in AstraZeneca’s ability to detect safety concerns in preclinical settings using predictive models, secondary pharmacology tools, and adoption of a rigorous and quantitative decision-making process. The analysis we have presented here is part of the tool set that led to these improvements.</div></div></div><div id="sec10" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23256" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23256" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">All development candidates have some level of off-target pharmacology. If this pharmacology leads to adverse events, it poses a risk to clinical and commercial development which is dependent on the safety margin between efficacious PK/PD profile and safety PK/PD profile. Understanding the off-target clinical PK/PD risk before clinical development is as important as knowing the PK/PD profile for clinical efficacy. This knowledge can in part be elucidated by the off-target screens that enable the design of better, safer medicines. Several general tools are at the disposal for the medicinal chemist such as pharmacophore models, legacy off-target SAR, general principles of lowering lipophilicity, and p<i>K</i><sub>a</sub>. Our analysis has provided an additional level of context of the individual physicochemical properties that describe hits at these targets, along with hit rates of each target and correlations of hits from one target to another. This information will provide a useful data set for the medicinal chemist who engages in mitigating these potential safety issues.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01625" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78483" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78483" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01625?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01625</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Assay descriptions and data and statistical analysis for <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>–<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01625/suppl_file/jm9b01625_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01625/suppl_file/jm9b01625_si_001.pdf">jm9b01625_si_001.pdf (605.88 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01625" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48848" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48848" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dean G. Brown</span> - <span class="hlFld-Affiliation affiliation">Hit
Discovery, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Waltham, Massachusetts 02451, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7130-3928" title="Orcid link">http://orcid.org/0000-0002-7130-3928</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#90f4f5f1febef2e2ffe7fed0f1e3e4e2f1eaf5fef5f3f1bef3fffd"><span class="__cf_email__" data-cfemail="d1b5b4b0bfffb3a3bea6bf91b0a2a5a3b0abb4bfb4b2b0ffb2bebc">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Heike J. Wobst</span> - <span class="hlFld-Affiliation affiliation">Neuroscience,
BioPharmaceuticals R&D, AstraZeneca, Waltham, Massachusetts 02451, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#115974787a743f467e73626551706b7f7464637e3f727e7c"><span class="__cf_email__" data-cfemail="105875797b753e477f72636450716a7e7565627f3e737f7d">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Graham F. Smith</span> - <span class="hlFld-Affiliation affiliation">Data
Science and Artificial Intelligence, Clinical Pharmacology & Safety
Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0393-3650" title="Orcid link">http://orcid.org/0000-0003-0393-3650</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01372" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01372" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Dean G. Brown</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=BIO-d7e2138-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Dean G. Brown</b> is Director of Chemistry at AstraZeneca within the Hit Discovery Department, Discovery Science, R&D BioPharmaceuticals Unit. He obtained a B.S. in Chemistry at Abilene Christian University (Abilene, TX) and a Ph.D. at the University of Minnesota (Minneapolis) in Organic Chemistry. He has over 20 years of experience in industry with AstraZeneca. Dean has been responsible for building many new scientific programs in both neuroscience and infection, several of which have resulted in successful transition to clinical trials. His scientific interests are in lead generation, library design, DNA-encoded library screening, synthetic chemistry, and applications of computational chemistry. Dean is listed as an author or coauthor on more than 50 publications and patent applications in medicinal chemistry and drug design, including granted patents on clinical candidates.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Graham F. Smith</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=BIO-d7e2143-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Graham F. Smith</b> is Associate Director within the Data Science and AI group, Clinical Pharmacology and Safety Science, R&D BioPharmaceuticals Unit. He received his degree and Ph.D. from the University of Nottingham before postdoctoral studies at The Ohio State University. He has over 20 years of experience in chemistry applied in several large pharmaceutical companies. His scientific interests include medicinal chemistry, lead discovery, chemical technologies, and the application of AI to drug design. Graham has authored or coauthored over 30 patents and peer reviewed publications in medicinal chemistry and drug design.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Heike J. Wobst</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=BIO-d7e2148-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Heike J. Wobst</b> is a Principal Scientist at AstraZeneca within the Neuroscience Department, R&D BioPharmaceuticals Unit. She obtained a B.Sc. in Molecular Biotechnology from Heidelberg University, an M.Sc. in Molecular Medicine from Charité Universitätsmedizin Berlin, and a D.Phil. in Physiology, Anatomy and Genetics from the University of Oxford. Her scientific interests are focused on molecular mechanisms of neurodegeneration and therapeutic intervention strategies targeting these mechanisms.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i28">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73545" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73545" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Lyn Rosenbrier Riberio for her valuable discussions.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">5-HT1B</td><td class="NLM_def"><p class="first last">5-hydroxytryptamine receptor 2B</p></td></tr><tr><td class="NLM_term">5-HT1D</td><td class="NLM_def"><p class="first last">5-hydroxytryptamine receptor 1D</p></td></tr><tr><td class="NLM_term">5-HT2B</td><td class="NLM_def"><p class="first last">5-hydroxytryptamine receptor 2B</p></td></tr><tr><td class="NLM_term">5-HT3</td><td class="NLM_def"><p class="first last">5-hydroxytryptamine receptor 3A</p></td></tr><tr><td class="NLM_term">5-HT4</td><td class="NLM_def"><p class="first last">5-hydroxytryptamine receptor 4</p></td></tr><tr><td class="NLM_term">5-HT7</td><td class="NLM_def"><p class="first last">5-hydroxytryptamine receptor 7</p></td></tr><tr><td class="NLM_term">5-HT2C</td><td class="NLM_def"><p class="first last">5-hydroxytryptamine receptor 2C</p></td></tr><tr><td class="NLM_term">α1A</td><td class="NLM_def"><p class="first last">α-1A adrenergic receptor</p></td></tr><tr><td class="NLM_term">α1B</td><td class="NLM_def"><p class="first last">α-1B adrenergic receptor</p></td></tr><tr><td class="NLM_term">α2A</td><td class="NLM_def"><p class="first last">α-2A adrenergic receptor</p></td></tr><tr><td class="NLM_term">α2C</td><td class="NLM_def"><p class="first last">α-2C adrenergic receptor</p></td></tr><tr><td class="NLM_term">A2A</td><td class="NLM_def"><p class="first last">adenosine receptor 2A</p></td></tr><tr><td class="NLM_term">ACHE</td><td class="NLM_def"><p class="first last">acetylcholine esterase</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">ALK</td><td class="NLM_def"><p class="first last">anaplastic lymphoma receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">AT Gpig</td><td class="NLM_def"><p class="first last">adenosine transporter in guinea pig</p></td></tr><tr><td class="NLM_term">Ang AT1</td><td class="NLM_def"><p class="first last">angiotension II AT1</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">AurKA</td><td class="NLM_def"><p class="first last">Aurora kinase A</p></td></tr><tr><td class="NLM_term">β1</td><td class="NLM_def"><p class="first last">β-1 adrenergic receptor</p></td></tr><tr><td class="NLM_term">β2</td><td class="NLM_def"><p class="first last">β-2 adrenergic receptor</p></td></tr><tr><td class="NLM_term">BK2</td><td class="NLM_def"><p class="first last">bradykinin 2 receptor</p></td></tr><tr><td class="NLM_term">CABP</td><td class="NLM_def"><p class="first last">community-acquired bacterial pneumonia</p></td></tr><tr><td class="NLM_term">Card-myo</td><td class="NLM_def"><p class="first last">cardiomyocyte assay</p></td></tr><tr><td class="NLM_term">CatS</td><td class="NLM_def"><p class="first last">cathepsin S</p></td></tr><tr><td class="NLM_term">Cav-DIL</td><td class="NLM_def"><p class="first last">L-type calcium channel diltiazem binding site</p></td></tr><tr><td class="NLM_term">Cav-VER</td><td class="NLM_def"><p class="first last">L-type calcium channel verapamil binding site</p></td></tr><tr><td class="NLM_term">CB1</td><td class="NLM_def"><p class="first last">cannabinoid receptor type 1</p></td></tr><tr><td class="NLM_term">CB2</td><td class="NLM_def"><p class="first last">cannabinoid receptor type 2</p></td></tr><tr><td class="NLM_term">cKIT</td><td class="NLM_def"><p class="first last">proto-oncogene cKIT</p></td></tr><tr><td class="NLM_term">COX-1</td><td class="NLM_def"><p class="first last">cyclooxygenase-1</p></td></tr><tr><td class="NLM_term">COX-2</td><td class="NLM_def"><p class="first last">cyclooxygenase-2</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">D1</td><td class="NLM_def"><p class="first last">dopamine receptor 1</p></td></tr><tr><td class="NLM_term">D2</td><td class="NLM_def"><p class="first last">dopamine receptor 2</p></td></tr><tr><td class="NLM_term">D3</td><td class="NLM_def"><p class="first last">dopamine receptor 3</p></td></tr><tr><td class="NLM_term">DAT</td><td class="NLM_def"><p class="first last">dopamine transporter</p></td></tr><tr><td class="NLM_term">DOP2</td><td class="NLM_def"><p class="first last">δ opioid receptor 2</p></td></tr><tr><td class="NLM_term">DSP</td><td class="NLM_def"><p class="first last">discovery screening panel</p></td></tr><tr><td class="NLM_term">EtA</td><td class="NLM_def"><p class="first last">endothelin A receptor</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">FGFR1</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor 1</p></td></tr><tr><td class="NLM_term">GABAB</td><td class="NLM_def"><p class="first last">γ-aminobutyric acid receptor B</p></td></tr><tr><td class="NLM_term">GABAAα1β2γ2</td><td class="NLM_def"><p class="first last">γ-aminobutyric acid receptor subtype α1 β2 γ2</p></td></tr><tr><td class="NLM_term">GABAA BNZ</td><td class="NLM_def"><p class="first last">γ-aminobutyric acid receptor A benzodiazepine site</p></td></tr><tr><td class="NLM_term">GABA TPBS</td><td class="NLM_def"><p class="first last">γ-aminobutyric acid receptor <i>tert</i>-butyl bicyclophosphorothionate site</p></td></tr><tr><td class="NLM_term">GlyR Strych-sen</td><td class="NLM_def"><p class="first last">glycine receptor strychnine sensitive site</p></td></tr><tr><td class="NLM_term">GSK3β</td><td class="NLM_def"><p class="first last">glycogen synthase kinase 3β</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">Gpig</td><td class="NLM_def"><p class="first last">guinea pig</p></td></tr><tr><td class="NLM_term">GR</td><td class="NLM_def"><p class="first last">glucocorticoid receptor</p></td></tr><tr><td class="NLM_term">H1</td><td class="NLM_def"><p class="first last">histamine receptor 1</p></td></tr><tr><td class="NLM_term">H2</td><td class="NLM_def"><p class="first last">histamine receptor 2</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">HGFR</td><td class="NLM_def"><p class="first last">hepatocyte growth factor</p></td></tr><tr><td class="NLM_term">IC</td><td class="NLM_def"><p class="first last">inhibitory concentration</p></td></tr><tr><td class="NLM_term">ICH</td><td class="NLM_def"><p class="first last">International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use</p></td></tr><tr><td class="NLM_term">IND</td><td class="NLM_def"><p class="first last">investigational new drug</p></td></tr><tr><td class="NLM_term">INSR</td><td class="NLM_def"><p class="first last">insulin receptor kinase</p></td></tr><tr><td class="NLM_term">KDR</td><td class="NLM_def"><p class="first last">kinase insert domain receptor</p></td></tr><tr><td class="NLM_term">MAP3K7</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase kinase kinase 7</p></td></tr><tr><td class="NLM_term">M1</td><td class="NLM_def"><p class="first last">muscarinic acetylcholine receptor 1</p></td></tr><tr><td class="NLM_term">M2</td><td class="NLM_def"><p class="first last">muscarinic acetylcholine receptor 2</p></td></tr><tr><td class="NLM_term">M5</td><td class="NLM_def"><p class="first last">muscarinic receptor 5</p></td></tr><tr><td class="NLM_term">MAO-B</td><td class="NLM_def"><p class="first last">monoamine oxidase B</p></td></tr><tr><td class="NLM_term">MR2</td><td class="NLM_def"><p class="first last">melanin receptor 2</p></td></tr><tr><td class="NLM_term">MSTR1</td><td class="NLM_def"><p class="first last">macrophage-stimulating protein receptor 1</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">molecular weight</p></td></tr><tr><td class="NLM_term">nAchR</td><td class="NLM_def"><p class="first last">nicotinic acetylcholine receptor</p></td></tr><tr><td class="NLM_term">Na<sup>+</sup>/K<sup>+</sup> ATPase</td><td class="NLM_def"><p class="first last">sodium/potassium ATPase pump</p></td></tr><tr><td class="NLM_term">NAchA1</td><td class="NLM_def"><p class="first last">nicotinic α1 acetylcholine receptor</p></td></tr><tr><td class="NLM_term">NAchA4</td><td class="NLM_def"><p class="first last">nicotinic α4 acetylcholine receptor</p></td></tr><tr><td class="NLM_term">NAchA7</td><td class="NLM_def"><p class="first last">nicotinic α7 acetylcholine receptor</p></td></tr><tr><td class="NLM_term">NK1</td><td class="NLM_def"><p class="first last">neurokinin-1 receptor</p></td></tr><tr><td class="NLM_term">NMBA</td><td class="NLM_def"><p class="first last">nondepolarizing muscular blocking agent</p></td></tr><tr><td class="NLM_term">NET</td><td class="NLM_def"><p class="first last">norepinephrine transporter</p></td></tr><tr><td class="NLM_term">NMDA AGO</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate receptor agonist binding site</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">OPRk1</td><td class="NLM_def"><p class="first last">opiod receptor κ receptor 1</p></td></tr><tr><td class="NLM_term">OPRm1</td><td class="NLM_def"><p class="first last">opiod receptor μ receptor 1</p></td></tr><tr><td class="NLM_term">PAINS</td><td class="NLM_def"><p class="first last">pan-assay interference compounds</p></td></tr><tr><td class="NLM_term">PDE6</td><td class="NLM_def"><p class="first last">phosphodiesterase subtype 6</p></td></tr><tr><td class="NLM_term">PDK1</td><td class="NLM_def"><p class="first last">phosphoinositide-dependent kinase 1</p></td></tr><tr><td class="NLM_term">PPARγ</td><td class="NLM_def"><p class="first last">peroxisome proliferative-activated receptor γ</p></td></tr><tr><td class="NLM_term">PROTAC</td><td class="NLM_def"><p class="first last">proteolysis targeting chimera</p></td></tr><tr><td class="NLM_term">PSA</td><td class="NLM_def"><p class="first last">polar surface area</p></td></tr><tr><td class="NLM_term">RARα</td><td class="NLM_def"><p class="first last">retinoic acid receptor α</p></td></tr><tr><td class="NLM_term">ROCK1</td><td class="NLM_def"><p class="first last">Rho-associated protein kinase 1</p></td></tr><tr><td class="NLM_term">ROCK2</td><td class="NLM_def"><p class="first last">Rho-associated protein kinase 2</p></td></tr><tr><td class="NLM_term">ROS1</td><td class="NLM_def"><p class="first last">proto-oncogene tyrosine-protein kinase</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">Src</td><td class="NLM_def"><p class="first last">tyrosine-protein kinase</p></td></tr><tr><td class="NLM_term">SET</td><td class="NLM_def"><p class="first last">serotonin transporter</p></td></tr><tr><td class="NLM_term">SST4</td><td class="NLM_def"><p class="first last">somatostatin receptor 4</p></td></tr><tr><td class="NLM_term">TSPO</td><td class="NLM_def"><p class="first last">mitochondrial translocator protein 18 kDa</p></td></tr><tr><td class="NLM_term">TRKA</td><td class="NLM_def"><p class="first last">tropomyosin receptor kinase A</p></td></tr><tr><td class="NLM_term">TXA2</td><td class="NLM_def"><p class="first last">thromboxane A2</p></td></tr><tr><td class="NLM_term">VER</td><td class="NLM_def"><p class="first last">verapamil</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01672" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01672" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 88 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blomme, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Toxicology Strategies for Drug Discovery: Present and Future</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">504</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.5b00407</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.5b00407" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOhu7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=473-504&author=E.+A.+Blommeauthor=Y.+Will&title=Toxicology+Strategies+for+Drug+Discovery%3A+Present+and+Future&doi=10.1021%2Facs.chemrestox.5b00407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Toxicology Strategies for Drug Discovery: Present and Future</span></div><div class="casAuthors">Blomme, Eric A. G.; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">473-504</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Attrition due to nonclin. safety represents a major issue for the productivity of pharmaceutical research and development (R&D) organizations, esp. during the compd. optimization stages of drug discovery and the early stages of clin. development.  Focusing on decreasing nonclin. safety-related attrition is not a new concept, and various approaches have been experimented with over the last two decades.  Front-loading testing funnels in Discovery with in vitro toxicity assays designed to rapidly identify unfavorable mols. was the approach adopted by most pharmaceutical R&D organizations a few years ago.  However, this approach has also a non-negligible opportunity cost.  Hence, significant refinements to the "fail early, fail often" paradigm have been proposed recently to reflect the complexity of accurately categorizing compds. with early data points without taking into account other important contextual aspects, in particular efficacious systemic and tissue exposures.  This review provides an overview of toxicol. approaches and models that can be used in pharmaceutical Discovery at the series/lead identification and lead optimization stages to guide and inform chem. efforts, as well as a personal view on how to best use them to meet nonclin. safety-related attrition objectives consistent with a sustainable pharmaceutical R&D model.  The scope of this review is limited to small mols., as large mols. are assocd. with challenges that are quite different.  Finally, a perspective on how several emerging technologies may impact toxicity evaluation is also provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnswsW0Ve2_rVg90H21EOLACvtfcHk0ljkiTsXmQnsLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOhu7vI&md5=ec2ad8b3576b7ba00f750e3f93469a2f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.5b00407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.5b00407%26sid%3Dliteratum%253Aachs%26aulast%3DBlomme%26aufirst%3DE.%2BA.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DToxicology%2520Strategies%2520for%2520Drug%2520Discovery%253A%2520Present%2520and%2520Future%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26spage%3D473%26epage%3D504%26doi%3D10.1021%2Facs.chemrestox.5b00407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span> <span> </span><span class="NLM_article-title">In Silico Prediction of Chemical Toxicity for Drug Design Using Machine Learning Methods and Structural Alerts</span>. <i>Front. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">30</span>, <span class="refDoi"> DOI: 10.3389/fchem.2018.00030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.3389%2Ffchem.2018.00030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=29515993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1WkurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=30&author=H.+Yangauthor=L.+Sunauthor=W.+Liauthor=G.+Liuauthor=Y.+Tang&title=In+Silico+Prediction+of+Chemical+Toxicity+for+Drug+Design+Using+Machine+Learning+Methods+and+Structural+Alerts&doi=10.3389%2Ffchem.2018.00030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">In Silico prediction of chemical toxicity for drug design using machine learning methods and structural alerts</span></div><div class="casAuthors">Yang, Hongbin; Sun, Lixia; Li, Weihua; Liu, Guixia; Tang, Yun</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Chemistry (Lausanne, Switzerland)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30/1-30/12</span>CODEN:
                <span class="NLM_cas:coden">FCLSAA</span>;
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">During drug development, safety is always the most important issue, including a variety of toxicities and adverse drug effects, which should be evaluated in preclin. and clin. trial phases.  This review article at first simply introduced the computational methods used in prediction of chem. toxicity for drug design, including machine learning methods and structural alerts.  Machine learning methods have been widely applied in qual. classification and quant. regression studies, while structural alerts can be regarded as a complementary tool for lead optimization.  The emphasis of this article was put on the recent progress of predictive models built for various toxicities.  Available databases and web servers were also provided.  Though the methods and models are very helpful for drug design, there are still some challenges and limitations to be improved for drug safety assessment in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWBAA05szn67Vg90H21EOLACvtfcHk0ljkiTsXmQnsLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1WkurvF&md5=bdbd0dd38587cb2849db12353e21b30d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2018.00030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2018.00030%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DY.%26atitle%3DIn%2520Silico%2520Prediction%2520of%2520Chemical%2520Toxicity%2520for%2520Drug%2520Design%2520Using%2520Machine%2520Learning%2520Methods%2520and%2520Structural%2520Alerts%26jtitle%3DFront.%2520Chem.%26date%3D2018%26volume%3D6%26spage%3D30%26doi%3D10.3389%2Ffchem.2018.00030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarolimek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, S.</span></span> <span> </span><span class="NLM_article-title">Reducing Safety-Related Drug Attrition: The Use of in Vitro Pharmacological Profiling</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">922</span>, <span class="refDoi"> DOI: 10.1038/nrd3845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fnrd3845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=23197038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=909-922&author=J.+Bowesauthor=A.+J.+Brownauthor=J.+Hamonauthor=W.+Jarolimekauthor=A.+Sridharauthor=G.+Waldronauthor=S.+Whitebread&title=Reducing+Safety-Related+Drug+Attrition%3A+The+Use+of+in+Vitro+Pharmacological+Profiling&doi=10.1038%2Fnrd3845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Reducing safety-related drug attrition: the use of in vitro pharmacological profiling</span></div><div class="casAuthors">Bowes, Joanne; Brown, Andrew J.; Hamon, Jacques; Jarolimek, Wolfgang; Sridhar, Arun; Waldron, Gareth; Whitebread, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">909-922</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In vitro pharmacol. profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved.  Here, for the first time, the rationale, strategies and methodologies for in vitro pharmacol. profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process.  We hope that this will enable other companies and academic institutions to benefit from this knowledge and consider joining us in our collaborative knowledge sharing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVp3wnTONWrVg90H21EOLACvtfcHk0ljkiTsXmQnsLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ&md5=7559001563ef3febd610535b8f096a45</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd3845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3845%26sid%3Dliteratum%253Aachs%26aulast%3DBowes%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DJarolimek%26aufirst%3DW.%26aulast%3DSridhar%26aufirst%3DA.%26aulast%3DWaldron%26aufirst%3DG.%26aulast%3DWhitebread%26aufirst%3DS.%26atitle%3DReducing%2520Safety-Related%2520Drug%2520Attrition%253A%2520The%2520Use%2520of%2520in%2520Vitro%2520Pharmacological%2520Profiling%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D909%26epage%3D922%26doi%3D10.1038%2Fnrd3845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumotier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekete, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, L.</span></span> <span> </span><span class="NLM_article-title">Secondary Pharmacology: Screening and Interpretation of Off-Target Activities - Focus on Translation</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1232</span>– <span class="NLM_lpage">1242</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.04.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.drudis.2016.04.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=27140035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsVymsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1232-1242&author=S.+Whitebreadauthor=B.+Dumotierauthor=D.+Armstrongauthor=A.+Feketeauthor=S.+Chenauthor=A.+Hartmannauthor=P.+Y.+Mullerauthor=L.+Urban&title=Secondary+Pharmacology%3A+Screening+and+Interpretation+of+Off-Target+Activities+-+Focus+on+Translation&doi=10.1016%2Fj.drudis.2016.04.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Secondary pharmacology: screening and interpretation of off-target activities - focus on translation</span></div><div class="casAuthors">Whitebread, Steven; Dumotier, Berengere; Armstrong, Duncan; Fekete, Alexander; Chen, Shanni; Hartmann, Andreas; Muller, Patrick Y.; Urban, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1232-1242</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Secondary pharmacol. is an essential component of drug discovery and is used extensively in the pharmaceutical industry for achieving optimal specificity of new drugs via early hazard identification and off-target mitigation.  The importance of this discipline has been achieved by increasing its translational value, based on the recognition of biol. target-drug mol.-adverse drug reaction (ADR) assocns. and integration of secondary pharmacol. data with pharmacokinetic parameters.  Information obtained from clin. ADRs, from recognition of specific phenotypes of animal models and from hereditary diseases provides increasing regulatory confidence in the target-based approach to ADR prediction and mitigation.  Here, we review the progress of secondary pharmacol. during the past decade and highlight and demonstrate its applications and impact in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFcLQoSKAUdLVg90H21EOLACvtfcHk0ljRRo1R0yibCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsVymsr0%253D&md5=acaabfea81c4e6e06639dd8c59d797e2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.04.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.04.021%26sid%3Dliteratum%253Aachs%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DDumotier%26aufirst%3DB.%26aulast%3DArmstrong%26aufirst%3DD.%26aulast%3DFekete%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DHartmann%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DP.%2BY.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DSecondary%2520Pharmacology%253A%2520Screening%2520and%2520Interpretation%2520of%2520Off-Target%2520Activities%2520-%2520Focus%2520on%2520Translation%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D1232%26epage%3D1242%26doi%3D10.1016%2Fj.drudis.2016.04.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papoian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elayan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagadeesh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laniyonu, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saulnier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span> <span> </span><span class="NLM_article-title">Secondary Pharmacology Data to Assess Potential Off-Target Activity of New Drugs: A Regulatory Perspective</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">294</span>, <span class="refDoi"> DOI: 10.1038/nrd3845-c1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fnrd3845-c1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=25792260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVynsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=294&author=T.+Papoianauthor=H.+J.+Chiuauthor=I.+Elayanauthor=G.+Jagadeeshauthor=I.+Khanauthor=A.+A.+Laniyonuauthor=C.+X.+Liauthor=M.+Saulnierauthor=N.+Simpsonauthor=B.+Yang&title=Secondary+Pharmacology+Data+to+Assess+Potential+Off-Target+Activity+of+New+Drugs%3A+A+Regulatory+Perspective&doi=10.1038%2Fnrd3845-c1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Secondary pharmacology data to assess potential off-target activity of new drugs: a regulatory perspective</span></div><div class="casAuthors">Papoian, Thomas; Chiu, Haw-Jyh; Elayan, Ikram; Jagadeesh, Gowraganahalli; Khan, Imran; Laniyonu, Adebayo A.; Li, Cindy Xinguang; Saulnier, Muriel; Simpson, Natalie; Yang, Baichun</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">294</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Useful aspects of submitted secondary pharmacol. data.  Detailed aspects of secondary pharmacol. data that are considered to be useful during regulatory safety assessments are summarized in Table 1.  Incorporation of these aspects into secondary pharmacol. study reports not only enhances the quality and regulatory utility of the reports but also decreases uncertainty in decision making owing to misinterpretation of data.  Regulatory assessment of in vitro secondary pharmacol. data.  Various protocols for secondary pharmacol. studies are commonly available and generally consist of binding assays, functional assays and enzyme assays, all of which provide important information regarding the pharmacol. activity of a drug and possible unanticipated side effects that may be seen in humans.  When the data suggest possible off-target activity, the extent of that risk under clin. relevant conditions and drug exposures is carefully assessed, and safety recommendations are made for the proposed clin. studies or addnl. non-clin. studies are requested to help to better understand or reduce the risk.  In our experience, the panels of targets that are employed vary widely and are often selected without justification or a description of their relevance to human safety.  In such cases, a repeat of the study may be recommended using a more appropriate selection of clin. relevant targets.  It is useful to det. whether a drug shares similar off-target activity with other drugs in the class - for example, the sedative and anticholinergic properties of certain histamine H1 receptor antagonists - so that such side effects in humans can be better anticipated and monitored.  Similarly, target panel selection may also include consideration of whether the intended drug target has structural or functional similarity to a related but unintended target.  If such a relationship is found, then clin. consequences of affecting those targets are considered.  Drugs may also possess specificity for, or a mechanism of action linked to, selected targets from a large family of related targets that have structural or functional similarity (for example, the ATP-binding site of protein tyrosine kinases).  In such cases, a broad panel screen of all closely related family members may be useful in distinguishing intended pharmacol. effects from unintended effects.  It is important to understand how findings relate to those obsd. with other members of the drug class or for a certain mechanism of action.  If the findings are similar, then the clin. risk may be considered to be similar as well.  If they are different, however, then further evaluation, such as follow-up in vitro or animal studies focusing on the different targets affected, may be recommended to better define the risk.  Correlations between pos. secondary pharmacol. results and results seen in animals may be used to det. whether in vitro activity translates to possible human risk under therapeutic conditions.  It is important to note that in vitro panels generally use human-specific targets, and in vitro results may not always correlate with those obsd. in animals.  Correlations between in vitro half-maximal inhibitory concn. (IC50) or inhibition const. (Ki) values with in vivo plasma drug levels are also used to assess possible effects at therapeutic exposures.  The closer the IC50 or Ki values are to plasma drug levels, the more likely the clin. effect.  Also considered in this context are local tissue drug concns. at the site of action that may be higher than circulating levels.  Use of focused profiling may be recommended to address specific issues of concern, such as the safety of active drug metabolites or unique major human metabolites not formed in animals but found during subsequent clin. testing.  Even if a compd. produces a pos. in vitro result at therapeutically relevant concns., certain risk-benefit considerations for particular patient populations are taken into account, such as the seriousness of the therapeutic indication and whether potential adverse effects are considered to be reversible.  Case examples of regulatory actions based on pos. off-target activity are provided in Table 2 and include endocrine disruptors, peroxisome proliferator-activated receptor-γ agonists, cardiac (voltage-gated) ion channel protein antagonists, 5-HT2B (serotonin) receptor agonists, ligand-gated ion channel protein (for example, N-methyl-d-aspartate receptor) antagonists and drugs with potential for abuse.  Although not exhaustive, these examples highlight current experience with certain classes and actions of drugs that have resulted in specific regulatory actions based on their potential risk for human safety.  Timing of secondary pharmacol. data submission.  For proper safety assessment, it is advantageous for secondary pharmacol. data to be available with the initial submission to support first-in-human (Phase I) clin. trials.  Such data can also be used to help to interpret clin. findings or adverse drug reactions that occur as drug development proceeds into later phases of clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD40Aby38TPrVg90H21EOLACvtfcHk0ljRRo1R0yibCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVynsrw%253D&md5=69b08c957679ef003271b07fef0d4de5</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd3845-c1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3845-c1%26sid%3Dliteratum%253Aachs%26aulast%3DPapoian%26aufirst%3DT.%26aulast%3DChiu%26aufirst%3DH.%2BJ.%26aulast%3DElayan%26aufirst%3DI.%26aulast%3DJagadeesh%26aufirst%3DG.%26aulast%3DKhan%26aufirst%3DI.%26aulast%3DLaniyonu%26aufirst%3DA.%2BA.%26aulast%3DLi%26aufirst%3DC.%2BX.%26aulast%3DSaulnier%26aufirst%3DM.%26aulast%3DSimpson%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DB.%26atitle%3DSecondary%2520Pharmacology%2520Data%2520to%2520Assess%2520Potential%2520Off-Target%2520Activity%2520of%2520New%2520Drugs%253A%2520A%2520Regulatory%2520Perspective%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D294%26doi%3D10.1038%2Fnrd3845-c1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pridgeon, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duckworth, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E. P.</span></span> <span> </span><span class="NLM_article-title">Stem Cell Models as an in Vitro Model for Predictive Toxicology</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>476</i></span>,  <span class="NLM_fpage">1149</span>– <span class="NLM_lpage">1158</span>, <span class="refDoi"> DOI: 10.1042/BCJ20170780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1042%2FBCJ20170780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=30988136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVWiu77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=476&publication_year=2019&pages=1149-1158&author=S.+Lynchauthor=C.+S.+Pridgeonauthor=C.+A.+Duckworthauthor=P.+Sharmaauthor=B.+K.+Parkauthor=C.+E.+P.+Goldring&title=Stem+Cell+Models+as+an+in+Vitro+Model+for+Predictive+Toxicology&doi=10.1042%2FBCJ20170780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Stem cell models as an in vitro model for predictive toxicology</span></div><div class="casAuthors">Lynch, Stephen; Pridgeon, Chris S.; Duckworth, Carrie A.; Sharma, Parveen; Park, B. Kevin; Goldring, Chris E. P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">476</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1149-1158</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Adverse drug reactions (ADRs) are the unintended side effects of drugs.  They are categorised as either predictable or unpredictable drug-induced injury and may be exhibited after a single or prolonged exposure to one or multiple compds.  Historically, toxicol. studies rely heavily on animal models to understand and characterize the toxicity of novel compds.  However, animal models are imperfect proxies for human toxicity and there have been several high-profile cases of failure of animal models to predict human toxicity e.g. fialuridine, TGN1412 which highlight the need for improved predictive models of human toxicity.  As a result, stem cell-derived models are under investigation as potential models for toxicity during early stages of drug development.  Stem cells retain the genotype of the individual from which they were derived, offering the opportunity to model the reproducibility of rare phenotypes in vitro.  Differentiated 2D stem cell cultures have been investigated as models of hepato- and cardiotoxicity.  However, insufficient maturity, particularly in the case of hepatocyte-like cells, means that their widespread use is not currently a feasible method to tackle the complex issues of off-target and often unpredictable toxicity of novel compds.  This review discusses the current state of the art for modeling clin. relevant toxicities, e.g. cardio- and hepatotoxicity, alongside the emerging need for modeling gastrointestinal toxicity and seeks to address whether stem cell technologies are a potential soln. to increase the accuracy of ADR predictivity in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGqruOzjnry7Vg90H21EOLACvtfcHk0lgW7cK6nKC07g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVWiu77J&md5=f5d313521f2d1f8dbfd500e81861c515</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1042%2FBCJ20170780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBCJ20170780%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DS.%26aulast%3DPridgeon%26aufirst%3DC.%2BS.%26aulast%3DDuckworth%26aufirst%3DC.%2BA.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%2BP.%26atitle%3DStem%2520Cell%2520Models%2520as%2520an%2520in%2520Vitro%2520Model%2520for%2520Predictive%2520Toxicology%26jtitle%3DBiochem.%2520J.%26date%3D2019%26volume%3D476%26spage%3D1149%26epage%3D1158%26doi%3D10.1042%2FBCJ20170780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tarcsay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keseru, G. M.</span></span> <span> </span><span class="NLM_article-title">Contributions of Molecular Properties to Drug Promiscuity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1789</span>– <span class="NLM_lpage">1795</span>, <span class="refDoi"> DOI: 10.1021/jm301514n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301514n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3sXns1ehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1789-1795&author=A.+Tarcsayauthor=G.+M.+Keseru&title=Contributions+of+Molecular+Properties+to+Drug+Promiscuity&doi=10.1021%2Fjm301514n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Contributions of Molecular Properties to Drug Promiscuity</span></div><div class="casAuthors">Tarcsay, Akos; Keseru, Gyorgy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1789-1795</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In contrast to designed polypharmacol. that can result in efficient drugs for complex disorders, unintended drug promiscuity has detrimental contribution to side effects and toxicol.  Characterization of promiscuous compds. enhances the understanding of complex interaction patterns and aids the design of compds. with broader selectivity against off-targets that has a major impact on medicinal chem. outcome.  In this Miniperspective we provide insights to the effect of physicochem. parameters on promiscuity.  Information collected from recent, large-scale in vitro studies enabled us to discuss the relationships between physicochem. properties and promiscuity in detail.  In light of these data, lipophilicity and basic character have the highest influence.  On the basis of the accumulated knowledge, we propose the extensive use of pre- and postsynthesis metrics, as well as strict control of physicochem. properties during medicinal chem. optimizations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf1J_jqkK3DrVg90H21EOLACvtfcHk0lgW7cK6nKC07g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXns1ehug%253D%253D&md5=c5763ee1aed897ff19e5a2344b95b9c1</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm301514n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301514n%26sid%3Dliteratum%253Aachs%26aulast%3DTarcsay%26aufirst%3DA.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26atitle%3DContributions%2520of%2520Molecular%2520Properties%2520to%2520Drug%2520Promiscuity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1789%26epage%3D1795%26doi%3D10.1021%2Fjm301514n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decrescenzo, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devraj, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellsworth, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fobian, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilles, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieger-Burke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loesel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Physiochemical Drug Properties Associated with in Vivo Toxicological Outcomes</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4872</span>– <span class="NLM_lpage">4875</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.07.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.bmcl.2008.07.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=18691886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4872-4875&author=J.+D.+Hughesauthor=J.+Blaggauthor=D.+A.+Priceauthor=S.+Baileyauthor=G.+A.+Decrescenzoauthor=R.+V.+Devrajauthor=E.+Ellsworthauthor=Y.+M.+Fobianauthor=M.+E.+Gibbsauthor=R.+W.+Gillesauthor=N.+Greeneauthor=E.+Huangauthor=T.+Krieger-Burkeauthor=J.+Loeselauthor=T.+Wagerauthor=L.+Whiteleyauthor=Y.+Zhang&title=Physiochemical+Drug+Properties+Associated+with+in+Vivo+Toxicological+Outcomes&doi=10.1016%2Fj.bmcl.2008.07.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Physiochemical drug properties associated with in vivo toxicological outcomes</span></div><div class="casAuthors">Hughes, Jason D.; Blagg, Julian; Price, David A.; Bailey, Simon; DeCrescenzo, Gary A.; Devraj, Rajesh V.; Ellsworth, Edmund; Fobian, Yvette M.; Gibbs, Michael E.; Gilles, Richard W.; Greene, Nigel; Huang, Enoch; Krieger-Burke, Teresa; Loesel, Jens; Wager, Travis; Whiteley, Larry; Zhang, Yao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4872-4875</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Relationships between physicochem. drug properties and toxicity were inferred from a data set consisting of animal in vivo toleration (IVT) studies on 245 preclin. Pfizer compds.; an increased likelihood of toxic events was found for less polar, more lipophilic compds.  This trend held across a wide range of types of toxicity and across a broad swath of chem. space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPMmGEpVF0mbVg90H21EOLACvtfcHk0lgW7cK6nKC07g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE&md5=80ea5ced359112a363f38b3545cd7646</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.071%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DJ.%2BD.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DDecrescenzo%26aufirst%3DG.%2BA.%26aulast%3DDevraj%26aufirst%3DR.%2BV.%26aulast%3DEllsworth%26aufirst%3DE.%26aulast%3DFobian%26aufirst%3DY.%2BM.%26aulast%3DGibbs%26aufirst%3DM.%2BE.%26aulast%3DGilles%26aufirst%3DR.%2BW.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DE.%26aulast%3DKrieger-Burke%26aufirst%3DT.%26aulast%3DLoesel%26aufirst%3DJ.%26aulast%3DWager%26aufirst%3DT.%26aulast%3DWhiteley%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DPhysiochemical%2520Drug%2520Properties%2520Associated%2520with%2520in%2520Vivo%2520Toxicological%2520Outcomes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4872%26epage%3D4875%26doi%3D10.1016%2Fj.bmcl.2008.07.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandrell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairaudeau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennie, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, A.</span></span> <span> </span><span class="NLM_article-title">An Analysis of the Attrition of Drug Candidates from Four Major Pharmaceutical Companies</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1038/nrd4609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fnrd4609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=26091267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=475-486&author=M.+J.+Waringauthor=J.+Arrowsmithauthor=A.+R.+Leachauthor=P.+D.+Leesonauthor=S.+Mandrellauthor=R.+M.+Owenauthor=G.+Pairaudeauauthor=W.+D.+Pennieauthor=S.+D.+Pickettauthor=J.+Wangauthor=O.+Wallaceauthor=A.+Weir&title=An+Analysis+of+the+Attrition+of+Drug+Candidates+from+Four+Major+Pharmaceutical+Companies&doi=10.1038%2Fnrd4609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span></div><div class="casAuthors">Waring, Michael J.; Arrowsmith, John; Leach, Andrew R.; Leeson, Paul D.; Mandrell, Sam; Owen, Robert M.; Pairaudeau, Garry; Pennie, William D.; Pickett, Stephen D.; Wang, Jibo; Wallace, Owen; Weir, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">475-486</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development.  Attempts to reduce the no. of efficacy- and safety-related failures by analyzing possible links to the physicochem. properties of small-mol. drug candidates have been inconclusive because of the limited size of data sets from individual companies.  Here, we describe the compilation and anal. of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer.  The anal. reaffirms that control of physicochem. properties during compd. optimization is beneficial in identifying compds. of candidate drug quality and indicates for the first time a link between the physicochem. properties of compds. and clin. failure due to safety issues.  The results also suggest that further control of physicochem. properties is unlikely to have a significant effect on attrition rates and that addnl. work is required to address safety-related failures.  Further cross-company collaborations will be crucial to future progress in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsLfBWrLC3ZLVg90H21EOLACvtfcHk0ljEpLoVjFSlxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM&md5=1fdc374d32816b1e91438152299dd1b1</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrd4609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4609%26sid%3Dliteratum%253Aachs%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DMandrell%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DR.%2BM.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DPennie%26aufirst%3DW.%2BD.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWallace%26aufirst%3DO.%26aulast%3DWeir%26aufirst%3DA.%26atitle%3DAn%2520Analysis%2520of%2520the%2520Attrition%2520of%2520Drug%2520Candidates%2520from%2520Four%2520Major%2520Pharmaceutical%2520Companies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D475%26epage%3D486%26doi%3D10.1038%2Fnrd4609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T.</span></span> <span> </span><span class="NLM_article-title">Physicochemical Drug Properties Associated with in Vivo Toxicological Outcomes: A Review</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">931</span>, <span class="refDoi"> DOI: 10.1517/17425250903042318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1517%2F17425250903042318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=19519283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovVCjtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=921-931&author=D.+A.+Priceauthor=J.+Blaggauthor=L.+Jonesauthor=N.+Greeneauthor=T.+Wager&title=Physicochemical+Drug+Properties+Associated+with+in+Vivo+Toxicological+Outcomes%3A+A+Review&doi=10.1517%2F17425250903042318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical drug properties associated with in vivo toxicological outcomes: a review</span></div><div class="casAuthors">Price, David A.; Blagg, Julian; Jones, Lyn; Greene, Nigel; Wager, Travis</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">921-931</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The genesis of any toxicol. or safety outcome is multifactorial and complex; for this reason, it can be difficult for drug discovery projects to factor the avoidance of toxicity outcomes into their target design.  A focus on readily measurable parameters from high-throughput in vitro assays (e.g., primary potency, clearance) is easier to handle and have become the mainstays of drug discovery projects.  However, the fundamental origins of adverse safety or toxicity findings can be considered as deriving from four parameters, all of which are in the control of the drug designer.  These can be described as primary pharmacol., off target pharmacol., the presence of a defined structural fragment that can be assocd. with adverse outcomes and the overall physicochem. properties of the mol. that may predispose it to adverse outcomes.  In the drug discovery community, there has been recognition for many years of the influence of physicochem. drug properties (in particular lipophilicity) on the toxicol. profile of compds., and recent research is now beginning to quantify that risk in a probabilistic sense.  This review focuses on the overall properties of classes of mols. that are assocd. with an increased probability of adverse outcomes in in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU8kwwUsaFIrVg90H21EOLACvtfcHk0ljEpLoVjFSlxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovVCjtb0%253D&md5=bd1cca3634afda14de2f8aa115d7d55e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1517%2F17425250903042318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425250903042318%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DL.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DWager%26aufirst%3DT.%26atitle%3DPhysicochemical%2520Drug%2520Properties%2520Associated%2520with%2520in%2520Vivo%2520Toxicological%2520Outcomes%253A%2520A%2520Review%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2009%26volume%3D5%26spage%3D921%26epage%3D931%26doi%3D10.1517%2F17425250903042318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span>Eurofins.
Cerep. <a href="https://www.eurofins.com/contact-us/worldwide-interactive-map/france/eurofins-cerep-france/" class="extLink">https://www.eurofins.com/contact-us/worldwide-interactive-map/france/eurofins-cerep-france/</a> (accessed Aug 29, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Eurofins.%0ACerep.+https%3A%2F%2Fwww.eurofins.com%2Fcontact-us%2Fworldwide-interactive-map%2Ffrance%2Feurofins-cerep-france%2F+%28accessed+Aug+29%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruneau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, N. R.</span></span> <span> </span><span class="NLM_article-title">Logd7.4 Modeling Using Bayesian Regularized Neural Networks. Assessment and Correction of the Errors of Prediction</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1379</span>– <span class="NLM_lpage">1387</span>, <span class="refDoi"> DOI: 10.1021/ci0504014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci0504014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlars73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=1379-1387&author=P.+Bruneauauthor=N.+R.+McElroy&title=Logd7.4+Modeling+Using+Bayesian+Regularized+Neural+Networks.+Assessment+and+Correction+of+the+Errors+of+Prediction&doi=10.1021%2Fci0504014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">logD7.4 Modeling Using Bayesian Regularized Neural Networks. Assessment and Correction of the Errors of Prediction</span></div><div class="casAuthors">Bruneau, Pierre; McElroy, Nathan R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1379-1387</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bayesian Regularized Neural Networks (BRNNs) employing Automatic Relevance Detn. (ARD) are used to construct a predictive model for the distribution coeff. logD7.4 from an inhouse data set of 5000 compds. with exptl. endpoints.  A method for assessing the accuracy of prediction is established based upon a query compd.'s distance to the training set. logD7.4 predictions are also dynamically cor. with an assocd. library of compds. of continuously updated, exptl. measured logD7.4 values.  A comparison of local models and assocd. libraries comprising sep. ionization class subsets of compds. to compds. of a homogeneous ionization class reveals in this case that local models and libraries have no advantage over global models and libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5roy_pM8ZtLVg90H21EOLACvtfcHk0ljEpLoVjFSlxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlars73N&md5=9ce727349c66a515585debf55631a85c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fci0504014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci0504014%26sid%3Dliteratum%253Aachs%26aulast%3DBruneau%26aufirst%3DP.%26aulast%3DMcElroy%26aufirst%3DN.%2BR.%26atitle%3DLogd7.4%2520Modeling%2520Using%2520Bayesian%2520Regularized%2520Neural%2520Networks.%2520Assessment%2520and%2520Correction%2520of%2520the%2520Errors%2520of%2520Prediction%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2006%26volume%3D46%26spage%3D1379%26epage%3D1387%26doi%3D10.1021%2Fci0504014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1701</span>– <span class="NLM_lpage">1714</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00686</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00686" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslait73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1701-1714&author=M.+D.+Shultz&title=Two+Decades+under+the+Influence+of+the+Rule+of+Five+and+the+Changing+Properties+of+Approved+Oral+Drugs&doi=10.1021%2Facs.jmedchem.8b00686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1701-1714</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two decades have passed since the rule of five ushered in the concept of "drug-like" properties.  Attempts to quantify, correlate, and categorize mols. based on Ro5 parameters evolved into the introduction of efficiency metrics with far reaching consequences in decision making by industry leaders and scientists seeking to discover new medicines.  Examn. of oral drug parameters approved before and after the original Ro5 anal. demonstrates that some parameters such as clogP and HBD remained const. while the cutoffs for parameters such as mol. wt. and HBA have increased substantially over the past 20 years.  The time dependent increase in the mol. wt. of oral drugs during the past 20 years provides compelling evidence to disprove the hypothesis that mol. wt. is a "drug-like" property.  This anal. does not validate parameters that have not changed as being "drug-like" but instead calls into question the entire hypothesis that "drug-like" properties exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAnoxpQsv2kbVg90H21EOLACvtfcHk0lh43OUCB11lQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslait73K&md5=d3c8b1107133dc0b7b277d22fa029597</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00686%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DTwo%2520Decades%2520under%2520the%2520Influence%2520of%2520the%2520Rule%2520of%2520Five%2520and%2520the%2520Changing%2520Properties%2520of%2520Approved%2520Oral%2520Drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1701%26epage%3D1714%26doi%3D10.1021%2Facs.jmedchem.8b00686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bostrom, J.</span></span> <span> </span><span class="NLM_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9442</span>– <span class="NLM_lpage">9468</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00675</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00675" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFKhsb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9442-9468&author=D.+G.+Brownauthor=J.+Bostrom&title=Where+Do+Recent+Small+Molecule+Clinical+Development+Candidates+Come+From%3F&doi=10.1021%2Facs.jmedchem.8b00675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Where Do Recent Small Molecule Clinical Development Candidates Come From?</span></div><div class="casAuthors">Brown, Dean G.; Bostrom, Jonas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9442-9468</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An anal. of 66 published clin. candidates from Journal of Medicinal Chem. has been conducted to shed light on which lead generation strategies are most frequently employed in identifying drug candidates.  The most frequent lead generation strategy (producing a drug candidate) was based on starting points derived from previously known compds. (43%) followed by random high throughput screening (29%).  The remainder of approaches included focused screening, structure-based drug design (SBDD), fragment-based lead generation (FBLG), and DNA-encoded library screening (DEL).  An anal. of physicochem. properties on the hit-to-clin. pairs shows an av. increase in mol. wt. (ΔMW = +85) but no change in lipophilicity (ΔclogP = -0.2), although exceptions are noted.  The majority (>50%) of clin. candidates were found to be structurally very different from their starting point and were more complex.  Finally, several reports of noncovalent scaffolds modified by a covalent warhead using SBDD approaches are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKVZOYYj87bLVg90H21EOLACvtfcHk0lh43OUCB11lQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFKhsb7F&md5=211341fa12156e9512650d3352893a5e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DBostrom%26aufirst%3DJ.%26atitle%3DWhere%2520Do%2520Recent%2520Small%2520Molecule%2520Clinical%2520Development%2520Candidates%2520Come%2520From%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9442%26epage%3D9468%26doi%3D10.1021%2Facs.jmedchem.8b00675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fredholm, B. B.</span></span> <span> </span><span class="NLM_article-title">Adenosine, an Endogenous Distress Signal, Modulates Tissue Damage and Repair</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1315</span>– <span class="NLM_lpage">1323</span>, <span class="refDoi"> DOI: 10.1038/sj.cdd.4402132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fsj.cdd.4402132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=17396131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1Srurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=1315-1323&author=B.+B.+Fredholm&title=Adenosine%2C+an+Endogenous+Distress+Signal%2C+Modulates+Tissue+Damage+and+Repair&doi=10.1038%2Fsj.cdd.4402132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine, an endogenous distress signal, modulates tissue damage and repair</span></div><div class="casAuthors">Fredholm, B. B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1315-1323</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Adenosine is formed inside cells or on their surface, mostly by breakdown of adenine nucleotides.  The formation of adenosine increases in different conditions of stress and distress.  Adenosine acts on four G-protein coupled receptors: two of them, A1 and A3, are primarily coupled to Gi family G proteins; and two of them, A2A and A2B, are mostly coupled to Gs like G proteins.  These receptors are antagonized by xanthines including caffeine.  Via these receptors it affects many cells and organs, usually having a cytoprotective function.  Joel Linden recently grouped these protective effects into four general modes of action: increased oxygen supply/demand ratio, preconditioning, anti-inflammatory effects and stimulation of angiogenesis.  This review will briefly summarize what is known and what is not in this regard.  It is argued that drugs targeting adenosine receptors might be useful adjuncts in many therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp106BDv5VC-7Vg90H21EOLACvtfcHk0lh43OUCB11lQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1Srurk%253D&md5=5e956ac2260cf45e9a93971094afd18a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fsj.cdd.4402132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cdd.4402132%26sid%3Dliteratum%253Aachs%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26atitle%3DAdenosine%252C%2520an%2520Endogenous%2520Distress%2520Signal%252C%2520Modulates%2520Tissue%2520Damage%2520and%2520Repair%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2007%26volume%3D14%26spage%3D1315%26epage%3D1323%26doi%3D10.1038%2Fsj.cdd.4402132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mirza, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, R. G.</span></span> <span> </span><span class="NLM_article-title">Xanomeline and the Antipsychotic Potential of Muscarinic Receptor Subtype Selective Agonists</span>. <i>CNS Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3458.2003.tb00247.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1111%2Fj.1527-3458.2003.tb00247.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=12847557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsl2qt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=159-186&author=N.+R.+Mirzaauthor=D.+Petersauthor=R.+G.+Sparks&title=Xanomeline+and+the+Antipsychotic+Potential+of+Muscarinic+Receptor+Subtype+Selective+Agonists&doi=10.1111%2Fj.1527-3458.2003.tb00247.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists</span></div><div class="casAuthors">Mirza, Naheed R.; Peters, Dan; Sparks, Robin G.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drug Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-186</span>CODEN:
                <span class="NLM_cas:coden">CDREFB</span>;
        ISSN:<span class="NLM_cas:issn">1080-563X</span>.
    
            (<span class="NLM_cas:orgname">Neva Press</span>)
        </div><div class="casAbstract">A review.  Binding studies initially suggested that the muscarinic agonist, xanomeline, was a subtype selective muscarinic M1 receptor agonist, and a potential new treatment for Alzheimer's disease.  However, later in vitro and in vivo functional studies suggest that this compd. is probably better described as a subtype selective M1/M4 muscarinic receptor agonist.  This subtype selectivity profile has been claimed to explain the limited classical cholinomimetic side effects, particularly gastrointestinal, seen with xanomeline in animals.  However, in both healthy volunteers and Alzheimer's patients many of these side effects have been reported for xanomeline and in the patient population this led to a >50% discontinuation rate.  Clearly, the preclin. studies have not been able to predict this adverse profile of xanomeline, and this suggests that either xanomeline is not as subtype selective as predicted from preclin. research or that there are differences between humans and animals with regard to muscarinic receptors.  Nevertheless, in Alzheimer's patients xanomeline dose-dependently improves aspects of behavioral disturbance and social behavior including a redn. in hallucinations, agitation, delusions, vocal outbursts and suspiciousness.  The effects on cognition are not as robust and mainly seen at the highest doses tested.  These effects in Alzheimer's patients have given impetus to the suggestion that muscarinic agonists have potential antipsychotic effects.  The current review assesses the antipsychotic profile of xanomeline within the framework of the limited clin. studies with cholinergic agents in man, and the preclin. research on xanomeline using various models commonly used for the assessment of new antipsychotic drugs.  In general, xanomeline has an antipsychotic-like profile in various dopamine models of psychosis and this agrees with the known interactions between the cholinergic and dopaminergic systems in the brain.  Moreover, current data suggests that the actions of xanomeline at the M4 muscarinic receptor subtype might mediate its antidopaminergic effects.  Particularly intriguing are studies showing that xanomeline, even after acute administration, selectively inhibits the firing of mesolimbic dopamine cells relative to dopamine cell bodies projecting to the striatum.  This data suggest that xanomeline would have a faster onset of action compared to current antipsychotics and would not induce extrapyramidal side effects.  The preclin. data on the whole are promising for an antipsychotic-like profile.  If in a new formulation (i.e., transdermal) xanomeline has less adverse effects, this drug may be valuable in the treatment of patients with psychosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvVnKMP2LfgbVg90H21EOLACvtfcHk0liGxHDAkpHWrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsl2qt7o%253D&md5=cf96dec926979e17599b2673a49f11c2</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2003.tb00247.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2003.tb00247.x%26sid%3Dliteratum%253Aachs%26aulast%3DMirza%26aufirst%3DN.%2BR.%26aulast%3DPeters%26aufirst%3DD.%26aulast%3DSparks%26aufirst%3DR.%2BG.%26atitle%3DXanomeline%2520and%2520the%2520Antipsychotic%2520Potential%2520of%2520Muscarinic%2520Receptor%2520Subtype%2520Selective%2520Agonists%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2003%26volume%3D9%26spage%3D159%26epage%3D186%26doi%3D10.1111%2Fj.1527-3458.2003.tb00247.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melancon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarr, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panarese, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span> <span> </span><span class="NLM_article-title">Allosteric Modulation of the M1 Muscarinic Acetylcholine Receptor: Improving Cognition and a Potential Treatment for Schizophrenia and Alzheimer’s Disease</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1185</span>– <span class="NLM_lpage">1199</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.drudis.2013.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=24051397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslSmu7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=1185-1199&author=B.+J.+Melanconauthor=J.+C.+Tarrauthor=J.+D.+Panareseauthor=M.+R.+Woodauthor=C.+W.+Lindsley&title=Allosteric+Modulation+of+the+M1+Muscarinic+Acetylcholine+Receptor%3A+Improving+Cognition+and+a+Potential+Treatment+for+Schizophrenia+and+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.drudis.2013.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease</span></div><div class="casAuthors">Melancon, Bruce J.; Tarr, James C.; Panarese, Joseph D.; Wood, Michael R.; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">1185-1199</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Allosteric modulation of AMPA, NR2B, mGlu2, mGlu5 and M1, targeting glutamatergic dysfunction, represents a significant area of research for the treatment of schizophrenia.  Of these targets, clin. promise has been demonstrated using muscarinic activators for the treatment of Alzheimer's disease (AD) and schizophrenia.  These diseases have inspired researchers to det. the effects of modulating cholinergic transmission in the forebrain, which is primarily regulated by one of five subtypes of muscarinic acetylcholine receptor (mAChR), a subfamily of G-protein-coupled receptors (GPCRs).  Of these five subtypes, M1 is highly expressed in brain regions responsible for learning, cognition and memory.  Xanomeline, an orthosteric muscarinic agonist with modest selectivity, was one of the first compds. that displayed improvements in behavioral disturbances in AD patients and efficacy in schizophrenics.  Since these initial clin. results, many scientists, including those in our labs., have strived to elucidate the role of M1 with compds. that display improved selectivity for this receptor by targeting allosteric modes of receptor activation.  A survey of selected compds. in this area will be presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxxLAJQLkeE7Vg90H21EOLACvtfcHk0liGxHDAkpHWrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslSmu7nL&md5=51ee8b978d708b7ddbcbde3fe3e72f50</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DMelancon%26aufirst%3DB.%2BJ.%26aulast%3DTarr%26aufirst%3DJ.%2BC.%26aulast%3DPanarese%26aufirst%3DJ.%2BD.%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DAllosteric%2520Modulation%2520of%2520the%2520M1%2520Muscarinic%2520Acetylcholine%2520Receptor%253A%2520Improving%2520Cognition%2520and%2520a%2520Potential%2520Treatment%2520for%2520Schizophrenia%2520and%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D1185%26epage%3D1199%26doi%3D10.1016%2Fj.drudis.2013.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clader, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Muscarinic Receptor Agonists and Antagonists in the Treatment of Alzheimer’s Disease</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3353</span>– <span class="NLM_lpage">3361</span>, <span class="refDoi"> DOI: 10.2174/138161205774370762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.2174%2F138161205774370762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=16250841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWrs7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=3353-3361&author=J.+W.+Claderauthor=Y.+Wang&title=Muscarinic+Receptor+Agonists+and+Antagonists+in+the+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.2174%2F138161205774370762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease</span></div><div class="casAuthors">Clader, John W.; Wang, Yuguang</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3353-3361</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  One of the consistent findings in the brains of Alzheimer's Disease (AD) patients is loss of cholinergic function.  The cholinergic approach to treatment of AD involves counteracting this loss in cholinergic activity by pharmacol. intervention to increase cholinergic transmission.  The cognitive effects of acetylcholine are mediated via the muscarinic M1 receptor.  Direct stimulation of this receptor using muscarinic M1 agonists improves cognition in animal models and improves performance in cognitive tests in Alzheimer's patients.  Alternatively, antagonists of central presynaptic M2 receptors improves cognition by increasing the central release of acetylcholine.  Both approaches require high selectivity for one muscarinic receptor sub-type both for efficacy and to avoid cholinergic side effects.  In this review summarizes recent progress in the identification and characterization of selective muscarinic receptor ligands for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2_wdSDisNRLVg90H21EOLACvtfcHk0liGxHDAkpHWrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWrs7vP&md5=d0d18c0299921abfbf6b815b223e743a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F138161205774370762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161205774370762%26sid%3Dliteratum%253Aachs%26aulast%3DClader%26aufirst%3DJ.%2BW.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DMuscarinic%2520Receptor%2520Agonists%2520and%2520Antagonists%2520in%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2005%26volume%3D11%26spage%3D3353%26epage%3D3361%26doi%3D10.2174%2F138161205774370762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alagha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofalvi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouitaa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charpin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanez, P.</span></span> <span> </span><span class="NLM_article-title">Long-Acting Muscarinic Receptor Antagonists for the Treatment of Chronic Airway Diseases</span>. <i>Ther. Adv. Chronic Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1177/2040622313518227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1177%2F2040622313518227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=24587893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1OntLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=85-98&author=K.+Alaghaauthor=A.+Palotauthor=T.+Sofalviauthor=L.+Pahusauthor=M.+Gouitaaauthor=C.+Tumminoauthor=S.+Martinezauthor=D.+Charpinauthor=A.+Bourdinauthor=P.+Chanez&title=Long-Acting+Muscarinic+Receptor+Antagonists+for+the+Treatment+of+Chronic+Airway+Diseases&doi=10.1177%2F2040622313518227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases</span></div><div class="casAuthors">Alagha, Khuder; Palot, Alain; Sofalvi, Tunde; Pahus, Laurie; Gouitaa, Marion; Tummino, Celine; Martinez, Stephanie; Charpin, Denis; Bourdin, Arnaud; Chanez, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Chronic Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-98, 14</span>CODEN:
                <span class="NLM_cas:coden">TACDCS</span>;
        ISSN:<span class="NLM_cas:issn">2040-6223</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Acetylcholine (neuronal and non-neuronal origin) regulates bronchoconstriction, and mucus secretion.  It has an inflammatory effect by inducing attraction, survival and cytokine release from inflammatory cells.  Muscarinic receptors throughout the bronchial tree are mainly restricted to muscarinic M1, M2 and M3 receptors.  Three long-acting muscarinic receptor antagonists (LAMAs) were approved for the treatment of chronic obstructive pulmonary disease (COPD) in Europe: once-daily tiotropium bromide; once-daily glycopyrronium bromide; and twice-daily aclidinium bromide.  All have higher selectivity for M3 receptors than for M2 receptors, and dissoc. more slowly from the M3 receptors than they do from the M2 receptors.  Some LAMAs showed anti-inflammatory effects [inhibition of neutrophil chemotactic activity and migration of alveolar neutrophils, decrease of several cytokines in the bronchoalveolar lavage (BAL) including interleukin (IL)-6, tumor necrosis factor (TNF)-α and leukotriene (LT)B4] and antiremodeling effects (inhibition of mucus gland hypertrophy and decrease in MUC5AC-pos. goblet cell no., decrease in MUC5AC overexpression).  In the clinic, LAMAs showed a significant improvement of forced expiratory vol. in 1 s (FEV1), quality of life, dyspnea and reduced the no. of exacerbations in COPD and more recently in asthma.  This review will focus on the three LAMAs approved in Europe in the treatment of chronic airway diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVv9hvW4HRY7Vg90H21EOLACvtfcHk0lhd2nq0a8a3tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1OntLjF&md5=4f1bf29c29adced609e3c61c36cec938</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1177%2F2040622313518227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040622313518227%26sid%3Dliteratum%253Aachs%26aulast%3DAlagha%26aufirst%3DK.%26aulast%3DPalot%26aufirst%3DA.%26aulast%3DSofalvi%26aufirst%3DT.%26aulast%3DPahus%26aufirst%3DL.%26aulast%3DGouitaa%26aufirst%3DM.%26aulast%3DTummino%26aufirst%3DC.%26aulast%3DMartinez%26aufirst%3DS.%26aulast%3DCharpin%26aufirst%3DD.%26aulast%3DBourdin%26aufirst%3DA.%26aulast%3DChanez%26aufirst%3DP.%26atitle%3DLong-Acting%2520Muscarinic%2520Receptor%2520Antagonists%2520for%2520the%2520Treatment%2520of%2520Chronic%2520Airway%2520Diseases%26jtitle%3DTher.%2520Adv.%2520Chronic%2520Dis.%26date%3D2014%26volume%3D5%26spage%3D85%26epage%3D98%26doi%3D10.1177%2F2040622313518227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campeau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olshansky, B.</span></span> <span> </span><span class="NLM_article-title">Cardiac Effects of Muscarinic Receptor Antagonists Used for Voiding Dysfunction</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2010.03813.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1111%2Fj.1365-2125.2010.03813.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=21595741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2011&pages=186-196&author=K.+E.+Anderssonauthor=L.+Campeauauthor=B.+Olshansky&title=Cardiac+Effects+of+Muscarinic+Receptor+Antagonists+Used+for+Voiding+Dysfunction&doi=10.1111%2Fj.1365-2125.2010.03813.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction</span></div><div class="casAuthors">Andersson, Karl-Erik; Campeau, Lysanne; Olshansky, Brian</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">186-196</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Antimuscarinic agents are the main drugs used to treat patients with the overactive bladder (OAB) syndrome, defined as urgency, with or without urgency incontinence, usually with increased daytime frequency and nocturia.  Since the treatment is not curative and since OAB is a chronic disease, treatment may be life-long.  Antimuscarinics are generally considered to be 'safe' drugs, but among the more serious concerns related to their use is the risk of cardiac adverse effects, particularly increases in heart rate (HR) and QT prolongation and induction of polymorphic ventricular tachycardia (torsade de pointes).  An elevated resting HR has been linked to overall increased morbidity and mortality, particularly in patients with cardiovascular diseases.  QT prolongation and its consequences are not related to blockade of muscarinic receptors, but rather linked to inhibition of the hERG potassium channel in the heart.  However, experience with terodiline, an antimuscarinic drug causing torsade de pointes in patients, has placed the whole drug class under scrutiny.  The potential of the different antimuscarinic agents to increase HR and/or prolong the QT time has not been extensively explored for all agents in clin. use.  Differences between drugs cannot be excluded, but risk assessments based on available evidence are not possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBGT557LD7g7Vg90H21EOLACvtfcHk0lhd2nq0a8a3tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtr3M&md5=1b0aa6a5b96a687bb2fc92ddcaef315d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2010.03813.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2010.03813.x%26sid%3Dliteratum%253Aachs%26aulast%3DAndersson%26aufirst%3DK.%2BE.%26aulast%3DCampeau%26aufirst%3DL.%26aulast%3DOlshansky%26aufirst%3DB.%26atitle%3DCardiac%2520Effects%2520of%2520Muscarinic%2520Receptor%2520Antagonists%2520Used%2520for%2520Voiding%2520Dysfunction%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D72%26spage%3D186%26epage%3D196%26doi%3D10.1111%2Fj.1365-2125.2010.03813.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giovannitti, J. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoms, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span> <span> </span><span class="NLM_article-title">Alpha-2 Adrenergic Receptor Agonists: A Review of Current Clinical Applications</span>. <i>Anesth Prog.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.2344/0003-3006-62.1.31</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.2344%2F0003-3006-62.1.31" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=25849473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BC2MjitVWqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=31-39&author=J.+A.+Giovannittiauthor=S.+M.+Thomsauthor=J.+J.+Crawford&title=Alpha-2+Adrenergic+Receptor+Agonists%3A+A+Review+of+Current+Clinical+Applications&doi=10.2344%2F0003-3006-62.1.31"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Alpha-2 adrenergic receptor agonists: a review of current clinical applications</span></div><div class="casAuthors">Giovannitti Joseph A Jr; Thoms Sean M; Crawford James J</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesia progress</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-9</span>
        ISSN:<span class="NLM_cas:issn">0003-3006</span>.
    </div><div class="casAbstract">The α-2 adrenergic receptor agonists have been used for decades to treat common medical conditions such as hypertension; attention-deficit/hyperactivity disorder; various pain and panic disorders; symptoms of opioid, benzodiazepine, and alcohol withdrawal; and cigarette craving. (1) However, in more recent years, these drugs have been used as adjuncts for sedation and to reduce anesthetic requirements.  This review will provide an historical perspective of this drug class, an understanding of pharmacological mechanisms, and an insight into current applications in clinical anesthesiology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQYy161IaNwq5WtyewyzkyLfW6udTcc2eZ--riZPvEa4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjitVWqug%253D%253D&md5=b2fa50caf320cec6dd2bd17d15e7a8f2</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2344%2F0003-3006-62.1.31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2344%252F0003-3006-62.1.31%26sid%3Dliteratum%253Aachs%26aulast%3DGiovannitti%26aufirst%3DJ.%2BA.%26aulast%3DThoms%26aufirst%3DS.%2BM.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26atitle%3DAlpha-2%2520Adrenergic%2520Receptor%2520Agonists%253A%2520A%2520Review%2520of%2520Current%2520Clinical%2520Applications%26jtitle%3DAnesth%2520Prog.%26date%3D2015%26volume%3D62%26spage%3D31%26epage%3D39%26doi%3D10.2344%2F0003-3006-62.1.31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, L. S.</span></span> <span> </span><span class="NLM_article-title">Phentolamine Therapy for Cocaine-Association Acute Coronary Syndrome (Caacs)</span>. <i>J. Med. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">108</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1007/BF03161019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1007%2FBF03161019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=18072128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BD2sjjsFSrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=108-111&author=G.+M.+Chanauthor=R.+Sharmaauthor=D.+Priceauthor=R.+S.+Hoffmanauthor=L.+S.+Nelson&title=Phentolamine+Therapy+for+Cocaine-Association+Acute+Coronary+Syndrome+%28Caacs%29&doi=10.1007%2FBF03161019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Phentolamine therapy for cocaine-association acute coronary syndrome (CAACS)</span></div><div class="casAuthors">Chan Gar Ming; Sharma Rahul; Price Dennis; Hoffman Robert S; Nelson Lewis S</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medical toxicology : official journal of the American College of Medical Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">108-11</span>
        ISSN:<span class="NLM_cas:issn">1556-9039</span>.
    </div><div class="casAbstract">INTRODUCTION:  The emergency department (ED) evaluation of cocaine-associated acute coronary syndrome (CAACS) is often a diagnostic and therapeutic challenge.  CASE REPORT:  We are reporting on the treatment of a patient with cocaine-associated acute coronary syndrome (CAACS) who did not benefit from standard therapy, but who eventually responded positively to phentolamine, an alpha-adrenergic receptor antagonist.  DISCUSSION:  This report should encourage physicians to add phentolamine to their pharmacotherapeutic armamentarium in the treatment of CAACS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSDnWJ92eNBADdblLE_E9PWfW6udTcc2eZ--riZPvEa4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjjsFSrsw%253D%253D&md5=715c4dbf7cf0fa6548c0ab8f3ec7cabf</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2FBF03161019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03161019%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DG.%2BM.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DPrice%26aufirst%3DD.%26aulast%3DHoffman%26aufirst%3DR.%2BS.%26aulast%3DNelson%26aufirst%3DL.%2BS.%26atitle%3DPhentolamine%2520Therapy%2520for%2520Cocaine-Association%2520Acute%2520Coronary%2520Syndrome%2520%2528Caacs%2529%26jtitle%3DJ.%2520Med.%2520Toxicol.%26date%3D2006%26volume%3D2%26spage%3D108%26epage%3D111%26doi%3D10.1007%2FBF03161019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltracco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vittorio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neto, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabrini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zangrillo, A.</span></span> <span> </span><span class="NLM_article-title">Dexmedetomidine as a Sedative Agent in Critically Ill Patients: A Meta-Analysis of Randomized Controlled Trials</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e82913</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0082913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1371%2Fjournal.pone.0082913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=24391726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2cXis1WjsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=L.+Pasinauthor=T.+Grecoauthor=P.+Feltraccoauthor=A.+Vittorioauthor=C.+N.+Netoauthor=L.+Cabriniauthor=G.+Landoniauthor=G.+Fincoauthor=A.+Zangrillo&title=Dexmedetomidine+as+a+Sedative+Agent+in+Critically+Ill+Patients%3A+A+Meta-Analysis+of+Randomized+Controlled+Trials&doi=10.1371%2Fjournal.pone.0082913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Dexmedetomidine as a sedative agent in critically ill patients: a meta-analysis of randomized controlled trials</span></div><div class="casAuthors">Pasin, Laura; Greco, Teresa; Feltracco, Paolo; Vittorio, Annalisa; Nigro Neto, Caetano; Cabrini, Luca; Landoni, Giovanni; Finco, Gabriele; Zangrillo, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e82913/1-e82913/13, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Introduction: The effect of dexmedetomidine on length of intensive care unit (ICU) stay and time to extubation is still unclear.  Materials and Methods: Pertinent studies were independently searched in BioMedCentral, PubMed, Embase, and the Cochrane Central Register of clin. trials.  Randomized studies (dexmedetomidine vs. any comparator) were included if including patients mech. ventilated in an intensive care unit (ICU).  Co-primary endpoints were the length of ICU stay (days) and time to extubation (hours).  Secondary endpoint was mortality rate at the longest follow-up available.  Results: The 27 included manuscripts (28 trials) randomized 3,648 patients (1,870 to dexmedetomidine and 1,778 to control).  Overall anal. showed that the use of dexmedetomidine was assocd. with a significant redn. in length of ICU stay (weighted mean difference (WMD) = -0.79 [-1.17 to -0.40] days, p for effect <0.001) and of time to extubation (WMD = -2.74 [-3.80 to -1.65] hours, p for effect <0.001).  Mortality was not different between dexmedetomidine and controls (risk ratio = 1.00 [0.84 to 1.21], p for effect = 0.9).  High heterogeneity between included studies was found.  Conclusions: This meta-anal. of randomized controlled studies suggests that dexmedetomidine could help to reduce ICU stay and time to extubation, in critically ill patients even if high heterogeneity between studies might confound the interpretation of these results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxK6BE_H7lnrVg90H21EOLACvtfcHk0ljlWr0LW3fAWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXis1WjsLo%253D&md5=3456cd6f9181d2142ab24a279d1f33c9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0082913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0082913%26sid%3Dliteratum%253Aachs%26aulast%3DPasin%26aufirst%3DL.%26aulast%3DGreco%26aufirst%3DT.%26aulast%3DFeltracco%26aufirst%3DP.%26aulast%3DVittorio%26aufirst%3DA.%26aulast%3DNeto%26aufirst%3DC.%2BN.%26aulast%3DCabrini%26aufirst%3DL.%26aulast%3DLandoni%26aufirst%3DG.%26aulast%3DFinco%26aufirst%3DG.%26aulast%3DZangrillo%26aufirst%3DA.%26atitle%3DDexmedetomidine%2520as%2520a%2520Sedative%2520Agent%2520in%2520Critically%2520Ill%2520Patients%253A%2520A%2520Meta-Analysis%2520of%2520Randomized%2520Controlled%2520Trials%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0082913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neil, M. J. E.</span></span> <span> </span><span class="NLM_article-title">Clonidine: Clinical Pharmacology and Therapeutic Use in Pain Management</span>. <i>Curr. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">280</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.2174/157488411798375886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.2174%2F157488411798375886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=21827389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=280-287&author=M.+J.+E.+Neil&title=Clonidine%3A+Clinical+Pharmacology+and+Therapeutic+Use+in+Pain+Management&doi=10.2174%2F157488411798375886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Clonidine: clinical pharmacology and therapeutic use in pain management</span></div><div class="casAuthors">Neil, Michael J. E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">280-287</span>CODEN:
                <span class="NLM_cas:coden">CCPUC5</span>;
        ISSN:<span class="NLM_cas:issn">1574-8847</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Pain is an unpleasant sensory perception warning of actual or impending tissue damage.  Pain serves a vital physiol. role, however, severe and uncontrolled pain in the peri-operative setting can adversely affect outcome from surgery and lead to chronic pain.  Multiple neurochem. and receptor processes are involved in pain perception but the role of pro-inflammatory cytokines and adrenergic pathways has only recently been recognized.  Clonidine is an agonist at the alpha2-adrenergic receptor that has been in clin. use for over 40 years.  Clonidine was recognized at an early stage as having analgesic properties however its systemic use was frequently limited by side-effects.  Recent advances in anesthetic practice, allowing more targeted drug delivery and a better understanding of the basic physiol. of pain have led to a re-evaluation of the role of clonidine in pain management.  Exptl. and clin. studies have identified a diverse action of clonidine in modifying not only the adrenergic component to pain perception but also an important effect on modifying the neurohumoral response to tissue injury.  This has implications for the management of a diverse range of pain problems and potentially offers a method of preventing the transition from acute to chronic pain.  Clonidine is likely to play an increasing role in clin. practice in anesthetics and pain management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVkkNR2hwrs7Vg90H21EOLACvtfcHk0lgBcAot2Oqjdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVGrsbo%253D&md5=971e8635ed85ca18ba6f3b88b184179e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F157488411798375886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488411798375886%26sid%3Dliteratum%253Aachs%26aulast%3DNeil%26aufirst%3DM.%2BJ.%2BE.%26atitle%3DClonidine%253A%2520Clinical%2520Pharmacology%2520and%2520Therapeutic%2520Use%2520in%2520Pain%2520Management%26jtitle%3DCurr.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D6%26spage%3D280%26epage%3D287%26doi%3D10.2174%2F157488411798375886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zamponi, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Striessnig, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koschak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolphin, A. C.</span></span> <span> </span><span class="NLM_article-title">The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">870</span>, <span class="refDoi"> DOI: 10.1124/pr.114.009654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1124%2Fpr.114.009654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=26362469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC28Xns1Gms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=821-870&author=G.+W.+Zamponiauthor=J.+Striessnigauthor=A.+Koschakauthor=A.+C.+Dolphin&title=The+Physiology%2C+Pathology%2C+and+Pharmacology+of+Voltage-Gated+Calcium+Channels+and+Their+Future+Therapeutic+Potential&doi=10.1124%2Fpr.114.009654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential</span></div><div class="casAuthors">Zamponi, Gerald W.; Striessnig, Joerg; Koschak, Alexandra; Dolphin, Annette C.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">821-870</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Voltage-gated calcium channels are required for many key functions in the body.  In this review, the different subtypes of voltage-gated calcium channels are described and their physiol. roles and pharmacol. are outlined.  We describe the current uses of drugs interacting with the different calcium channel subtypes and subunits, as well as specific areas in which there is strong potential for future drug development.  Current therapeutic agents include drugs targeting L-type CaV1.2 calcium channels, particularly 1,4-dihydropyridines, which are widely used in the treatment of hypertension.  T-type (CaV3) channels are a target of ethosuximide, widely used in absence epilepsy.  The auxiliary subunit α2δ-1 is the therapeutic target of the gabapentinoid drugs, which are of value in certain epilepsies and chronic neuropathic pain.  The limited use of intrathecal ziconotide, a peptide blocker of N-type (CaV2.2) calcium channels, as a treatment of intractable pain, gives an indication that these channels represent excellent drug targets for various pain conditions.  We describe how selectivity for different subtypes of calcium channels (e.g., CaV1.2 and CaV1.3 L-type channels) may be achieved in the future by exploiting differences between channel isoforms in terms of sequence and biophys. properties, variation in splicing in different target tissues, and differences in the properties of the target tissues themselves in terms of membrane potential or firing frequency.  Thus, use-dependent blockers of the different isoforms could selectively block calcium channels in particular pathologies, such as nociceptive neurons in pain states or in epileptic brain circuits.  Of important future potential are selective CaV1.3 blockers for neuropsychiatric diseases, neuroprotection in Parkinson's disease, and resistant hypertension.  In addn., selective or nonselective T-type channel blockers are considered potential therapeutic targets in epilepsy, pain, obesity, sleep, and anxiety.  Use-dependent N-type calcium channel blockers are likely to be of therapeutic use in chronic pain conditions.  Thus, more selective calcium channel blockers hold promise for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0k6JL9CCXi7Vg90H21EOLACvtfcHk0lgBcAot2Oqjdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xns1Gms7s%253D&md5=1e5a19b9974b119fc2c00cfa0089e172</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1124%2Fpr.114.009654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.114.009654%26sid%3Dliteratum%253Aachs%26aulast%3DZamponi%26aufirst%3DG.%2BW.%26aulast%3DStriessnig%26aufirst%3DJ.%26aulast%3DKoschak%26aufirst%3DA.%26aulast%3DDolphin%26aufirst%3DA.%2BC.%26atitle%3DThe%2520Physiology%252C%2520Pathology%252C%2520and%2520Pharmacology%2520of%2520Voltage-Gated%2520Calcium%2520Channels%2520and%2520Their%2520Future%2520Therapeutic%2520Potential%26jtitle%3DPharmacol.%2520Rev.%26date%3D2015%26volume%3D67%26spage%3D821%26epage%3D870%26doi%3D10.1124%2Fpr.114.009654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E.</span></span> <span> </span><span class="NLM_article-title">Regulation of the Dopamine Transporter: Aspects Relevant to Psychostimulant Drugs of Abuse</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1187</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.2009.05148.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1111%2Fj.1749-6632.2009.05148.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=20201860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3cXks1Smsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1187&publication_year=2010&pages=316-340&author=K.+C.+Schmittauthor=M.+E.+Reith&title=Regulation+of+the+Dopamine+Transporter%3A+Aspects+Relevant+to+Psychostimulant+Drugs+of+Abuse&doi=10.1111%2Fj.1749-6632.2009.05148.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse</span></div><div class="casAuthors">Schmitt, Kyle C.; Reith, Maarten E. A.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1187</span>
        (<span class="NLM_cas:issue">Addiction Reviews 2</span>),
    <span class="NLM_cas:pages">316-340</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Dopaminergic signaling in the brain is primarily modulated by dopamine transporters (DATs), which actively translocate extraneuronal dopamine back into dopaminergic neurons.  Transporter proteins are highly dynamic, continuously trafficking between plasmalemmal and endosomal membranes.  Changes in DAT membrane trafficking kinetics can rapidly regulate dopaminergic tone by altering the no. of transporters present at the cell surface.  Various psychostimulant DAT ligands-acting either as amphetamine-like substrates or cocaine-like nontranslocated inhibitors-affect transporter trafficking, triggering rapid insertion or removal of plasmalemmal DATs.  In this review, we focus on the effects of psychostimulants of addiction (particularly D-methamphetamine and cocaine) on DAT regulation and membrane trafficking, with an emphasis on how these drugs may influence intracellular signaling cascades and transporter-assocd. scaffolding proteins to affect DAT regulation.  In addn., we consider involvement of presynaptic receptors for dopamine and other ligands in DAT regulation.  Finally, we discuss possible implications of transporter regulation to the putative toxicity of several substituted amphetamine derivs. commonly used as recreational drugs, as well as to the design of therapeutics for cocaine addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKPcrkSAoXX7Vg90H21EOLACvtfcHk0lgBcAot2Oqjdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXks1Smsrk%253D&md5=31977cbff667a331923e279d4b1be89f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2009.05148.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2009.05148.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DK.%2BC.%26aulast%3DReith%26aufirst%3DM.%2BE.%26atitle%3DRegulation%2520of%2520the%2520Dopamine%2520Transporter%253A%2520Aspects%2520Relevant%2520to%2520Psychostimulant%2520Drugs%2520of%2520Abuse%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2010%26volume%3D1187%26spage%3D316%26epage%3D340%26doi%3D10.1111%2Fj.1749-6632.2009.05148.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sokoloff, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Foll, B.</span></span> <span> </span><span class="NLM_article-title">The Dopamine D3 Receptor, a Quarter Century Later</span>. <i>Eur. J. Neurosci</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1111/ejn.13390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1111%2Fejn.13390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=27600596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BC2szotVGgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=2-19&author=P.+Sokoloffauthor=B.+Le+Foll&title=The+Dopamine+D3+Receptor%2C+a+Quarter+Century+Later&doi=10.1111%2Fejn.13390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The dopamine D3 receptor, a quarter century later</span></div><div class="casAuthors">Sokoloff Pierre; Le Foll Bernard; Le Foll Bernard</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-19</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This review updates the existing knowledge suggesting a role for the D3 receptor in schizophrenia and drug addiction.  The D3 receptor is expressed in brain regions controlling reward, emotions, and motivation.  Antipsychotics bind in vitro to the D3 receptor with similar affinity as to the D2 receptor, and occupancy of D3 receptors in vivo by these compounds given acutely at clinical dosage have been demonstrated in Positron Emission Tomography (PET) studies.  The D3 receptor modulates glutamatergic pathways from the prefrontal cortex to subcortical areas, either directly by interacting with N-methyl-D-aspartate (NMDA) receptors in the nucleus accumbens, or indirectly by controlling dopamine release from ventral tegmental area neurons.  In animals, D3 receptor antagonists reverse behavioral manifestations of NMDA receptor blockade and improve cognitive performances in various paradigms.  Two D3 receptor-selective compounds have reached clinical trials in schizophrenia, with negative results seemingly due to insufficient target engagement; the results with a third compound, F17464, have not been disclosed yet.  There is converging evidence that D3 receptors do not control the reinforcing effects of drugs of abuse (with the exception of alcohol under low requirement), but rather affects the motivation to take the drugs under high requirement, reactivity to drug-associated cues, and drug-seeking behaviors triggered by stimuli associated with relapse in humans.  D3 receptor expression measured by PET is upregulated in humans with various drug addictions.  A single administration of the D3 receptor-selective antagonist, GSK598809, in humans transiently alleviated craving in smokers after overnight abstinence.  The clinical development of D3-selective compounds will benefit from initial assessment of target engagement through the use of PET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTl1Ipw5ULUy5HZzFRCXxVKfW6udTcc2eaGCubE4iSvr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szotVGgtA%253D%253D&md5=e2e57a242a7bbdd9d97f0644392b2c0d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1111%2Fejn.13390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fejn.13390%26sid%3Dliteratum%253Aachs%26aulast%3DSokoloff%26aufirst%3DP.%26aulast%3DLe%2BFoll%26aufirst%3DB.%26atitle%3DThe%2520Dopamine%2520D3%2520Receptor%252C%2520a%2520Quarter%2520Century%2520Later%26jtitle%3DEur.%2520J.%2520Neurosci%26date%3D2017%26volume%3D45%26spage%3D2%26epage%3D19%26doi%3D10.1111%2Fejn.13390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andersohn, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, E.</span></span> <span> </span><span class="NLM_article-title">Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1002/mds.22385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1002%2Fmds.22385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=19170199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BD1M7gvFegsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2009&pages=129-133&author=F.+Andersohnauthor=E.+Garbe&title=Cardiac+and+Noncardiac+Fibrotic+Reactions+Caused+by+Ergot-and+Nonergot-Derived+Dopamine+Agonists&doi=10.1002%2Fmds.22385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists</span></div><div class="casAuthors">Andersohn Frank; Garbe Edeltraut</div><div class="citationInfo"><span class="NLM_cas:title">Movement disorders : official journal of the Movement Disorder Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">129-33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">There is growing evidence that the ergot-derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy.  Data on other fibrotic reactions and nonergot-derived dopamine agonists are sparse.  Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions.  We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database.  Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs).  For ergot-derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot-derived drugs (apomorphine, pramipexole, ropinirole, rotigotine).  Fibrotic reactions due to ergot-derived dopamine agonists may not be limited to heart valves.  For nonergot-derived dopamine agonists, no drug safety signals were evident.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcToIeivIvRguNXdcedVHT5tfW6udTcc2ebTMqWE4bLwMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M7gvFegsg%253D%253D&md5=c5c0f9bfc43f0158b3f76920327a2270</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fmds.22385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.22385%26sid%3Dliteratum%253Aachs%26aulast%3DAndersohn%26aufirst%3DF.%26aulast%3DGarbe%26aufirst%3DE.%26atitle%3DCardiac%2520and%2520Noncardiac%2520Fibrotic%2520Reactions%2520Caused%2520by%2520Ergot-and%2520Nonergot-Derived%2520Dopamine%2520Agonists%26jtitle%3DMov.%2520Disord.%26date%3D2009%26volume%3D24%26spage%3D129%26epage%3D133%26doi%3D10.1002%2Fmds.22385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheffler, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Aripiprazole: A Novel Atypical Antipsychotic Drug with a Uniquely Robust Pharmacology</span>. <i>CNS Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3458.2004.tb00030.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1111%2Fj.1527-3458.2004.tb00030.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=15592581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFejsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=317-336&author=M.+A.+Daviesauthor=D.+J.+Shefflerauthor=B.+L.+Roth&title=Aripiprazole%3A+A+Novel+Atypical+Antipsychotic+Drug+with+a+Uniquely+Robust+Pharmacology&doi=10.1111%2Fj.1527-3458.2004.tb00030.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology</span></div><div class="casAuthors">Davies, Marilyn A.; Sheffler, Douglas J.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drug Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">317-336</span>CODEN:
                <span class="NLM_cas:coden">CDREFB</span>;
        ISSN:<span class="NLM_cas:issn">1080-563X</span>.
    
            (<span class="NLM_cas:orgname">Neva Press</span>)
        </div><div class="casAbstract">A review.  Aripiprazole (Abilify) is an atypical antipsychotic drug that has been recently introduced for clin. use in the treatment of schizophrenia.  Aripiprazole has a unique pharmacol. profile that includes partial agonism at several G-protein coupled receptors (GPCRs) [esp. dopamine (D2) and 5-HT1A] and antagonistic action at others (esp. 5-HT2A).  Clin. trials indicate that aripiprazole is effective in treating the pos. and neg. symptoms of schizophrenia.  In short-term studies rapid onset of action (within one week) has been demonstrated.  Preliminary data indicate that aripiprazole may also be effective in the treatment of manic symptoms of bipolar disorder.  At recommended doses, aripiprazole appears to be safe and well tolerated in most adult patients with schizophrenia and schizoaffective disorder.  There is only limited information available on the use of aripiprazole in children and adolescents, and pilot data suggest that a revised dosing strategy, based on wt., is indicated in this population.  In the long-term studies, the use of aripiprazole was assocd. with continued efficacy, good compliance and increased time-to-relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUPyxiyqhQzrVg90H21EOLACvtfcHk0lg7ilJlIg7lxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFejsLo%253D&md5=dc4d48c70799660137c731cee3c67f42</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2004.tb00030.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2004.tb00030.x%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DM.%2BA.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DAripiprazole%253A%2520A%2520Novel%2520Atypical%2520Antipsychotic%2520Drug%2520with%2520a%2520Uniquely%2520Robust%2520Pharmacology%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2004%26volume%3D10%26spage%3D317%26epage%3D336%26doi%3D10.1111%2Fj.1527-3458.2004.tb00030.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New Substructure Filters for Removal of Pan Assay Interference Compounds (Pains) from Screening Libraries and for Their Exclusion in Bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+Substructure+Filters+for+Removal+of+Pan+Assay+Interference+Compounds+%28Pains%29+from+Screening+Libraries+and+for+Their+Exclusion+in+Bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0lg7ilJlIg7lxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520Substructure%2520Filters%2520for%2520Removal%2520of%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528Pains%2529%2520from%2520Screening%2520Libraries%2520and%2520for%2520Their%2520Exclusion%2520in%2520Bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bissantz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillebrecht, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerebtzoff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migeon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guba, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span> <span> </span><span class="NLM_article-title">Can We Discover Pharmacological Promiscuity Early in the Drug Discovery Process?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2012.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.drudis.2012.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=22269136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BC38vgvFKruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=325-335&author=J.+U.+Petersauthor=J.+Hertauthor=C.+Bissantzauthor=A.+Hillebrechtauthor=G.+Gerebtzoffauthor=S.+Bendelsauthor=F.+Tillierauthor=J.+Migeonauthor=H.+Fischerauthor=W.+Gubaauthor=M.+Kansy&title=Can+We+Discover+Pharmacological+Promiscuity+Early+in+the+Drug+Discovery+Process%3F&doi=10.1016%2Fj.drudis.2012.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Can we discover pharmacological promiscuity early in the drug discovery process?</span></div><div class="casAuthors">Peters Jens-Uwe; Hert Jerome; Bissantz Caterina; Hillebrecht Alexander; Gerebtzoff Gregori; Bendels Stefanie; Tillier Fabien; Migeon Jacques; Fischer Holger; Guba Wolfgang; Kansy Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">325-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The term 'pharmacological promiscuity' describes the activity of a single compound against multiple targets.  When undesired, promiscuity is a major safety concern that needs to be detected as early as possible in the drug discovery process.  The analysis of large datasets reveals that the majority of promiscuous compounds are characterized by recognizable molecular properties and structural motifs, the most important one being a basic center with a pK(a)(B)>6.  These compounds interact with a small set of targets such as aminergic GPCRs; some of these targets attract surprisingly high hit rates.  In this review, we discuss current trends in the assessment of pharmacological promiscuity and propose strategies to enable early detection and mitigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbWSRyt5nWSCSm0e6ZOaemfW6udTcc2ebztKKhFymHxrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vgvFKruw%253D%253D&md5=0ec70daf771d0917270d58f5e74c78b8</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2012.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2012.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26aulast%3DHert%26aufirst%3DJ.%26aulast%3DBissantz%26aufirst%3DC.%26aulast%3DHillebrecht%26aufirst%3DA.%26aulast%3DGerebtzoff%26aufirst%3DG.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DTillier%26aufirst%3DF.%26aulast%3DMigeon%26aufirst%3DJ.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DGuba%26aufirst%3DW.%26aulast%3DKansy%26aufirst%3DM.%26atitle%3DCan%2520We%2520Discover%2520Pharmacological%2520Promiscuity%2520Early%2520in%2520the%2520Drug%2520Discovery%2520Process%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D325%26epage%3D335%26doi%3D10.1016%2Fj.drudis.2012.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sameshima, T.</span>; <span class="NLM_string-name">Yukawa, T.</span>; <span class="NLM_string-name">Hirozane, Y.</span>; <span class="NLM_string-name">Yoshikawa, M.</span>; <span class="NLM_string-name">Katoh, T.</span>; <span class="NLM_string-name">Hara, H.</span>; <span class="NLM_string-name">Yogo, T.</span>; <span class="NLM_string-name">Miyahisa, I.</span>; <span class="NLM_string-name">Okuda, T.</span>; <span class="NLM_string-name">Miyamoto, M.</span>; <span class="NLM_string-name">Naven, R.</span></span> <span> </span><span class="NLM_article-title">Small-Scale Panel Comprising Diverse Gene Family Targets To Evaluate Compound Promiscuity</span>.  <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.9b00128</span> .</span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.9b00128" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=T.+Sameshima&author=T.+Yukawa&author=Y.+Hirozane&author=M.+Yoshikawa&author=T.+Katoh&author=H.+Hara&author=T.+Yogo&author=I.+Miyahisa&author=T.+Okuda&author=M.+Miyamoto&author=R.+Naven&title=Small-Scale+Panel+Comprising+Diverse+Gene+Family+Targets+To+Evaluate+Compound+Promiscuity&doi=10.1021%2Facs.chemrestox.9b00128"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.9b00128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.9b00128%26sid%3Dliteratum%253Aachs%26aulast%3DSameshima%26aufirst%3DT.%26atitle%3DSmall-Scale%2520Panel%2520Comprising%2520Diverse%2520Gene%2520Family%2520Targets%2520To%2520Evaluate%2520Compound%2520Promiscuity%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2019%26doi%3D10.1021%2Facs.chemrestox.9b00128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, N.</span></span> <span> </span><span class="NLM_article-title">Comparing Measures of Promiscuity and Exploring Their Relationship to Toxicity</span>. <i>Mol. Inf.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1002/minf.201100148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1002%2Fminf.201100148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=27476959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=145-159&author=X.+Wangauthor=N.+Greene&title=Comparing+Measures+of+Promiscuity+and+Exploring+Their+Relationship+to+Toxicity&doi=10.1002%2Fminf.201100148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Comparing Measures of Promiscuity and Exploring Their Relationship to Toxicity</span></div><div class="casAuthors">Wang, Xiangyun; Greene, Nigel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Informatics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-159</span>CODEN:
                <span class="NLM_cas:coden">MIONBS</span>;
        ISSN:<span class="NLM_cas:issn">1868-1743</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Recent research has focused on algorithms to derive numerical measures of selectivity based on panels of in vitro pharmacol. assays so that one mol.'s activity profile may be compared easily with that of another.  However, the questions concerning which method or algorithm is best to use, the optimal no. of assays required to give an accurate measure of selectivity and the correlation of these measures to in vivo toxicity have remained largely unexplored.  In this manuscript we describe a systematic approach to compare and contrast different calcn. methods for promiscuity and det. the optimal no. and constitution of a panel of assays to measure the selectivity/promiscuity of compds. across all targets.  We then go on to examine their relationship to toxicity using a Pfizer proprietary compd. set that has both selectivity profiles and exploratory toxicol. study results.  From this study we conclude that all five methods studied are useful in estg. compd. selectivity; that a small panel of between 15 to 30 binding assays can be used as a surrogate for a broader panel enabling higher throughput with lower costs and this panel will most likely have the highest prediction power when correlating this measure to in vivo effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroFZPz4tPdDrVg90H21EOLACvtfcHk0liFGdFWM_ceDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKju70%253D&md5=1aa9606472722e3a7d18c153d34a8f10</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fminf.201100148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fminf.201100148%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGreene%26aufirst%3DN.%26atitle%3DComparing%2520Measures%2520of%2520Promiscuity%2520and%2520Exploring%2520Their%2520Relationship%2520to%2520Toxicity%26jtitle%3DMol.%2520Inf.%26date%3D2012%26volume%3D31%26spage%3D145%26epage%3D159%26doi%3D10.1002%2Fminf.201100148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlin, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulos, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevrioukova, I. F.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Inhibitor Design for Evaluation of a Cyp3a4 Pharmacophore Model</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4210</span>– <span class="NLM_lpage">4220</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01146</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01146" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2mtLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4210-4220&author=P.+Kaurauthor=A.+R.+Chamberlinauthor=T.+L.+Poulosauthor=I.+F.+Sevrioukova&title=Structure-Based+Inhibitor+Design+for+Evaluation+of+a+Cyp3a4+Pharmacophore+Model&doi=10.1021%2Facs.jmedchem.5b01146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model</span></div><div class="casAuthors">Kaur, Parminder; Chamberlin, A. Richard; Poulos, Thomas L.; Sevrioukova, Irina F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4210-4220</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human cytochrome P 450 3A4 (CYP3A4) is a key xenobiotic-metabolizing enzyme that oxidizes and clears the majority of drugs.  CYP3A4 inhibition may lead to drug-drug interactions, toxicity, and other adverse effects but, in some cases, could be beneficial and enhance therapeutic efficiency of coadministered pharmaceuticals that are metabolized by CYP3A4.  On the basis of the investigations of analogs of ritonavir, a potent CYP3A4 inactivator and pharmacoenhancer, the authors have built a pharmacophore model for a CYP3A4-specific inhibitor.  This study is the first attempt to test this model using a set of rationally designed compds.  The functional and structural data presented here agree well with the proposed pharmacophore.  In particular, the authors confirmed the importance of a flexible backbone, the H-bond donor/acceptor moiety, and aromaticity of the side group analogous to Phe-2 of ritonavir and demonstrated the leading role of hydrophobic interactions at the sites adjacent to the heme and phenylalanine cluster in the ligand binding process.  The x-ray structures of CYP3A4 bound to the rationally designed inhibitors provide deeper insights into the mechanism of the CYP3A4-ligand interaction.  Most importantly, two of the compds. I and II that are less complex than ritonavir have comparable submicromolar affinity and inhibitory potency for CYP3A4 and, thus, could serve as templates for synthesis of second generation inhibitors for further evaluation and optimization of the pharmacophore model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2kZVZ3OeVr7Vg90H21EOLACvtfcHk0lid-QTZYBwegA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2mtLvM&md5=4c9cd27c3a091aae985fcb70d7ffd957</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01146%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DChamberlin%26aufirst%3DA.%2BR.%26aulast%3DPoulos%26aufirst%3DT.%2BL.%26aulast%3DSevrioukova%26aufirst%3DI.%2BF.%26atitle%3DStructure-Based%2520Inhibitor%2520Design%2520for%2520Evaluation%2520of%2520a%2520Cyp3a4%2520Pharmacophore%2520Model%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4210%26epage%3D4220%26doi%3D10.1021%2Facs.jmedchem.5b01146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schonherr, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cernak, T.</span></span> <span> </span><span class="NLM_article-title">Profound Methyl Effects in Drug Discovery and a Call for New C-H Methylation Reactions</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">12256</span>– <span class="NLM_lpage">12267</span>, <span class="refDoi"> DOI: 10.1002/anie.201303207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1002%2Fanie.201303207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FptVahuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=12256-12267&author=H.+Schonherrauthor=T.+Cernak&title=Profound+Methyl+Effects+in+Drug+Discovery+and+a+Call+for+New+C-H+Methylation+Reactions&doi=10.1002%2Fanie.201303207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Profound methyl effects in drug discovery and a call for new C-H methylation reactions</span></div><div class="casAuthors">Schonherr Heike; Cernak Tim</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">12256-67</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The methyl group is one of the most commonly occurring carbon fragments in small-molecule drugs.  This simplest alkyl fragment appears in more than 67 % of the top-selling drugs of 2011 and can modulate both the biological and physical properties of a molecule.  This Review focuses on so-called magic methyl effects on binding potency, where the seemingly mundane change of C H to C Me improves the IC50  value of a drug candidate more than 100-fold.  This discussion is followed by a survey of recent advances in synthetic chemistry that allow the direct methylation of C(sp(2) ) H and C(sp(3) ) H bonds.  It is our hope that the relevance of the meager methyl group to drug discovery as presented herein will inspire reports on new C H methylation reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyoLZDDgvsMh0LsK7uFuY7fW6udTcc2eZ26_UvvUP4-bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FptVahuw%253D%253D&md5=ef08f80e55b2c530b49e4306da024902</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fanie.201303207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201303207%26sid%3Dliteratum%253Aachs%26aulast%3DSchonherr%26aufirst%3DH.%26aulast%3DCernak%26aufirst%3DT.%26atitle%3DProfound%2520Methyl%2520Effects%2520in%2520Drug%2520Discovery%2520and%2520a%2520Call%2520for%2520New%2520C-H%2520Methylation%2520Reactions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D12256%26epage%3D12267%26doi%3D10.1002%2Fanie.201303207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado-Rives, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span> <span> </span><span class="NLM_article-title">Methyl Effects on Protein-Ligand Binding</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4489</span>– <span class="NLM_lpage">4500</span>, <span class="refDoi"> DOI: 10.1021/jm3003697</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003697" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsV2iu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4489-4500&author=C.+S.+Leungauthor=S.+S.+Leungauthor=J.+Tirado-Rivesauthor=W.+L.+Jorgensen&title=Methyl+Effects+on+Protein-Ligand+Binding&doi=10.1021%2Fjm3003697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Methyl Effects on Protein-Ligand Binding</span></div><div class="casAuthors">Leung, Cheryl S.; Leung, Siegfried S. F.; Tirado-Rives, Julian; Jorgensen, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4489-4500</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The effects of addn. of a Me group to a lead compd. on biol. activity are examd.  A literature anal. of >2000 cases reveals that an activity boost of a factor of 10 or more is found with an 8% frequency, and a 100-fold boost is a 1 in 200 event.  Four cases in the latter category are analyzed in depth to elucidate any unusual aspects of the protein-ligand binding, distribution of water mols., and changes in conformational energetics.  The analyses include Monte Carlo/free-energy perturbation (MC/FEP) calcns. for Me replacements in inhibitor series for p38α MAP kinase, ACK1, PTP1B, and thrombin.  Me substitutions ortho to an aryl ring can be particularly effective at improving activity by inducing a propitious conformational change.  The greatest improvements in activity arise from coupling the conformational gain with the burial of the Me group in a hydrophobic region of the protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX0Czyhgy6KbVg90H21EOLACvtfcHk0lid-QTZYBwegA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsV2iu7Y%253D&md5=0ea58d9c1bf845d383931b6a017f9b37</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm3003697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003697%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DC.%2BS.%26aulast%3DLeung%26aufirst%3DS.%2BS.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DMethyl%2520Effects%2520on%2520Protein-Ligand%2520Binding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4489%26epage%3D4500%26doi%3D10.1021%2Fjm3003697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillis, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Applications of Fluorine in Medicinal Chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8315</span>– <span class="NLM_lpage">8359</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8315-8359&author=E.+P.+Gillisauthor=K.+J.+Eastmanauthor=M.+D.+Hillauthor=D.+J.+Donnellyauthor=N.+A.+Meanwell&title=Applications+of+Fluorine+in+Medicinal+Chemistry&doi=10.1021%2Facs.jmedchem.5b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of Fluorine in Medicinal Chemistry</span></div><div class="casAuthors">Gillis, Eric P.; Eastman, Kyle J.; Hill, Matthew D.; Donnelly, David J.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8315-8359</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with meta-anal. The role of fluorine in drug design and development is expanding rapidly as we learn more about the unique properties assocd. with this unusual element and how to deploy it with greater sophistication.  The judicious introduction of fluorine into a mol. can productively influence conformation, pKa, intrinsic potency, membrane permeability, metabolic pathways, and pharmacokinetic properties.  In addn., 18F has been established as a useful positron emitting isotope for use with in vivo imaging technol. that potentially has extensive application in drug discovery and development, often limited only by convenient synthetic accessibility to labeled compds.  The wide ranging applications of fluorine in drug design are providing a strong stimulus for the development of new synthetic methodologies that allow more facile access to a wide range of fluorinated compds.  In this review, we provide an update on the effects of the strategic incorporation of fluorine in drug mols. and applications in positron emission tomog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8fUUtkPB4L7Vg90H21EOLACvtfcHk0lid-QTZYBwegA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK&md5=9995829a94a8c0b8d9fb0d21bdfd5a1d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00258%26sid%3Dliteratum%253Aachs%26aulast%3DGillis%26aufirst%3DE.%2BP.%26aulast%3DEastman%26aufirst%3DK.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DDonnelly%26aufirst%3DD.%2BJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DApplications%2520of%2520Fluorine%2520in%2520Medicinal%2520Chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8315%26epage%3D8359%26doi%3D10.1021%2Facs.jmedchem.5b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagnon, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bostrom, J.</span></span> <span> </span><span class="NLM_article-title">Understanding Our Love Affair with P-Chlorophenyl: Present Day Implications from Historical Biases of Reagent Selection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2390</span>– <span class="NLM_lpage">2405</span>, <span class="refDoi"> DOI: 10.1021/jm501894t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501894t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Snsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2390-2405&author=D.+G.+Brownauthor=M.+M.+Gagnonauthor=J.+Bostrom&title=Understanding+Our+Love+Affair+with+P-Chlorophenyl%3A+Present+Day+Implications+from+Historical+Biases+of+Reagent+Selection&doi=10.1021%2Fjm501894t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding Our Love Affair with p-Chlorophenyl: Present Day Implications from Historical Biases of Reagent Selection</span></div><div class="casAuthors">Brown, Dean G.; Gagnon, Moriah M.; Bostrom, Jonas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2390-2405</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with further theor. anal. We report here an unexpectedly strong preference toward para substitution in Ph rings within drug discovery programs.  A population anal. of arom. rings in various drug databases demonstrated that para substitution is favored over meta and ortho regioisomers, with p-chlorophenyl (p-ClPh) being one of the most predominant examples.  We speculate that the frequency of p-ClPh is traced back to historical models of medicinal chem. where para-substituted regioisomers were perhaps more easily accessed, and further reinforced by Topliss in 1972 that if Ph was active, the p-ClPh should be made because of ease of synthesis and hydrophobicity driven potency effects.  On the basis of our anal., the para bias has become useful conventional wisdom but perhaps so much so that a perception has been created that druglike space favors a linear arom. structure.  It is hoped this anal. will catalyze a new look at design of reagent databases and screening collections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZxc2KY5KeHrVg90H21EOLACvtfcHk0lgzWDz5jK7cjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Snsr0%253D&md5=7f8a3a4eff01600299e04d59341a34dd</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm501894t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501894t%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DGagnon%26aufirst%3DM.%2BM.%26aulast%3DBostrom%26aufirst%3DJ.%26atitle%3DUnderstanding%2520Our%2520Love%2520Affair%2520with%2520P-Chlorophenyl%253A%2520Present%2520Day%2520Implications%2520from%2520Historical%2520Biases%2520of%2520Reagent%2520Selection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2390%26epage%3D2405%26doi%3D10.1021%2Fjm501894t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jalencas, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestres, J.</span></span> <span> </span><span class="NLM_article-title">On the Origins of Drug Polypharmacology</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1039/C2MD20242E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1039%2FC2MD20242E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVynu7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=80-87&author=X.+Jalencasauthor=J.+Mestres&title=On+the+Origins+of+Drug+Polypharmacology&doi=10.1039%2FC2MD20242E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">On the origins of drug polypharmacology</span></div><div class="casAuthors">Jalencas, Xavier; Mestres, Jordi</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-87</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The ability of small mols. to interact with multiple proteins is commonly referred to as polypharmacol.  The now widely accepted polypharmacol. of drugs is of particular interest for human health as it has implications beyond therapeutic efficacy, from anticipating adverse drug reactions to identifying potential repurposing opportunities.  There have been a no. of studies relating the extent of drug polypharmacol. to the physicochem. properties and fragment compn. of the drug itself, but also to the protein family and distant binding site similarities of the drug's primary target.  Taken together, all these observations lead to speculate that the origins of drug polypharmacol. may lie at the heart of protein evolution and that polypharmacol. may just be a reminiscent signature of some of the mechanisms of adaptation that primitive biol. systems developed to increase the chances of survival in a highly variable early chem. environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB1qsCiSthHLVg90H21EOLACvtfcHk0lgzWDz5jK7cjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVynu7vI&md5=77fe84731536e5008cca3b0faf1e58dd</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1039%2FC2MD20242E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2MD20242E%26sid%3Dliteratum%253Aachs%26aulast%3DJalencas%26aufirst%3DX.%26aulast%3DMestres%26aufirst%3DJ.%26atitle%3DOn%2520the%2520Origins%2520of%2520Drug%2520Polypharmacology%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26spage%3D80%26epage%3D87%26doi%3D10.1039%2FC2MD20242E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The Influence of Drug-Like Concepts on Decision-Making in Medicinal Chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+Influence+of+Drug-Like+Concepts+on+Decision-Making+in+Medicinal+Chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lgzWDz5jK7cjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520Influence%2520of%2520Drug-Like%2520Concepts%2520on%2520Decision-Making%2520in%2520Medicinal%2520Chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeGoey, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. D.</span></span> <span> </span><span class="NLM_article-title">Beyond the Rule of 5: Lessons Learned from Abbvie’s Drugs and Compound Collection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2636</span>– <span class="NLM_lpage">2651</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00717</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00717" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFeitbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2636-2651&author=D.+A.+DeGoeyauthor=H.+J.+Chenauthor=P.+B.+Coxauthor=M.+D.+Wendt&title=Beyond+the+Rule+of+5%3A+Lessons+Learned+from+Abbvie%E2%80%99s+Drugs+and+Compound+Collection&doi=10.1021%2Facs.jmedchem.7b00717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection</span></div><div class="casAuthors">DeGoey, David A.; Chen, Hui-Ju; Cox, Philip B.; Wendt, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2636-2651</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recently, there has been an increasing focus on the pursuit of targets considered to be less druggable that offer potential for development of promising new therapeutic agents for the treatment of diseases with large unmet medical need, particularly in the areas of oncol. and virol.  However, conducting drug discovery campaigns in "beyond rule of 5" (bRo5) chem. space presents a significant drug design and development challenge to medicinal chemists to achieve acceptable oral pharmacokinetics.  Retrospective anal. of past successes and failures in drug discovery bRo5 may shed light on the key principles that contribute to the oral bioavailability of successful bRo5 compds. and improve the efficiency of drug design for future projects.  We present here highlights and case studies of lessons learned from discovery of bRo5 compds.  A simple multiparametric scoring function (AB-MPS) was devised that correlated preclin. PK results with cLogD, no. of rotatable bonds, and no. of arom. rings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTHuaXbtjlALVg90H21EOLACvtfcHk0ljBBafOdA0f9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFeitbjJ&md5=48984dc65410d83d4ac8ddaca030b024</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00717%26sid%3Dliteratum%253Aachs%26aulast%3DDeGoey%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DH.%2BJ.%26aulast%3DCox%26aufirst%3DP.%2BB.%26aulast%3DWendt%26aufirst%3DM.%2BD.%26atitle%3DBeyond%2520the%2520Rule%2520of%25205%253A%2520Lessons%2520Learned%2520from%2520Abbvie%25E2%2580%2599s%2520Drugs%2520and%2520Compound%2520Collection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2636%26epage%3D2651%26doi%3D10.1021%2Facs.jmedchem.7b00717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steeno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wassermann, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span> <span> </span><span class="NLM_article-title">Amine Promiscuity and Toxicology Analysis</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">653</span>– <span class="NLM_lpage">657</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.11.085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.bmcl.2016.11.085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=28011216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCmt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=653-657&author=E.+C.+Leeauthor=G.+Steenoauthor=A.+M.+Wassermannauthor=L.+Zhangauthor=F.+Shahauthor=D.+A.+Price&title=Amine+Promiscuity+and+Toxicology+Analysis&doi=10.1016%2Fj.bmcl.2016.11.085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Amine promiscuity and toxicology analysis</span></div><div class="casAuthors">Lee, Esther C. Y.; Steeno, Gregory; Wassermann, Anne Mai; Zhang, Liying; Shah, Falgun; Price, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">653-657</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Drug discovery programs often face challenges to obtain sufficient duration of action of the drug (i.e., seek longer half-lives).  If the pharmacodynamic response is driven by free plasma concn. of the drug then extending the plasma drug concn. is a valid approach.  Half-life is dependent on the vol. of distribution, which in turn can be dependent upon the ionization state of the mol.  Basic compds. tend to have a higher vol. of distribution leading to longer half-lives.  However, it has been shown that bases may also have higher promiscuity.  The authors describe an anal. of in vitro pharmacol. profiling and toxicol. data investigating the role of primary, secondary, and tertiary amines in imparting promiscuity and thus off-target toxicity.  Primary amines are found to be less promiscuous in in vitro assays and have improved profiles in in vivo toxicol. studies compared to secondary and tertiary amines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr96I58aFeB-bVg90H21EOLACvtfcHk0ljBBafOdA0f9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCmt7zI&md5=c48413a44f3df5ced931cb93b81e8a8f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.11.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.11.085%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DE.%2BC.%26aulast%3DSteeno%26aufirst%3DG.%26aulast%3DWassermann%26aufirst%3DA.%2BM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DShah%26aufirst%3DF.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26atitle%3DAmine%2520Promiscuity%2520and%2520Toxicology%2520Analysis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D653%26epage%3D657%26doi%3D10.1016%2Fj.bmcl.2016.11.085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span> <span> </span><span class="NLM_article-title">Molecular Complexity and Fragment-Based Drug Discovery: Ten Years On</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2011.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.cbpa.2011.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=21665521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFCltrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=489-496&author=A.+R.+Leachauthor=M.+M.+Hann&title=Molecular+Complexity+and+Fragment-Based+Drug+Discovery%3A+Ten+Years+On&doi=10.1016%2Fj.cbpa.2011.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular complexity and fragment-based drug discovery: ten years on</span></div><div class="casAuthors">Leach, Andrew R.; Hann, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">489-496</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We review the concept of mol. complexity in the context of the very simple model of mol. interactions that we introduced over 10 years ago.  A summary is presented of efforts to validate this simple model using screening data.  The relationship between the complexity model and the problem of sampling chem. space is discussed, together with the relevance of these theor. concepts to fragment-based drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNcMgTT6eLC7Vg90H21EOLACvtfcHk0ljBBafOdA0f9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFCltrg%253D&md5=19c2d65de80a8bab1059468828da6ce2</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2011.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2011.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DHann%26aufirst%3DM.%2BM.%26atitle%3DMolecular%2520Complexity%2520and%2520Fragment-Based%2520Drug%2520Discovery%253A%2520Ten%2520Years%2520On%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D15%26spage%3D489%26epage%3D496%26doi%3D10.1016%2Fj.cbpa.2011.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">Can. We Rationally Design Promiscuous Drugs?</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1016/j.sbi.2006.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.sbi.2006.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=16442279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=127-136&author=A.+L.+Hopkinsauthor=J.+S.+Masonauthor=J.+P.+Overington&title=Can.+We+Rationally+Design+Promiscuous+Drugs%3F&doi=10.1016%2Fj.sbi.2006.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Can we rationally design promiscuous drugs?</span></div><div class="casAuthors">Hopkins, Andrew L.; Mason, Jonathan S.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-136</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Structure-based drug design is now used widely in modern medicinal chem.  The application of structural biol. to medicinal chem. has heralded the 'rational drug design' vision of discovering exquisitely selective ligands.  However, recent advances in post-genomic biol. are indicating that polypharmacol. may be a necessary trait for the efficacy of many drugs, therefore questioning the 'one drug, one target' assumption of current rational drug design.  By combining advances in chemoinformatics and structural biol., it might be possible to rationally design the next generation of promiscuous drugs with polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQWdh60x9AHrVg90H21EOLACvtfcHk0ljBBafOdA0f9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D&md5=8f9e95a41976b8e3ac790f2fff2c406f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2006.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2006.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DCan.%2520We%2520Rationally%2520Design%2520Promiscuous%2520Drugs%253F%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2006%26volume%3D16%26spage%3D127%26epage%3D136%26doi%3D10.1016%2Fj.sbi.2006.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azzaoui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacoby, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, L.</span></span> <span> </span><span class="NLM_article-title">Modeling Promiscuity Based on in Vitro Safety Pharmacology Profiling Data</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">874</span>– <span class="NLM_lpage">880</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200700036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1002%2Fcmdc.200700036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=17492703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntVShu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=874-880&author=K.+Azzaouiauthor=J.+Hamonauthor=B.+Fallerauthor=S.+Whitebreadauthor=E.+Jacobyauthor=A.+Benderauthor=J.+L.+Jenkinsauthor=L.+Urban&title=Modeling+Promiscuity+Based+on+in+Vitro+Safety+Pharmacology+Profiling+Data&doi=10.1002%2Fcmdc.200700036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling promiscuity based on in vitro safety pharmacology profiling data</span></div><div class="casAuthors">Azzaoui, Kamal; Hamon, Jacques; Faller, Bernard; Whitebread, Steven; Jacoby, Edgar; Bender, Andreas; Jenkins, Jeremy L.; Urban, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">874-880</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">This study describes a method for mining and modeling binding data obtained from a large panel of targets (in vitro safety pharmacol.) to distinguish differences between promiscuous and selective compds.  Two naive Bayes models for promiscuity and selectivity were generated and validated on a test set as well as publicly available drug databases.  The model shows a higher score (lower promiscuity) for marketed drugs than for compds. in early development or compds. that failed during clin. development.  Such models can be used in triaging high-throughput screening data or for lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw2wR-U-z9YrVg90H21EOLACvtfcHk0lgGgBhPYIg0hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntVShu78%253D&md5=30c8923e136d16ffd0b1ecd62afb8ff3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700036%26sid%3Dliteratum%253Aachs%26aulast%3DAzzaoui%26aufirst%3DK.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DFaller%26aufirst%3DB.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DJacoby%26aufirst%3DE.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DModeling%2520Promiscuity%2520Based%2520on%2520in%2520Vitro%2520Safety%2520Pharmacology%2520Profiling%2520Data%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D874%26epage%3D880%26doi%3D10.1002%2Fcmdc.200700036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span> <span> </span><span class="NLM_article-title">The Influence of Target Family and Functional Activity on the Physicochemical Properties of Pre-Clinical Compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2969</span>– <span class="NLM_lpage">2978</span>, <span class="refDoi"> DOI: 10.1021/jm0512185</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0512185" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtlOit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=2969-2978&author=R.+Morphy&title=The+Influence+of+Target+Family+and+Functional+Activity+on+the+Physicochemical+Properties+of+Pre-Clinical+Compounds&doi=10.1021%2Fjm0512185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The Influence of Target Family and Functional Activity on the Physicochemical Properties of Pre-Clinical Compounds</span></div><div class="casAuthors">Morphy, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2969-2978</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The target families of greatest interest in drug discovery can be differentiated on the basis of the physicochem. properties of their preclin. ligands.  The ligands for peptidergic targets, such as peptide G protein-coupled receptors (GPCRs) and integrin receptors, possess significantly higher median property values than those for aminergic targets, such as monoamine transporters and GPCRs.  The ligands for peptide GPCRs were found to be less efficient, in terms of their binding energy per unit of mol. wt. or lipophilicity, than ligands for monoamine GPCRs.  The changes in the property values during the optimization process were found to vary only slightly across the target families, with the main determinant of the drug-likeness of the optimized compds. being the profile of the starting compds.  Agonists for monoamine GPCRs, opioid receptors and ion channels were typically smaller and less lipophilic than the antagonists, but there was no difference between the agonists and the antagonists for peptide GPCRs and nuclear receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0EegclZUHNbVg90H21EOLACvtfcHk0lgGgBhPYIg0hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtlOit7g%253D&md5=fcf63bff570d58d56492b46ddecb5eb1</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm0512185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0512185%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26atitle%3DThe%2520Influence%2520of%2520Target%2520Family%2520and%2520Functional%2520Activity%2520on%2520the%2520Physicochemical%2520Properties%2520of%2520Pre-Clinical%2520Compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D2969%26epage%3D2978%26doi%3D10.1021%2Fjm0512185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aronov, A. M.</span></span> <span> </span><span class="NLM_article-title">Common Pharmacophores for Uncharged Human Ether-a-Go-Go-Related Gene (Herg) Blockers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6917</span>– <span class="NLM_lpage">6921</span>, <span class="refDoi"> DOI: 10.1021/jm060500o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060500o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVyntbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6917-6921&author=A.+M.+Aronov&title=Common+Pharmacophores+for+Uncharged+Human+Ether-a-Go-Go-Related+Gene+%28Herg%29+Blockers&doi=10.1021%2Fjm060500o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Common Pharmacophores for Uncharged Human Ether-a-go-go-Related Gene (hERG) Blockers</span></div><div class="casAuthors">Aronov, Alex M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6917-6921</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In silico approaches are widely used to predict human ether-a-go-go-related gene (hERG) channel blockade.  Published pharmacophore models of hERG blockers typically contain a basic nitrogen center flanked by arom. or hydrophobic groups.  However, hERG blockade has been obsd. in series lacking the basic nitrogen.  By utilizing screening data for 194 potent uncharged hERG actives, we propose a pharmacophore for neutral hERG blockers, and provide guidance on eliminating hERG liability in an uncharged hERG active chem. series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhdisypaGQgbVg90H21EOLACvtfcHk0lgGgBhPYIg0hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVyntbrJ&md5=a557f6239ec176243f9823a36b3b9ec4</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm060500o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060500o%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26atitle%3DCommon%2520Pharmacophores%2520for%2520Uncharged%2520Human%2520Ether-a-Go-Go-Related%2520Gene%2520%2528Herg%2529%2520Blockers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6917%26epage%3D6921%26doi%3D10.1021%2Fjm060500o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aronov, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, B. B.</span></span> <span> </span><span class="NLM_article-title">A Model for Identifying Herg K+ Channel Blockers</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2307</span>– <span class="NLM_lpage">2315</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2004.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.bmc.2004.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=15080928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtVKqu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=2307-2315&author=A.+M.+Aronovauthor=B.+B.+Goldman&title=A+Model+for+Identifying+Herg+K%2B+Channel+Blockers&doi=10.1016%2Fj.bmc.2004.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A model for identifying HERG K+ channel blockers</span></div><div class="casAuthors">Aronov, Alex M.; Goldman, Brian B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2307-2315</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Acquired long QT syndrome (LQTS) occurs frequently as a side effect of blockade of cardiac HERG K+ channels by commonly used medications.  A large no. of structurally diverse compds. have been shown to inhibit K+ current through HERG.  There is considerable interest in developing in silico tools to filter out potential HERG blockers early in the drug discovery process.  We describe a binary classification model that combines a 2D topol. similarity filter with a 3D pharmacophore ensemble procedure to discriminate between HERG actives and inactives with an overall accuracy of 82%, with false neg. and false pos. rates of 29% and 15%, resp.  This model should be generally applicable in virtual library counterscreening against HERG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK7a2-P1CNkLVg90H21EOLACvtfcHk0limrzsT0YFkCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtVKqu7g%253D&md5=acfa27de5815ccbe7cb1ebbefefc99e2</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2004.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2004.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26aulast%3DGoldman%26aufirst%3DB.%2BB.%26atitle%3DA%2520Model%2520for%2520Identifying%2520Herg%2520K%252B%2520Channel%2520Blockers%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2004%26volume%3D12%26spage%3D2307%26epage%3D2315%26doi%3D10.1016%2Fj.bmc.2004.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shamovsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norden, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbahns, K.</span></span> <span> </span><span class="NLM_article-title">Overcoming Undesirable Herg Potency of Chemokine Receptor Antagonists Using Baseline Lipophilicity Relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1162</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.1021/jm070543k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070543k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhslWju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1162-1178&author=I.+Shamovskyauthor=S.+Connollyauthor=L.+Davidauthor=S.+Ivanovaauthor=B.+Nordenauthor=B.+Springthorpeauthor=K.+Urbahns&title=Overcoming+Undesirable+Herg+Potency+of+Chemokine+Receptor+Antagonists+Using+Baseline+Lipophilicity+Relationships&doi=10.1021%2Fjm070543k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming Undesirable hERG Potency of Chemokine Receptor Antagonists Using Baseline Lipophilicity Relationships</span></div><div class="casAuthors">Shamovsky, Igor; Connolly, Stephen; David, Laurent; Ivanova, Svetlana; Norden, Bo; Springthorpe, Brian; Urbahns, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1162-1178</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The inhibition of the hERG channel by noncardiovascular drugs is a side effect that severely impedes the development of new medications.  To increase hERG selectivity of preclin. compds., the authors recommend the study of nondesolvation related interactions with the intended target and hERG using a baseline lipophilicity relationship approach.  While this approach is conventionally used in studies of potency, the authors demonstrate here that it can help in selectivity issues.  Studies of hERG selectivity in four inhouse classes of chemokine receptor (CCR) antagonists suggest that the selectivity is improved most effectively by structural alterations that increase the lipophilicity-adjusted primary potency, pIC50CCR - LogD.  Fragment-based QSAR anal. is performed using the lipophilicity-adjusted hERG potency, pIC50hERG - LogD, to identify moieties that form nonhydrophobic interactions with the hERG channel.  These moieties, which erode hERG selectivity, can then be avoided.  A novel two-dimensional fragment-based QSAR anal. helps visualizing the lipophilicity-adjusted hERG and CCR potencies within chem. series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1BNQlA8irybVg90H21EOLACvtfcHk0limrzsT0YFkCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhslWju78%253D&md5=04596a9552c5cf3b47a3edf9c0bd5498</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm070543k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070543k%26sid%3Dliteratum%253Aachs%26aulast%3DShamovsky%26aufirst%3DI.%26aulast%3DConnolly%26aufirst%3DS.%26aulast%3DDavid%26aufirst%3DL.%26aulast%3DIvanova%26aufirst%3DS.%26aulast%3DNorden%26aufirst%3DB.%26aulast%3DSpringthorpe%26aufirst%3DB.%26aulast%3DUrbahns%26aufirst%3DK.%26atitle%3DOvercoming%2520Undesirable%2520Herg%2520Potency%2520of%2520Chemokine%2520Receptor%2520Antagonists%2520Using%2520Baseline%2520Lipophilicity%2520Relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1162%26epage%3D1178%26doi%3D10.1021%2Fjm070543k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moir, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span> <span> </span><span class="NLM_article-title">Medicinal Chemistry of Herg Optimizations: Highlights and Hang-Ups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5029</span>– <span class="NLM_lpage">5046</span>, <span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+Chemistry+of+Herg+Optimizations%3A+Highlights+and+Hang-Ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0limrzsT0YFkCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520Chemistry%2520of%2520Herg%2520Optimizations%253A%2520Highlights%2520and%2520Hang-Ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Redfern, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKenzie, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palethorpe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegl, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camm, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, T. G.</span></span> <span> </span><span class="NLM_article-title">Relationships between Preclinical Cardiac Electrophysiology, Clinical QT Interval Prolongation and Torsade De Pointes for a Broad Range of Drugs: Evidence for a Provisional Safety Margin in Drug Development</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/S0008-6363(02)00846-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2FS0008-6363%2802%2900846-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=12667944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2003&pages=32-45&author=W.+S.+Redfernauthor=L.+Carlssonauthor=A.+S.+Davisauthor=W.+G.+Lynchauthor=I.+MacKenzieauthor=S.+Palethorpeauthor=P.+K.+Sieglauthor=I.+Strangauthor=A.+T.+Sullivanauthor=R.+Wallisauthor=A.+J.+Cammauthor=T.+G.+Hammond&title=Relationships+between+Preclinical+Cardiac+Electrophysiology%2C+Clinical+QT+Interval+Prolongation+and+Torsade+De+Pointes+for+a+Broad+Range+of+Drugs%3A+Evidence+for+a+Provisional+Safety+Margin+in+Drug+Development&doi=10.1016%2FS0008-6363%2802%2900846-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development</span></div><div class="casAuthors">Redfern, W. S.; Carlsson, L.; Davis, A. S.; Lynch, W. G.; MacKenzie, I.; Palethorpe, S.; Siegl, P. K. S.; Strang, I.; Sullivan, A. T.; Wallis, R.; Camm, A. J.; Hammond, T. G.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-45</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review discussing attempts to det. the relative value of preclin. cardiac electrophysiol. data (in vitro and in vivo) for predicting risk of torsades de pointes (TdP) in clin. use.  Published data on human ether-a-go-go-related gene-encoded voltage-dependent potassium channel (hERG) (or IKr) activity, cardiac action potential duration (at 90% repolarization; APD90), and QT prolongation in dogs were compared against QT effects and reports of TdP in humans for 100 drugs.  These data were set against the free plasma concns. attained during clin. use (effective therapeutic plasma concns.; ETPCunbound).  The drugs were divided into five categories: (1) Class Ia and III antiarrhythmics; (2) withdrawn from market due to TdP; (3) measurable incidence/numerous reports of TdP in humans; (4) isolated reports of TdP in humans; (5) no reports of TdP in humans.  Data from hERG (or IKr) assays in addn. to ETPCunbound data were available for 52 drugs.  For Category 1 drugs, data for hERG/IKr IC50, APD90, QTc in animals and QTc in humans were generally close to or superimposed on the ETPCunbound values.  This relationship was uncoupled in the other categories, with more complex relationships between the data.  In Category 1 (except amiodarone), the ratios between hERG/IKr IC50 and ETPCunbound (max) ranged 0.1-31-fold.  Similar ranges were obtained for drugs in Category 2 (0.31-13-fold) and Category 3 (0.03-35-fold).  A large spread was found for Category 4 drugs (0.13-35,700-fold); this category embraced an assortment of mechanisms ranging from drugs which may well be affecting IKr currents in clin. use (e.g., sparfloxacin) to others such as nifedipine (35,700-fold) where channel block is not involved.  Finally, for the majority of Category 5 drugs there was a >30-fold sepn. between hERG/IKr activity and ETPCunbound values, with the notable exception of verapamil (1.7-fold), which is free from QT prolongation in man; this is probably explained by its multiple interactions with cardiac ion channels.  The dataset confirms the widely held belief that most drugs assocd. with TdP in humans are also assocd. with hERG K+ channel block at concns. close to or superimposed upon the free plasma concns. found in clin. use.  A 30-fold margin between Cmax and hERG IC50 may suffice for drugs currently undergoing clin. evaluation, but for future drug discovery programs, pharmaceutical companies should consider increasing this margin, particularly for drugs aimed at nondebilitating diseases.  However, interactions with multiple cardiac ion channels can either mitigate or exacerbate the prolongation of APD and QT that would ensue from block of IKr currents alone, and delay of repolarization per se is not necessarily torsadogenic.  Clearly, an integrated assessment of in vitro and in vivo data is required in order to predict the torsadogenic risk of a new candidate drug in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkpRDUH0rhyrVg90H21EOLACvtfcHk0ljWJSbG5R4aoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D&md5=a236c07febd2e05fe70e61604619bf2e</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0008-6363%2802%2900846-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0008-6363%252802%252900846-5%26sid%3Dliteratum%253Aachs%26aulast%3DRedfern%26aufirst%3DW.%2BS.%26aulast%3DCarlsson%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DA.%2BS.%26aulast%3DLynch%26aufirst%3DW.%2BG.%26aulast%3DMacKenzie%26aufirst%3DI.%26aulast%3DPalethorpe%26aufirst%3DS.%26aulast%3DSiegl%26aufirst%3DP.%2BK.%26aulast%3DStrang%26aufirst%3DI.%26aulast%3DSullivan%26aufirst%3DA.%2BT.%26aulast%3DWallis%26aufirst%3DR.%26aulast%3DCamm%26aufirst%3DA.%2BJ.%26aulast%3DHammond%26aufirst%3DT.%2BG.%26atitle%3DRelationships%2520between%2520Preclinical%2520Cardiac%2520Electrophysiology%252C%2520Clinical%2520QT%2520Interval%2520Prolongation%2520and%2520Torsade%2520De%2520Pointes%2520for%2520a%2520Broad%2520Range%2520of%2520Drugs%253A%2520Evidence%2520for%2520a%2520Provisional%2520Safety%2520Margin%2520in%2520Drug%2520Development%26jtitle%3DCardiovasc.%2520Res.%26date%3D2003%26volume%3D58%26spage%3D32%26epage%3D45%26doi%3D10.1016%2FS0008-6363%2802%2900846-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leishman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, E. N.</span></span> <span> </span><span class="NLM_article-title">A Pharmacokinetic-Pharmacodynamic Model for the Quantitative Prediction of Dofetilide Clinical Qt Prolongation from Human Ether-a-Go-Go-Related Gene Current Inhibition Data</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">572</span>– <span class="NLM_lpage">582</span>, <span class="refDoi"> DOI: 10.1016/j.clpt.2005.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.clpt.2005.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=15961988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlt1Gqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2005&pages=572-582&author=D.+M.+Jonkerauthor=L.+A.+Kennaauthor=D.+Leishmanauthor=R.+Wallisauthor=P.+A.+Milliganauthor=E.+N.+Jonsson&title=A+Pharmacokinetic-Pharmacodynamic+Model+for+the+Quantitative+Prediction+of+Dofetilide+Clinical+Qt+Prolongation+from+Human+Ether-a-Go-Go-Related+Gene+Current+Inhibition+Data&doi=10.1016%2Fj.clpt.2005.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data</span></div><div class="casAuthors">Jonker, Daniel M.; Kenna, Leslie A.; Leishman, Derek; Wallis, Rob; Milligan, Peter A.; Jonsson, E. Niclas</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">572-582</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background: QT prolongation is an important biomarker of the arrhythmia torsades de pointes and appears to be related mainly to blockade of delayed inward cardiac rectifier potassium currents.  The aim of this study was to quantify the relationship between in vitro human ether-a-go-go-related gene (hERG) potassium channel blockade and the magnitude of QT prolongation in humans for the class III antiarrhythmic dofetilide.  Methods: The in vitro affinity and activity of dofetilide were detd. in recombinant cell cultures expressing the hERG channel, and the QT-prolonging effect of dofetilide was assessed in 5 clin. studies (80 healthy volunteers and 17 patients with ischemic heart disease).  A population pharmacokinetic-pharmacodynamic anal. of the in vitro and in vivo data was performed in NONMEM by use of the operational model of pharmacol. agonism to est. the efficiency of transduction from ion channel binding to Fridericia-cor. QT response.  Results: A 3-compartment pharmacokinetic model with first-order absorption characterized the time course of dofetilide concns.  On the basis of an in vitro potency of 5.13 ng/mL for potassium current inhibition and predicted unbound dofetilide concns., the estd. transducer ratio (τ) of 6.2 suggests that the QT response plateaus before currents are fully blocked.  In our study population, 10% hERG blockade corresponds to a QT prolongation of 20 ms (95% confidence interval, 12-32 ms).  With long-term dofetilide administration, tolerance develops with a half-life of 4.7 days.  Conclusions: The current mechanism-based pharmacokinetic-pharmacodynamic model quantified the relationship between in vitro hERG channel blockade and clin. QT prolongation for dofetilide.  This model may prove valuable for assessing the risk of QT prolongation in humans for other drugs that selectively block the hERG channel on the basis of in vitro assays and pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTnqkGXeIQarVg90H21EOLACvtfcHk0ljWJSbG5R4aoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlt1Gqt7c%253D&md5=85eae08f9ac8076e77040e99b3718a03</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2005.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2005.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DJonker%26aufirst%3DD.%2BM.%26aulast%3DKenna%26aufirst%3DL.%2BA.%26aulast%3DLeishman%26aufirst%3DD.%26aulast%3DWallis%26aufirst%3DR.%26aulast%3DMilligan%26aufirst%3DP.%2BA.%26aulast%3DJonsson%26aufirst%3DE.%2BN.%26atitle%3DA%2520Pharmacokinetic-Pharmacodynamic%2520Model%2520for%2520the%2520Quantitative%2520Prediction%2520of%2520Dofetilide%2520Clinical%2520Qt%2520Prolongation%2520from%2520Human%2520Ether-a-Go-Go-Related%2520Gene%2520Current%2520Inhibition%2520Data%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2005%26volume%3D77%26spage%3D572%26epage%3D582%26doi%3D10.1016%2Fj.clpt.2005.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Drugs and Valvular Heart Disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1056/NEJMp068265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1056%2FNEJMp068265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=17202450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlCitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=6-9&author=B.+L.+Roth&title=Drugs+and+Valvular+Heart+Disease&doi=10.1056%2FNEJMp068265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs and valvular heart disease</span></div><div class="casAuthors">Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6-9</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOaFEwabTP8rVg90H21EOLACvtfcHk0ljWJSbG5R4aoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlCitQ%253D%253D&md5=e5161a25f1a2596cef68030f0f8a7b61</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1056%2FNEJMp068265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp068265%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DDrugs%2520and%2520Valvular%2520Heart%2520Disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D6%26epage%3D9%26doi%3D10.1056%2FNEJMp068265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kheirbek, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ing, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viol, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilbar, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geis, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hano, J. E.</span></span> <span> </span><span class="NLM_article-title">Treatment of Metabolic Alkalosis with Hemofiltration in Patients with Renal Insufficiency</span>. <i>Nephron</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1159/000181691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1159%2F000181691" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=91-92&author=A.+O.+Kheirbekauthor=T.+S.+Ingauthor=G.+W.+Violauthor=R.+M.+Vilbarauthor=V.+K.+Bansalauthor=V.+C.+Gandhiauthor=W.+P.+Geisauthor=J.+E.+Hano&title=Treatment+of+Metabolic+Alkalosis+with+Hemofiltration+in+Patients+with+Renal+Insufficiency&doi=10.1159%2F000181691"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1159%2F000181691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000181691%26sid%3Dliteratum%253Aachs%26aulast%3DKheirbek%26aufirst%3DA.%2BO.%26aulast%3DIng%26aufirst%3DT.%2BS.%26aulast%3DViol%26aufirst%3DG.%2BW.%26aulast%3DVilbar%26aufirst%3DR.%2BM.%26aulast%3DBansal%26aufirst%3DV.%2BK.%26aulast%3DGandhi%26aufirst%3DV.%2BC.%26aulast%3DGeis%26aufirst%3DW.%2BP.%26aulast%3DHano%26aufirst%3DJ.%2BE.%26atitle%3DTreatment%2520of%2520Metabolic%2520Alkalosis%2520with%2520Hemofiltration%2520in%2520Patients%2520with%2520Renal%2520Insufficiency%26jtitle%3DNephron%26date%3D2004%26volume%3D24%26spage%3D91%26epage%3D92%26doi%3D10.1159%2F000181691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caccia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conforti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garattini, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of Fenfluramine and Norfenfluramine in Volunteers Given D- and Dl-Fenfluramine for 15 Days</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.1007/BF00547426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1007%2FBF00547426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=4076322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADyaL28XksFarsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1985&pages=221-224&author=S.+Cacciaauthor=I.+Confortiauthor=J.+Duchierauthor=S.+Garattini&title=Pharmacokinetics+of+Fenfluramine+and+Norfenfluramine+in+Volunteers+Given+D-+and+Dl-Fenfluramine+for+15+Days&doi=10.1007%2FBF00547426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of fenfluramine and norfenfluramine in volunteers given d- and dl-fenfluramine for 15 days</span></div><div class="casAuthors">Caccia, S.; Conforti, I.; Duchier, J.; Garattini, S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-4</span>CODEN:
                <span class="NLM_cas:coden">EJCPAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    </div><div class="casAbstract">The kinetics of accumulation and elimination d-fenfluramine  [3239-44-9], l-fenfluramine (F)  [37577-24-5], d-norfenfluramine (d-NF)  [19036-73-8], and l-norfenfluramine (l-NF)  [37577-22-3] were studied in healthy volunteers given daily doses of 3 20-mg tablets of dl-fenfluramine  [458-24-2] as the HCl-salt or 2 15-mg capsules of d-F-HCl for 15 days.  Pharmacokinetic parameters measured after repeated doses of dl-F were similar to those obtained with d-F.  Steady-state concns. of all compds. were achieved within 4-8 days.  The predicted mean steady-state concns. of d-F and elimination half-lives calcd. from the results of a previous single dose study were similar to those measured at steady state in this study.  Plasma levels of d-NF were approx. half those of the parent drug and the half-life was almost twice as long.  Steady state concns. both of l-F and l-NF were consistently about 40-50% higher than of the d-isomers; the half-lives of l-isomers were also longer than the d-isomers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjjKkOiVIH7rVg90H21EOLACvtfcHk0lihcrhqdtkqHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XksFarsA%253D%253D&md5=0d8a89b4815978c153d9672d260e1116</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1007%2FBF00547426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00547426%26sid%3Dliteratum%253Aachs%26aulast%3DCaccia%26aufirst%3DS.%26aulast%3DConforti%26aufirst%3DI.%26aulast%3DDuchier%26aufirst%3DJ.%26aulast%3DGarattini%26aufirst%3DS.%26atitle%3DPharmacokinetics%2520of%2520Fenfluramine%2520and%2520Norfenfluramine%2520in%2520Volunteers%2520Given%2520D-%2520and%2520Dl-Fenfluramine%2520for%252015%2520Days%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1985%26volume%3D29%26spage%3D221%26epage%3D224%26doi%3D10.1007%2FBF00547426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frachon, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Gal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroyer, C.</span></span> <span> </span><span class="NLM_article-title">Benfluorex Withdrawal in France: Still Be Hiding Somewhere in the World?</span>. <i>J. Pharmacol. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.4103/0976-500X.85942</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.4103%2F0976-500X.85942" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=22025868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BC3MbjvVWktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=307-308&author=I.+Frachonauthor=G.+Le+Galauthor=C.+Hillauthor=C.+Leroyer&title=Benfluorex+Withdrawal+in+France%3A+Still+Be+Hiding+Somewhere+in+the+World%3F&doi=10.4103%2F0976-500X.85942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Benfluorex withdrawal in France: Still be hiding somewhere in the world?</span></div><div class="casAuthors">Frachon Irene; Le Gal Gregoire; Hill Catherine; Leroyer Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacology & pharmacotherapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTPw3xVJ6b_BLDWw4HIq2sfW6udTcc2ebt_CIsWVVjv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MbjvVWktw%253D%253D&md5=49d1cda8192f8ff6745036072f890865</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.4103%2F0976-500X.85942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0976-500X.85942%26sid%3Dliteratum%253Aachs%26aulast%3DFrachon%26aufirst%3DI.%26aulast%3DLe%2BGal%26aufirst%3DG.%26aulast%3DHill%26aufirst%3DC.%26aulast%3DLeroyer%26aufirst%3DC.%26atitle%3DBenfluorex%2520Withdrawal%2520in%2520France%253A%2520Still%2520Be%2520Hiding%2520Somewhere%2520in%2520the%2520World%253F%26jtitle%3DJ.%2520Pharmacol.%2520Pharmacother.%26date%3D2011%26volume%3D2%26spage%3D307%26epage%3D308%26doi%3D10.4103%2F0976-500X.85942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomain, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldman, S. A.</span></span> <span> </span><span class="NLM_article-title">Antiobesity Pharmacotherapy: New Drugs and Emerging Targets</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1038/clpt.2013.204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fclpt.2013.204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=24105257" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2013&pages=53-66&author=G.+W.+Kimauthor=J.+E.+Linauthor=E.+S.+Blomainauthor=S.+A.+Waldman&title=Antiobesity+Pharmacotherapy%3A+New+Drugs+and+Emerging+Targets&doi=10.1038%2Fclpt.2013.204"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2013.204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2013.204%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DG.%2BW.%26aulast%3DLin%26aufirst%3DJ.%2BE.%26aulast%3DBlomain%26aufirst%3DE.%2BS.%26aulast%3DWaldman%26aufirst%3DS.%2BA.%26atitle%3DAntiobesity%2520Pharmacotherapy%253A%2520New%2520Drugs%2520and%2520Emerging%2520Targets%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D95%26spage%3D53%26epage%3D66%26doi%3D10.1038%2Fclpt.2013.204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, D. J.</span></span> <span> </span><span class="NLM_article-title">Dopamine Agonists: Their Role in the Treatment of Parkinson’s Disease</span>. <i>J. Neurol., Neurosurg. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">685</span>– <span class="NLM_lpage">689</span>, <span class="refDoi"> DOI: 10.1136/jnnp.68.6.685</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1136%2Fjnnp.68.6.685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10811688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BD3c3ntF2mtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2000&pages=685-689&author=D.+J.+Brooks&title=Dopamine+Agonists%3A+Their+Role+in+the+Treatment+of+Parkinson%E2%80%99s+Disease&doi=10.1136%2Fjnnp.68.6.685"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine agonists: their role in the treatment of Parkinson's disease</span></div><div class="casAuthors">Brooks D J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurology, neurosurgery, and psychiatry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">685-9</span>
        ISSN:<span class="NLM_cas:issn">0022-3050</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjW5OabTzZ4TQLBVDQn4bCfW6udTcc2ebt_CIsWVVjv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c3ntF2mtA%253D%253D&md5=82168189acbf718f702e5e0ecc697380</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1136%2Fjnnp.68.6.685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjnnp.68.6.685%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DD.%2BJ.%26atitle%3DDopamine%2520Agonists%253A%2520Their%2520Role%2520in%2520the%2520Treatment%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Neurol.%252C%2520Neurosurg.%2520Psychiatry%26date%3D2000%26volume%3D68%26spage%3D685%26epage%3D689%26doi%3D10.1136%2Fjnnp.68.6.685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borovac, J. A.</span></span> <span> </span><span class="NLM_article-title">Side Effects of a Dopamine Agonist Therapy for Parkinson’s Disease: A Mini-Review of Clinical Pharmacology</span>. <i>Yale J. Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">47</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=27505015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtlaitbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=37-47&author=J.+A.+Borovac&title=Side+Effects+of+a+Dopamine+Agonist+Therapy+for+Parkinson%E2%80%99s+Disease%3A+A+Mini-Review+of+Clinical+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology</span></div><div class="casAuthors">Borovac, Josip Andjelo</div><div class="citationInfo"><span class="NLM_cas:title">Yale Journal of Biology and Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-47</span>CODEN:
                <span class="NLM_cas:coden">YJBMAU</span>;
        ISSN:<span class="NLM_cas:issn">0044-0086</span>.
    
            (<span class="NLM_cas:orgname">Yale Journal of Biology and Medicine</span>)
        </div><div class="casAbstract">Dopamine agonists (DA) are therapeutic agents that are commonly used in the treatment of Parkinson's disease (PD).  They can reduce undesired motor fluctuations and delay the administration of levodopa therapy.  However, this drug family is assocd. with specific side effects that can significantly diminish the quality of life among PD patients.  Some of them impose significant risks for individuals who have a history of cardiovascular diseases, psychosis, and depression, or those older patients who suffer from renal or hepatic insufficiency.  Various pharmacokinetic and pharmacodynamic considerations need to be taken into account when administering DA therapy.  The goal of this review is to provide a comprehensive, up-to-date overview of DA therapeutic modalities for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcr2x3aPsDe7Vg90H21EOLACvtfcHk0lhixMiY50MZDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtlaitbo%253D&md5=b0da71799d291c8dc9ce4484c234ad4c</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBorovac%26aufirst%3DJ.%2BA.%26atitle%3DSide%2520Effects%2520of%2520a%2520Dopamine%2520Agonist%2520Therapy%2520for%2520Parkinson%25E2%2580%2599s%2520Disease%253A%2520A%2520Mini-Review%2520of%2520Clinical%2520Pharmacology%26jtitle%3DYale%2520J.%2520Biol.%2520Med.%26date%3D2016%26volume%3D89%26spage%3D37%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jahnichen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertz, H. H.</span></span> <span> </span><span class="NLM_article-title">Agonism at 5-Ht2b Receptors Is Not a Class Effect of the Ergolines</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>513</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2005.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.ejphar.2005.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=15862804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BD2M3ivVaksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=513&publication_year=2005&pages=225-228&author=S.+Jahnichenauthor=R.+Horowskiauthor=H.+H.+Pertz&title=Agonism+at+5-Ht2b+Receptors+Is+Not+a+Class+Effect+of+the+Ergolines&doi=10.1016%2Fj.ejphar.2005.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Agonism at 5-HT2B receptors is not a class effect of the ergolines</span></div><div class="casAuthors">Jahnichen Sven; Horowski Reinhard; Pertz Heinz H</div><div class="citationInfo"><span class="NLM_cas:title">European journal of pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">513</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">225-8</span>
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">Restrictive cardiac valvulopathies observed in Parkinson patients treated with the ergoline dopamine agonist pergolide have recently been associated with the agonist efficacy of the drug at 5-hydroxytryptamine2B (5-HT2B) receptors.  To evaluate whether agonism at 5-HT2B receptors is a phenomenon of the class of the ergolines, we studied 5-HT2B receptor-mediated relaxation in porcine pulmonary arteries to five ergolines which are used as antiparkinsonian drugs.  Pergolide and cabergoline were potent full agonists in this tissue (pEC50 8.42 and 8.72).  Bromocriptine acted as a partial agonist (pEC50 6.86).  Lisuride and terguride, however, failed to relax the arteries but potently antagonized 5-HT-induced relaxation (pKB 10.32 and 8.49).  Thus, agonism at 5-HT2B receptors seems not to be a class effect of the ergolines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjpMe6eCTBV5ggzHGM8X5CfW6udTcc2eY2kfG60-4Yg7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M3ivVaksg%253D%253D&md5=9ffdbec67605e8e0960d1a94d5d47ecd</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2005.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2005.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DJahnichen%26aufirst%3DS.%26aulast%3DHorowski%26aufirst%3DR.%26aulast%3DPertz%26aufirst%3DH.%2BH.%26atitle%3DAgonism%2520at%25205-Ht2b%2520Receptors%2520Is%2520Not%2520a%2520Class%2520Effect%2520of%2520the%2520Ergolines%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2005%26volume%3D513%26spage%3D225%26epage%3D228%26doi%3D10.1016%2Fj.ejphar.2005.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goudsouzian, N. G.</span></span> <span> </span><span class="NLM_article-title">Rapacuronium and Bronchospasm</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">728</span>, <span class="refDoi"> DOI: 10.1097/00000542-200105000-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1097%2F00000542-200105000-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=11388519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BD3MzhsVKksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2001&pages=727-728&author=N.+G.+Goudsouzian&title=Rapacuronium+and+Bronchospasm&doi=10.1097%2F00000542-200105000-00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Rapacuronium and bronchospasm</span></div><div class="casAuthors">Goudsouzian N G</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">727-8</span>
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJhGoKiK-pxiEJCPKhJPuqfW6udTcc2eY2kfG60-4Yg7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MzhsVKksQ%253D%253D&md5=0b0beacba1687dd86db09de216bb5367</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1097%2F00000542-200105000-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000542-200105000-00006%26sid%3Dliteratum%253Aachs%26aulast%3DGoudsouzian%26aufirst%3DN.%2BG.%26atitle%3DRapacuronium%2520and%2520Bronchospasm%26jtitle%3DAnesthesiology%26date%3D2001%26volume%3D94%26spage%3D727%26epage%3D728%26doi%3D10.1097%2F00000542-200105000-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jooste, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emala, C. W.</span></span> <span> </span><span class="NLM_article-title">Neuromuscular Blocking Agents’ Differential Bronchoconstrictive Potential in Guinea Pig Airways</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">763</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1097/01.anes.0000264763.48920.c9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1097%2F01.anes.0000264763.48920.c9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=17413914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjvVKit7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2007&pages=763-772&author=E.+Joosteauthor=Y.+Zhangauthor=C.+W.+Emala&title=Neuromuscular+Blocking+Agents%E2%80%99+Differential+Bronchoconstrictive+Potential+in+Guinea+Pig+Airways&doi=10.1097%2F01.anes.0000264763.48920.c9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Neuromuscular blocking agents' differential bronchoconstrictive potential in guinea pig airways</span></div><div class="casAuthors">Jooste, Edmund; Zhang, Yi; Emala, Charles W.</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">763-772</span>CODEN:
                <span class="NLM_cas:coden">ANESAV</span>;
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Neuromuscular blocking agents are designed to antagonize nicotinic cholinergic receptors on skeletal muscle but also antagonize muscarinic receptors.  Several muscle relaxants have the potential to promote bronchoconstriction due to unintended effects exemplified by histamine release of atracurium or mivacurium and detrimental interactions with muscarinic receptors by rapacuronium.  Although interactions of muscle relaxants with muscarinic receptors have been extensively characterized in vitro, limited information is available on their potential interactions with airway tone in vivo.  Changes in pulmonary inflation pressures and heart rates induced by vagal nerve stimulation and i.v. acetylcholine were measured in the absence and presence of increasing doses of gallamine, pancuronium, mivacurium, vecuronium, cisatracurium, rocuronium, or rapacuronium in guinea pigs.  Mivacurium's and rapacuronium's potential of inducing bronchoconstriction by histamine release was also evaluated.  Rapacuronium potentiated both vagal nerve-stimulated and i.v. acetylcholine-induced increases in airway pressures, which were totally blocked by atropine but not pyrilamine.  Vecuronium, rocuronium, mivacurium, and cisatracurium were devoid of significant airway effects.  Mivacurium, at high doses, increased pulmonary inflation pressures, which were attenuated by pyrilamine.  Rapacuronium was unique among muscle relaxants evaluated in that it potentiated both vagal nerve- and i.v. acetylcholine-induced bronchoconstriction with no evidence of histamine release.  The dual detrimental interactions of rapacuronium with muscarinic receptors previously demonstrated in vitro correlate with in vivo muscarinic receptor mechanisms of bronchoconstriction and may account for the profound bronchoconstriction seen with its clin. use.  These findings may establish pharmacol. characteristics to avoid with new muscle relaxants intended for clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiHquLGqJz4LVg90H21EOLACvtfcHk0lhixMiY50MZDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjvVKit7Y%253D&md5=d614d5c685f5bee7cd75b8ab38302010</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1097%2F01.anes.0000264763.48920.c9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.anes.0000264763.48920.c9%26sid%3Dliteratum%253Aachs%26aulast%3DJooste%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DEmala%26aufirst%3DC.%2BW.%26atitle%3DNeuromuscular%2520Blocking%2520Agents%25E2%2580%2599%2520Differential%2520Bronchoconstrictive%2520Potential%2520in%2520Guinea%2520Pig%2520Airways%26jtitle%3DAnesthesiology%26date%3D2007%26volume%3D106%26spage%3D763%26epage%3D772%26doi%3D10.1097%2F01.anes.0000264763.48920.c9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, V. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirshman, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emala, C. W.</span></span> <span> </span><span class="NLM_article-title">Neuromuscular Relaxants as Antagonists for M2 and M3 Muscarinic Receptors</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">744</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1097/00000542-199803000-00026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1097%2F00000542-199803000-00026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=9523819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADyaK1cXitFamtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1998&pages=744-750&author=V.+Y.+Houauthor=C.+A.+Hirshmanauthor=C.+W.+Emala&title=Neuromuscular+Relaxants+as+Antagonists+for+M2+and+M3+Muscarinic+Receptors&doi=10.1097%2F00000542-199803000-00026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors</span></div><div class="casAuthors">Hou, Vivian Y.; Hirshman, Carol A.; Emala, Charles W.</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">744-750</span>CODEN:
                <span class="NLM_cas:coden">ANESAV</span>;
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven Publishers</span>)
        </div><div class="casAbstract">Neuromuscular relaxants such as pancuronium bind to M2 and M3 muscarinic receptors as antagonists.  Blockade of muscarinic receptors in atria of the M2 subtype mediates tachycardia.  In the lung, blockade of M2 receptors on parasympathetic nerves potentiates vagally induced bronchospasm, whereas blockade of M3 receptors on bronchial smooth muscle inhibits bronchospasm.  The current study was designed to quantify the affinity of a series of neuromuscular relaxants for the M2 and M3 muscarinic receptors, which were individually stably transfected in Chinese hamster ovary cell lines.  All muscle relaxants evaluated displaced muscarinic receptor antagonist (3H-QNB3) from muscarinic receptors.  The relative order of potency for the M2 muscarinic receptor (highest to lowest) was pancuronium, gallamine, rocuronium, atracurium, pipecuronium, doxacurium, mivacurium, and succinylcholine.  The relative order of potency for the M3 muscarinic receptor (highest to lowest) was pancuronium, atracurium, pipecuronium, rocuronium, mivacurium, gallamine, succinylcholine, and doxacurium.  All neuromuscular relaxants studied had affinities for the M2 and M3 muscarinic receptor, but only pancuronium and gallamine had affinities within the range of concns. achieved with clin. use.  The high affinities of gallamine and pancuronium for the M2 muscarinic receptor are consistent with a mechanism of M2 receptor blockade in relaxant-induced tachycardia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHOs4wH2oag7Vg90H21EOLACvtfcHk0liv1h9WJF7Lqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitFamtL4%253D&md5=91c80c50cec8ddfe7b1ea731b08bce19</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1097%2F00000542-199803000-00026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000542-199803000-00026%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DV.%2BY.%26aulast%3DHirshman%26aufirst%3DC.%2BA.%26aulast%3DEmala%26aufirst%3DC.%2BW.%26atitle%3DNeuromuscular%2520Relaxants%2520as%2520Antagonists%2520for%2520M2%2520and%2520M3%2520Muscarinic%2520Receptors%26jtitle%3DAnesthesiology%26date%3D1998%26volume%3D88%26spage%3D744%26epage%3D750%26doi%3D10.1097%2F00000542-199803000-00026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jooste, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klafter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirshman, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emala, C. W.</span></span> <span> </span><span class="NLM_article-title">A Mechanism for Rapacuronium-Induced Bronchospasm: M2 Muscarinic Receptor Antagonism</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">906</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1097/00000542-200304000-00017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1097%2F00000542-200304000-00017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=12657852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlKiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2003&pages=906-911&author=E.+Joosteauthor=F.+Klafterauthor=C.+A.+Hirshmanauthor=C.+W.+Emala&title=A+Mechanism+for+Rapacuronium-Induced+Bronchospasm%3A+M2+Muscarinic+Receptor+Antagonism&doi=10.1097%2F00000542-200304000-00017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">A Mechanism for Rapacuronium-induced Bronchospasm: M2 Muscarinic Receptor Antagonism</span></div><div class="casAuthors">Jooste, Edmund; Klafter, Farrah; Hirshman, Carol A.; Emala, Charles W.</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">906-911</span>CODEN:
                <span class="NLM_cas:coden">ANESAV</span>;
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A safe and effective ultra-short-acting nondepolarizing neuromuscular blocking agent is required to block nicotinic receptors to facilitate intubation.  Rapacuronium, which sought to fulfill these criteria, was withdrawn from clin. use due to a high incidence of bronchospasm resulting in death.  Understanding the mechanism by which rapacuronium induces fatal bronchospasm is imperative so that newly synthesized neuromuscular blocking agents that share this mechanism will not be introduced clin.  Selective inhibition of M2 muscarinic receptors by muscle relaxants during periods of parasympathetic nerve stimulation (e.g., intubation) can result in the massive release METHODS of acetylcholine to act on unopposed M3 muscarinic receptors in airway smooth muscle, thereby facilitating bronchoconstriction.  Competitive radioligand binding detd. the binding affinities of rapacuronium, vecuronium, cisatracurium, methoctramine (selective M2 antagonist), and 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP; selective M3 antagonist) for M2 and M3 muscarinic receptors.  Rapacuronium competitively displaced 3H-QNB from the M2 muscarinic receptors but not from the M3 muscarinic receptors within clin. relevant concns.  Fifty percent inhibitory concns. (mean ± SE) for rapacuronium were as follows: M2 muscarinic receptor, 5.10±1.5 μm (n = 6); M3 muscarinic receptor, 77.9±11 μm (n = 8).  Cisatracurium and vecuronium competitively displaced 3H-QNB from both M2 and M3 muscarinic receptors but had affinities at greater than clin. achieved concns. for these relaxants.  Rapacuronium in clin. significant doses has a higher affinity for M2 muscarinic receptors as compared with M3 muscarinic receptors.  A potential mechanism by which rapacuronium may potentiate bronchoconstriction is by blockade of M2 muscarinic receptors on prejunctional parasympathetic nerves, leading to increased release of acetylcholine and thereby resulting in M3 muscarinic receptor-mediated airway smooth muscle constriction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAmsOfmK2j97Vg90H21EOLACvtfcHk0liv1h9WJF7Lqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlKiu74%253D&md5=f29a2c7abdd2d2a7d6383e10814da5a0</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1097%2F00000542-200304000-00017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000542-200304000-00017%26sid%3Dliteratum%253Aachs%26aulast%3DJooste%26aufirst%3DE.%26aulast%3DKlafter%26aufirst%3DF.%26aulast%3DHirshman%26aufirst%3DC.%2BA.%26aulast%3DEmala%26aufirst%3DC.%2BW.%26atitle%3DA%2520Mechanism%2520for%2520Rapacuronium-Induced%2520Bronchospasm%253A%2520M2%2520Muscarinic%2520Receptor%2520Antagonism%26jtitle%3DAnesthesiology%26date%3D2003%26volume%3D98%26spage%3D906%26epage%3D911%26doi%3D10.1097%2F00000542-200304000-00017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dore, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiBello, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapane, K. L.</span></span> <span> </span><span class="NLM_article-title">Telithromycin Use and Spontaneous Reports of Hepatotoxicity</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">703</span>, <span class="refDoi"> DOI: 10.2165/00002018-200730080-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.2165%2F00002018-200730080-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=17696582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BD2svotVGhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2007&pages=697-703&author=D.+D.+Doreauthor=J.+R.+DiBelloauthor=K.+L.+Lapane&title=Telithromycin+Use+and+Spontaneous+Reports+of+Hepatotoxicity&doi=10.2165%2F00002018-200730080-00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Telithromycin use and spontaneous reports of hepatotoxicity</span></div><div class="casAuthors">Dore David D; DiBello Julia R; Lapane Kate L</div><div class="citationInfo"><span class="NLM_cas:title">Drug safety</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">697-703</span>
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    </div><div class="casAbstract">BACKGROUND AND OBJECTIVE:  Recent reports have described cases of telithromycin-related hepatotoxicity.  The objective of this study is to quantify the effect of telithromycin use on the risk of hepatotoxicity.  METHODS:  We conducted a spontaneous-report case-control study of hepatotoxicity in telithromycin recipients using reports from the US FDA Adverse Event Reporting System.  Reports from between 1 January 2005 and 30 June 2005 were examined.  Cases included reports of patients with abnormal liver function tests, hepatocellular damage and hepatic impairment, while patients with reported conditions with similar reporting probabilities were considered as controls.  The primary outcome measure of the analysis was the reporting odds ratio (ROR) evaluating the a priori hypothesis that telithromycin use confers an elevated risk of hepatotoxicity relative to other agents.  RESULTS:  A total of 2219 cases and 20,667 controls were identified.  We estimated an ROR for hepatotoxicity associated with telithromycin compared with other agents of 1.82 (95% CI 1.12, 2.96) after controlling for age and gender, approximating an 82% excess risk in users of telithromycin relative to users of other agents.  CONCLUSIONS:  This analysis is the first to specifically quantify the effect of telithromycin on the risk of hepatotoxicity.  Telithromycin use may increase the risk of hepatotoxicity by >80%.  Biases inherent in spontaneous reports include under-reporting of events and differential or time-varying reporting due to enhanced clinician awareness.  Future studies should employ alternative data sources because of the inherent limitations of passive surveillance systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSv7TVZm2oNUn6oPH0mYWL1fW6udTcc2eZxdkXf-n2kRbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svotVGhtQ%253D%253D&md5=fc34ce6f1ef8a2db4d4e12334e1fed48</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.2165%2F00002018-200730080-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00002018-200730080-00006%26sid%3Dliteratum%253Aachs%26aulast%3DDore%26aufirst%3DD.%2BD.%26aulast%3DDiBello%26aufirst%3DJ.%2BR.%26aulast%3DLapane%26aufirst%3DK.%2BL.%26atitle%3DTelithromycin%2520Use%2520and%2520Spontaneous%2520Reports%2520of%2520Hepatotoxicity%26jtitle%3DDrug%2520Saf.%26date%3D2007%26volume%3D30%26spage%3D697%26epage%3D703%26doi%3D10.2165%2F00002018-200730080-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. B.</span></span> <span> </span><span class="NLM_article-title">The Fda and the Case of Ketek</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">1601</span>– <span class="NLM_lpage">1604</span>, <span class="refDoi"> DOI: 10.1056/NEJMp078032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1056%2FNEJMp078032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=17442902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksFCgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=1601-1604&author=D.+B.+Ross&title=The+Fda+and+the+Case+of+Ketek&doi=10.1056%2FNEJMp078032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective: the FDA and the case of Ketek</span></div><div class="casAuthors">Ross, David B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1601-1604</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxg3oJZMs06LVg90H21EOLACvtfcHk0lizDoas5wY1YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksFCgtb4%253D&md5=f077976e1f2d38a66f7730fe4e6fb184</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1056%2FNEJMp078032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp078032%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DD.%2BB.%26atitle%3DThe%2520Fda%2520and%2520the%2520Case%2520of%2520Ketek%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D1601%26epage%3D1604%26doi%3D10.1056%2FNEJMp078032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, P.</span></span> <span> </span><span class="NLM_article-title">Molecular Characterization of Off-Target Activities of Telithromycin: A Potential Role for Nicotinic Acetylcholine Receptors</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5399</span>– <span class="NLM_lpage">5402</span>, <span class="refDoi"> DOI: 10.1128/AAC.00840-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1128%2FAAC.00840-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=20855733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2msrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=5399-5402&author=D.+Bertrandauthor=S.+Bertrandauthor=E.+Neveuauthor=P.+Fernandes&title=Molecular+Characterization+of+Off-Target+Activities+of+Telithromycin%3A+A+Potential+Role+for+Nicotinic+Acetylcholine+Receptors&doi=10.1128%2FAAC.00840-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors</span></div><div class="casAuthors">Bertrand, Daniel; Bertrand, Sonia; Neveu, Estelle; Fernandes, Prabhavathi</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5399-5402</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Adverse effects have limited the clin. use of telithromycin.  Preferential inhibition of the nicotinic acetylcholine receptors (nAChR) at the neuromuscular junction (α3β2 and NMJ), the ciliary ganglion of the eye (α3β4 and α7), and the vagus nerve innervating the liver (α7) could account for the exacerbation of myasthenia gravis, the visual disturbance, and the liver failure seen with telithromycin use.  The studies presented here enable the prediction of expected side effects of macrolides in development, such as solithromycin (CEM-101).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0NSdRTqlSyrVg90H21EOLACvtfcHk0lizDoas5wY1YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2msrzK&md5=5991da1c22328f9ec9abc93c0da200df</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1128%2FAAC.00840-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00840-10%26sid%3Dliteratum%253Aachs%26aulast%3DBertrand%26aufirst%3DD.%26aulast%3DBertrand%26aufirst%3DS.%26aulast%3DNeveu%26aufirst%3DE.%26aulast%3DFernandes%26aufirst%3DP.%26atitle%3DMolecular%2520Characterization%2520of%2520Off-Target%2520Activities%2520of%2520Telithromycin%253A%2520A%2520Potential%2520Role%2520for%2520Nicotinic%2520Acetylcholine%2520Receptors%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D5399%26epage%3D5402%26doi%3D10.1128%2FAAC.00840-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, D.</span></span> <span> </span><span class="NLM_article-title">The Solithromycin Journey-It Is All in the Chemistry</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6420</span>– <span class="NLM_lpage">6428</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.08.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.bmc.2016.08.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=27595539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVCgsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=6420-6428&author=P.+Fernandesauthor=E.+Martensauthor=D.+Bertrandauthor=D.+Pereira&title=The+Solithromycin+Journey-It+Is+All+in+the+Chemistry&doi=10.1016%2Fj.bmc.2016.08.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">The solithromycin journey-It is all in the chemistry</span></div><div class="casAuthors">Fernandes, Prabhavathi; Martens, Evan; Bertrand, Daniel; Pereira, David</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6420-6428</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The macrolide class of antibiotics, including the early generation macrolides erythromycin, clarithromycin and azithromycin, have been used broadly for treatment of respiratory tract infections.  An increase of treatment failures of early generation macrolides is due to the upturn in bacterial macrolide resistance to 48% in the US and over 80% in Asian countries and has led to the use of alternate therapies, such as fluoroquinolones.  The safety of the fluoroquinolones is now in question and alternate antibiotics for the outpatient treatment of community acquired bacterial pneumonia are needed.  Telithromycin, approved in 2003, is no longer used owing to serious adverse events, collectively called the 'Ketek effects'.  Telithromycin has a side chain pyridine moiety that blocks nicotinic acetylcholine receptors.  Blockade of these receptors is known exptl. to cause the side effects seen with telithromycin in patients use.  Solithromycin is a new macrolide, the first fluoroketolide, which has been tested successfully in two Phase 3 trials and is undergoing regulatory review at the FDA.  Solithromycin is differentiated from telithromycin chem. and biol. in that its side chain is chem. different and does not significantly block nicotinic acetylcholine receptors.  Solithromycin was well tolerated and effective in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7LdWo7aa8ZrVg90H21EOLACvtfcHk0lizDoas5wY1YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVCgsrbN&md5=9d19bc32264ad1bb80d19b5d7709f514</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.08.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.08.035%26sid%3Dliteratum%253Aachs%26aulast%3DFernandes%26aufirst%3DP.%26aulast%3DMartens%26aufirst%3DE.%26aulast%3DBertrand%26aufirst%3DD.%26aulast%3DPereira%26aufirst%3DD.%26atitle%3DThe%2520Solithromycin%2520Journey-It%2520Is%2520All%2520in%2520the%2520Chemistry%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D6420%26epage%3D6428%26doi%3D10.1016%2Fj.bmc.2016.08.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Origlia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzano, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moretti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domenici, L.</span></span> <span> </span><span class="NLM_article-title">Visual Acuity Is Reduced in Alpha 7 Nicotinic Receptor Knockout Mice</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1211</span>– <span class="NLM_lpage">1218</span>, <span class="refDoi"> DOI: 10.1167/iovs.11-8007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1167%2Fiovs.11-8007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=22281823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38XmslKlt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=1211-1218&author=N.+Origliaauthor=D.+R.+Valenzanoauthor=M.+Morettiauthor=C.+Gottiauthor=L.+Domenici&title=Visual+Acuity+Is+Reduced+in+Alpha+7+Nicotinic+Receptor+Knockout+Mice&doi=10.1167%2Fiovs.11-8007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Visual acuity is reduced in alpha 7 nicotinic receptor knockout mice</span></div><div class="casAuthors">Origlia, Nicola; Valenzano, Dario Riccardo; Moretti, Milena; Gotti, Cecilia; Domenici, Luciano</div><div class="citationInfo"><span class="NLM_cas:title">Investigative Ophthalmology & Visual Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1211-1218</span>CODEN:
                <span class="NLM_cas:coden">IOVSDA</span>;
        ISSN:<span class="NLM_cas:issn">1552-5783</span>.
    
            (<span class="NLM_cas:orgname">Association for Research in Vision and Ophthalmology</span>)
        </div><div class="casAbstract">Purpose: Nicotinic receptors (nAChRs) are part of a heterogeneous family of pentameric ligand-gated ion channels that are widely expressed in the visual system.  The impact of α7 homomeric nAChRs on visual function was investigated using mutant mice lacking the α7 nicotinic receptor subunit.  Methods: The spatial resoln. limit was measured in α7 knockout (α7 KO) and age-matched control mice using three independent methods: an operant behavioral visual task (Prusky maze), cortical visual evoked potentials (VEPs), and the pattern electroretinogram (PERG) evoked by alternating gratings of different spatial frequencies and contrasts.  Results: Visual acuity measured by means of the visual water maze task was significantly decreased in the α7 KO mice and, concordantly, there was a redn. of the cortical spatial resoln. limit measured by VEPs.  However, the PERG was normal in α7 KO mice, compared with control mice.  The use of fluorescently tagged cholera toxin showed that projections from the retina segregate normally in α7 KO mice and, in line with this, the visual cortical responses elicited by stimulating either eye were normally balanced in both visual cortices and showed no retinotopic anomalies.  Conclusions: These findings indicate that the absence of the α7 nicotinic subunit reduces visual acuity.  Because the cortical output has an abnormal spatial resoln. but retinal output is preserved, it can be concluded that the low visual acuity was due to a deficit specifically present in the visual cortex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMRWjl-VN877Vg90H21EOLACvtfcHk0ljAbA3u2qPJUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmslKlt7k%253D&md5=2c6c80ec1fa74695f21a4907e7a8c5e9</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1167%2Fiovs.11-8007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.11-8007%26sid%3Dliteratum%253Aachs%26aulast%3DOriglia%26aufirst%3DN.%26aulast%3DValenzano%26aufirst%3DD.%2BR.%26aulast%3DMoretti%26aufirst%3DM.%26aulast%3DGotti%26aufirst%3DC.%26aulast%3DDomenici%26aufirst%3DL.%26atitle%3DVisual%2520Acuity%2520Is%2520Reduced%2520in%2520Alpha%25207%2520Nicotinic%2520Receptor%2520Knockout%2520Mice%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2012%26volume%3D53%26spage%3D1211%26epage%3D1218%26doi%3D10.1167%2Fiovs.11-8007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewart, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nylander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidaway, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Giezen, J. J.</span></span> <span> </span><span class="NLM_article-title">Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1</span>. <i>J. Cardiovasc. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1177/1074248413511693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1177%2F1074248413511693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=24414167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnt1artbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=209-219&author=D.+Armstrongauthor=C.+Summersauthor=L.+Ewartauthor=S.+Nylanderauthor=J.+E.+Sidawayauthor=J.+J.+van+Giezen&title=Characterization+of+the+Adenosine+Pharmacology+of+Ticagrelor+Reveals+Therapeutically+Relevant+Inhibition+of+Equilibrative+Nucleoside+Transporter+1&doi=10.1177%2F1074248413511693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter I</span></div><div class="casAuthors">Armstrong, Duncan; Summers, Claire; Ewart, Lorna; Nylander, Sven; Sidaway, James E.; van Giezen, J. J. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-219</span>CODEN:
                <span class="NLM_cas:coden">JCPTFE</span>;
        ISSN:<span class="NLM_cas:issn">1074-2484</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Introduction: Studies have shown that ticagrelor has a further adenosine-mediated mechanism of action in addn. to its potent inhibition of the P2Y12 receptor, which may explain some of ticagrelor's clin. characteristics.  This study aimed to further characterize the adenosine pharmacol. of ticagrelor, its major metabolites, and other P2Y12 receptor antagonists.  Methods: Inhibition of nucleoside transporter-mediated [3H]adenosine uptake by ticagrelor, its major metabolites, and alternative P2Y12 antagonists was examd. in recombinant Madin-Darby canine kidney (MDCK) cells.  The pharmacol. of ticagrelor and its major metabolites at adenosine A1, A2A, A2B, and A3 receptor subtypes was examd. using in vitro radioligand binding and functional assays and ex vivo C-fiber expts. in rat and guinea pig vagus nerves.  Results: Ticagrelor (and less effectively its metabolites) and the main cangrelor metabolite inhibited [3H]adenosine uptake in equilibrative nucleoside transporter (ENT) I-expressing MDCK cells, whereas cangrelor and the active metabolites of prasugrel or clopidogrel had no effect.  No significant inhibitory activity was obsd. in MDCK cells expressing ENT2 or concentrative nucleoside transporters 2/3.  Ticagrelor demonstrated high affinity (inhibition const. [Ki] = 41 nmol/L) for ENT I.  In adenosine receptor-binding expts., ticagrelor and its major circulating metabolite, AR-C124910XX, had low affinity (Ki > 6 μmol/L) for each of the adenosine A1, A2A, and A2B receptors, whereas ticagrelor had a submicromolar (Ki = 190 nmol/L) affinity for the adenosine A3 receptor.  However, in functional assays, at high concns. (10 μmol/L) ticagrelor only partially inhibited 3 mmol/L adenosine-induced depolarizations in the guinea pig and rat vagus nerve prepns. (by 35% and 49%, resp.).  Conclusions: Ticagrelor inhibits cellular adenosine uptake selectively via ENT I inhibition at concns. of clin. relevance.  However, the low-binding affinity and functional inhibition of adenosine receptors obsd. with ticagrelor or its metabolites indicate that they possess a negligible adenosine-like activity at clin. relevant concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuplo327ow5bVg90H21EOLACvtfcHk0ljAbA3u2qPJUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnt1artbc%253D&md5=3994d5d66af983e28a4fa59351e6145c</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1177%2F1074248413511693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1074248413511693%26sid%3Dliteratum%253Aachs%26aulast%3DArmstrong%26aufirst%3DD.%26aulast%3DSummers%26aufirst%3DC.%26aulast%3DEwart%26aufirst%3DL.%26aulast%3DNylander%26aufirst%3DS.%26aulast%3DSidaway%26aufirst%3DJ.%2BE.%26aulast%3Dvan%2BGiezen%26aufirst%3DJ.%2BJ.%26atitle%3DCharacterization%2520of%2520the%2520Adenosine%2520Pharmacology%2520of%2520Ticagrelor%2520Reveals%2520Therapeutically%2520Relevant%2520Inhibition%2520of%2520Equilibrative%2520Nucleoside%2520Transporter%25201%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%2520Ther.%26date%3D2014%26volume%3D19%26spage%3D209%26epage%3D219%26doi%3D10.1177%2F1074248413511693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
den Berg, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Messaoudi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rongen, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den
Broek, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donders, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riksen, N. P.</span></span> <span> </span><span class="NLM_article-title">Ticagrelor Does Not Inhibit Adenosine Transport at Relevant Concentrations: A Randomized Cross-over Study in Healthy Subjects in Vivo</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0137560</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0137560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1371%2Fjournal.pone.0137560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=26509673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKmsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=T.+N.+van%0Aden+Bergauthor=S.+El+Messaoudiauthor=G.+A.+Rongenauthor=P.+H.+van+den%0ABroekauthor=A.+Bilosauthor=A.+R.+Dondersauthor=M.+E.+Gomesauthor=N.+P.+Riksen&title=Ticagrelor+Does+Not+Inhibit+Adenosine+Transport+at+Relevant+Concentrations%3A+A+Randomized+Cross-over+Study+in+Healthy+Subjects+in+Vivo&doi=10.1371%2Fjournal.pone.0137560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Ticagrelor does not inhibit adenosine transport at relevant concentrations: a randomized cross-over study in healthy subjects in vivo</span></div><div class="casAuthors">van den Berg, T. N. A.; El Messaoudi, S.; Rongen, G. A.; van den Broek, P. H. H.; Bilos, A.; Donders, A. R. T.; Gomes, M. E.; Riksen, N. P.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e0137560/1-e0137560/15</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background and Purpose: In patients with myocardial infarction, ticagrelor reduces cardiovascular and sepsis-related mortality, and can cause dyspnea.  It is suggested that this is caused by adenosine receptor stimulation, because in preclin. studies, ticagrelor blocks the nucleoside transporter and increases cellular ATP release.  We now investigated the effects of ticagrelor on the adenosine system in humans in vivo.  Exptl. Approach: In a double-blinded, placebo-controlled cross-over trial in 14 healthy subjects, we have tested whether ticagrelor (180 mg) affects adenosine- and dipyridamole-induced forearm vasodilation, as surrogates of nucleoside uptake inhibition and adenosine formation, resp.  Also, ex vivo uptake of adenosine and uridine in isolated red blood cells was measured.  Primary endpoint was adenosine-induced vasodilation.  Key Results: Ticagrelor did not affect adenosine- or dipyridamole-induced forearm vasodilation.  Also, ex vivo uptake of adenosine and uridine in isolated red blood cells was not affected by ticagrelor.  In vitro, ticagrelor dose-dependently inhibited nucleoside uptake, but only at supra-physiol. concns.  Conclusion and Implications: In conclusion, at relevant plasma concn., ticagrelor does not affect adenosine transport, nor adenosine formation in healthy subjects.  Therefore, it is unlikely that this mechanism is a relevant pleiotropic effect of ticagrelor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxA-ml-YX0CbVg90H21EOLACvtfcHk0ljAbA3u2qPJUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKmsbjP&md5=c91c884cb2118890754e5388fbe2a3ce</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0137560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0137560%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bden%2BBerg%26aufirst%3DT.%2BN.%26aulast%3DEl%2BMessaoudi%26aufirst%3DS.%26aulast%3DRongen%26aufirst%3DG.%2BA.%26aulast%3Dvan%2Bden%2BBroek%26aufirst%3DP.%2BH.%26aulast%3DBilos%26aufirst%3DA.%26aulast%3DDonders%26aufirst%3DA.%2BR.%26aulast%3DGomes%26aufirst%3DM.%2BE.%26aulast%3DRiksen%26aufirst%3DN.%2BP.%26atitle%3DTicagrelor%2520Does%2520Not%2520Inhibit%2520Adenosine%2520Transport%2520at%2520Relevant%2520Concentrations%253A%2520A%2520Randomized%2520Cross-over%2520Study%2520in%2520Healthy%2520Subjects%2520in%2520Vivo%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0137560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. U.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology - Foe or Friend?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8955</span>– <span class="NLM_lpage">8971</span>, <span class="refDoi"> DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&author=J.+U.+Peters&title=Polypharmacology+-+Foe+or+Friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology - Foe or Friend?</span></div><div class="casAuthors">Peters, Jens-Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8955-8971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. describes the activity of compds. at multiple targets.  Current research focuses on two aspects of polypharmacol.: (1) unintended polypharmacol. can lead to adverse effects; (2) polypharmacol. across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects.  This perspective reviews these interconnected aspects of polypharmacol.  The first part discusses the relevance of polypharmacol. for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacol. compds. early in the drug discovery process.  The second part discusses the advantages of polypharmacol. in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing.  This perspective aims to provide a balanced view on polypharmacol., which can compromise the safety of drugs, but can also confer superior efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vnFGPfTnGLVg90H21EOLACvtfcHk0lj8oTf0vMyLNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO&md5=f4aeb6efddd4bfdf4e94656303323cba</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26atitle%3DPolypharmacology%2520-%2520Foe%2520or%2520Friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D8971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arango, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Los, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span> <span> </span><span class="NLM_article-title">An Orally Available Small-Molecule Inhibitor of C-Met, Pf-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">4408</span>– <span class="NLM_lpage">4417</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-4443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.+P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=S.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+Orally+Available+Small-Molecule+Inhibitor+of+C-Met%2C+Pf-2341066%2C+Exhibits+Cytoreductive+Antitumor+Efficacy+through+Antiproliferative+and+Antiangiogenic+Mechanisms&doi=10.1158%2F0008-5472.CAN-06-4443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0lj8oTf0vMyLNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520Orally%2520Available%2520Small-Molecule%2520Inhibitor%2520of%2520C-Met%252C%2520Pf-2341066%252C%2520Exhibits%2520Cytoreductive%2520Antitumor%2520Efficacy%2520through%2520Antiproliferative%2520and%2520Antiangiogenic%2520Mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417%26doi%3D10.1158%2F0008-5472.CAN-06-4443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasothan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Crizotinib</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">897</span>– <span class="NLM_lpage">898</span>, <span class="refDoi"> DOI: 10.1038/nrd3600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fnrd3600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=22129984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFGktbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=897-898&author=A.+T.+Shawauthor=U.+Yasothanauthor=P.+Kirkpatrick&title=Crizotinib&doi=10.1038%2Fnrd3600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib</span></div><div class="casAuthors">Shaw, Alice T.; Yasothan, Uma; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">897-898</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In August 2011 crizotinib (Xalkori; Pfizer), a small-mol. kinase inhibitor, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer that is anaplastic lymphoma kinase-pos., as detected by an FDA-approved test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw1A3bWW-DjbVg90H21EOLACvtfcHk0lgXnIx2gwlMwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFGktbnF&md5=6d2b5ff87f4f61a88929759e79422d99</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fnrd3600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3600%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DYasothan%26aufirst%3DU.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DCrizotinib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D897%26epage%3D898%26doi%3D10.1038%2Fnrd3600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran-Dube, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botrous, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grodsky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padrique, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Structure Based Drug Design of Crizotinib (Pf-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (C-Met) Kinase and Anaplastic Lymphoma Kinase (Alk)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6342</span>– <span class="NLM_lpage">6363</span>, <span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dubeauthor=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+Based+Drug+Design+of+Crizotinib+%28Pf-02341066%29%2C+a+Potent+and+Selective+Dual+Inhibitor+of+Mesenchymal-Epithelial+Transition+Factor+%28C-Met%29+Kinase+and+Anaplastic+Lymphoma+Kinase+%28Alk%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0lhhc1c1IGgUnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520Based%2520Drug%2520Design%2520of%2520Crizotinib%2520%2528Pf-02341066%2529%252C%2520a%2520Potent%2520and%2520Selective%2520Dual%2520Inhibitor%2520of%2520Mesenchymal-Epithelial%2520Transition%2520Factor%2520%2528C-Met%2529%2520Kinase%2520and%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528Alk%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enomoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurashina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bando, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span> <span> </span><span class="NLM_article-title">Identification of the Transforming Eml4-Alk Fusion Gene in Non-Small-Cell Lung Cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nature05945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+Transforming+Eml4-Alk+Fusion+Gene+in+Non-Small-Cell+Lung+Cancer&doi=10.1038%2Fnature05945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0lhhc1c1IGgUnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520Transforming%2520Eml4-Alk%2520Fusion%2520Gene%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566%26doi%3D10.1038%2Fnature05945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shioda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Classon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheswaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulkus, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhlmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greninger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span> <span> </span><span class="NLM_article-title">Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">3389</span>– <span class="NLM_lpage">3395</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-6186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1158%2F0008-5472.CAN-07-6186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=18451166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlSlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=3389-3395&author=U.+McDermottauthor=A.+J.+Iafrateauthor=N.+S.+Grayauthor=T.+Shiodaauthor=M.+Classonauthor=S.+Maheswaranauthor=W.+Zhouauthor=H.+G.+Choiauthor=S.+L.+Smithauthor=L.+Dowellauthor=L.+E.+Ulkusauthor=G.+Kuhlmannauthor=P.+Greningerauthor=J.+G.+Christensenauthor=D.+A.+Haberauthor=J.+Settleman&title=Genomic+Alterations+of+Anaplastic+Lymphoma+Kinase+May+Sensitize+Tumors+to+Anaplastic+Lymphoma+Kinase+Inhibitors&doi=10.1158%2F0008-5472.CAN-07-6186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">McDermott, Ultan; Iafrate, A. John; Gray, Nathanael S.; Shioda, Toshi; Classon, Marie; Maheswaran, Shyamala; Zhou, Wenjun; Choi, Hwan Geun; Smith, Shannon L.; Dowell, Lori; Ulkus, Lindsey E.; Kuhlmann, Georgiana; Greninger, Patricia; Christensen, James G.; Haber, Daniel A.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3389-3395</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Selective kinase inhibitors have had a substantial impact on the field of medical oncol.  Whereas these agents can elicit dramatic clin. responses in some settings, their activity is generally limited to a subset of treated patients whose tumor cells harbor a specific genetic lesion.  We have established an automated platform for examg. the sensitivity to various molecularly targeted inhibitors across a large panel of human tumor-derived cell lines to identify addnl. genotype-correlated responses that may be clin. relevant.  Among the inhibitors tested in a panel of 602 cell lines derived from a variety of human cancers, we found that a selective inhibitor of the anaplastic lymphoma kinase (ALK) potently suppressed growth of a small subset of tumor cells.  This subset included lines derived from anaplastic large cell lymphomas, non-small-cell lung cancers, and neuroblastomas.  ALK is a receptor tyrosine kinase that was first identified as part of a protein fusion derived from a chromosomal translocation detected in the majority of anaplastic large cell lymphoma patients, and has recently been implicated as an oncogene in a small fraction of non-small-cell lung cancers and neuroblastomas.  Significantly, sensitivity in these cell lines was well correlated with specific ALK genomic rearrangements, including chromosomal translocations and gene amplification.  Moreover, in such cell lines, ALK kinase inhibition can lead to potent suppression of downstream survival signaling and an apoptotic response.  These findings suggest that a subset of lung cancers, lymphomas, and neuroblastomas that harbor genomic ALK alterations may be clin. responsive to pharmacol. ALK inhibition. [Cancer Res 2008;68(9):3389-95].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwtwwG7vhYTbVg90H21EOLACvtfcHk0lhDbC3zEe1zkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlSlsbg%253D&md5=5168e6ce3ea650df3722dbd4f1aa53ea</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6186%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DShioda%26aufirst%3DT.%26aulast%3DClasson%26aufirst%3DM.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DSmith%26aufirst%3DS.%2BL.%26aulast%3DDowell%26aufirst%3DL.%26aulast%3DUlkus%26aufirst%3DL.%2BE.%26aulast%3DKuhlmann%26aufirst%3DG.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DGenomic%2520Alterations%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520May%2520Sensitize%2520Tumors%2520to%2520Anaplastic%2520Lymphoma%2520Kinase%2520Inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D3389%26epage%3D3395%26doi%3D10.1158%2F0008-5472.CAN-07-6186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theodoro, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skokan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berge, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracciano, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappuzzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Incarbone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roncalli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alloisio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span> <span> </span><span class="NLM_article-title">Identifying and Targeting Ros1 Gene Fusions in Non-Small Cell Lung Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4570</span>– <span class="NLM_lpage">4579</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0550</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1158%2F1078-0432.CCR-12-0550" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=22919003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ygsLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4570-4579&author=K.+D.+Daviesauthor=A.+T.+Leauthor=M.+F.+Theodoroauthor=M.+C.+Skokanauthor=D.+L.+Aisnerauthor=E.+M.+Bergeauthor=L.+M.+Terraccianoauthor=F.+Cappuzzoauthor=M.+Incarboneauthor=M.+Roncalliauthor=M.+Alloisioauthor=A.+Santoroauthor=D.+R.+Camidgeauthor=M.+Varella-Garciaauthor=R.+C.+Doebele&title=Identifying+and+Targeting+Ros1+Gene+Fusions+in+Non-Small+Cell+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-12-0550"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Davies, Kurtis D.; Le, Anh T.; Theodoro, Mariana F.; Skokan, Margaret C.; Aisner, Dara L.; Berge, Eamon M.; Terracciano, Luigi M.; Cappuzzo, Federico; Incarbone, Matteo; Roncalli, Massimo; Alloisio, Marco; Santoro, Armando; Camidge, D. Ross; Varella-Garcia, Marileila; Doebele, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4570-4579</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Oncogenic gene fusions involving the 3' region of ROS1 kinase have been identified in various human cancers.  In this study, we sought to characterize ROS1 fusion genes in non-small cell lung cancer (NSCLC) and establish the fusion proteins as drug targets.  Exptl. Design: An NSCLC tissue microarray (TMA) panel contg. 447 samples was screened for ROS1 rearrangement by FISH.  This assay was also used to screen patients with NSCLC.  In pos. samples, the identity of the fusion partner was detd. through inverse PCR and reverse transcriptase PCR.  In addn., the clin. efficacy of ROS1 inhibition was assessed by treating a ROS1-pos. patient with crizotinib.  The HCC78 cell line, which expresses the SLC34A2-ROS1 fusion, was treated with kinase inhibitors that have activity against ROS1.  The effects of ROS1 inhibition on proliferation, cell-cycle progression, and cell signaling pathways were analyzed by MTS assay, flow cytometry, and Western blotting.  Results: In the TMA panel, 5 of 428 (1.2%) evaluable samples were found to be pos. for ROS1 rearrangement.  In addn., 1 of 48 patients tested pos. for rearrangement, and this patient showed tumor shrinkage upon treatment with crizotinib.  The patient and one TMA sample displayed expression of the recently identified SDC4-ROS1 fusion, whereas two TMA samples expressed the CD74-ROS1 fusion and two others expressed the SLC34A2-ROS1 fusion.  In HCC78 cells, treatment with ROS1 inhibitors was antiproliferative and downregulated signaling pathways that are crit. for growth and survival.  Conclusions: ROS1 inhibition may be an effective treatment strategy for the subset of patients with NSCLC whose tumors express ROS1 fusion genes.  Clin Cancer Res; 18(17); 4570-9. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7gJ6dvuC1ObVg90H21EOLACvtfcHk0lhDbC3zEe1zkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ygsLvJ&md5=e515420290d04150e87f8f4c057c64cd</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0550%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DK.%2BD.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DTheodoro%26aufirst%3DM.%2BF.%26aulast%3DSkokan%26aufirst%3DM.%2BC.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DBerge%26aufirst%3DE.%2BM.%26aulast%3DTerracciano%26aufirst%3DL.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DIncarbone%26aufirst%3DM.%26aulast%3DRoncalli%26aufirst%3DM.%26aulast%3DAlloisio%26aufirst%3DM.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26atitle%3DIdentifying%2520and%2520Targeting%2520Ros1%2520Gene%2520Fusions%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4570%26epage%3D4579%26doi%3D10.1158%2F1078-0432.CCR-12-0550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Figueiredo-Pontes, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B.</span></span> <span> </span><span class="NLM_article-title">Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in Ros1-Translocated Lung Cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1086</span>– <span class="NLM_lpage">1090</span>, <span class="refDoi"> DOI: 10.1097/JTO.0b013e3182570919</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1097%2FJTO.0b013e3182570919" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=22617245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1aisbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1086-1090&author=H.+Yasudaauthor=L.+L.+de+Figueiredo-Pontesauthor=S.+Kobayashiauthor=D.+B.+Costa&title=Preclinical+Rationale+for+Use+of+the+Clinically+Available+Multitargeted+Tyrosine+Kinase+Inhibitor+Crizotinib+in+Ros1-Translocated+Lung+Cancer&doi=10.1097%2FJTO.0b013e3182570919"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer</span></div><div class="casAuthors">Yasuda, Hiroyuki; de Figueiredo-Pontes, Lorena L.; Kobayashi, Susumu; Costa, Daniel B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1086-1090</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: Most clin. available small-mol. kinase inhibitors are multi-targeted and can inhibit multiple kinases.  Our driving hypothesis was that one of these multi-targeted tyrosine kinase inhibitors (TKIs) would have antiproliferative activity against ROS1 translocated non-small-cell lung cancer (NSCLC).  Methods: We selected NSCLC cell lines-A549 (KRAS G12S), NCI-H3255 (EGFR L858R), NCI-H3122 (EML4-ALK E13;A20), and HCC78 (SLC34A2-ROS1)-to evaluate the antiproliferative effects of submicromolar concns. of the multitargeted TKIs imatinib, sorafenib, erlotinib, and crizotinib.  Results: Imatinib and sorafenib were unable to significantly inhibit proliferation of the aforementioned cell lines.  Erlotinib only inhibited EGFR mutated NCI-H3255, as expected.  Crizotinib displayed dose-dependent inhibition of anaplastic lymphoma kinase translocated NCI-H3122 and also ROS1-translocated HCC78.  The SLC34A2-ROS1 translocated HCC78 cell line had phosphorylated levels of ROS1, AKT, and ERK inhibited by submicromolar doses of crizotinib, and subsequently underwent apoptosis.  Conclusions: The ROS1-translocated HCC78 cell line was sensitive to inhibition by the multitargeted ALK/MET/RON/ROS1 inhibitor crizotinib.  Preclin. data supports the clin. development of crizotinib for ROS1-translocated NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr29dxq_z12VLVg90H21EOLACvtfcHk0lhDbC3zEe1zkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1aisbzM&md5=05078de948bc1543886167175cdca4c4</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e3182570919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e3182570919%26sid%3Dliteratum%253Aachs%26aulast%3DYasuda%26aufirst%3DH.%26aulast%3Dde%2BFigueiredo-Pontes%26aufirst%3DL.%2BL.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26atitle%3DPreclinical%2520Rationale%2520for%2520Use%2520of%2520the%2520Clinically%2520Available%2520Multitargeted%2520Tyrosine%2520Kinase%2520Inhibitor%2520Crizotinib%2520in%2520Ros1-Translocated%2520Lung%2520Cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2012%26volume%3D7%26spage%3D1086%26epage%3D1090%26doi%3D10.1097%2FJTO.0b013e3182570919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span> <span> </span><span class="NLM_article-title">Crizotinib in Ros1-Rearranged Advanced Non-Small-Cell Lung Cancer (Nsclc): Updated Results, Including Overall Survival, from Profile 1001</span>. <i>Ann. Oncol</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1121</span>– <span class="NLM_lpage">1126</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdz131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1093%2Fannonc%2Fmdz131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=30980071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FkvFCmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=1121-1126&author=A.+T.+Shawauthor=G.+J.+Rielyauthor=Y.+J.+Bangauthor=D.+W.+Kimauthor=D.+R.+Camidgeauthor=B.+J.+Solomonauthor=M.+Varella-Garciaauthor=A.+J.+Iafrateauthor=G.+I.+Shapiroauthor=T.+Usariauthor=S.+C.+Wangauthor=K.+D.+Wilnerauthor=J.+W.+Clarkauthor=S.+I.+Ou&title=Crizotinib+in+Ros1-Rearranged+Advanced+Non-Small-Cell+Lung+Cancer+%28Nsclc%29%3A+Updated+Results%2C+Including+Overall+Survival%2C+from+Profile+1001&doi=10.1093%2Fannonc%2Fmdz131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001</span></div><div class="casAuthors">Shaw A T; Riely G J; Bang Y-J; Kim D-W; Camidge D R; Varella-Garcia M; Solomon B J; Iafrate A J; Clark J W; Shapiro G I; Usari T; Wang S C; Wilner K D; Ou S-H I</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1121-1126</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  In the ongoing phase I PROFILE 1001 study, crizotinib showed antitumor activity in patients with ROS1-rearranged advanced non-small-cell lung cancer (NSCLC).  Here, we present updated antitumor activity, overall survival (OS) and safety data (additional 46.2 months follow-up) for patients with ROS1-rearranged advanced NSCLC from PROFILE 1001.  PATIENTS AND METHODS:  ROS1 status was determined by FISH or reverse transcriptase-polymerase chain reaction.  All patients received crizotinib at a starting dose of 250 mg twice daily.  RESULTS:  Fifty-three patients received crizotinib, with a median duration of treatment of 22.4 months.  At data cut-off, treatment was ongoing in 12 patients (23%).  The objective response rate (ORR) was 72% [95% confidence interval (CI), 58% to 83%], including six confirmed complete responses and 32 confirmed partial responses; 10 patients had stable disease.  Responses were durable (median duration of response 24.7 months; 95% CI, 15.2-45.3).  ORRs were consistent across different patient subgroups.  Median progression-free survival was 19.3 months (95% CI, 15.2-39.1).  A total of 26 deaths (49%) occurred (median follow-up period of 62.6 months), and of the remaining 27 patients (51%), 14 (26%) were in follow-up at data cut-off.  Median OS was 51.4 months (95% CI, 29.3 to not reached) and survival probabilities at 12, 24, 36, and 48 months were 79%, 67%, 53%, and 51%, respectively.  No correlation was observed between OS and specific ROS1 fusion partner.  Treatment-related adverse events (TRAEs) were mainly grade 1 or 2, per CTCAE v3.0.  There were no grade ≥4 TRAEs and no TRAEs associated with permanent discontinuation.  No new safety signals were reported with long-term crizotinib treatment.  CONCLUSIONS:  These findings serve as a new benchmark for OS in ROS1-rearranged advanced NSCLC, and continue to show the clinically meaningful benefit and safety of crizotinib in this molecular subgroup.  TRIAL REGISTRATION NUMBER:  ClinicalTrials.gov identifier NCT00585195.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcToezgxb-wVeFUIs6wFK5xJfW6udTcc2eYUiIdSxJPWb7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FkvFCmsg%253D%253D&md5=f11ca150cea3e3be11586eb7db3236ff</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdz131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdz131%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DUsari%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DS.%2BC.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DOu%26aufirst%3DS.%2BI.%26atitle%3DCrizotinib%2520in%2520Ros1-Rearranged%2520Advanced%2520Non-Small-Cell%2520Lung%2520Cancer%2520%2528Nsclc%2529%253A%2520Updated%2520Results%252C%2520Including%2520Overall%2520Survival%252C%2520from%2520Profile%25201001%26jtitle%3DAnn.%2520Oncol%26date%3D2019%26volume%3D30%26spage%3D1121%26epage%3D1126%26doi%3D10.1093%2Fannonc%2Fmdz131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shreeve, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tye, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span> <span> </span><span class="NLM_article-title">Crizotinib in Ros1-Rearranged Non-Small-Cell Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">1963</span>– <span class="NLM_lpage">1971</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1406766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1056%2FNEJMoa1406766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=25264305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslGgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=1963-1971&author=A.+T.+Shawauthor=S.+H.+Ouauthor=Y.+J.+Bangauthor=D.+R.+Camidgeauthor=B.+J.+Solomonauthor=R.+Salgiaauthor=G.+J.+Rielyauthor=M.+Varella-Garciaauthor=G.+I.+Shapiroauthor=D.+B.+Costaauthor=R.+C.+Doebeleauthor=L.+P.+Leauthor=Z.+Zhengauthor=W.+Tanauthor=P.+Stephensonauthor=S.+M.+Shreeveauthor=L.+M.+Tyeauthor=J.+G.+Christensenauthor=K.+D.+Wilnerauthor=J.+W.+Clarkauthor=A.+J.+Iafrate&title=Crizotinib+in+Ros1-Rearranged+Non-Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1406766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib in ROS1-rearranged non-small-cell lung cancer</span></div><div class="casAuthors">Shaw, Alice T.; Ou, Sai-Hong I.; Bang, Yung-Jue; Camidge, D. Ross; Solomon, Benjamin J.; Salgia, Ravi; Riely, Gregory J.; Varella-Garcia, Marileila; Shapiro, Geoffrey I.; Costa, Daniel B.; Doebele, Robert C.; Le, Long Phi; Zheng, Zongli; Tan, Weiwei; Stephenson, Patricia; Shreeve, S. Martin; Tye, Lesley M.; Christensen, James G.; Wilner, Keith D.; Clark, Jeffrey W.; Iafrate, A. John</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1963-1971, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Chromosomal rearrangements of the gene encoding ROS1 proto-oncogene receptor tyrosine kinase (ROS1) define a distinct mol. subgroup of non-small-cell lung cancers (NSCLCs) that may be susceptible to therapeutic ROS1 kinase inhibition.  Crizotinib is a small-mol. tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK), ROS1, and another proto-oncogene receptor tyrosine kinase, MET.  Methods: We enrolled 50 patients with advanced NSCLC who tested pos. for ROS1 rearrangement in an expansion cohort of the phase 1 study of crizotinib.  Patients were treated with crizotinib at the std. oral dose of 250 mg twice daily and assessed for safety, pharmacokinetics, and response to therapy.  ROS1 fusion partners were identified with the use of next-generation sequencing or reverse-transcriptase-polymerase-chain-reaction assays.  Results: The objective response rate was 72% (95% confidence interval [CI], 58 to 84), with 3 complete responses and 33 partial responses.  The median duration of response was 17.6 mo (95% CI, 14.5 to not reached).  Median progression-free survival was 19.2 mo (95% CI, 14.4 to not reached), with 25 patients (50%) still in follow-up for progression.  Among 30 tumors that were tested, we identified 7 ROS1 fusion partners: 5 known and 2 novel partner genes.  No correlation was obsd. between the type of ROS1 rearrangement and the clin. response to crizotinib.  The safety profile of crizotinib was similar to that seen in patients with ALK-rearranged NSCLC.  Conclusions: In this study, crizotinib showed marked antitumor activity in patients with advanced ROS1-rearranged NSCLC.  ROS1 rearrangement defines a second mol. subgroup of NSCLC for which crizotinib is highly active.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoboSXi9RMETrVg90H21EOLACvtfcHk0lgLmOqlRlSkUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslGgtQ%253D%253D&md5=10f332ff122809bef11f4a0d8aafd45a</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1406766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1406766%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DLe%26aufirst%3DL.%2BP.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DStephenson%26aufirst%3DP.%26aulast%3DShreeve%26aufirst%3DS.%2BM.%26aulast%3DTye%26aufirst%3DL.%2BM.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DCrizotinib%2520in%2520Ros1-Rearranged%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D1963%26epage%3D1971%26doi%3D10.1056%2FNEJMoa1406766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vladimer, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snijder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigenzahn, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K. V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lardeau, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanjiv, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, U. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Fuente, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knobl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubicek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jager, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Superti-Furga, G.</span></span> <span> </span><span class="NLM_article-title">Global Survey of the Immunomodulatory Potential of Common Drugs</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fnchembio.2360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=28437395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVCltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=681-690&author=G.+I.+Vladimerauthor=B.+Snijderauthor=N.+Krallauthor=J.+W.+Bigenzahnauthor=K.+V.+M.+Huberauthor=C.+H.+Lardeauauthor=K.+Sanjivauthor=A.+Ringlerauthor=U.+W.+Berglundauthor=M.+Sablerauthor=O.+L.+de+la+Fuenteauthor=P.+Knoblauthor=S.+Kubicekauthor=T.+Helledayauthor=U.+Jagerauthor=G.+Superti-Furga&title=Global+Survey+of+the+Immunomodulatory+Potential+of+Common+Drugs&doi=10.1038%2Fnchembio.2360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Global survey of the immunomodulatory potential of common drugs</span></div><div class="casAuthors">Vladimer, Gregory I.; Snijder, Berend; Krall, Nikolaus; Bigenzahn, Johannes W.; Huber, Kilian V. M.; Lardeau, Charles-Hugues; Sanjiv, Kumar; Ringler, Anna; Berglund, Ulrika Warpman; Sabler, Monika; de la Fuente, Oscar Lopez; Knoebl, Paul; Kubicek, Stefan; Helleday, Thomas; Jaeger, Ulrich; Superti-Furga, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">681-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drugs may complement antibody-based therapies in an immune-oncol. setting, yet systematic methods for the identification and characterization of the immunomodulatory properties of these entities are lacking.  We surveyed the immumomodulatory potential of 1,402 small chem. mols., as defined by their ability to alter the cell-cell interactions among peripheral mononuclear leukocytes ex vivo, using automated microscopy and population-wide single-cell image anal.  Unexpectedly, ∼10% of the agents tested affected these cell-cell interactions differentially.  The results accurately recapitulated known immunomodulatory drug classes and revealed several clin. approved drugs that unexpectedly harbor the ability to modulate the immune system, which could potentially contribute to their physiol. mechanism of action.  For instance, the kinase inhibitor crizotinib promoted T cell interactions with monocytes, as well as with cancer cells, through inhibition of the receptor tyrosine kinase MSTR1 and subsequent upregulation of the expression of major histocompatibility complex mols.  The approach offers an attractive platform for the personalized identification and characterization of immunomodulatory therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXf0_7KFGbY7Vg90H21EOLACvtfcHk0lj7Q6qn0ofN5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVCltbg%253D&md5=c177974d4daf99d7a40b5c2a73c6504a</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2360%26sid%3Dliteratum%253Aachs%26aulast%3DVladimer%26aufirst%3DG.%2BI.%26aulast%3DSnijder%26aufirst%3DB.%26aulast%3DKrall%26aufirst%3DN.%26aulast%3DBigenzahn%26aufirst%3DJ.%2BW.%26aulast%3DHuber%26aufirst%3DK.%2BV.%2BM.%26aulast%3DLardeau%26aufirst%3DC.%2BH.%26aulast%3DSanjiv%26aufirst%3DK.%26aulast%3DRingler%26aufirst%3DA.%26aulast%3DBerglund%26aufirst%3DU.%2BW.%26aulast%3DSabler%26aufirst%3DM.%26aulast%3Dde%2Bla%2BFuente%26aufirst%3DO.%2BL.%26aulast%3DKnobl%26aufirst%3DP.%26aulast%3DKubicek%26aufirst%3DS.%26aulast%3DHelleday%26aufirst%3DT.%26aulast%3DJager%26aufirst%3DU.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DGlobal%2520Survey%2520of%2520the%2520Immunomodulatory%2520Potential%2520of%2520Common%2520Drugs%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D681%26epage%3D690%26doi%3D10.1038%2Fnchembio.2360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oleaga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernabini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLamb, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santhanam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najjar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akanda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esch, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouedraogo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotovio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuler, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, J. J.</span></span> <span> </span><span class="NLM_article-title">Multi-Organ Toxicity Demonstration in a Functional Human in Vitro System Composed of Four Organs</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">20030</span>, <span class="refDoi"> DOI: 10.1038/srep20030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fsrep20030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=26837601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFahsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=20030&author=C.+Oleagaauthor=C.+Bernabiniauthor=A.+S.+Smithauthor=B.+Srinivasanauthor=M.+Jacksonauthor=W.+McLambauthor=V.+Plattauthor=R.+Bridgesauthor=Y.+Caiauthor=N.+Santhanamauthor=B.+Berryauthor=S.+Najjarauthor=N.+Akandaauthor=X.+Guoauthor=C.+Martinauthor=G.+Ekmanauthor=M.+B.+Eschauthor=J.+Langerauthor=G.+Ouedraogoauthor=J.+Cotovioauthor=L.+Bretonauthor=M.+L.+Shulerauthor=J.+J.+Hickman&title=Multi-Organ+Toxicity+Demonstration+in+a+Functional+Human+in+Vitro+System+Composed+of+Four+Organs&doi=10.1038%2Fsrep20030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs</span></div><div class="casAuthors">Oleaga, Carlota; Bernabini, Catia; Smith, Alec S. T.; Srinivasan, Balaji; Jackson, Max; McLamb, William; Platt, Vivien; Bridges, Richard; Cai, Yunqing; Santhanam, Navaneetha; Berry, Bonnie; Najjar, Sarah; Akanda, Nesar; Guo, Xiufang; Martin, Candace; Ekman, Gail; Esch, Mandy B.; Langer, Jessica; Ouedraogo, Gladys; Cotovio, Jose; Breton, Lionel; Shuler, Michael L.; Hickman, James J.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20030</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report on a functional human model to evaluate multi-organ toxicity in a 4-organ system under continuous flow conditions in a serum-free defined medium utilizing a pumpless platform for 14 days.  Computer simulations of the platform established flow rates and resultant shear stress within accepted ranges.  Viability of the system was demonstrated for 14 days as well as functional activity of cardiac, muscle, neuronal and liver modules.  The pharmacol. relevance of the integrated modules were evaluated for their response at 7 days to 5 drugs with known side effects after a 48 h drug treatment regime.  The results of all drug treatments were in general agreement with published toxicity results from human and animal data.  The presented phenotypic culture model exhibits a multi-organ toxicity response, representing the next generation of in vitro systems, and constitutes a step towards an in vitro "human-on-a-chip" assay for systemic toxicity screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraQVY4O7h9I7Vg90H21EOLACvtfcHk0lj7Q6qn0ofN5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFahsLY%253D&md5=3113c7d8206d0748549686f604c52f6c</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fsrep20030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep20030%26sid%3Dliteratum%253Aachs%26aulast%3DOleaga%26aufirst%3DC.%26aulast%3DBernabini%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DA.%2BS.%26aulast%3DSrinivasan%26aufirst%3DB.%26aulast%3DJackson%26aufirst%3DM.%26aulast%3DMcLamb%26aufirst%3DW.%26aulast%3DPlatt%26aufirst%3DV.%26aulast%3DBridges%26aufirst%3DR.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DSanthanam%26aufirst%3DN.%26aulast%3DBerry%26aufirst%3DB.%26aulast%3DNajjar%26aufirst%3DS.%26aulast%3DAkanda%26aufirst%3DN.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DMartin%26aufirst%3DC.%26aulast%3DEkman%26aufirst%3DG.%26aulast%3DEsch%26aufirst%3DM.%2BB.%26aulast%3DLanger%26aufirst%3DJ.%26aulast%3DOuedraogo%26aufirst%3DG.%26aulast%3DCotovio%26aufirst%3DJ.%26aulast%3DBreton%26aufirst%3DL.%26aulast%3DShuler%26aufirst%3DM.%2BL.%26aulast%3DHickman%26aufirst%3DJ.%2BJ.%26atitle%3DMulti-Organ%2520Toxicity%2520Demonstration%2520in%2520a%2520Functional%2520Human%2520in%2520Vitro%2520System%2520Composed%2520of%2520Four%2520Organs%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D20030%26doi%3D10.1038%2Fsrep20030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maschmeyer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasenberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramme, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambo, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonntag, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, U.</span></span> <span> </span><span class="NLM_article-title">A Four-Organ-Chip for Interconnected Long-Term Co-Culture of Human Intestine, Liver, Skin and Kidney Equivalents</span>. <i>Lab Chip</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2688</span>– <span class="NLM_lpage">2699</span>, <span class="refDoi"> DOI: 10.1039/C5LC00392J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1039%2FC5LC00392J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=25996126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXot1Wqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=2688-2699&author=I.+Maschmeyerauthor=A.+K.+Lorenzauthor=K.+Schimekauthor=T.+Hasenbergauthor=A.+P.+Rammeauthor=J.+Hubnerauthor=M.+Lindnerauthor=C.+Drewellauthor=S.+Bauerauthor=A.+Thomasauthor=N.+S.+Samboauthor=F.+Sonntagauthor=R.+Lausterauthor=U.+Marx&title=A+Four-Organ-Chip+for+Interconnected+Long-Term+Co-Culture+of+Human+Intestine%2C+Liver%2C+Skin+and+Kidney+Equivalents&doi=10.1039%2FC5LC00392J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents</span></div><div class="casAuthors">Maschmeyer, Ilka; Lorenz, Alexandra K.; Schimek, Katharina; Hasenberg, Tobias; Ramme, Anja P.; Huebner, Juliane; Lindner, Marcus; Drewell, Christopher; Bauer, Sophie; Thomas, Alexander; Sambo, Naomia Sisoli; Sonntag, Frank; Lauster, Roland; Marx, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Lab on a Chip</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2688-2699</span>CODEN:
                <span class="NLM_cas:coden">LCAHAM</span>;
        ISSN:<span class="NLM_cas:issn">1473-0189</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Systemic absorption and metab. of drugs in the small intestine, metab. by the liver as well as excretion by the kidney are key determinants of efficacy and safety for therapeutic candidates.  However, these systemic responses of applied substances lack in most in vitro assays.  In this study, a microphysiol. system maintaining the functionality of four organs over 28 days in co-culture has been established at a minute but standardized microsystem scale.  Preformed human intestine and skin models have been integrated into the four-organ-chip on std. cell culture inserts at a size 100 000-fold smaller than their human counterpart organs.  A 3D-based spheroid, equiv. to ten liver lobules, mimics liver function.  Finally, a barrier segregating the media flow through the organs from fluids excreted by the kidney has been generated by a polymeric membrane covered by a monolayer of human proximal tubule epithelial cells.  A peristaltic on-chip micropump ensures pulsatile media flow interconnecting the four tissue culture compartments through microfluidic channels.  A second microfluidic circuit ensures drainage of the fluid excreted through the kidney epithelial cell layer.  This four-organ-chip system assures near to physiol. fluid-to-tissue ratios.  In-depth metabolic and gene anal. revealed the establishment of reproducible homeostasis among the co-cultures within two to four days, sustainable over at least 28 days independent of the individual human cell line or tissue donor background used for each organ equiv.  Lastly, 3D imaging two-photon microscopy visualized details of spatiotemporal segregation of the two microfluidic flows by proximal tubule epithelia.  To our knowledge, this study is the first approach to establish a system for in vitro microfluidic ADME profiling and repeated dose systemic toxicity testing of drug candidates over 28 days.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3CptSfAmHS7Vg90H21EOLACvtfcHk0lhSbWePBMY9LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXot1Wqs7w%253D&md5=625936c873db1f9c06adf22e294bbf95</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1039%2FC5LC00392J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5LC00392J%26sid%3Dliteratum%253Aachs%26aulast%3DMaschmeyer%26aufirst%3DI.%26aulast%3DLorenz%26aufirst%3DA.%2BK.%26aulast%3DSchimek%26aufirst%3DK.%26aulast%3DHasenberg%26aufirst%3DT.%26aulast%3DRamme%26aufirst%3DA.%2BP.%26aulast%3DHubner%26aufirst%3DJ.%26aulast%3DLindner%26aufirst%3DM.%26aulast%3DDrewell%26aufirst%3DC.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DSambo%26aufirst%3DN.%2BS.%26aulast%3DSonntag%26aufirst%3DF.%26aulast%3DLauster%26aufirst%3DR.%26aulast%3DMarx%26aufirst%3DU.%26atitle%3DA%2520Four-Organ-Chip%2520for%2520Interconnected%2520Long-Term%2520Co-Culture%2520of%2520Human%2520Intestine%252C%2520Liver%252C%2520Skin%2520and%2520Kidney%2520Equivalents%26jtitle%3DLab%2520Chip%26date%3D2015%26volume%3D15%26spage%3D2688%26epage%3D2699%26doi%3D10.1039%2FC5LC00392J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamren, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">March, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matcham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mettetal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snowden, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pangalos, M. N.</span></span> <span> </span><span class="NLM_article-title">Impact of a Five-Dimensional Framework on R&D Productivity at Astrazeneca</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fnrd.2017.244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=29348681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1SitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=167-181&author=P.+Morganauthor=D.+G.+Brownauthor=S.+Lennardauthor=M.+J.+Andertonauthor=J.+C.+Barrettauthor=U.+Erikssonauthor=M.+Fidockauthor=B.+Hamrenauthor=A.+Johnsonauthor=R.+E.+Marchauthor=J.+Matchamauthor=J.+Mettetalauthor=D.+J.+Nichollsauthor=S.+Platzauthor=S.+Reesauthor=M.+A.+Snowdenauthor=M.+N.+Pangalos&title=Impact+of+a+Five-Dimensional+Framework+on+R%26D+Productivity+at+Astrazeneca&doi=10.1038%2Fnrd.2017.244"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of a five-dimensional framework on R&D productivity at AstraZeneca</span></div><div class="casAuthors">Morgan, Paul; Brown, Dean G.; Lennard, Simon; Anderton, Mark J.; Barrett, J. Carl; Eriksson, Ulf; Fidock, Mark; Hamren, Bengt; Johnson, Anthony; March, Ruth E.; Matcham, James; Mettetal, Jerome; Nicholls, David J.; Platz, Stefan; Rees, Steve; Snowden, Michael A.; Pangalos, Menelas N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">167-181</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">In 2011, AstraZeneca embarked on a major revision of its research and development (R&D) strategy with the aim of improving R&D productivity, which was below industry avs. in 2005-2010.  A cornerstone of the revised strategy was to focus decision-making on five tech. determinants (the right target, right tissue, right safety, right patient and right com. potential).  In this article, we describe the progress made using this '5R framework' in the hope that our experience could be useful to other companies tackling R&D productivity issues.  We focus on the evolution of our approach to target validation, hit and lead optimization, pharmacokinetic/pharmacodynamic modeling and drug safety testing, which have helped improve the quality of candidate drug nomination, as well as the development of the right culture, where 'truth seeking' is encouraged by more rigorous and quant. decision-making.  We also discuss where the approach has failed and the lessons learned.  Overall, the continued evolution and application of the 5R framework are beginning to have an impact, with success rates from candidate drug nomination to phase III completion improving from 4% in 2005-2010 to 19% in 2012-2016.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwdx6OlRZpzrVg90H21EOLACvtfcHk0lhSbWePBMY9LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1SitL4%253D&md5=06906e0bc59dc715941998660a514ffe</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.244%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DLennard%26aufirst%3DS.%26aulast%3DAnderton%26aufirst%3DM.%2BJ.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DEriksson%26aufirst%3DU.%26aulast%3DFidock%26aufirst%3DM.%26aulast%3DHamren%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DMarch%26aufirst%3DR.%2BE.%26aulast%3DMatcham%26aufirst%3DJ.%26aulast%3DMettetal%26aufirst%3DJ.%26aulast%3DNicholls%26aufirst%3DD.%2BJ.%26aulast%3DPlatz%26aufirst%3DS.%26aulast%3DRees%26aufirst%3DS.%26aulast%3DSnowden%26aufirst%3DM.%2BA.%26aulast%3DPangalos%26aufirst%3DM.%2BN.%26atitle%3DImpact%2520of%2520a%2520Five-Dimensional%2520Framework%2520on%2520R%2526D%2520Productivity%2520at%2520Astrazeneca%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D167%26epage%3D181%26doi%3D10.1038%2Fnrd.2017.244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lounkine, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keiser, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikhailov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doak, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, L.</span></span> <span> </span><span class="NLM_article-title">Large-Scale Prediction and Testing of Drug Activity on Side-Effect Targets</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>486</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1038/nature11159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fnature11159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=22722194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFyrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=361-367&author=E.+Lounkineauthor=M.+J.+Keiserauthor=S.+Whitebreadauthor=D.+Mikhailovauthor=J.+Hamonauthor=J.+L.+Jenkinsauthor=P.+Lavanauthor=E.+Weberauthor=A.+K.+Doakauthor=S.+Coteauthor=B.+K.+Shoichetauthor=L.+Urban&title=Large-Scale+Prediction+and+Testing+of+Drug+Activity+on+Side-Effect+Targets&doi=10.1038%2Fnature11159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Large-scale prediction and testing of drug activity on side-effect targets</span></div><div class="casAuthors">Lounkine, Eugen; Keiser, Michael J.; Whitebread, Steven; Mikhailov, Dmitri; Hamon, Jacques; Jenkins, Jeremy L.; Lavan, Paul; Weber, Eckhard; Doak, Allison K.; Cote, Serge; Shoichet, Brian K.; Urban, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7403</span>),
    <span class="NLM_cas:pages">361-367</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Discovering the unintended off-targets' that predict adverse drug reactions is daunting by empirical methods alone.  Drugs can act on several protein targets, some of which can be unrelated by conventional mol. metrics, and hundreds of proteins have been implicated in side effects.  Here we use a computational strategy to predict the activity of 656 marketed drugs on 73 unintended side-effect' targets.  Approx. half of the predictions were confirmed, either from proprietary databases unknown to the method or by new exptl. assays.  Affinities for these new off-targets ranged from 1 nM to 30 μM.  To explore relevance, we developed an assocn. metric to prioritize those new off-targets that explained side effects better than any known target of a given drug, creating a drug-target-adverse drug reaction network.  Among these new assocns. was the prediction that the abdominal pain side effect of the synthetic estrogen chlorotrianisene was mediated through its newly discovered inhibition of the enzyme cyclooxygenase-1.  The clin. relevance of this inhibition was borne out in whole human blood platelet aggregation assays.  This approach may have wide application to de-risking toxicol. liabilities in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5sVjfn4mgLLVg90H21EOLACvtfcHk0lhSbWePBMY9LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFyrtb0%253D&md5=9c133b839d9527818a27a5834e4dfe11</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fnature11159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11159%26sid%3Dliteratum%253Aachs%26aulast%3DLounkine%26aufirst%3DE.%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DMikhailov%26aufirst%3DD.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DLavan%26aufirst%3DP.%26aulast%3DWeber%26aufirst%3DE.%26aulast%3DDoak%26aufirst%3DA.%2BK.%26aulast%3DCote%26aufirst%3DS.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DLarge-Scale%2520Prediction%2520and%2520Testing%2520of%2520Drug%2520Activity%2520on%2520Side-Effect%2520Targets%26jtitle%3DNature%26date%3D2012%26volume%3D486%26spage%3D361%26epage%3D367%26doi%3D10.1038%2Fnature11159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chartier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morency, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zylber, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najmanovich, R. J.</span></span> <span> </span><span class="NLM_article-title">Large-Scale Detection of Drug Off-Targets: Hypotheses for Drug Repurposing and Understanding Side-Effects</span>. <i>BMC Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">18</span>, <span class="refDoi"> DOI: 10.1186/s40360-017-0128-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1186%2Fs40360-017-0128-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=28449705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvVGgt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=18&author=M.+Chartierauthor=L.+P.+Morencyauthor=M.+I.+Zylberauthor=R.+J.+Najmanovich&title=Large-Scale+Detection+of+Drug+Off-Targets%3A+Hypotheses+for+Drug+Repurposing+and+Understanding+Side-Effects&doi=10.1186%2Fs40360-017-0128-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Large-scale detection of drug off-targets: hypotheses for drug repurposing and understanding side-effects</span></div><div class="casAuthors">Chartier, Matthieu; Morency, Louis-Philippe; Zylber, Maria Ines; Najmanovich, Rafael J.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18/1-18/16</span>CODEN:
                <span class="NLM_cas:coden">BPTMAB</span>;
        ISSN:<span class="NLM_cas:issn">2050-6511</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Promiscuity in mol. interactions between small-mols., including drugs, and proteins is widespread.  Such unintended interactions can be exploited to suggest drug repurposing possibilities as well as to identify potential mol. mechanisms responsible for obsd. side-effects.  Methods: We perform a large-scale anal. to detect binding-site mol. interaction field similarities between the binding-sites of the primary target of 400 drugs against a dataset of 14082 cavities within 7895 different proteins representing a non-redundant dataset of all proteins with known structure.  Statistically-significant cases with high levels of similarities represent potential cases where the drugs that bind the original target may in principle bind the suggested off-target.  Such cases are further analyzed with docking simulations to verify if indeed the drug could, in principle, bind the off-target.  Diverse sources of data are integrated to assocd. potential cross-reactivity targets with side-effects.  Results: We observe that promiscuous binding-sites tend to display higher levels of hydrophobic and arom. similarities.  Focusing on the most statistically significant similarities (Z-score ≥ 3.0) and corroborating docking results (RMSD < 2.0 Å), we find 2923 cases involving 140 unique drugs and 1216 unique potential cross-reactivity protein targets.  We highlight a few cases with a potential for drug repurposing (acetazolamide as a chorismate pyruvate lyase inhibitor, raloxifene as a bacterial quorum sensing inhibitor) as well as to explain the side-effects of zanamivir and captopril.  A web-interface permits to explore the detected similarities for each of the 400 binding-sites of the primary drug targets and visualise them for the most statistically significant cases.  Conclusions: The detection of mol. interaction field similarities provide the opportunity to suggest drug repurposing opportunities as well as to identify potential mol. mechanisms responsible for side-effects.  All methods utilized are freely available and can be readily applied to new query binding-sites.  All data is freely available and represents an invaluable source to identify further candidates for repurposing and suggest potential mechanisms responsible for side-effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh2PZMwidAObVg90H21EOLACvtfcHk0ljms08qoGPdlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvVGgt7w%253D&md5=86cc822c1993f213623995248eceb62b</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1186%2Fs40360-017-0128-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40360-017-0128-7%26sid%3Dliteratum%253Aachs%26aulast%3DChartier%26aufirst%3DM.%26aulast%3DMorency%26aufirst%3DL.%2BP.%26aulast%3DZylber%26aufirst%3DM.%2BI.%26aulast%3DNajmanovich%26aufirst%3DR.%2BJ.%26atitle%3DLarge-Scale%2520Detection%2520of%2520Drug%2520Off-Targets%253A%2520Hypotheses%2520for%2520Drug%2520Repurposing%2520and%2520Understanding%2520Side-Effects%26jtitle%3DBMC%2520Pharmacol.%2520Toxicol.%26date%3D2017%26volume%3D18%26spage%3D18%26doi%3D10.1186%2Fs40360-017-0128-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cook, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">March, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pangalos, M. N.</span></span> <span> </span><span class="NLM_article-title">Lessons Learned from the Fate of Astrazeneca’s Drug Pipeline: A Five-Dimensional Framework</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1038/nrd4309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fnrd4309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=24833294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVyqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=419-431&author=D.+Cookauthor=D.+Brownauthor=R.+Alexanderauthor=R.+Marchauthor=P.+Morganauthor=G.+Satterthwaiteauthor=M.+N.+Pangalos&title=Lessons+Learned+from+the+Fate+of+Astrazeneca%E2%80%99s+Drug+Pipeline%3A+A+Five-Dimensional+Framework&doi=10.1038%2Fnrd4309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework</span></div><div class="casAuthors">Cook, David; Brown, Dearg; Alexander, Robert; March, Ruth; Morgan, Paul; Satterthwaite, Gemma; Pangalos, Menelas N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">419-431</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry.  In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-mol. drug projects from 2005 to 2010.  The anal. allowed us to establish a framework based on the five most important tech. determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right com. potential.  A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these tech. determinants.  AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and anal. here in the hope that it may assist the industry overall in addressing this key challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4yhPFZOUNO7Vg90H21EOLACvtfcHk0ljms08qoGPdlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVyqtrw%253D&md5=746a86c7223f170f7e6c4f9817760e5b</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1038%2Fnrd4309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4309%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DAlexander%26aufirst%3DR.%26aulast%3DMarch%26aufirst%3DR.%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DSatterthwaite%26aufirst%3DG.%26aulast%3DPangalos%26aufirst%3DM.%2BN.%26atitle%3DLessons%2520Learned%2520from%2520the%2520Fate%2520of%2520Astrazeneca%25E2%2580%2599s%2520Drug%2520Pipeline%253A%2520A%2520Five-Dimensional%2520Framework%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D419%26epage%3D431%26doi%3D10.1038%2Fnrd4309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 4 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Paul D. Leeson, A. Patricia Bento, Anna Gaulton, Anne Hersey, Emma J. Manners, Chris J. Radoux, <span class="NLM_string-name hlFld-ContribAuthor">Andrew R. Leach</span>. </span><span class="cited-content_cbyCitation_article-title">Target-Based Evaluation of “Drug-Like” Properties and Ligand Efficiencies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (11)
                                     , 7210-7230. <a href="https://doi.org/10.1021/acs.jmedchem.1c00416" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00416</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00416%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTarget-Based%252BEvaluation%252Bof%252B%2525E2%252580%25259CDrug-Like%2525E2%252580%25259D%252BProperties%252Band%252BLigand%252BEfficiencies%26aulast%3DLeeson%26aufirst%3DPaul%2BD.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D08032021%26date%3D13052021%26volume%3D64%26issue%3D11%26spage%3D7210%26epage%3D7230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Christopher P. Tinworth, <span class="NLM_string-name hlFld-ContribAuthor">Robert J. Young</span>. </span><span class="cited-content_cbyCitation_article-title">Facts, Patterns, and Principles in Drug Discovery: Appraising the Rule of 5 with Measured Physicochemical Data. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (18)
                                     , 10091-10108. <a href="https://doi.org/10.1021/acs.jmedchem.9b01596" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01596</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01596%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFacts%25252C%252BPatterns%25252C%252Band%252BPrinciples%252Bin%252BDrug%252BDiscovery%25253A%252BAppraising%252Bthe%252BRule%252Bof%252B5%252Bwith%252BMeasured%252BPhysicochemical%252BData%26aulast%3DTinworth%26aufirst%3DChristopher%2BP.%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D25092019%26date%3D11052020%26date%3D23042020%26volume%3D63%26issue%3D18%26spage%3D10091%26epage%3D10108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Clinton G. L.  Veale</span>. </span><span class="cited-content_cbyCitation_article-title">Into the Fray! A Beginner's Guide to Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (8)
                                     , 1199-1225. <a href="https://doi.org/10.1002/cmdc.202000929" title="DOI URL">https://doi.org/10.1002/cmdc.202000929</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000929%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DInto%252Bthe%252BFray%252521%252BA%252BBeginner%252527s%252BGuide%252Bto%252BMedicinal%252BChemistry%26aulast%3DVeale%26aufirst%3DClinton%2BG.%2BL.%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D8%26spage%3D1199%26epage%3D1225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yun  Zhang</span>, <span class="hlFld-ContribAuthor ">Andrew  Pike</span>. </span><span class="cited-content_cbyCitation_article-title">Pyridones in drug discovery: Recent advances. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>38 </em>, 127849. <a href="https://doi.org/10.1016/j.bmcl.2021.127849" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127849</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127849%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPyridones%252Bin%252Bdrug%252Bdiscovery%25253A%252BRecent%252Badvances%26aulast%3DZhang%26aufirst%3DYun%26date%3D2021%26volume%3D38%26spage%3D127849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0027.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) DSP panel assay types categorized as binding, cell-based, or biochemical/enzymatic assay. (b) DSP panel target class distribution.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Comparison of ion class distribution in the DSP versus random (Rand) set. (b) Average lipophilicity in DSP set for clogP or clogD (7.4). (c) Average molecular weight for DSP set versus random set. (d) Average PSA for DSP set versus random set. DSP = 1445 compounds tested in the panel; Rand = 100K random compounds from the AstraZeneca screening collection. Error bars denote the standard deviation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Average molecular volume in DSP set vs random set. (b) Average rotatable bonds DSP set vs random set. (c) Average number of H-bond donors in DSP set vs random set. (d) Average number of H-bond acceptors DSP set vs random set. DSP = 1445 compounds tested in the panel; Rand = 100K random compounds from the AstraZeneca screening collection.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Most frequent targets (binding assays) in the DSP panel of assays. Where the species is not indicated, the assay was run using the human recombinant protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Most frequent targets (cell-based assays) in the DSP panel of assays. Dark (light) green color denotes functional antagonists at <10 μM (<2 μM), dark (light) red denotes functional agonist at <10 μM (<2 μM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Hit rates for biochemical/enzymatic assays in the DSP panel of assays.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Average clogP and clogD (7.4) of hits (IC<sub>50</sub> < 10 μM) vs inactives (IC<sub>50</sub> > 100 μM) in functional biochemical/enzymatic assays. <i>N</i> = 45 assays with at least 30 actives against that target with IC<sub>50</sub> < 10 μM. ∗ = statistical significance as determined by <i>t</i> tests performed and corrected for multiple comparisons using the Holm–Sidak method (<i>p</i> < 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Average clogP and clogD (7.4) of hits (IC<sub>50</sub> < 10 μM) vs inactives (IC<sub>50</sub> > 100 μM) in functional biochemical/enzymatic assays. <i>N</i> = 29 assays with at least 30 actives against that target with IC<sub>50</sub> < 10 μM. ∗ = statistical significance as determined by <i>t</i> tests performed and corrected for multiple comparisons using the Holm–Sidak method (<i>p</i> < 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Average clogP and clogD (7.4) of actives (IC<sub>50</sub> < 10 μM) vs inactives (IC<sub>50</sub> > 100 μM) in functional biochemical/enzymatic assays. <i>N</i> = 19 assays with at least 30 actives against that target with IC<sub>50</sub> < 10 μM. ∗ = statistical significance as determined by <i>t</i> tests performed and corrected for multiple comparisons using the Holm–Sidak method (<i>p</i> < 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Average MW of hits (IC<sub>50</sub> < 10 μM) vs inactives (IC<sub>50</sub> > 100 μM) in functional cell-based assays. <i>N</i> = 45 assays which had at least 30 actives against that target <10 μM. ∗ = statistical significance as determined by <i>t</i> tests performed and corrected for multiple comparisons using the Holm–Sidak method (<i>p</i> < 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Average MW of hits (IC<sub>50</sub> < 10 μM) vs inactives (IC<sub>50</sub> > 100 μM) in functional cell-based assays. <i>N</i> = 29 assays which had at least 30 actives against that target <10 μM. ∗ = statistical significance as determined by <i>t</i> tests performed and corrected for multiple comparisons using the Holm–Sidak method (<i>p</i> < 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Average MW of hits (IC<sub>50</sub> < 10 μM) vs inactives (IC<sub>50</sub> > 100 μM) in biochemical/enzymatic assays. <i>N</i> = 19 assays which had at least 30 actives against that target < 10 μM. * = statistical significance as determined by <i>t</i> tests performed and corrected for multiple comparisons using the Holm−Sidak method (<i>p</i> < 0.05).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Distribution of compound ion class in binding assays. <i>N</i> = 45 assays with at least 30 actives against that target <10 μM. All cpds = the proportion ion class of all 1445 compounds screened in the DSP panel.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Distribution of compound ion class in cellular/functional assays. <i>N</i> = 29 assays with at least 30 actives against that target <10 μM. All cpds = the proportion ion class of all 1445 screened in the DSP panel.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Distribution of compound ion class in biochemical/enzymatic assays. <i>N</i> = 19 assays with at least 30 actives against that target <10 μM. All cpds = the proportion ion class of all 1445 compounds screened in the DSP panel.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Correlation plots between physicochemical properties of hits (IC<sub>50</sub> < 10 μM) and hits rates for (a) Avg. clogP, (b) Avg. clogD (7.4), (c) Avg. MW, and (d) percent basic ion class.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Binding assays (<i>N</i> = 36) having at least 30 hits with IC<sub>50</sub> < 2 μM. Colors denote % of hits common between two assays: dark red >75%, red = 50–74%, orange = 25–49%, yellow = 5–24%, green <5%. As the number and identity of hits differ between assays, the matrix of pairwise comparisons is not symmetrical. For example, there were 37 hits at M5, 31 of which overlap at M1 (31/37 = 83% overlap relative to M5 = dark red), while there were 175 hits at M1, which results in only an 18% overlap (31/175) relative to M1 = yellow.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Binding assays (<i>n</i> = 36) having at least 30 hits with IC<sub>50</sub> < 10 μM. Colors denote % of hits common between two assays: dark red >75%, red = 50–74%, orange = 25–49%, yellow = 5–24%, green <5%. As the number and identity of hits differ between assays, the matrix of pairwise comparisons is not symmetrical.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Example target classes and compounds where off-target pharmacology was addressed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/medium/jm9b01625_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Example target classes and compounds where off-target pharmacology was addressed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-12/acs.jmedchem.9b01625/20200618/images/large/jm9b01625_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01625&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i30">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34201" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34201" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 88 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blomme, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Will, Y.</span></span> <span> </span><span class="NLM_article-title">Toxicology Strategies for Drug Discovery: Present and Future</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">473</span>– <span class="NLM_lpage">504</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.5b00407</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.5b00407" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOhu7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=473-504&author=E.+A.+Blommeauthor=Y.+Will&title=Toxicology+Strategies+for+Drug+Discovery%3A+Present+and+Future&doi=10.1021%2Facs.chemrestox.5b00407"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Toxicology Strategies for Drug Discovery: Present and Future</span></div><div class="casAuthors">Blomme, Eric A. G.; Will, Yvonne</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">473-504</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Attrition due to nonclin. safety represents a major issue for the productivity of pharmaceutical research and development (R&D) organizations, esp. during the compd. optimization stages of drug discovery and the early stages of clin. development.  Focusing on decreasing nonclin. safety-related attrition is not a new concept, and various approaches have been experimented with over the last two decades.  Front-loading testing funnels in Discovery with in vitro toxicity assays designed to rapidly identify unfavorable mols. was the approach adopted by most pharmaceutical R&D organizations a few years ago.  However, this approach has also a non-negligible opportunity cost.  Hence, significant refinements to the "fail early, fail often" paradigm have been proposed recently to reflect the complexity of accurately categorizing compds. with early data points without taking into account other important contextual aspects, in particular efficacious systemic and tissue exposures.  This review provides an overview of toxicol. approaches and models that can be used in pharmaceutical Discovery at the series/lead identification and lead optimization stages to guide and inform chem. efforts, as well as a personal view on how to best use them to meet nonclin. safety-related attrition objectives consistent with a sustainable pharmaceutical R&D model.  The scope of this review is limited to small mols., as large mols. are assocd. with challenges that are quite different.  Finally, a perspective on how several emerging technologies may impact toxicity evaluation is also provided.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnswsW0Ve2_rVg90H21EOLACvtfcHk0lggwMeHjvCNNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOhu7vI&md5=ec2ad8b3576b7ba00f750e3f93469a2f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.5b00407&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.5b00407%26sid%3Dliteratum%253Aachs%26aulast%3DBlomme%26aufirst%3DE.%2BA.%26aulast%3DWill%26aufirst%3DY.%26atitle%3DToxicology%2520Strategies%2520for%2520Drug%2520Discovery%253A%2520Present%2520and%2520Future%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2016%26volume%3D29%26spage%3D473%26epage%3D504%26doi%3D10.1021%2Facs.chemrestox.5b00407" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span> <span> </span><span class="NLM_article-title">In Silico Prediction of Chemical Toxicity for Drug Design Using Machine Learning Methods and Structural Alerts</span>. <i>Front. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">30</span>, <span class="refDoi"> DOI: 10.3389/fchem.2018.00030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.3389%2Ffchem.2018.00030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=29515993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1WkurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=30&author=H.+Yangauthor=L.+Sunauthor=W.+Liauthor=G.+Liuauthor=Y.+Tang&title=In+Silico+Prediction+of+Chemical+Toxicity+for+Drug+Design+Using+Machine+Learning+Methods+and+Structural+Alerts&doi=10.3389%2Ffchem.2018.00030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">In Silico prediction of chemical toxicity for drug design using machine learning methods and structural alerts</span></div><div class="casAuthors">Yang, Hongbin; Sun, Lixia; Li, Weihua; Liu, Guixia; Tang, Yun</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Chemistry (Lausanne, Switzerland)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30/1-30/12</span>CODEN:
                <span class="NLM_cas:coden">FCLSAA</span>;
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">During drug development, safety is always the most important issue, including a variety of toxicities and adverse drug effects, which should be evaluated in preclin. and clin. trial phases.  This review article at first simply introduced the computational methods used in prediction of chem. toxicity for drug design, including machine learning methods and structural alerts.  Machine learning methods have been widely applied in qual. classification and quant. regression studies, while structural alerts can be regarded as a complementary tool for lead optimization.  The emphasis of this article was put on the recent progress of predictive models built for various toxicities.  Available databases and web servers were also provided.  Though the methods and models are very helpful for drug design, there are still some challenges and limitations to be improved for drug safety assessment in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWBAA05szn67Vg90H21EOLACvtfcHk0lggwMeHjvCNNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1WkurvF&md5=bdbd0dd38587cb2849db12353e21b30d</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2018.00030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2018.00030%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DTang%26aufirst%3DY.%26atitle%3DIn%2520Silico%2520Prediction%2520of%2520Chemical%2520Toxicity%2520for%2520Drug%2520Design%2520Using%2520Machine%2520Learning%2520Methods%2520and%2520Structural%2520Alerts%26jtitle%3DFront.%2520Chem.%26date%3D2018%26volume%3D6%26spage%3D30%26doi%3D10.3389%2Ffchem.2018.00030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarolimek, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, S.</span></span> <span> </span><span class="NLM_article-title">Reducing Safety-Related Drug Attrition: The Use of in Vitro Pharmacological Profiling</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">922</span>, <span class="refDoi"> DOI: 10.1038/nrd3845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fnrd3845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=23197038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=909-922&author=J.+Bowesauthor=A.+J.+Brownauthor=J.+Hamonauthor=W.+Jarolimekauthor=A.+Sridharauthor=G.+Waldronauthor=S.+Whitebread&title=Reducing+Safety-Related+Drug+Attrition%3A+The+Use+of+in+Vitro+Pharmacological+Profiling&doi=10.1038%2Fnrd3845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Reducing safety-related drug attrition: the use of in vitro pharmacological profiling</span></div><div class="casAuthors">Bowes, Joanne; Brown, Andrew J.; Hamon, Jacques; Jarolimek, Wolfgang; Sridhar, Arun; Waldron, Gareth; Whitebread, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">909-922</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In vitro pharmacol. profiling is increasingly being used earlier in the drug discovery process to identify undesirable off-target activity profiles that could hinder or halt the development of candidate drugs or even lead to market withdrawal if discovered after a drug is approved.  Here, for the first time, the rationale, strategies and methodologies for in vitro pharmacol. profiling at four major pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) are presented and illustrated with examples of their impact on the drug discovery process.  We hope that this will enable other companies and academic institutions to benefit from this knowledge and consider joining us in our collaborative knowledge sharing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomVp3wnTONWrVg90H21EOLACvtfcHk0lgQI5ircloCmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslCnur%252FJ&md5=7559001563ef3febd610535b8f096a45</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd3845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3845%26sid%3Dliteratum%253Aachs%26aulast%3DBowes%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DJarolimek%26aufirst%3DW.%26aulast%3DSridhar%26aufirst%3DA.%26aulast%3DWaldron%26aufirst%3DG.%26aulast%3DWhitebread%26aufirst%3DS.%26atitle%3DReducing%2520Safety-Related%2520Drug%2520Attrition%253A%2520The%2520Use%2520of%2520in%2520Vitro%2520Pharmacological%2520Profiling%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D909%26epage%3D922%26doi%3D10.1038%2Fnrd3845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dumotier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fekete, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, L.</span></span> <span> </span><span class="NLM_article-title">Secondary Pharmacology: Screening and Interpretation of Off-Target Activities - Focus on Translation</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1232</span>– <span class="NLM_lpage">1242</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2016.04.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.drudis.2016.04.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=27140035" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsVymsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=1232-1242&author=S.+Whitebreadauthor=B.+Dumotierauthor=D.+Armstrongauthor=A.+Feketeauthor=S.+Chenauthor=A.+Hartmannauthor=P.+Y.+Mullerauthor=L.+Urban&title=Secondary+Pharmacology%3A+Screening+and+Interpretation+of+Off-Target+Activities+-+Focus+on+Translation&doi=10.1016%2Fj.drudis.2016.04.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Secondary pharmacology: screening and interpretation of off-target activities - focus on translation</span></div><div class="casAuthors">Whitebread, Steven; Dumotier, Berengere; Armstrong, Duncan; Fekete, Alexander; Chen, Shanni; Hartmann, Andreas; Muller, Patrick Y.; Urban, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1232-1242</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Secondary pharmacol. is an essential component of drug discovery and is used extensively in the pharmaceutical industry for achieving optimal specificity of new drugs via early hazard identification and off-target mitigation.  The importance of this discipline has been achieved by increasing its translational value, based on the recognition of biol. target-drug mol.-adverse drug reaction (ADR) assocns. and integration of secondary pharmacol. data with pharmacokinetic parameters.  Information obtained from clin. ADRs, from recognition of specific phenotypes of animal models and from hereditary diseases provides increasing regulatory confidence in the target-based approach to ADR prediction and mitigation.  Here, we review the progress of secondary pharmacol. during the past decade and highlight and demonstrate its applications and impact in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFcLQoSKAUdLVg90H21EOLACvtfcHk0lgQI5ircloCmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsVymsr0%253D&md5=acaabfea81c4e6e06639dd8c59d797e2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2016.04.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2016.04.021%26sid%3Dliteratum%253Aachs%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DDumotier%26aufirst%3DB.%26aulast%3DArmstrong%26aufirst%3DD.%26aulast%3DFekete%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DHartmann%26aufirst%3DA.%26aulast%3DMuller%26aufirst%3DP.%2BY.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DSecondary%2520Pharmacology%253A%2520Screening%2520and%2520Interpretation%2520of%2520Off-Target%2520Activities%2520-%2520Focus%2520on%2520Translation%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D1232%26epage%3D1242%26doi%3D10.1016%2Fj.drudis.2016.04.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Papoian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elayan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jagadeesh, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laniyonu, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saulnier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span> <span> </span><span class="NLM_article-title">Secondary Pharmacology Data to Assess Potential Off-Target Activity of New Drugs: A Regulatory Perspective</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">294</span>, <span class="refDoi"> DOI: 10.1038/nrd3845-c1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fnrd3845-c1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=25792260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkvVynsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=294&author=T.+Papoianauthor=H.+J.+Chiuauthor=I.+Elayanauthor=G.+Jagadeeshauthor=I.+Khanauthor=A.+A.+Laniyonuauthor=C.+X.+Liauthor=M.+Saulnierauthor=N.+Simpsonauthor=B.+Yang&title=Secondary+Pharmacology+Data+to+Assess+Potential+Off-Target+Activity+of+New+Drugs%3A+A+Regulatory+Perspective&doi=10.1038%2Fnrd3845-c1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Secondary pharmacology data to assess potential off-target activity of new drugs: a regulatory perspective</span></div><div class="casAuthors">Papoian, Thomas; Chiu, Haw-Jyh; Elayan, Ikram; Jagadeesh, Gowraganahalli; Khan, Imran; Laniyonu, Adebayo A.; Li, Cindy Xinguang; Saulnier, Muriel; Simpson, Natalie; Yang, Baichun</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">294</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Useful aspects of submitted secondary pharmacol. data.  Detailed aspects of secondary pharmacol. data that are considered to be useful during regulatory safety assessments are summarized in Table 1.  Incorporation of these aspects into secondary pharmacol. study reports not only enhances the quality and regulatory utility of the reports but also decreases uncertainty in decision making owing to misinterpretation of data.  Regulatory assessment of in vitro secondary pharmacol. data.  Various protocols for secondary pharmacol. studies are commonly available and generally consist of binding assays, functional assays and enzyme assays, all of which provide important information regarding the pharmacol. activity of a drug and possible unanticipated side effects that may be seen in humans.  When the data suggest possible off-target activity, the extent of that risk under clin. relevant conditions and drug exposures is carefully assessed, and safety recommendations are made for the proposed clin. studies or addnl. non-clin. studies are requested to help to better understand or reduce the risk.  In our experience, the panels of targets that are employed vary widely and are often selected without justification or a description of their relevance to human safety.  In such cases, a repeat of the study may be recommended using a more appropriate selection of clin. relevant targets.  It is useful to det. whether a drug shares similar off-target activity with other drugs in the class - for example, the sedative and anticholinergic properties of certain histamine H1 receptor antagonists - so that such side effects in humans can be better anticipated and monitored.  Similarly, target panel selection may also include consideration of whether the intended drug target has structural or functional similarity to a related but unintended target.  If such a relationship is found, then clin. consequences of affecting those targets are considered.  Drugs may also possess specificity for, or a mechanism of action linked to, selected targets from a large family of related targets that have structural or functional similarity (for example, the ATP-binding site of protein tyrosine kinases).  In such cases, a broad panel screen of all closely related family members may be useful in distinguishing intended pharmacol. effects from unintended effects.  It is important to understand how findings relate to those obsd. with other members of the drug class or for a certain mechanism of action.  If the findings are similar, then the clin. risk may be considered to be similar as well.  If they are different, however, then further evaluation, such as follow-up in vitro or animal studies focusing on the different targets affected, may be recommended to better define the risk.  Correlations between pos. secondary pharmacol. results and results seen in animals may be used to det. whether in vitro activity translates to possible human risk under therapeutic conditions.  It is important to note that in vitro panels generally use human-specific targets, and in vitro results may not always correlate with those obsd. in animals.  Correlations between in vitro half-maximal inhibitory concn. (IC50) or inhibition const. (Ki) values with in vivo plasma drug levels are also used to assess possible effects at therapeutic exposures.  The closer the IC50 or Ki values are to plasma drug levels, the more likely the clin. effect.  Also considered in this context are local tissue drug concns. at the site of action that may be higher than circulating levels.  Use of focused profiling may be recommended to address specific issues of concern, such as the safety of active drug metabolites or unique major human metabolites not formed in animals but found during subsequent clin. testing.  Even if a compd. produces a pos. in vitro result at therapeutically relevant concns., certain risk-benefit considerations for particular patient populations are taken into account, such as the seriousness of the therapeutic indication and whether potential adverse effects are considered to be reversible.  Case examples of regulatory actions based on pos. off-target activity are provided in Table 2 and include endocrine disruptors, peroxisome proliferator-activated receptor-γ agonists, cardiac (voltage-gated) ion channel protein antagonists, 5-HT2B (serotonin) receptor agonists, ligand-gated ion channel protein (for example, N-methyl-d-aspartate receptor) antagonists and drugs with potential for abuse.  Although not exhaustive, these examples highlight current experience with certain classes and actions of drugs that have resulted in specific regulatory actions based on their potential risk for human safety.  Timing of secondary pharmacol. data submission.  For proper safety assessment, it is advantageous for secondary pharmacol. data to be available with the initial submission to support first-in-human (Phase I) clin. trials.  Such data can also be used to help to interpret clin. findings or adverse drug reactions that occur as drug development proceeds into later phases of clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD40Aby38TPrVg90H21EOLACvtfcHk0lgQI5ircloCmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkvVynsrw%253D&md5=69b08c957679ef003271b07fef0d4de5</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnrd3845-c1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3845-c1%26sid%3Dliteratum%253Aachs%26aulast%3DPapoian%26aufirst%3DT.%26aulast%3DChiu%26aufirst%3DH.%2BJ.%26aulast%3DElayan%26aufirst%3DI.%26aulast%3DJagadeesh%26aufirst%3DG.%26aulast%3DKhan%26aufirst%3DI.%26aulast%3DLaniyonu%26aufirst%3DA.%2BA.%26aulast%3DLi%26aufirst%3DC.%2BX.%26aulast%3DSaulnier%26aufirst%3DM.%26aulast%3DSimpson%26aufirst%3DN.%26aulast%3DYang%26aufirst%3DB.%26atitle%3DSecondary%2520Pharmacology%2520Data%2520to%2520Assess%2520Potential%2520Off-Target%2520Activity%2520of%2520New%2520Drugs%253A%2520A%2520Regulatory%2520Perspective%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D294%26doi%3D10.1038%2Fnrd3845-c1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pridgeon, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duckworth, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldring, C. E. P.</span></span> <span> </span><span class="NLM_article-title">Stem Cell Models as an in Vitro Model for Predictive Toxicology</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>476</i></span>,  <span class="NLM_fpage">1149</span>– <span class="NLM_lpage">1158</span>, <span class="refDoi"> DOI: 10.1042/BCJ20170780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1042%2FBCJ20170780" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=30988136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVWiu77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=476&publication_year=2019&pages=1149-1158&author=S.+Lynchauthor=C.+S.+Pridgeonauthor=C.+A.+Duckworthauthor=P.+Sharmaauthor=B.+K.+Parkauthor=C.+E.+P.+Goldring&title=Stem+Cell+Models+as+an+in+Vitro+Model+for+Predictive+Toxicology&doi=10.1042%2FBCJ20170780"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Stem cell models as an in vitro model for predictive toxicology</span></div><div class="casAuthors">Lynch, Stephen; Pridgeon, Chris S.; Duckworth, Carrie A.; Sharma, Parveen; Park, B. Kevin; Goldring, Chris E. P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">476</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1149-1158</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Adverse drug reactions (ADRs) are the unintended side effects of drugs.  They are categorised as either predictable or unpredictable drug-induced injury and may be exhibited after a single or prolonged exposure to one or multiple compds.  Historically, toxicol. studies rely heavily on animal models to understand and characterize the toxicity of novel compds.  However, animal models are imperfect proxies for human toxicity and there have been several high-profile cases of failure of animal models to predict human toxicity e.g. fialuridine, TGN1412 which highlight the need for improved predictive models of human toxicity.  As a result, stem cell-derived models are under investigation as potential models for toxicity during early stages of drug development.  Stem cells retain the genotype of the individual from which they were derived, offering the opportunity to model the reproducibility of rare phenotypes in vitro.  Differentiated 2D stem cell cultures have been investigated as models of hepato- and cardiotoxicity.  However, insufficient maturity, particularly in the case of hepatocyte-like cells, means that their widespread use is not currently a feasible method to tackle the complex issues of off-target and often unpredictable toxicity of novel compds.  This review discusses the current state of the art for modeling clin. relevant toxicities, e.g. cardio- and hepatotoxicity, alongside the emerging need for modeling gastrointestinal toxicity and seeks to address whether stem cell technologies are a potential soln. to increase the accuracy of ADR predictivity in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGqruOzjnry7Vg90H21EOLACvtfcHk0ljP--IMsE2nLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVWiu77J&md5=f5d313521f2d1f8dbfd500e81861c515</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1042%2FBCJ20170780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBCJ20170780%26sid%3Dliteratum%253Aachs%26aulast%3DLynch%26aufirst%3DS.%26aulast%3DPridgeon%26aufirst%3DC.%2BS.%26aulast%3DDuckworth%26aufirst%3DC.%2BA.%26aulast%3DSharma%26aufirst%3DP.%26aulast%3DPark%26aufirst%3DB.%2BK.%26aulast%3DGoldring%26aufirst%3DC.%2BE.%2BP.%26atitle%3DStem%2520Cell%2520Models%2520as%2520an%2520in%2520Vitro%2520Model%2520for%2520Predictive%2520Toxicology%26jtitle%3DBiochem.%2520J.%26date%3D2019%26volume%3D476%26spage%3D1149%26epage%3D1158%26doi%3D10.1042%2FBCJ20170780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tarcsay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keseru, G. M.</span></span> <span> </span><span class="NLM_article-title">Contributions of Molecular Properties to Drug Promiscuity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1789</span>– <span class="NLM_lpage">1795</span>, <span class="refDoi"> DOI: 10.1021/jm301514n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301514n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3sXns1ehug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1789-1795&author=A.+Tarcsayauthor=G.+M.+Keseru&title=Contributions+of+Molecular+Properties+to+Drug+Promiscuity&doi=10.1021%2Fjm301514n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Contributions of Molecular Properties to Drug Promiscuity</span></div><div class="casAuthors">Tarcsay, Akos; Keseru, Gyorgy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1789-1795</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  In contrast to designed polypharmacol. that can result in efficient drugs for complex disorders, unintended drug promiscuity has detrimental contribution to side effects and toxicol.  Characterization of promiscuous compds. enhances the understanding of complex interaction patterns and aids the design of compds. with broader selectivity against off-targets that has a major impact on medicinal chem. outcome.  In this Miniperspective we provide insights to the effect of physicochem. parameters on promiscuity.  Information collected from recent, large-scale in vitro studies enabled us to discuss the relationships between physicochem. properties and promiscuity in detail.  In light of these data, lipophilicity and basic character have the highest influence.  On the basis of the accumulated knowledge, we propose the extensive use of pre- and postsynthesis metrics, as well as strict control of physicochem. properties during medicinal chem. optimizations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf1J_jqkK3DrVg90H21EOLACvtfcHk0ljP--IMsE2nLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXns1ehug%253D%253D&md5=c5763ee1aed897ff19e5a2344b95b9c1</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Fjm301514n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301514n%26sid%3Dliteratum%253Aachs%26aulast%3DTarcsay%26aufirst%3DA.%26aulast%3DKeseru%26aufirst%3DG.%2BM.%26atitle%3DContributions%2520of%2520Molecular%2520Properties%2520to%2520Drug%2520Promiscuity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1789%26epage%3D1795%26doi%3D10.1021%2Fjm301514n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decrescenzo, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devraj, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellsworth, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fobian, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbs, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilles, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieger-Burke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loesel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteley, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Physiochemical Drug Properties Associated with in Vivo Toxicological Outcomes</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4872</span>– <span class="NLM_lpage">4875</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.07.071</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.bmcl.2008.07.071" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=18691886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4872-4875&author=J.+D.+Hughesauthor=J.+Blaggauthor=D.+A.+Priceauthor=S.+Baileyauthor=G.+A.+Decrescenzoauthor=R.+V.+Devrajauthor=E.+Ellsworthauthor=Y.+M.+Fobianauthor=M.+E.+Gibbsauthor=R.+W.+Gillesauthor=N.+Greeneauthor=E.+Huangauthor=T.+Krieger-Burkeauthor=J.+Loeselauthor=T.+Wagerauthor=L.+Whiteleyauthor=Y.+Zhang&title=Physiochemical+Drug+Properties+Associated+with+in+Vivo+Toxicological+Outcomes&doi=10.1016%2Fj.bmcl.2008.07.071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Physiochemical drug properties associated with in vivo toxicological outcomes</span></div><div class="casAuthors">Hughes, Jason D.; Blagg, Julian; Price, David A.; Bailey, Simon; DeCrescenzo, Gary A.; Devraj, Rajesh V.; Ellsworth, Edmund; Fobian, Yvette M.; Gibbs, Michael E.; Gilles, Richard W.; Greene, Nigel; Huang, Enoch; Krieger-Burke, Teresa; Loesel, Jens; Wager, Travis; Whiteley, Larry; Zhang, Yao</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4872-4875</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Relationships between physicochem. drug properties and toxicity were inferred from a data set consisting of animal in vivo toleration (IVT) studies on 245 preclin. Pfizer compds.; an increased likelihood of toxic events was found for less polar, more lipophilic compds.  This trend held across a wide range of types of toxicity and across a broad swath of chem. space.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPMmGEpVF0mbVg90H21EOLACvtfcHk0ljP--IMsE2nLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVOnsbjE&md5=80ea5ced359112a363f38b3545cd7646</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.07.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.07.071%26sid%3Dliteratum%253Aachs%26aulast%3DHughes%26aufirst%3DJ.%2BD.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBailey%26aufirst%3DS.%26aulast%3DDecrescenzo%26aufirst%3DG.%2BA.%26aulast%3DDevraj%26aufirst%3DR.%2BV.%26aulast%3DEllsworth%26aufirst%3DE.%26aulast%3DFobian%26aufirst%3DY.%2BM.%26aulast%3DGibbs%26aufirst%3DM.%2BE.%26aulast%3DGilles%26aufirst%3DR.%2BW.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DHuang%26aufirst%3DE.%26aulast%3DKrieger-Burke%26aufirst%3DT.%26aulast%3DLoesel%26aufirst%3DJ.%26aulast%3DWager%26aufirst%3DT.%26aulast%3DWhiteley%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DPhysiochemical%2520Drug%2520Properties%2520Associated%2520with%2520in%2520Vivo%2520Toxicological%2520Outcomes%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4872%26epage%3D4875%26doi%3D10.1016%2Fj.bmcl.2008.07.071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandrell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairaudeau, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennie, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, A.</span></span> <span> </span><span class="NLM_article-title">An Analysis of the Attrition of Drug Candidates from Four Major Pharmaceutical Companies</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">475</span>– <span class="NLM_lpage">486</span>, <span class="refDoi"> DOI: 10.1038/nrd4609</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fnrd4609" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=26091267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=475-486&author=M.+J.+Waringauthor=J.+Arrowsmithauthor=A.+R.+Leachauthor=P.+D.+Leesonauthor=S.+Mandrellauthor=R.+M.+Owenauthor=G.+Pairaudeauauthor=W.+D.+Pennieauthor=S.+D.+Pickettauthor=J.+Wangauthor=O.+Wallaceauthor=A.+Weir&title=An+Analysis+of+the+Attrition+of+Drug+Candidates+from+Four+Major+Pharmaceutical+Companies&doi=10.1038%2Fnrd4609"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">An analysis of the attrition of drug candidates from four major pharmaceutical companies</span></div><div class="casAuthors">Waring, Michael J.; Arrowsmith, John; Leach, Andrew R.; Leeson, Paul D.; Mandrell, Sam; Owen, Robert M.; Pairaudeau, Garry; Pennie, William D.; Pickett, Stephen D.; Wang, Jibo; Wallace, Owen; Weir, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">475-486</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The pharmaceutical industry remains under huge pressure to address the high attrition rates in drug development.  Attempts to reduce the no. of efficacy- and safety-related failures by analyzing possible links to the physicochem. properties of small-mol. drug candidates have been inconclusive because of the limited size of data sets from individual companies.  Here, we describe the compilation and anal. of combined data on the attrition of drug candidates from AstraZeneca, Eli Lilly and Company, GlaxoSmithKline and Pfizer.  The anal. reaffirms that control of physicochem. properties during compd. optimization is beneficial in identifying compds. of candidate drug quality and indicates for the first time a link between the physicochem. properties of compds. and clin. failure due to safety issues.  The results also suggest that further control of physicochem. properties is unlikely to have a significant effect on attrition rates and that addnl. work is required to address safety-related failures.  Further cross-company collaborations will be crucial to future progress in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsLfBWrLC3ZLVg90H21EOLACvtfcHk0lgVqVne2JMYKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFeju7jM&md5=1fdc374d32816b1e91438152299dd1b1</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrd4609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4609%26sid%3Dliteratum%253Aachs%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DArrowsmith%26aufirst%3DJ.%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DMandrell%26aufirst%3DS.%26aulast%3DOwen%26aufirst%3DR.%2BM.%26aulast%3DPairaudeau%26aufirst%3DG.%26aulast%3DPennie%26aufirst%3DW.%2BD.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWallace%26aufirst%3DO.%26aulast%3DWeir%26aufirst%3DA.%26atitle%3DAn%2520Analysis%2520of%2520the%2520Attrition%2520of%2520Drug%2520Candidates%2520from%2520Four%2520Major%2520Pharmaceutical%2520Companies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D475%26epage%3D486%26doi%3D10.1038%2Fnrd4609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blagg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wager, T.</span></span> <span> </span><span class="NLM_article-title">Physicochemical Drug Properties Associated with in Vivo Toxicological Outcomes: A Review</span>. <i>Expert Opin. Drug Metab. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">931</span>, <span class="refDoi"> DOI: 10.1517/17425250903042318</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1517%2F17425250903042318" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=19519283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD1MXovVCjtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=921-931&author=D.+A.+Priceauthor=J.+Blaggauthor=L.+Jonesauthor=N.+Greeneauthor=T.+Wager&title=Physicochemical+Drug+Properties+Associated+with+in+Vivo+Toxicological+Outcomes%3A+A+Review&doi=10.1517%2F17425250903042318"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical drug properties associated with in vivo toxicological outcomes: a review</span></div><div class="casAuthors">Price, David A.; Blagg, Julian; Jones, Lyn; Greene, Nigel; Wager, Travis</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">921-931</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The genesis of any toxicol. or safety outcome is multifactorial and complex; for this reason, it can be difficult for drug discovery projects to factor the avoidance of toxicity outcomes into their target design.  A focus on readily measurable parameters from high-throughput in vitro assays (e.g., primary potency, clearance) is easier to handle and have become the mainstays of drug discovery projects.  However, the fundamental origins of adverse safety or toxicity findings can be considered as deriving from four parameters, all of which are in the control of the drug designer.  These can be described as primary pharmacol., off target pharmacol., the presence of a defined structural fragment that can be assocd. with adverse outcomes and the overall physicochem. properties of the mol. that may predispose it to adverse outcomes.  In the drug discovery community, there has been recognition for many years of the influence of physicochem. drug properties (in particular lipophilicity) on the toxicol. profile of compds., and recent research is now beginning to quantify that risk in a probabilistic sense.  This review focuses on the overall properties of classes of mols. that are assocd. with an increased probability of adverse outcomes in in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpU8kwwUsaFIrVg90H21EOLACvtfcHk0lgVqVne2JMYKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXovVCjtb0%253D&md5=bd1cca3634afda14de2f8aa115d7d55e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1517%2F17425250903042318&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425250903042318%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBlagg%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DL.%26aulast%3DGreene%26aufirst%3DN.%26aulast%3DWager%26aufirst%3DT.%26atitle%3DPhysicochemical%2520Drug%2520Properties%2520Associated%2520with%2520in%2520Vivo%2520Toxicological%2520Outcomes%253A%2520A%2520Review%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2009%26volume%3D5%26spage%3D921%26epage%3D931%26doi%3D10.1517%2F17425250903042318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span>Eurofins.
Cerep. <a href="https://www.eurofins.com/contact-us/worldwide-interactive-map/france/eurofins-cerep-france/" class="extLink">https://www.eurofins.com/contact-us/worldwide-interactive-map/france/eurofins-cerep-france/</a> (accessed Aug 29, <span class="NLM_year">2019</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Eurofins.%0ACerep.+https%3A%2F%2Fwww.eurofins.com%2Fcontact-us%2Fworldwide-interactive-map%2Ffrance%2Feurofins-cerep-france%2F+%28accessed+Aug+29%2C+2019%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruneau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, N. R.</span></span> <span> </span><span class="NLM_article-title">Logd7.4 Modeling Using Bayesian Regularized Neural Networks. Assessment and Correction of the Errors of Prediction</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">1379</span>– <span class="NLM_lpage">1387</span>, <span class="refDoi"> DOI: 10.1021/ci0504014</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci0504014" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlars73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2006&pages=1379-1387&author=P.+Bruneauauthor=N.+R.+McElroy&title=Logd7.4+Modeling+Using+Bayesian+Regularized+Neural+Networks.+Assessment+and+Correction+of+the+Errors+of+Prediction&doi=10.1021%2Fci0504014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">logD7.4 Modeling Using Bayesian Regularized Neural Networks. Assessment and Correction of the Errors of Prediction</span></div><div class="casAuthors">Bruneau, Pierre; McElroy, Nathan R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1379-1387</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bayesian Regularized Neural Networks (BRNNs) employing Automatic Relevance Detn. (ARD) are used to construct a predictive model for the distribution coeff. logD7.4 from an inhouse data set of 5000 compds. with exptl. endpoints.  A method for assessing the accuracy of prediction is established based upon a query compd.'s distance to the training set. logD7.4 predictions are also dynamically cor. with an assocd. library of compds. of continuously updated, exptl. measured logD7.4 values.  A comparison of local models and assocd. libraries comprising sep. ionization class subsets of compds. to compds. of a homogeneous ionization class reveals in this case that local models and libraries have no advantage over global models and libraries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5roy_pM8ZtLVg90H21EOLACvtfcHk0lggUv6HmH_xOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlars73N&md5=9ce727349c66a515585debf55631a85c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fci0504014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci0504014%26sid%3Dliteratum%253Aachs%26aulast%3DBruneau%26aufirst%3DP.%26aulast%3DMcElroy%26aufirst%3DN.%2BR.%26atitle%3DLogd7.4%2520Modeling%2520Using%2520Bayesian%2520Regularized%2520Neural%2520Networks.%2520Assessment%2520and%2520Correction%2520of%2520the%2520Errors%2520of%2520Prediction%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2006%26volume%3D46%26spage%3D1379%26epage%3D1387%26doi%3D10.1021%2Fci0504014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shultz, M. D.</span></span> <span> </span><span class="NLM_article-title">Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1701</span>– <span class="NLM_lpage">1714</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00686</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00686" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslait73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1701-1714&author=M.+D.+Shultz&title=Two+Decades+under+the+Influence+of+the+Rule+of+Five+and+the+Changing+Properties+of+Approved+Oral+Drugs&doi=10.1021%2Facs.jmedchem.8b00686"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs</span></div><div class="casAuthors">Shultz, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1701-1714</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Two decades have passed since the rule of five ushered in the concept of "drug-like" properties.  Attempts to quantify, correlate, and categorize mols. based on Ro5 parameters evolved into the introduction of efficiency metrics with far reaching consequences in decision making by industry leaders and scientists seeking to discover new medicines.  Examn. of oral drug parameters approved before and after the original Ro5 anal. demonstrates that some parameters such as clogP and HBD remained const. while the cutoffs for parameters such as mol. wt. and HBA have increased substantially over the past 20 years.  The time dependent increase in the mol. wt. of oral drugs during the past 20 years provides compelling evidence to disprove the hypothesis that mol. wt. is a "drug-like" property.  This anal. does not validate parameters that have not changed as being "drug-like" but instead calls into question the entire hypothesis that "drug-like" properties exist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAnoxpQsv2kbVg90H21EOLACvtfcHk0lggUv6HmH_xOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslait73K&md5=d3c8b1107133dc0b7b277d22fa029597</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00686%26sid%3Dliteratum%253Aachs%26aulast%3DShultz%26aufirst%3DM.%2BD.%26atitle%3DTwo%2520Decades%2520under%2520the%2520Influence%2520of%2520the%2520Rule%2520of%2520Five%2520and%2520the%2520Changing%2520Properties%2520of%2520Approved%2520Oral%2520Drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1701%26epage%3D1714%26doi%3D10.1021%2Facs.jmedchem.8b00686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bostrom, J.</span></span> <span> </span><span class="NLM_article-title">Where Do Recent Small Molecule Clinical Development Candidates Come From?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9442</span>– <span class="NLM_lpage">9468</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00675</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00675" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFKhsb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9442-9468&author=D.+G.+Brownauthor=J.+Bostrom&title=Where+Do+Recent+Small+Molecule+Clinical+Development+Candidates+Come+From%3F&doi=10.1021%2Facs.jmedchem.8b00675"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Where Do Recent Small Molecule Clinical Development Candidates Come From?</span></div><div class="casAuthors">Brown, Dean G.; Bostrom, Jonas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9442-9468</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An anal. of 66 published clin. candidates from Journal of Medicinal Chem. has been conducted to shed light on which lead generation strategies are most frequently employed in identifying drug candidates.  The most frequent lead generation strategy (producing a drug candidate) was based on starting points derived from previously known compds. (43%) followed by random high throughput screening (29%).  The remainder of approaches included focused screening, structure-based drug design (SBDD), fragment-based lead generation (FBLG), and DNA-encoded library screening (DEL).  An anal. of physicochem. properties on the hit-to-clin. pairs shows an av. increase in mol. wt. (ΔMW = +85) but no change in lipophilicity (ΔclogP = -0.2), although exceptions are noted.  The majority (>50%) of clin. candidates were found to be structurally very different from their starting point and were more complex.  Finally, several reports of noncovalent scaffolds modified by a covalent warhead using SBDD approaches are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKVZOYYj87bLVg90H21EOLACvtfcHk0lggUv6HmH_xOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFKhsb7F&md5=211341fa12156e9512650d3352893a5e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00675&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00675%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DBostrom%26aufirst%3DJ.%26atitle%3DWhere%2520Do%2520Recent%2520Small%2520Molecule%2520Clinical%2520Development%2520Candidates%2520Come%2520From%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9442%26epage%3D9468%26doi%3D10.1021%2Facs.jmedchem.8b00675" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fredholm, B. B.</span></span> <span> </span><span class="NLM_article-title">Adenosine, an Endogenous Distress Signal, Modulates Tissue Damage and Repair</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1315</span>– <span class="NLM_lpage">1323</span>, <span class="refDoi"> DOI: 10.1038/sj.cdd.4402132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fsj.cdd.4402132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=17396131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1Srurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2007&pages=1315-1323&author=B.+B.+Fredholm&title=Adenosine%2C+an+Endogenous+Distress+Signal%2C+Modulates+Tissue+Damage+and+Repair&doi=10.1038%2Fsj.cdd.4402132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Adenosine, an endogenous distress signal, modulates tissue damage and repair</span></div><div class="casAuthors">Fredholm, B. B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1315-1323</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Adenosine is formed inside cells or on their surface, mostly by breakdown of adenine nucleotides.  The formation of adenosine increases in different conditions of stress and distress.  Adenosine acts on four G-protein coupled receptors: two of them, A1 and A3, are primarily coupled to Gi family G proteins; and two of them, A2A and A2B, are mostly coupled to Gs like G proteins.  These receptors are antagonized by xanthines including caffeine.  Via these receptors it affects many cells and organs, usually having a cytoprotective function.  Joel Linden recently grouped these protective effects into four general modes of action: increased oxygen supply/demand ratio, preconditioning, anti-inflammatory effects and stimulation of angiogenesis.  This review will briefly summarize what is known and what is not in this regard.  It is argued that drugs targeting adenosine receptors might be useful adjuncts in many therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp106BDv5VC-7Vg90H21EOLACvtfcHk0lggUv6HmH_xOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1Srurk%253D&md5=5e956ac2260cf45e9a93971094afd18a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fsj.cdd.4402132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cdd.4402132%26sid%3Dliteratum%253Aachs%26aulast%3DFredholm%26aufirst%3DB.%2BB.%26atitle%3DAdenosine%252C%2520an%2520Endogenous%2520Distress%2520Signal%252C%2520Modulates%2520Tissue%2520Damage%2520and%2520Repair%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2007%26volume%3D14%26spage%3D1315%26epage%3D1323%26doi%3D10.1038%2Fsj.cdd.4402132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mirza, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparks, R. G.</span></span> <span> </span><span class="NLM_article-title">Xanomeline and the Antipsychotic Potential of Muscarinic Receptor Subtype Selective Agonists</span>. <i>CNS Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3458.2003.tb00247.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1111%2Fj.1527-3458.2003.tb00247.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=12847557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsl2qt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=159-186&author=N.+R.+Mirzaauthor=D.+Petersauthor=R.+G.+Sparks&title=Xanomeline+and+the+Antipsychotic+Potential+of+Muscarinic+Receptor+Subtype+Selective+Agonists&doi=10.1111%2Fj.1527-3458.2003.tb00247.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists</span></div><div class="casAuthors">Mirza, Naheed R.; Peters, Dan; Sparks, Robin G.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drug Reviews</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-186</span>CODEN:
                <span class="NLM_cas:coden">CDREFB</span>;
        ISSN:<span class="NLM_cas:issn">1080-563X</span>.
    
            (<span class="NLM_cas:orgname">Neva Press</span>)
        </div><div class="casAbstract">A review.  Binding studies initially suggested that the muscarinic agonist, xanomeline, was a subtype selective muscarinic M1 receptor agonist, and a potential new treatment for Alzheimer's disease.  However, later in vitro and in vivo functional studies suggest that this compd. is probably better described as a subtype selective M1/M4 muscarinic receptor agonist.  This subtype selectivity profile has been claimed to explain the limited classical cholinomimetic side effects, particularly gastrointestinal, seen with xanomeline in animals.  However, in both healthy volunteers and Alzheimer's patients many of these side effects have been reported for xanomeline and in the patient population this led to a >50% discontinuation rate.  Clearly, the preclin. studies have not been able to predict this adverse profile of xanomeline, and this suggests that either xanomeline is not as subtype selective as predicted from preclin. research or that there are differences between humans and animals with regard to muscarinic receptors.  Nevertheless, in Alzheimer's patients xanomeline dose-dependently improves aspects of behavioral disturbance and social behavior including a redn. in hallucinations, agitation, delusions, vocal outbursts and suspiciousness.  The effects on cognition are not as robust and mainly seen at the highest doses tested.  These effects in Alzheimer's patients have given impetus to the suggestion that muscarinic agonists have potential antipsychotic effects.  The current review assesses the antipsychotic profile of xanomeline within the framework of the limited clin. studies with cholinergic agents in man, and the preclin. research on xanomeline using various models commonly used for the assessment of new antipsychotic drugs.  In general, xanomeline has an antipsychotic-like profile in various dopamine models of psychosis and this agrees with the known interactions between the cholinergic and dopaminergic systems in the brain.  Moreover, current data suggests that the actions of xanomeline at the M4 muscarinic receptor subtype might mediate its antidopaminergic effects.  Particularly intriguing are studies showing that xanomeline, even after acute administration, selectively inhibits the firing of mesolimbic dopamine cells relative to dopamine cell bodies projecting to the striatum.  This data suggest that xanomeline would have a faster onset of action compared to current antipsychotics and would not induce extrapyramidal side effects.  The preclin. data on the whole are promising for an antipsychotic-like profile.  If in a new formulation (i.e., transdermal) xanomeline has less adverse effects, this drug may be valuable in the treatment of patients with psychosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvVnKMP2LfgbVg90H21EOLACvtfcHk0lhQkhAwWGEofA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsl2qt7o%253D&md5=cf96dec926979e17599b2673a49f11c2</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2003.tb00247.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2003.tb00247.x%26sid%3Dliteratum%253Aachs%26aulast%3DMirza%26aufirst%3DN.%2BR.%26aulast%3DPeters%26aufirst%3DD.%26aulast%3DSparks%26aufirst%3DR.%2BG.%26atitle%3DXanomeline%2520and%2520the%2520Antipsychotic%2520Potential%2520of%2520Muscarinic%2520Receptor%2520Subtype%2520Selective%2520Agonists%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2003%26volume%3D9%26spage%3D159%26epage%3D186%26doi%3D10.1111%2Fj.1527-3458.2003.tb00247.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Melancon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarr, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panarese, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span> <span> </span><span class="NLM_article-title">Allosteric Modulation of the M1 Muscarinic Acetylcholine Receptor: Improving Cognition and a Potential Treatment for Schizophrenia and Alzheimer’s Disease</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1185</span>– <span class="NLM_lpage">1199</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.09.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.drudis.2013.09.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=24051397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslSmu7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=1185-1199&author=B.+J.+Melanconauthor=J.+C.+Tarrauthor=J.+D.+Panareseauthor=M.+R.+Woodauthor=C.+W.+Lindsley&title=Allosteric+Modulation+of+the+M1+Muscarinic+Acetylcholine+Receptor%3A+Improving+Cognition+and+a+Potential+Treatment+for+Schizophrenia+and+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.drudis.2013.09.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease</span></div><div class="casAuthors">Melancon, Bruce J.; Tarr, James C.; Panarese, Joseph D.; Wood, Michael R.; Lindsley, Craig W.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">1185-1199</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Allosteric modulation of AMPA, NR2B, mGlu2, mGlu5 and M1, targeting glutamatergic dysfunction, represents a significant area of research for the treatment of schizophrenia.  Of these targets, clin. promise has been demonstrated using muscarinic activators for the treatment of Alzheimer's disease (AD) and schizophrenia.  These diseases have inspired researchers to det. the effects of modulating cholinergic transmission in the forebrain, which is primarily regulated by one of five subtypes of muscarinic acetylcholine receptor (mAChR), a subfamily of G-protein-coupled receptors (GPCRs).  Of these five subtypes, M1 is highly expressed in brain regions responsible for learning, cognition and memory.  Xanomeline, an orthosteric muscarinic agonist with modest selectivity, was one of the first compds. that displayed improvements in behavioral disturbances in AD patients and efficacy in schizophrenics.  Since these initial clin. results, many scientists, including those in our labs., have strived to elucidate the role of M1 with compds. that display improved selectivity for this receptor by targeting allosteric modes of receptor activation.  A survey of selected compds. in this area will be presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxxLAJQLkeE7Vg90H21EOLACvtfcHk0lhQkhAwWGEofA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslSmu7nL&md5=51ee8b978d708b7ddbcbde3fe3e72f50</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.09.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.09.005%26sid%3Dliteratum%253Aachs%26aulast%3DMelancon%26aufirst%3DB.%2BJ.%26aulast%3DTarr%26aufirst%3DJ.%2BC.%26aulast%3DPanarese%26aufirst%3DJ.%2BD.%26aulast%3DWood%26aufirst%3DM.%2BR.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26atitle%3DAllosteric%2520Modulation%2520of%2520the%2520M1%2520Muscarinic%2520Acetylcholine%2520Receptor%253A%2520Improving%2520Cognition%2520and%2520a%2520Potential%2520Treatment%2520for%2520Schizophrenia%2520and%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D1185%26epage%3D1199%26doi%3D10.1016%2Fj.drudis.2013.09.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clader, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Muscarinic Receptor Agonists and Antagonists in the Treatment of Alzheimer’s Disease</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">3353</span>– <span class="NLM_lpage">3361</span>, <span class="refDoi"> DOI: 10.2174/138161205774370762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.2174%2F138161205774370762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=16250841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWrs7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=3353-3361&author=J.+W.+Claderauthor=Y.+Wang&title=Muscarinic+Receptor+Agonists+and+Antagonists+in+the+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.2174%2F138161205774370762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease</span></div><div class="casAuthors">Clader, John W.; Wang, Yuguang</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">3353-3361</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  One of the consistent findings in the brains of Alzheimer's Disease (AD) patients is loss of cholinergic function.  The cholinergic approach to treatment of AD involves counteracting this loss in cholinergic activity by pharmacol. intervention to increase cholinergic transmission.  The cognitive effects of acetylcholine are mediated via the muscarinic M1 receptor.  Direct stimulation of this receptor using muscarinic M1 agonists improves cognition in animal models and improves performance in cognitive tests in Alzheimer's patients.  Alternatively, antagonists of central presynaptic M2 receptors improves cognition by increasing the central release of acetylcholine.  Both approaches require high selectivity for one muscarinic receptor sub-type both for efficacy and to avoid cholinergic side effects.  In this review summarizes recent progress in the identification and characterization of selective muscarinic receptor ligands for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2_wdSDisNRLVg90H21EOLACvtfcHk0lhQkhAwWGEofA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWrs7vP&md5=d0d18c0299921abfbf6b815b223e743a</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2174%2F138161205774370762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161205774370762%26sid%3Dliteratum%253Aachs%26aulast%3DClader%26aufirst%3DJ.%2BW.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DMuscarinic%2520Receptor%2520Agonists%2520and%2520Antagonists%2520in%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2005%26volume%3D11%26spage%3D3353%26epage%3D3361%26doi%3D10.2174%2F138161205774370762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alagha, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palot, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sofalvi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouitaa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charpin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourdin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chanez, P.</span></span> <span> </span><span class="NLM_article-title">Long-Acting Muscarinic Receptor Antagonists for the Treatment of Chronic Airway Diseases</span>. <i>Ther. Adv. Chronic Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1177/2040622313518227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1177%2F2040622313518227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=24587893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1OntLjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=85-98&author=K.+Alaghaauthor=A.+Palotauthor=T.+Sofalviauthor=L.+Pahusauthor=M.+Gouitaaauthor=C.+Tumminoauthor=S.+Martinezauthor=D.+Charpinauthor=A.+Bourdinauthor=P.+Chanez&title=Long-Acting+Muscarinic+Receptor+Antagonists+for+the+Treatment+of+Chronic+Airway+Diseases&doi=10.1177%2F2040622313518227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases</span></div><div class="casAuthors">Alagha, Khuder; Palot, Alain; Sofalvi, Tunde; Pahus, Laurie; Gouitaa, Marion; Tummino, Celine; Martinez, Stephanie; Charpin, Denis; Bourdin, Arnaud; Chanez, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic Advances in Chronic Disease</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">85-98, 14</span>CODEN:
                <span class="NLM_cas:coden">TACDCS</span>;
        ISSN:<span class="NLM_cas:issn">2040-6223</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Acetylcholine (neuronal and non-neuronal origin) regulates bronchoconstriction, and mucus secretion.  It has an inflammatory effect by inducing attraction, survival and cytokine release from inflammatory cells.  Muscarinic receptors throughout the bronchial tree are mainly restricted to muscarinic M1, M2 and M3 receptors.  Three long-acting muscarinic receptor antagonists (LAMAs) were approved for the treatment of chronic obstructive pulmonary disease (COPD) in Europe: once-daily tiotropium bromide; once-daily glycopyrronium bromide; and twice-daily aclidinium bromide.  All have higher selectivity for M3 receptors than for M2 receptors, and dissoc. more slowly from the M3 receptors than they do from the M2 receptors.  Some LAMAs showed anti-inflammatory effects [inhibition of neutrophil chemotactic activity and migration of alveolar neutrophils, decrease of several cytokines in the bronchoalveolar lavage (BAL) including interleukin (IL)-6, tumor necrosis factor (TNF)-α and leukotriene (LT)B4] and antiremodeling effects (inhibition of mucus gland hypertrophy and decrease in MUC5AC-pos. goblet cell no., decrease in MUC5AC overexpression).  In the clinic, LAMAs showed a significant improvement of forced expiratory vol. in 1 s (FEV1), quality of life, dyspnea and reduced the no. of exacerbations in COPD and more recently in asthma.  This review will focus on the three LAMAs approved in Europe in the treatment of chronic airway diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVv9hvW4HRY7Vg90H21EOLACvtfcHk0lh7eUbHh0qPgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1OntLjF&md5=4f1bf29c29adced609e3c61c36cec938</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1177%2F2040622313518227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2040622313518227%26sid%3Dliteratum%253Aachs%26aulast%3DAlagha%26aufirst%3DK.%26aulast%3DPalot%26aufirst%3DA.%26aulast%3DSofalvi%26aufirst%3DT.%26aulast%3DPahus%26aufirst%3DL.%26aulast%3DGouitaa%26aufirst%3DM.%26aulast%3DTummino%26aufirst%3DC.%26aulast%3DMartinez%26aufirst%3DS.%26aulast%3DCharpin%26aufirst%3DD.%26aulast%3DBourdin%26aufirst%3DA.%26aulast%3DChanez%26aufirst%3DP.%26atitle%3DLong-Acting%2520Muscarinic%2520Receptor%2520Antagonists%2520for%2520the%2520Treatment%2520of%2520Chronic%2520Airway%2520Diseases%26jtitle%3DTher.%2520Adv.%2520Chronic%2520Dis.%26date%3D2014%26volume%3D5%26spage%3D85%26epage%3D98%26doi%3D10.1177%2F2040622313518227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campeau, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olshansky, B.</span></span> <span> </span><span class="NLM_article-title">Cardiac Effects of Muscarinic Receptor Antagonists Used for Voiding Dysfunction</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">186</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2125.2010.03813.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1111%2Fj.1365-2125.2010.03813.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=21595741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2011&pages=186-196&author=K.+E.+Anderssonauthor=L.+Campeauauthor=B.+Olshansky&title=Cardiac+Effects+of+Muscarinic+Receptor+Antagonists+Used+for+Voiding+Dysfunction&doi=10.1111%2Fj.1365-2125.2010.03813.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction</span></div><div class="casAuthors">Andersson, Karl-Erik; Campeau, Lysanne; Olshansky, Brian</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">186-196</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">0306-5251</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Antimuscarinic agents are the main drugs used to treat patients with the overactive bladder (OAB) syndrome, defined as urgency, with or without urgency incontinence, usually with increased daytime frequency and nocturia.  Since the treatment is not curative and since OAB is a chronic disease, treatment may be life-long.  Antimuscarinics are generally considered to be 'safe' drugs, but among the more serious concerns related to their use is the risk of cardiac adverse effects, particularly increases in heart rate (HR) and QT prolongation and induction of polymorphic ventricular tachycardia (torsade de pointes).  An elevated resting HR has been linked to overall increased morbidity and mortality, particularly in patients with cardiovascular diseases.  QT prolongation and its consequences are not related to blockade of muscarinic receptors, but rather linked to inhibition of the hERG potassium channel in the heart.  However, experience with terodiline, an antimuscarinic drug causing torsade de pointes in patients, has placed the whole drug class under scrutiny.  The potential of the different antimuscarinic agents to increase HR and/or prolong the QT time has not been extensively explored for all agents in clin. use.  Differences between drugs cannot be excluded, but risk assessments based on available evidence are not possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBGT557LD7g7Vg90H21EOLACvtfcHk0lh7eUbHh0qPgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2qtr3M&md5=1b0aa6a5b96a687bb2fc92ddcaef315d</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2125.2010.03813.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2125.2010.03813.x%26sid%3Dliteratum%253Aachs%26aulast%3DAndersson%26aufirst%3DK.%2BE.%26aulast%3DCampeau%26aufirst%3DL.%26aulast%3DOlshansky%26aufirst%3DB.%26atitle%3DCardiac%2520Effects%2520of%2520Muscarinic%2520Receptor%2520Antagonists%2520Used%2520for%2520Voiding%2520Dysfunction%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D72%26spage%3D186%26epage%3D196%26doi%3D10.1111%2Fj.1365-2125.2010.03813.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giovannitti, J. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoms, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span> <span> </span><span class="NLM_article-title">Alpha-2 Adrenergic Receptor Agonists: A Review of Current Clinical Applications</span>. <i>Anesth Prog.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.2344/0003-3006-62.1.31</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.2344%2F0003-3006-62.1.31" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=25849473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BC2MjitVWqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2015&pages=31-39&author=J.+A.+Giovannittiauthor=S.+M.+Thomsauthor=J.+J.+Crawford&title=Alpha-2+Adrenergic+Receptor+Agonists%3A+A+Review+of+Current+Clinical+Applications&doi=10.2344%2F0003-3006-62.1.31"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Alpha-2 adrenergic receptor agonists: a review of current clinical applications</span></div><div class="casAuthors">Giovannitti Joseph A Jr; Thoms Sean M; Crawford James J</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesia progress</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-9</span>
        ISSN:<span class="NLM_cas:issn">0003-3006</span>.
    </div><div class="casAbstract">The α-2 adrenergic receptor agonists have been used for decades to treat common medical conditions such as hypertension; attention-deficit/hyperactivity disorder; various pain and panic disorders; symptoms of opioid, benzodiazepine, and alcohol withdrawal; and cigarette craving. (1) However, in more recent years, these drugs have been used as adjuncts for sedation and to reduce anesthetic requirements.  This review will provide an historical perspective of this drug class, an understanding of pharmacological mechanisms, and an insight into current applications in clinical anesthesiology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQYy161IaNwq5WtyewyzkyLfW6udTcc2ea8ly1sLKU_9rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjitVWqug%253D%253D&md5=b2fa50caf320cec6dd2bd17d15e7a8f2</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.2344%2F0003-3006-62.1.31&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2344%252F0003-3006-62.1.31%26sid%3Dliteratum%253Aachs%26aulast%3DGiovannitti%26aufirst%3DJ.%2BA.%26aulast%3DThoms%26aufirst%3DS.%2BM.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26atitle%3DAlpha-2%2520Adrenergic%2520Receptor%2520Agonists%253A%2520A%2520Review%2520of%2520Current%2520Clinical%2520Applications%26jtitle%3DAnesth%2520Prog.%26date%3D2015%26volume%3D62%26spage%3D31%26epage%3D39%26doi%3D10.2344%2F0003-3006-62.1.31" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, L. S.</span></span> <span> </span><span class="NLM_article-title">Phentolamine Therapy for Cocaine-Association Acute Coronary Syndrome (Caacs)</span>. <i>J. Med. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">108</span>– <span class="NLM_lpage">111</span>, <span class="refDoi"> DOI: 10.1007/BF03161019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1007%2FBF03161019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=18072128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BD2sjjsFSrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=108-111&author=G.+M.+Chanauthor=R.+Sharmaauthor=D.+Priceauthor=R.+S.+Hoffmanauthor=L.+S.+Nelson&title=Phentolamine+Therapy+for+Cocaine-Association+Acute+Coronary+Syndrome+%28Caacs%29&doi=10.1007%2FBF03161019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Phentolamine therapy for cocaine-association acute coronary syndrome (CAACS)</span></div><div class="casAuthors">Chan Gar Ming; Sharma Rahul; Price Dennis; Hoffman Robert S; Nelson Lewis S</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medical toxicology : official journal of the American College of Medical Toxicology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">108-11</span>
        ISSN:<span class="NLM_cas:issn">1556-9039</span>.
    </div><div class="casAbstract">INTRODUCTION:  The emergency department (ED) evaluation of cocaine-associated acute coronary syndrome (CAACS) is often a diagnostic and therapeutic challenge.  CASE REPORT:  We are reporting on the treatment of a patient with cocaine-associated acute coronary syndrome (CAACS) who did not benefit from standard therapy, but who eventually responded positively to phentolamine, an alpha-adrenergic receptor antagonist.  DISCUSSION:  This report should encourage physicians to add phentolamine to their pharmacotherapeutic armamentarium in the treatment of CAACS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSDnWJ92eNBADdblLE_E9PWfW6udTcc2ea8ly1sLKU_9rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2sjjsFSrsw%253D%253D&md5=715c4dbf7cf0fa6548c0ab8f3ec7cabf</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2FBF03161019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF03161019%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DG.%2BM.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DPrice%26aufirst%3DD.%26aulast%3DHoffman%26aufirst%3DR.%2BS.%26aulast%3DNelson%26aufirst%3DL.%2BS.%26atitle%3DPhentolamine%2520Therapy%2520for%2520Cocaine-Association%2520Acute%2520Coronary%2520Syndrome%2520%2528Caacs%2529%26jtitle%3DJ.%2520Med.%2520Toxicol.%26date%3D2006%26volume%3D2%26spage%3D108%26epage%3D111%26doi%3D10.1007%2FBF03161019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feltracco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vittorio, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neto, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabrini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zangrillo, A.</span></span> <span> </span><span class="NLM_article-title">Dexmedetomidine as a Sedative Agent in Critically Ill Patients: A Meta-Analysis of Randomized Controlled Trials</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e82913</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0082913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1371%2Fjournal.pone.0082913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=24391726" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2cXis1WjsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=L.+Pasinauthor=T.+Grecoauthor=P.+Feltraccoauthor=A.+Vittorioauthor=C.+N.+Netoauthor=L.+Cabriniauthor=G.+Landoniauthor=G.+Fincoauthor=A.+Zangrillo&title=Dexmedetomidine+as+a+Sedative+Agent+in+Critically+Ill+Patients%3A+A+Meta-Analysis+of+Randomized+Controlled+Trials&doi=10.1371%2Fjournal.pone.0082913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Dexmedetomidine as a sedative agent in critically ill patients: a meta-analysis of randomized controlled trials</span></div><div class="casAuthors">Pasin, Laura; Greco, Teresa; Feltracco, Paolo; Vittorio, Annalisa; Nigro Neto, Caetano; Cabrini, Luca; Landoni, Giovanni; Finco, Gabriele; Zangrillo, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e82913/1-e82913/13, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Introduction: The effect of dexmedetomidine on length of intensive care unit (ICU) stay and time to extubation is still unclear.  Materials and Methods: Pertinent studies were independently searched in BioMedCentral, PubMed, Embase, and the Cochrane Central Register of clin. trials.  Randomized studies (dexmedetomidine vs. any comparator) were included if including patients mech. ventilated in an intensive care unit (ICU).  Co-primary endpoints were the length of ICU stay (days) and time to extubation (hours).  Secondary endpoint was mortality rate at the longest follow-up available.  Results: The 27 included manuscripts (28 trials) randomized 3,648 patients (1,870 to dexmedetomidine and 1,778 to control).  Overall anal. showed that the use of dexmedetomidine was assocd. with a significant redn. in length of ICU stay (weighted mean difference (WMD) = -0.79 [-1.17 to -0.40] days, p for effect <0.001) and of time to extubation (WMD = -2.74 [-3.80 to -1.65] hours, p for effect <0.001).  Mortality was not different between dexmedetomidine and controls (risk ratio = 1.00 [0.84 to 1.21], p for effect = 0.9).  High heterogeneity between included studies was found.  Conclusions: This meta-anal. of randomized controlled studies suggests that dexmedetomidine could help to reduce ICU stay and time to extubation, in critically ill patients even if high heterogeneity between studies might confound the interpretation of these results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxK6BE_H7lnrVg90H21EOLACvtfcHk0ljGoP47bECs8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXis1WjsLo%253D&md5=3456cd6f9181d2142ab24a279d1f33c9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0082913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0082913%26sid%3Dliteratum%253Aachs%26aulast%3DPasin%26aufirst%3DL.%26aulast%3DGreco%26aufirst%3DT.%26aulast%3DFeltracco%26aufirst%3DP.%26aulast%3DVittorio%26aufirst%3DA.%26aulast%3DNeto%26aufirst%3DC.%2BN.%26aulast%3DCabrini%26aufirst%3DL.%26aulast%3DLandoni%26aufirst%3DG.%26aulast%3DFinco%26aufirst%3DG.%26aulast%3DZangrillo%26aufirst%3DA.%26atitle%3DDexmedetomidine%2520as%2520a%2520Sedative%2520Agent%2520in%2520Critically%2520Ill%2520Patients%253A%2520A%2520Meta-Analysis%2520of%2520Randomized%2520Controlled%2520Trials%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0082913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neil, M. J. E.</span></span> <span> </span><span class="NLM_article-title">Clonidine: Clinical Pharmacology and Therapeutic Use in Pain Management</span>. <i>Curr. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">280</span>– <span class="NLM_lpage">287</span>, <span class="refDoi"> DOI: 10.2174/157488411798375886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.2174%2F157488411798375886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=21827389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=280-287&author=M.+J.+E.+Neil&title=Clonidine%3A+Clinical+Pharmacology+and+Therapeutic+Use+in+Pain+Management&doi=10.2174%2F157488411798375886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Clonidine: clinical pharmacology and therapeutic use in pain management</span></div><div class="casAuthors">Neil, Michael J. E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">280-287</span>CODEN:
                <span class="NLM_cas:coden">CCPUC5</span>;
        ISSN:<span class="NLM_cas:issn">1574-8847</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Pain is an unpleasant sensory perception warning of actual or impending tissue damage.  Pain serves a vital physiol. role, however, severe and uncontrolled pain in the peri-operative setting can adversely affect outcome from surgery and lead to chronic pain.  Multiple neurochem. and receptor processes are involved in pain perception but the role of pro-inflammatory cytokines and adrenergic pathways has only recently been recognized.  Clonidine is an agonist at the alpha2-adrenergic receptor that has been in clin. use for over 40 years.  Clonidine was recognized at an early stage as having analgesic properties however its systemic use was frequently limited by side-effects.  Recent advances in anesthetic practice, allowing more targeted drug delivery and a better understanding of the basic physiol. of pain have led to a re-evaluation of the role of clonidine in pain management.  Exptl. and clin. studies have identified a diverse action of clonidine in modifying not only the adrenergic component to pain perception but also an important effect on modifying the neurohumoral response to tissue injury.  This has implications for the management of a diverse range of pain problems and potentially offers a method of preventing the transition from acute to chronic pain.  Clonidine is likely to play an increasing role in clin. practice in anesthetics and pain management.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVkkNR2hwrs7Vg90H21EOLACvtfcHk0ljGoP47bECs8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVGrsbo%253D&md5=971e8635ed85ca18ba6f3b88b184179e</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F157488411798375886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157488411798375886%26sid%3Dliteratum%253Aachs%26aulast%3DNeil%26aufirst%3DM.%2BJ.%2BE.%26atitle%3DClonidine%253A%2520Clinical%2520Pharmacology%2520and%2520Therapeutic%2520Use%2520in%2520Pain%2520Management%26jtitle%3DCurr.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D6%26spage%3D280%26epage%3D287%26doi%3D10.2174%2F157488411798375886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zamponi, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Striessnig, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koschak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolphin, A. C.</span></span> <span> </span><span class="NLM_article-title">The Physiology, Pathology, and Pharmacology of Voltage-Gated Calcium Channels and Their Future Therapeutic Potential</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">821</span>– <span class="NLM_lpage">870</span>, <span class="refDoi"> DOI: 10.1124/pr.114.009654</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1124%2Fpr.114.009654" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=26362469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC28Xns1Gms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=821-870&author=G.+W.+Zamponiauthor=J.+Striessnigauthor=A.+Koschakauthor=A.+C.+Dolphin&title=The+Physiology%2C+Pathology%2C+and+Pharmacology+of+Voltage-Gated+Calcium+Channels+and+Their+Future+Therapeutic+Potential&doi=10.1124%2Fpr.114.009654"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential</span></div><div class="casAuthors">Zamponi, Gerald W.; Striessnig, Joerg; Koschak, Alexandra; Dolphin, Annette C.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">821-870</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">1521-0081</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Voltage-gated calcium channels are required for many key functions in the body.  In this review, the different subtypes of voltage-gated calcium channels are described and their physiol. roles and pharmacol. are outlined.  We describe the current uses of drugs interacting with the different calcium channel subtypes and subunits, as well as specific areas in which there is strong potential for future drug development.  Current therapeutic agents include drugs targeting L-type CaV1.2 calcium channels, particularly 1,4-dihydropyridines, which are widely used in the treatment of hypertension.  T-type (CaV3) channels are a target of ethosuximide, widely used in absence epilepsy.  The auxiliary subunit α2δ-1 is the therapeutic target of the gabapentinoid drugs, which are of value in certain epilepsies and chronic neuropathic pain.  The limited use of intrathecal ziconotide, a peptide blocker of N-type (CaV2.2) calcium channels, as a treatment of intractable pain, gives an indication that these channels represent excellent drug targets for various pain conditions.  We describe how selectivity for different subtypes of calcium channels (e.g., CaV1.2 and CaV1.3 L-type channels) may be achieved in the future by exploiting differences between channel isoforms in terms of sequence and biophys. properties, variation in splicing in different target tissues, and differences in the properties of the target tissues themselves in terms of membrane potential or firing frequency.  Thus, use-dependent blockers of the different isoforms could selectively block calcium channels in particular pathologies, such as nociceptive neurons in pain states or in epileptic brain circuits.  Of important future potential are selective CaV1.3 blockers for neuropsychiatric diseases, neuroprotection in Parkinson's disease, and resistant hypertension.  In addn., selective or nonselective T-type channel blockers are considered potential therapeutic targets in epilepsy, pain, obesity, sleep, and anxiety.  Use-dependent N-type calcium channel blockers are likely to be of therapeutic use in chronic pain conditions.  Thus, more selective calcium channel blockers hold promise for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0k6JL9CCXi7Vg90H21EOLACvtfcHk0ljGoP47bECs8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xns1Gms7s%253D&md5=1e5a19b9974b119fc2c00cfa0089e172</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1124%2Fpr.114.009654&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.114.009654%26sid%3Dliteratum%253Aachs%26aulast%3DZamponi%26aufirst%3DG.%2BW.%26aulast%3DStriessnig%26aufirst%3DJ.%26aulast%3DKoschak%26aufirst%3DA.%26aulast%3DDolphin%26aufirst%3DA.%2BC.%26atitle%3DThe%2520Physiology%252C%2520Pathology%252C%2520and%2520Pharmacology%2520of%2520Voltage-Gated%2520Calcium%2520Channels%2520and%2520Their%2520Future%2520Therapeutic%2520Potential%26jtitle%3DPharmacol.%2520Rev.%26date%3D2015%26volume%3D67%26spage%3D821%26epage%3D870%26doi%3D10.1124%2Fpr.114.009654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reith, M. E.</span></span> <span> </span><span class="NLM_article-title">Regulation of the Dopamine Transporter: Aspects Relevant to Psychostimulant Drugs of Abuse</span>. <i>Ann. N. Y. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>1187</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">340</span>, <span class="refDoi"> DOI: 10.1111/j.1749-6632.2009.05148.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1111%2Fj.1749-6632.2009.05148.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=20201860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3cXks1Smsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1187&publication_year=2010&pages=316-340&author=K.+C.+Schmittauthor=M.+E.+Reith&title=Regulation+of+the+Dopamine+Transporter%3A+Aspects+Relevant+to+Psychostimulant+Drugs+of+Abuse&doi=10.1111%2Fj.1749-6632.2009.05148.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse</span></div><div class="casAuthors">Schmitt, Kyle C.; Reith, Maarten E. A.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the New York Academy of Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1187</span>
        (<span class="NLM_cas:issue">Addiction Reviews 2</span>),
    <span class="NLM_cas:pages">316-340</span>CODEN:
                <span class="NLM_cas:coden">ANYAA9</span>;
        ISSN:<span class="NLM_cas:issn">0077-8923</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Dopaminergic signaling in the brain is primarily modulated by dopamine transporters (DATs), which actively translocate extraneuronal dopamine back into dopaminergic neurons.  Transporter proteins are highly dynamic, continuously trafficking between plasmalemmal and endosomal membranes.  Changes in DAT membrane trafficking kinetics can rapidly regulate dopaminergic tone by altering the no. of transporters present at the cell surface.  Various psychostimulant DAT ligands-acting either as amphetamine-like substrates or cocaine-like nontranslocated inhibitors-affect transporter trafficking, triggering rapid insertion or removal of plasmalemmal DATs.  In this review, we focus on the effects of psychostimulants of addiction (particularly D-methamphetamine and cocaine) on DAT regulation and membrane trafficking, with an emphasis on how these drugs may influence intracellular signaling cascades and transporter-assocd. scaffolding proteins to affect DAT regulation.  In addn., we consider involvement of presynaptic receptors for dopamine and other ligands in DAT regulation.  Finally, we discuss possible implications of transporter regulation to the putative toxicity of several substituted amphetamine derivs. commonly used as recreational drugs, as well as to the design of therapeutics for cocaine addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKPcrkSAoXX7Vg90H21EOLACvtfcHk0liPfEXLlhoNKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXks1Smsrk%253D&md5=31977cbff667a331923e279d4b1be89f</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1111%2Fj.1749-6632.2009.05148.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1749-6632.2009.05148.x%26sid%3Dliteratum%253Aachs%26aulast%3DSchmitt%26aufirst%3DK.%2BC.%26aulast%3DReith%26aufirst%3DM.%2BE.%26atitle%3DRegulation%2520of%2520the%2520Dopamine%2520Transporter%253A%2520Aspects%2520Relevant%2520to%2520Psychostimulant%2520Drugs%2520of%2520Abuse%26jtitle%3DAnn.%2520N.%2520Y.%2520Acad.%2520Sci.%26date%3D2010%26volume%3D1187%26spage%3D316%26epage%3D340%26doi%3D10.1111%2Fj.1749-6632.2009.05148.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sokoloff, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Foll, B.</span></span> <span> </span><span class="NLM_article-title">The Dopamine D3 Receptor, a Quarter Century Later</span>. <i>Eur. J. Neurosci</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">19</span>, <span class="refDoi"> DOI: 10.1111/ejn.13390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1111%2Fejn.13390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=27600596" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BC2szotVGgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2017&pages=2-19&author=P.+Sokoloffauthor=B.+Le+Foll&title=The+Dopamine+D3+Receptor%2C+a+Quarter+Century+Later&doi=10.1111%2Fejn.13390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The dopamine D3 receptor, a quarter century later</span></div><div class="casAuthors">Sokoloff Pierre; Le Foll Bernard; Le Foll Bernard</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-19</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This review updates the existing knowledge suggesting a role for the D3 receptor in schizophrenia and drug addiction.  The D3 receptor is expressed in brain regions controlling reward, emotions, and motivation.  Antipsychotics bind in vitro to the D3 receptor with similar affinity as to the D2 receptor, and occupancy of D3 receptors in vivo by these compounds given acutely at clinical dosage have been demonstrated in Positron Emission Tomography (PET) studies.  The D3 receptor modulates glutamatergic pathways from the prefrontal cortex to subcortical areas, either directly by interacting with N-methyl-D-aspartate (NMDA) receptors in the nucleus accumbens, or indirectly by controlling dopamine release from ventral tegmental area neurons.  In animals, D3 receptor antagonists reverse behavioral manifestations of NMDA receptor blockade and improve cognitive performances in various paradigms.  Two D3 receptor-selective compounds have reached clinical trials in schizophrenia, with negative results seemingly due to insufficient target engagement; the results with a third compound, F17464, have not been disclosed yet.  There is converging evidence that D3 receptors do not control the reinforcing effects of drugs of abuse (with the exception of alcohol under low requirement), but rather affects the motivation to take the drugs under high requirement, reactivity to drug-associated cues, and drug-seeking behaviors triggered by stimuli associated with relapse in humans.  D3 receptor expression measured by PET is upregulated in humans with various drug addictions.  A single administration of the D3 receptor-selective antagonist, GSK598809, in humans transiently alleviated craving in smokers after overnight abstinence.  The clinical development of D3-selective compounds will benefit from initial assessment of target engagement through the use of PET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTl1Ipw5ULUy5HZzFRCXxVKfW6udTcc2ebRiRdgWEbeprntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szotVGgtA%253D%253D&md5=e2e57a242a7bbdd9d97f0644392b2c0d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1111%2Fejn.13390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fejn.13390%26sid%3Dliteratum%253Aachs%26aulast%3DSokoloff%26aufirst%3DP.%26aulast%3DLe%2BFoll%26aufirst%3DB.%26atitle%3DThe%2520Dopamine%2520D3%2520Receptor%252C%2520a%2520Quarter%2520Century%2520Later%26jtitle%3DEur.%2520J.%2520Neurosci%26date%3D2017%26volume%3D45%26spage%3D2%26epage%3D19%26doi%3D10.1111%2Fejn.13390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andersohn, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbe, E.</span></span> <span> </span><span class="NLM_article-title">Cardiac and Noncardiac Fibrotic Reactions Caused by Ergot-and Nonergot-Derived Dopamine Agonists</span>. <i>Mov. Disord.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1002/mds.22385</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1002%2Fmds.22385" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=19170199" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BD1M7gvFegsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2009&pages=129-133&author=F.+Andersohnauthor=E.+Garbe&title=Cardiac+and+Noncardiac+Fibrotic+Reactions+Caused+by+Ergot-and+Nonergot-Derived+Dopamine+Agonists&doi=10.1002%2Fmds.22385"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists</span></div><div class="casAuthors">Andersohn Frank; Garbe Edeltraut</div><div class="citationInfo"><span class="NLM_cas:title">Movement disorders : official journal of the Movement Disorder Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">129-33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">There is growing evidence that the ergot-derived dopamine agonists cabergoline and pergolide can cause fibrotic cardiac valvulopathy.  Data on other fibrotic reactions and nonergot-derived dopamine agonists are sparse.  Aim of this study was to investigate whether there are signals that dopamine agonists are related to cardiac and other fibrotic reactions.  We identified all reports of fibrotic reactions at the heart, lung, and retroperitoneal space associated with dopamine agonists within the US Adverse Event Reporting System database.  Disproportionality analyses were used to calculate adjusted reporting odds ratios (RORs).  For ergot-derived dopamine agonists (bromocriptine, cabergoline, pergolide), the RORs of all reactions under study were increased, whereas no such increases were observed for nonergot-derived drugs (apomorphine, pramipexole, ropinirole, rotigotine).  Fibrotic reactions due to ergot-derived dopamine agonists may not be limited to heart valves.  For nonergot-derived dopamine agonists, no drug safety signals were evident.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcToIeivIvRguNXdcedVHT5tfW6udTcc2ebRiRdgWEbeprntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M7gvFegsg%253D%253D&md5=c5c0f9bfc43f0158b3f76920327a2270</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fmds.22385&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmds.22385%26sid%3Dliteratum%253Aachs%26aulast%3DAndersohn%26aufirst%3DF.%26aulast%3DGarbe%26aufirst%3DE.%26atitle%3DCardiac%2520and%2520Noncardiac%2520Fibrotic%2520Reactions%2520Caused%2520by%2520Ergot-and%2520Nonergot-Derived%2520Dopamine%2520Agonists%26jtitle%3DMov.%2520Disord.%26date%3D2009%26volume%3D24%26spage%3D129%26epage%3D133%26doi%3D10.1002%2Fmds.22385" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheffler, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Aripiprazole: A Novel Atypical Antipsychotic Drug with a Uniquely Robust Pharmacology</span>. <i>CNS Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">317</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3458.2004.tb00030.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1111%2Fj.1527-3458.2004.tb00030.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=15592581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFejsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=317-336&author=M.+A.+Daviesauthor=D.+J.+Shefflerauthor=B.+L.+Roth&title=Aripiprazole%3A+A+Novel+Atypical+Antipsychotic+Drug+with+a+Uniquely+Robust+Pharmacology&doi=10.1111%2Fj.1527-3458.2004.tb00030.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology</span></div><div class="casAuthors">Davies, Marilyn A.; Sheffler, Douglas J.; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drug Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">317-336</span>CODEN:
                <span class="NLM_cas:coden">CDREFB</span>;
        ISSN:<span class="NLM_cas:issn">1080-563X</span>.
    
            (<span class="NLM_cas:orgname">Neva Press</span>)
        </div><div class="casAbstract">A review.  Aripiprazole (Abilify) is an atypical antipsychotic drug that has been recently introduced for clin. use in the treatment of schizophrenia.  Aripiprazole has a unique pharmacol. profile that includes partial agonism at several G-protein coupled receptors (GPCRs) [esp. dopamine (D2) and 5-HT1A] and antagonistic action at others (esp. 5-HT2A).  Clin. trials indicate that aripiprazole is effective in treating the pos. and neg. symptoms of schizophrenia.  In short-term studies rapid onset of action (within one week) has been demonstrated.  Preliminary data indicate that aripiprazole may also be effective in the treatment of manic symptoms of bipolar disorder.  At recommended doses, aripiprazole appears to be safe and well tolerated in most adult patients with schizophrenia and schizoaffective disorder.  There is only limited information available on the use of aripiprazole in children and adolescents, and pilot data suggest that a revised dosing strategy, based on wt., is indicated in this population.  In the long-term studies, the use of aripiprazole was assocd. with continued efficacy, good compliance and increased time-to-relapse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUPyxiyqhQzrVg90H21EOLACvtfcHk0liPfEXLlhoNKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFejsLo%253D&md5=dc4d48c70799660137c731cee3c67f42</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2004.tb00030.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2004.tb00030.x%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DM.%2BA.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DAripiprazole%253A%2520A%2520Novel%2520Atypical%2520Antipsychotic%2520Drug%2520with%2520a%2520Uniquely%2520Robust%2520Pharmacology%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2004%26volume%3D10%26spage%3D317%26epage%3D336%26doi%3D10.1111%2Fj.1527-3458.2004.tb00030.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baell, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, G. A.</span></span> <span> </span><span class="NLM_article-title">New Substructure Filters for Removal of Pan Assay Interference Compounds (Pains) from Screening Libraries and for Their Exclusion in Bioassays</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">2719</span>– <span class="NLM_lpage">2740</span>, <span class="refDoi"> DOI: 10.1021/jm901137j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901137j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2719-2740&author=J.+B.+Baellauthor=G.+A.+Holloway&title=New+Substructure+Filters+for+Removal+of+Pan+Assay+Interference+Compounds+%28Pains%29+from+Screening+Libraries+and+for+Their+Exclusion+in+Bioassays&doi=10.1021%2Fjm901137j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in Bioassays</span></div><div class="casAuthors">Baell, Jonathan B.; Holloway, Georgina A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2719-2740</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This report describes a no. of substructural features which can help to identify compds. that appear as frequent hitters (promiscuous compds.) in many biochem. high throughput screens.  The compds. identified by such substructural features are not recognized by filters commonly used to identify reactive compds.  Even though these substructural features were identified using only one assay detection technol., such compds. have been reported to be active from many different assays.  In fact, these compds. are increasingly prevalent in the literature as potential starting points for further exploration, whereas they may not be.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro_JARcceWjLVg90H21EOLACvtfcHk0li5JK_VuKN7CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2qsLw%253D&md5=fbf397aa4910753c550425708c866fd2</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm901137j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901137j%26sid%3Dliteratum%253Aachs%26aulast%3DBaell%26aufirst%3DJ.%2BB.%26aulast%3DHolloway%26aufirst%3DG.%2BA.%26atitle%3DNew%2520Substructure%2520Filters%2520for%2520Removal%2520of%2520Pan%2520Assay%2520Interference%2520Compounds%2520%2528Pains%2529%2520from%2520Screening%2520Libraries%2520and%2520for%2520Their%2520Exclusion%2520in%2520Bioassays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2719%26epage%3D2740%26doi%3D10.1021%2Fjm901137j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bissantz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillebrecht, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerebtzoff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Migeon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guba, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansy, M.</span></span> <span> </span><span class="NLM_article-title">Can We Discover Pharmacological Promiscuity Early in the Drug Discovery Process?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">325</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2012.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.drudis.2012.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=22269136" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BC38vgvFKruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=325-335&author=J.+U.+Petersauthor=J.+Hertauthor=C.+Bissantzauthor=A.+Hillebrechtauthor=G.+Gerebtzoffauthor=S.+Bendelsauthor=F.+Tillierauthor=J.+Migeonauthor=H.+Fischerauthor=W.+Gubaauthor=M.+Kansy&title=Can+We+Discover+Pharmacological+Promiscuity+Early+in+the+Drug+Discovery+Process%3F&doi=10.1016%2Fj.drudis.2012.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Can we discover pharmacological promiscuity early in the drug discovery process?</span></div><div class="casAuthors">Peters Jens-Uwe; Hert Jerome; Bissantz Caterina; Hillebrecht Alexander; Gerebtzoff Gregori; Bendels Stefanie; Tillier Fabien; Migeon Jacques; Fischer Holger; Guba Wolfgang; Kansy Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Drug discovery today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7-8</span>),
    <span class="NLM_cas:pages">325-35</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The term 'pharmacological promiscuity' describes the activity of a single compound against multiple targets.  When undesired, promiscuity is a major safety concern that needs to be detected as early as possible in the drug discovery process.  The analysis of large datasets reveals that the majority of promiscuous compounds are characterized by recognizable molecular properties and structural motifs, the most important one being a basic center with a pK(a)(B)>6.  These compounds interact with a small set of targets such as aminergic GPCRs; some of these targets attract surprisingly high hit rates.  In this review, we discuss current trends in the assessment of pharmacological promiscuity and propose strategies to enable early detection and mitigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRbWSRyt5nWSCSm0e6ZOaemfW6udTcc2ebELbN8Z9ayI7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vgvFKruw%253D%253D&md5=0ec70daf771d0917270d58f5e74c78b8</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2012.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2012.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26aulast%3DHert%26aufirst%3DJ.%26aulast%3DBissantz%26aufirst%3DC.%26aulast%3DHillebrecht%26aufirst%3DA.%26aulast%3DGerebtzoff%26aufirst%3DG.%26aulast%3DBendels%26aufirst%3DS.%26aulast%3DTillier%26aufirst%3DF.%26aulast%3DMigeon%26aufirst%3DJ.%26aulast%3DFischer%26aufirst%3DH.%26aulast%3DGuba%26aufirst%3DW.%26aulast%3DKansy%26aufirst%3DM.%26atitle%3DCan%2520We%2520Discover%2520Pharmacological%2520Promiscuity%2520Early%2520in%2520the%2520Drug%2520Discovery%2520Process%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D325%26epage%3D335%26doi%3D10.1016%2Fj.drudis.2012.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sameshima, T.</span>; <span class="NLM_string-name">Yukawa, T.</span>; <span class="NLM_string-name">Hirozane, Y.</span>; <span class="NLM_string-name">Yoshikawa, M.</span>; <span class="NLM_string-name">Katoh, T.</span>; <span class="NLM_string-name">Hara, H.</span>; <span class="NLM_string-name">Yogo, T.</span>; <span class="NLM_string-name">Miyahisa, I.</span>; <span class="NLM_string-name">Okuda, T.</span>; <span class="NLM_string-name">Miyamoto, M.</span>; <span class="NLM_string-name">Naven, R.</span></span> <span> </span><span class="NLM_article-title">Small-Scale Panel Comprising Diverse Gene Family Targets To Evaluate Compound Promiscuity</span>.  <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="refDoi"> DOI: 10.1021/acs.chemrestox.9b00128</span> .</span><div class="citationLinks">[<a href="/doi/10.1021/acs.chemrestox.9b00128" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=T.+Sameshima&author=T.+Yukawa&author=Y.+Hirozane&author=M.+Yoshikawa&author=T.+Katoh&author=H.+Hara&author=T.+Yogo&author=I.+Miyahisa&author=T.+Okuda&author=M.+Miyamoto&author=R.+Naven&title=Small-Scale+Panel+Comprising+Diverse+Gene+Family+Targets+To+Evaluate+Compound+Promiscuity&doi=10.1021%2Facs.chemrestox.9b00128"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facs.chemrestox.9b00128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.chemrestox.9b00128%26sid%3Dliteratum%253Aachs%26aulast%3DSameshima%26aufirst%3DT.%26atitle%3DSmall-Scale%2520Panel%2520Comprising%2520Diverse%2520Gene%2520Family%2520Targets%2520To%2520Evaluate%2520Compound%2520Promiscuity%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2019%26doi%3D10.1021%2Facs.chemrestox.9b00128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greene, N.</span></span> <span> </span><span class="NLM_article-title">Comparing Measures of Promiscuity and Exploring Their Relationship to Toxicity</span>. <i>Mol. Inf.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1002/minf.201100148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1002%2Fminf.201100148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=27476959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=145-159&author=X.+Wangauthor=N.+Greene&title=Comparing+Measures+of+Promiscuity+and+Exploring+Their+Relationship+to+Toxicity&doi=10.1002%2Fminf.201100148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Comparing Measures of Promiscuity and Exploring Their Relationship to Toxicity</span></div><div class="casAuthors">Wang, Xiangyun; Greene, Nigel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Informatics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-159</span>CODEN:
                <span class="NLM_cas:coden">MIONBS</span>;
        ISSN:<span class="NLM_cas:issn">1868-1743</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Recent research has focused on algorithms to derive numerical measures of selectivity based on panels of in vitro pharmacol. assays so that one mol.'s activity profile may be compared easily with that of another.  However, the questions concerning which method or algorithm is best to use, the optimal no. of assays required to give an accurate measure of selectivity and the correlation of these measures to in vivo toxicity have remained largely unexplored.  In this manuscript we describe a systematic approach to compare and contrast different calcn. methods for promiscuity and det. the optimal no. and constitution of a panel of assays to measure the selectivity/promiscuity of compds. across all targets.  We then go on to examine their relationship to toxicity using a Pfizer proprietary compd. set that has both selectivity profiles and exploratory toxicol. study results.  From this study we conclude that all five methods studied are useful in estg. compd. selectivity; that a small panel of between 15 to 30 binding assays can be used as a surrogate for a broader panel enabling higher throughput with lower costs and this panel will most likely have the highest prediction power when correlating this measure to in vivo effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroFZPz4tPdDrVg90H21EOLACvtfcHk0li5rVw_-eH8-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKju70%253D&md5=1aa9606472722e3a7d18c153d34a8f10</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fminf.201100148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fminf.201100148%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DGreene%26aufirst%3DN.%26atitle%3DComparing%2520Measures%2520of%2520Promiscuity%2520and%2520Exploring%2520Their%2520Relationship%2520to%2520Toxicity%26jtitle%3DMol.%2520Inf.%26date%3D2012%26volume%3D31%26spage%3D145%26epage%3D159%26doi%3D10.1002%2Fminf.201100148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamberlin, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulos, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sevrioukova, I. F.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Inhibitor Design for Evaluation of a Cyp3a4 Pharmacophore Model</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4210</span>– <span class="NLM_lpage">4220</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01146</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01146" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2mtLvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=4210-4220&author=P.+Kaurauthor=A.+R.+Chamberlinauthor=T.+L.+Poulosauthor=I.+F.+Sevrioukova&title=Structure-Based+Inhibitor+Design+for+Evaluation+of+a+Cyp3a4+Pharmacophore+Model&doi=10.1021%2Facs.jmedchem.5b01146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model</span></div><div class="casAuthors">Kaur, Parminder; Chamberlin, A. Richard; Poulos, Thomas L.; Sevrioukova, Irina F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4210-4220</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human cytochrome P 450 3A4 (CYP3A4) is a key xenobiotic-metabolizing enzyme that oxidizes and clears the majority of drugs.  CYP3A4 inhibition may lead to drug-drug interactions, toxicity, and other adverse effects but, in some cases, could be beneficial and enhance therapeutic efficiency of coadministered pharmaceuticals that are metabolized by CYP3A4.  On the basis of the investigations of analogs of ritonavir, a potent CYP3A4 inactivator and pharmacoenhancer, the authors have built a pharmacophore model for a CYP3A4-specific inhibitor.  This study is the first attempt to test this model using a set of rationally designed compds.  The functional and structural data presented here agree well with the proposed pharmacophore.  In particular, the authors confirmed the importance of a flexible backbone, the H-bond donor/acceptor moiety, and aromaticity of the side group analogous to Phe-2 of ritonavir and demonstrated the leading role of hydrophobic interactions at the sites adjacent to the heme and phenylalanine cluster in the ligand binding process.  The x-ray structures of CYP3A4 bound to the rationally designed inhibitors provide deeper insights into the mechanism of the CYP3A4-ligand interaction.  Most importantly, two of the compds. I and II that are less complex than ritonavir have comparable submicromolar affinity and inhibitory potency for CYP3A4 and, thus, could serve as templates for synthesis of second generation inhibitors for further evaluation and optimization of the pharmacophore model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2kZVZ3OeVr7Vg90H21EOLACvtfcHk0li5rVw_-eH8-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2mtLvM&md5=4c9cd27c3a091aae985fcb70d7ffd957</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01146%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DP.%26aulast%3DChamberlin%26aufirst%3DA.%2BR.%26aulast%3DPoulos%26aufirst%3DT.%2BL.%26aulast%3DSevrioukova%26aufirst%3DI.%2BF.%26atitle%3DStructure-Based%2520Inhibitor%2520Design%2520for%2520Evaluation%2520of%2520a%2520Cyp3a4%2520Pharmacophore%2520Model%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D4210%26epage%3D4220%26doi%3D10.1021%2Facs.jmedchem.5b01146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schonherr, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cernak, T.</span></span> <span> </span><span class="NLM_article-title">Profound Methyl Effects in Drug Discovery and a Call for New C-H Methylation Reactions</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">12256</span>– <span class="NLM_lpage">12267</span>, <span class="refDoi"> DOI: 10.1002/anie.201303207</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1002%2Fanie.201303207" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BC2c%252FptVahuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=12256-12267&author=H.+Schonherrauthor=T.+Cernak&title=Profound+Methyl+Effects+in+Drug+Discovery+and+a+Call+for+New+C-H+Methylation+Reactions&doi=10.1002%2Fanie.201303207"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Profound methyl effects in drug discovery and a call for new C-H methylation reactions</span></div><div class="casAuthors">Schonherr Heike; Cernak Tim</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie (International ed. in English)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">12256-67</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The methyl group is one of the most commonly occurring carbon fragments in small-molecule drugs.  This simplest alkyl fragment appears in more than 67 % of the top-selling drugs of 2011 and can modulate both the biological and physical properties of a molecule.  This Review focuses on so-called magic methyl effects on binding potency, where the seemingly mundane change of C H to C Me improves the IC50  value of a drug candidate more than 100-fold.  This discussion is followed by a survey of recent advances in synthetic chemistry that allow the direct methylation of C(sp(2) ) H and C(sp(3) ) H bonds.  It is our hope that the relevance of the meager methyl group to drug discovery as presented herein will inspire reports on new C H methylation reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTyoLZDDgvsMh0LsK7uFuY7fW6udTcc2eZZtOO88xiFLrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c%252FptVahuw%253D%253D&md5=ef08f80e55b2c530b49e4306da024902</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1002%2Fanie.201303207&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201303207%26sid%3Dliteratum%253Aachs%26aulast%3DSchonherr%26aufirst%3DH.%26aulast%3DCernak%26aufirst%3DT.%26atitle%3DProfound%2520Methyl%2520Effects%2520in%2520Drug%2520Discovery%2520and%2520a%2520Call%2520for%2520New%2520C-H%2520Methylation%2520Reactions%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D12256%26epage%3D12267%26doi%3D10.1002%2Fanie.201303207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tirado-Rives, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorgensen, W. L.</span></span> <span> </span><span class="NLM_article-title">Methyl Effects on Protein-Ligand Binding</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4489</span>– <span class="NLM_lpage">4500</span>, <span class="refDoi"> DOI: 10.1021/jm3003697</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003697" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsV2iu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4489-4500&author=C.+S.+Leungauthor=S.+S.+Leungauthor=J.+Tirado-Rivesauthor=W.+L.+Jorgensen&title=Methyl+Effects+on+Protein-Ligand+Binding&doi=10.1021%2Fjm3003697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Methyl Effects on Protein-Ligand Binding</span></div><div class="casAuthors">Leung, Cheryl S.; Leung, Siegfried S. F.; Tirado-Rives, Julian; Jorgensen, William L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4489-4500</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The effects of addn. of a Me group to a lead compd. on biol. activity are examd.  A literature anal. of >2000 cases reveals that an activity boost of a factor of 10 or more is found with an 8% frequency, and a 100-fold boost is a 1 in 200 event.  Four cases in the latter category are analyzed in depth to elucidate any unusual aspects of the protein-ligand binding, distribution of water mols., and changes in conformational energetics.  The analyses include Monte Carlo/free-energy perturbation (MC/FEP) calcns. for Me replacements in inhibitor series for p38α MAP kinase, ACK1, PTP1B, and thrombin.  Me substitutions ortho to an aryl ring can be particularly effective at improving activity by inducing a propitious conformational change.  The greatest improvements in activity arise from coupling the conformational gain with the burial of the Me group in a hydrophobic region of the protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX0Czyhgy6KbVg90H21EOLACvtfcHk0li5rVw_-eH8-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsV2iu7Y%253D&md5=0ea58d9c1bf845d383931b6a017f9b37</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm3003697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003697%26sid%3Dliteratum%253Aachs%26aulast%3DLeung%26aufirst%3DC.%2BS.%26aulast%3DLeung%26aufirst%3DS.%2BS.%26aulast%3DTirado-Rives%26aufirst%3DJ.%26aulast%3DJorgensen%26aufirst%3DW.%2BL.%26atitle%3DMethyl%2520Effects%2520on%2520Protein-Ligand%2520Binding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4489%26epage%3D4500%26doi%3D10.1021%2Fjm3003697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillis, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Applications of Fluorine in Medicinal Chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8315</span>– <span class="NLM_lpage">8359</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8315-8359&author=E.+P.+Gillisauthor=K.+J.+Eastmanauthor=M.+D.+Hillauthor=D.+J.+Donnellyauthor=N.+A.+Meanwell&title=Applications+of+Fluorine+in+Medicinal+Chemistry&doi=10.1021%2Facs.jmedchem.5b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of Fluorine in Medicinal Chemistry</span></div><div class="casAuthors">Gillis, Eric P.; Eastman, Kyle J.; Hill, Matthew D.; Donnelly, David J.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8315-8359</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with meta-anal. The role of fluorine in drug design and development is expanding rapidly as we learn more about the unique properties assocd. with this unusual element and how to deploy it with greater sophistication.  The judicious introduction of fluorine into a mol. can productively influence conformation, pKa, intrinsic potency, membrane permeability, metabolic pathways, and pharmacokinetic properties.  In addn., 18F has been established as a useful positron emitting isotope for use with in vivo imaging technol. that potentially has extensive application in drug discovery and development, often limited only by convenient synthetic accessibility to labeled compds.  The wide ranging applications of fluorine in drug design are providing a strong stimulus for the development of new synthetic methodologies that allow more facile access to a wide range of fluorinated compds.  In this review, we provide an update on the effects of the strategic incorporation of fluorine in drug mols. and applications in positron emission tomog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8fUUtkPB4L7Vg90H21EOLACvtfcHk0liL5NUioYDW3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK&md5=9995829a94a8c0b8d9fb0d21bdfd5a1d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00258%26sid%3Dliteratum%253Aachs%26aulast%3DGillis%26aufirst%3DE.%2BP.%26aulast%3DEastman%26aufirst%3DK.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DDonnelly%26aufirst%3DD.%2BJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DApplications%2520of%2520Fluorine%2520in%2520Medicinal%2520Chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8315%26epage%3D8359%26doi%3D10.1021%2Facs.jmedchem.5b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gagnon, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bostrom, J.</span></span> <span> </span><span class="NLM_article-title">Understanding Our Love Affair with P-Chlorophenyl: Present Day Implications from Historical Biases of Reagent Selection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2390</span>– <span class="NLM_lpage">2405</span>, <span class="refDoi"> DOI: 10.1021/jm501894t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501894t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXit1Snsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=2390-2405&author=D.+G.+Brownauthor=M.+M.+Gagnonauthor=J.+Bostrom&title=Understanding+Our+Love+Affair+with+P-Chlorophenyl%3A+Present+Day+Implications+from+Historical+Biases+of+Reagent+Selection&doi=10.1021%2Fjm501894t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding Our Love Affair with p-Chlorophenyl: Present Day Implications from Historical Biases of Reagent Selection</span></div><div class="casAuthors">Brown, Dean G.; Gagnon, Moriah M.; Bostrom, Jonas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2390-2405</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with further theor. anal. We report here an unexpectedly strong preference toward para substitution in Ph rings within drug discovery programs.  A population anal. of arom. rings in various drug databases demonstrated that para substitution is favored over meta and ortho regioisomers, with p-chlorophenyl (p-ClPh) being one of the most predominant examples.  We speculate that the frequency of p-ClPh is traced back to historical models of medicinal chem. where para-substituted regioisomers were perhaps more easily accessed, and further reinforced by Topliss in 1972 that if Ph was active, the p-ClPh should be made because of ease of synthesis and hydrophobicity driven potency effects.  On the basis of our anal., the para bias has become useful conventional wisdom but perhaps so much so that a perception has been created that druglike space favors a linear arom. structure.  It is hoped this anal. will catalyze a new look at design of reagent databases and screening collections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZxc2KY5KeHrVg90H21EOLACvtfcHk0liL5NUioYDW3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXit1Snsr0%253D&md5=7f8a3a4eff01600299e04d59341a34dd</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm501894t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501894t%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DGagnon%26aufirst%3DM.%2BM.%26aulast%3DBostrom%26aufirst%3DJ.%26atitle%3DUnderstanding%2520Our%2520Love%2520Affair%2520with%2520P-Chlorophenyl%253A%2520Present%2520Day%2520Implications%2520from%2520Historical%2520Biases%2520of%2520Reagent%2520Selection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D2390%26epage%3D2405%26doi%3D10.1021%2Fjm501894t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jalencas, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestres, J.</span></span> <span> </span><span class="NLM_article-title">On the Origins of Drug Polypharmacology</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1039/C2MD20242E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1039%2FC2MD20242E" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVynu7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=80-87&author=X.+Jalencasauthor=J.+Mestres&title=On+the+Origins+of+Drug+Polypharmacology&doi=10.1039%2FC2MD20242E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">On the origins of drug polypharmacology</span></div><div class="casAuthors">Jalencas, Xavier; Mestres, Jordi</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">80-87</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The ability of small mols. to interact with multiple proteins is commonly referred to as polypharmacol.  The now widely accepted polypharmacol. of drugs is of particular interest for human health as it has implications beyond therapeutic efficacy, from anticipating adverse drug reactions to identifying potential repurposing opportunities.  There have been a no. of studies relating the extent of drug polypharmacol. to the physicochem. properties and fragment compn. of the drug itself, but also to the protein family and distant binding site similarities of the drug's primary target.  Taken together, all these observations lead to speculate that the origins of drug polypharmacol. may lie at the heart of protein evolution and that polypharmacol. may just be a reminiscent signature of some of the mechanisms of adaptation that primitive biol. systems developed to increase the chances of survival in a highly variable early chem. environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB1qsCiSthHLVg90H21EOLACvtfcHk0lh-xx5sm26Cyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVynu7vI&md5=77fe84731536e5008cca3b0faf1e58dd</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1039%2FC2MD20242E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC2MD20242E%26sid%3Dliteratum%253Aachs%26aulast%3DJalencas%26aufirst%3DX.%26aulast%3DMestres%26aufirst%3DJ.%26atitle%3DOn%2520the%2520Origins%2520of%2520Drug%2520Polypharmacology%26jtitle%3DMedChemComm%26date%3D2013%26volume%3D4%26spage%3D80%26epage%3D87%26doi%3D10.1039%2FC2MD20242E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The Influence of Drug-Like Concepts on Decision-Making in Medicinal Chemistry</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+Influence+of+Drug-Like+Concepts+on+Decision-Making+in+Medicinal+Chemistry&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lh-xx5sm26Cyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520Influence%2520of%2520Drug-Like%2520Concepts%2520on%2520Decision-Making%2520in%2520Medicinal%2520Chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeGoey, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendt, M. D.</span></span> <span> </span><span class="NLM_article-title">Beyond the Rule of 5: Lessons Learned from Abbvie’s Drugs and Compound Collection</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2636</span>– <span class="NLM_lpage">2651</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00717</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00717" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFeitbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2636-2651&author=D.+A.+DeGoeyauthor=H.+J.+Chenauthor=P.+B.+Coxauthor=M.+D.+Wendt&title=Beyond+the+Rule+of+5%3A+Lessons+Learned+from+Abbvie%E2%80%99s+Drugs+and+Compound+Collection&doi=10.1021%2Facs.jmedchem.7b00717"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection</span></div><div class="casAuthors">DeGoey, David A.; Chen, Hui-Ju; Cox, Philip B.; Wendt, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2636-2651</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recently, there has been an increasing focus on the pursuit of targets considered to be less druggable that offer potential for development of promising new therapeutic agents for the treatment of diseases with large unmet medical need, particularly in the areas of oncol. and virol.  However, conducting drug discovery campaigns in "beyond rule of 5" (bRo5) chem. space presents a significant drug design and development challenge to medicinal chemists to achieve acceptable oral pharmacokinetics.  Retrospective anal. of past successes and failures in drug discovery bRo5 may shed light on the key principles that contribute to the oral bioavailability of successful bRo5 compds. and improve the efficiency of drug design for future projects.  We present here highlights and case studies of lessons learned from discovery of bRo5 compds.  A simple multiparametric scoring function (AB-MPS) was devised that correlated preclin. PK results with cLogD, no. of rotatable bonds, and no. of arom. rings.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTHuaXbtjlALVg90H21EOLACvtfcHk0lh-xx5sm26Cyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFeitbjJ&md5=48984dc65410d83d4ac8ddaca030b024</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00717%26sid%3Dliteratum%253Aachs%26aulast%3DDeGoey%26aufirst%3DD.%2BA.%26aulast%3DChen%26aufirst%3DH.%2BJ.%26aulast%3DCox%26aufirst%3DP.%2BB.%26aulast%3DWendt%26aufirst%3DM.%2BD.%26atitle%3DBeyond%2520the%2520Rule%2520of%25205%253A%2520Lessons%2520Learned%2520from%2520Abbvie%25E2%2580%2599s%2520Drugs%2520and%2520Compound%2520Collection%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2636%26epage%3D2651%26doi%3D10.1021%2Facs.jmedchem.7b00717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steeno, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wassermann, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span> <span> </span><span class="NLM_article-title">Amine Promiscuity and Toxicology Analysis</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">653</span>– <span class="NLM_lpage">657</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2016.11.085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.bmcl.2016.11.085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=28011216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCmt7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=653-657&author=E.+C.+Leeauthor=G.+Steenoauthor=A.+M.+Wassermannauthor=L.+Zhangauthor=F.+Shahauthor=D.+A.+Price&title=Amine+Promiscuity+and+Toxicology+Analysis&doi=10.1016%2Fj.bmcl.2016.11.085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Amine promiscuity and toxicology analysis</span></div><div class="casAuthors">Lee, Esther C. Y.; Steeno, Gregory; Wassermann, Anne Mai; Zhang, Liying; Shah, Falgun; Price, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">653-657</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Drug discovery programs often face challenges to obtain sufficient duration of action of the drug (i.e., seek longer half-lives).  If the pharmacodynamic response is driven by free plasma concn. of the drug then extending the plasma drug concn. is a valid approach.  Half-life is dependent on the vol. of distribution, which in turn can be dependent upon the ionization state of the mol.  Basic compds. tend to have a higher vol. of distribution leading to longer half-lives.  However, it has been shown that bases may also have higher promiscuity.  The authors describe an anal. of in vitro pharmacol. profiling and toxicol. data investigating the role of primary, secondary, and tertiary amines in imparting promiscuity and thus off-target toxicity.  Primary amines are found to be less promiscuous in in vitro assays and have improved profiles in in vivo toxicol. studies compared to secondary and tertiary amines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr96I58aFeB-bVg90H21EOLACvtfcHk0lh-xx5sm26Cyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCmt7zI&md5=c48413a44f3df5ced931cb93b81e8a8f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.11.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.11.085%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DE.%2BC.%26aulast%3DSteeno%26aufirst%3DG.%26aulast%3DWassermann%26aufirst%3DA.%2BM.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DShah%26aufirst%3DF.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26atitle%3DAmine%2520Promiscuity%2520and%2520Toxicology%2520Analysis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D653%26epage%3D657%26doi%3D10.1016%2Fj.bmcl.2016.11.085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span> <span> </span><span class="NLM_article-title">Molecular Complexity and Fragment-Based Drug Discovery: Ten Years On</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">496</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2011.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.cbpa.2011.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=21665521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvFCltrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2011&pages=489-496&author=A.+R.+Leachauthor=M.+M.+Hann&title=Molecular+Complexity+and+Fragment-Based+Drug+Discovery%3A+Ten+Years+On&doi=10.1016%2Fj.cbpa.2011.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular complexity and fragment-based drug discovery: ten years on</span></div><div class="casAuthors">Leach, Andrew R.; Hann, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">489-496</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We review the concept of mol. complexity in the context of the very simple model of mol. interactions that we introduced over 10 years ago.  A summary is presented of efforts to validate this simple model using screening data.  The relationship between the complexity model and the problem of sampling chem. space is discussed, together with the relevance of these theor. concepts to fragment-based drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNcMgTT6eLC7Vg90H21EOLACvtfcHk0linoLoN9e28IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvFCltrg%253D&md5=19c2d65de80a8bab1059468828da6ce2</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2011.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2011.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DHann%26aufirst%3DM.%2BM.%26atitle%3DMolecular%2520Complexity%2520and%2520Fragment-Based%2520Drug%2520Discovery%253A%2520Ten%2520Years%2520On%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D15%26spage%3D489%26epage%3D496%26doi%3D10.1016%2Fj.cbpa.2011.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">Can. We Rationally Design Promiscuous Drugs?</span>. <i>Curr. Opin. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1016/j.sbi.2006.01.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.sbi.2006.01.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=16442279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=127-136&author=A.+L.+Hopkinsauthor=J.+S.+Masonauthor=J.+P.+Overington&title=Can.+We+Rationally+Design+Promiscuous+Drugs%3F&doi=10.1016%2Fj.sbi.2006.01.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Can we rationally design promiscuous drugs?</span></div><div class="casAuthors">Hopkins, Andrew L.; Mason, Jonathan S.; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Structural Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-136</span>CODEN:
                <span class="NLM_cas:coden">COSBEF</span>;
        ISSN:<span class="NLM_cas:issn">0959-440X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Structure-based drug design is now used widely in modern medicinal chem.  The application of structural biol. to medicinal chem. has heralded the 'rational drug design' vision of discovering exquisitely selective ligands.  However, recent advances in post-genomic biol. are indicating that polypharmacol. may be a necessary trait for the efficacy of many drugs, therefore questioning the 'one drug, one target' assumption of current rational drug design.  By combining advances in chemoinformatics and structural biol., it might be possible to rationally design the next generation of promiscuous drugs with polypharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQWdh60x9AHrVg90H21EOLACvtfcHk0linoLoN9e28IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhsFOjsrc%253D&md5=8f9e95a41976b8e3ac790f2fff2c406f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.sbi.2006.01.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.sbi.2006.01.013%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DA.%2BL.%26aulast%3DMason%26aufirst%3DJ.%2BS.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DCan.%2520We%2520Rationally%2520Design%2520Promiscuous%2520Drugs%253F%26jtitle%3DCurr.%2520Opin.%2520Struct.%2520Biol.%26date%3D2006%26volume%3D16%26spage%3D127%26epage%3D136%26doi%3D10.1016%2Fj.sbi.2006.01.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azzaoui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacoby, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, L.</span></span> <span> </span><span class="NLM_article-title">Modeling Promiscuity Based on in Vitro Safety Pharmacology Profiling Data</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">874</span>– <span class="NLM_lpage">880</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200700036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1002%2Fcmdc.200700036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=17492703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2sXntVShu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=874-880&author=K.+Azzaouiauthor=J.+Hamonauthor=B.+Fallerauthor=S.+Whitebreadauthor=E.+Jacobyauthor=A.+Benderauthor=J.+L.+Jenkinsauthor=L.+Urban&title=Modeling+Promiscuity+Based+on+in+Vitro+Safety+Pharmacology+Profiling+Data&doi=10.1002%2Fcmdc.200700036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Modeling promiscuity based on in vitro safety pharmacology profiling data</span></div><div class="casAuthors">Azzaoui, Kamal; Hamon, Jacques; Faller, Bernard; Whitebread, Steven; Jacoby, Edgar; Bender, Andreas; Jenkins, Jeremy L.; Urban, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">874-880</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">This study describes a method for mining and modeling binding data obtained from a large panel of targets (in vitro safety pharmacol.) to distinguish differences between promiscuous and selective compds.  Two naive Bayes models for promiscuity and selectivity were generated and validated on a test set as well as publicly available drug databases.  The model shows a higher score (lower promiscuity) for marketed drugs than for compds. in early development or compds. that failed during clin. development.  Such models can be used in triaging high-throughput screening data or for lead optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrw2wR-U-z9YrVg90H21EOLACvtfcHk0linoLoN9e28IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXntVShu78%253D&md5=30c8923e136d16ffd0b1ecd62afb8ff3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200700036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200700036%26sid%3Dliteratum%253Aachs%26aulast%3DAzzaoui%26aufirst%3DK.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DFaller%26aufirst%3DB.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DJacoby%26aufirst%3DE.%26aulast%3DBender%26aufirst%3DA.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DModeling%2520Promiscuity%2520Based%2520on%2520in%2520Vitro%2520Safety%2520Pharmacology%2520Profiling%2520Data%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D874%26epage%3D880%26doi%3D10.1002%2Fcmdc.200700036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span> <span> </span><span class="NLM_article-title">The Influence of Target Family and Functional Activity on the Physicochemical Properties of Pre-Clinical Compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">2969</span>– <span class="NLM_lpage">2978</span>, <span class="refDoi"> DOI: 10.1021/jm0512185</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0512185" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD28XjtlOit7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=2969-2978&author=R.+Morphy&title=The+Influence+of+Target+Family+and+Functional+Activity+on+the+Physicochemical+Properties+of+Pre-Clinical+Compounds&doi=10.1021%2Fjm0512185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The Influence of Target Family and Functional Activity on the Physicochemical Properties of Pre-Clinical Compounds</span></div><div class="casAuthors">Morphy, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2969-2978</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The target families of greatest interest in drug discovery can be differentiated on the basis of the physicochem. properties of their preclin. ligands.  The ligands for peptidergic targets, such as peptide G protein-coupled receptors (GPCRs) and integrin receptors, possess significantly higher median property values than those for aminergic targets, such as monoamine transporters and GPCRs.  The ligands for peptide GPCRs were found to be less efficient, in terms of their binding energy per unit of mol. wt. or lipophilicity, than ligands for monoamine GPCRs.  The changes in the property values during the optimization process were found to vary only slightly across the target families, with the main determinant of the drug-likeness of the optimized compds. being the profile of the starting compds.  Agonists for monoamine GPCRs, opioid receptors and ion channels were typically smaller and less lipophilic than the antagonists, but there was no difference between the agonists and the antagonists for peptide GPCRs and nuclear receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0EegclZUHNbVg90H21EOLACvtfcHk0lhC6EXqvzAtmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjtlOit7g%253D&md5=fcf63bff570d58d56492b46ddecb5eb1</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fjm0512185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0512185%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26atitle%3DThe%2520Influence%2520of%2520Target%2520Family%2520and%2520Functional%2520Activity%2520on%2520the%2520Physicochemical%2520Properties%2520of%2520Pre-Clinical%2520Compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D2969%26epage%3D2978%26doi%3D10.1021%2Fjm0512185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aronov, A. M.</span></span> <span> </span><span class="NLM_article-title">Common Pharmacophores for Uncharged Human Ether-a-Go-Go-Related Gene (Herg) Blockers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6917</span>– <span class="NLM_lpage">6921</span>, <span class="refDoi"> DOI: 10.1021/jm060500o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060500o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVyntbrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6917-6921&author=A.+M.+Aronov&title=Common+Pharmacophores+for+Uncharged+Human+Ether-a-Go-Go-Related+Gene+%28Herg%29+Blockers&doi=10.1021%2Fjm060500o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Common Pharmacophores for Uncharged Human Ether-a-go-go-Related Gene (hERG) Blockers</span></div><div class="casAuthors">Aronov, Alex M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6917-6921</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In silico approaches are widely used to predict human ether-a-go-go-related gene (hERG) channel blockade.  Published pharmacophore models of hERG blockers typically contain a basic nitrogen center flanked by arom. or hydrophobic groups.  However, hERG blockade has been obsd. in series lacking the basic nitrogen.  By utilizing screening data for 194 potent uncharged hERG actives, we propose a pharmacophore for neutral hERG blockers, and provide guidance on eliminating hERG liability in an uncharged hERG active chem. series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhdisypaGQgbVg90H21EOLACvtfcHk0lhC6EXqvzAtmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVyntbrJ&md5=a557f6239ec176243f9823a36b3b9ec4</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm060500o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060500o%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26atitle%3DCommon%2520Pharmacophores%2520for%2520Uncharged%2520Human%2520Ether-a-Go-Go-Related%2520Gene%2520%2528Herg%2529%2520Blockers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6917%26epage%3D6921%26doi%3D10.1021%2Fjm060500o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aronov, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, B. B.</span></span> <span> </span><span class="NLM_article-title">A Model for Identifying Herg K+ Channel Blockers</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2307</span>– <span class="NLM_lpage">2315</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2004.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.bmc.2004.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=15080928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtVKqu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=2307-2315&author=A.+M.+Aronovauthor=B.+B.+Goldman&title=A+Model+for+Identifying+Herg+K%2B+Channel+Blockers&doi=10.1016%2Fj.bmc.2004.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A model for identifying HERG K+ channel blockers</span></div><div class="casAuthors">Aronov, Alex M.; Goldman, Brian B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2307-2315</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Acquired long QT syndrome (LQTS) occurs frequently as a side effect of blockade of cardiac HERG K+ channels by commonly used medications.  A large no. of structurally diverse compds. have been shown to inhibit K+ current through HERG.  There is considerable interest in developing in silico tools to filter out potential HERG blockers early in the drug discovery process.  We describe a binary classification model that combines a 2D topol. similarity filter with a 3D pharmacophore ensemble procedure to discriminate between HERG actives and inactives with an overall accuracy of 82%, with false neg. and false pos. rates of 29% and 15%, resp.  This model should be generally applicable in virtual library counterscreening against HERG.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK7a2-P1CNkLVg90H21EOLACvtfcHk0lhC6EXqvzAtmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtVKqu7g%253D&md5=acfa27de5815ccbe7cb1ebbefefc99e2</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2004.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2004.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DAronov%26aufirst%3DA.%2BM.%26aulast%3DGoldman%26aufirst%3DB.%2BB.%26atitle%3DA%2520Model%2520for%2520Identifying%2520Herg%2520K%252B%2520Channel%2520Blockers%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2004%26volume%3D12%26spage%3D2307%26epage%3D2315%26doi%3D10.1016%2Fj.bmc.2004.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shamovsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">David, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ivanova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norden, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbahns, K.</span></span> <span> </span><span class="NLM_article-title">Overcoming Undesirable Herg Potency of Chemokine Receptor Antagonists Using Baseline Lipophilicity Relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1162</span>– <span class="NLM_lpage">1178</span>, <span class="refDoi"> DOI: 10.1021/jm070543k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070543k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhslWju78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1162-1178&author=I.+Shamovskyauthor=S.+Connollyauthor=L.+Davidauthor=S.+Ivanovaauthor=B.+Nordenauthor=B.+Springthorpeauthor=K.+Urbahns&title=Overcoming+Undesirable+Herg+Potency+of+Chemokine+Receptor+Antagonists+Using+Baseline+Lipophilicity+Relationships&doi=10.1021%2Fjm070543k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming Undesirable hERG Potency of Chemokine Receptor Antagonists Using Baseline Lipophilicity Relationships</span></div><div class="casAuthors">Shamovsky, Igor; Connolly, Stephen; David, Laurent; Ivanova, Svetlana; Norden, Bo; Springthorpe, Brian; Urbahns, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1162-1178</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The inhibition of the hERG channel by noncardiovascular drugs is a side effect that severely impedes the development of new medications.  To increase hERG selectivity of preclin. compds., the authors recommend the study of nondesolvation related interactions with the intended target and hERG using a baseline lipophilicity relationship approach.  While this approach is conventionally used in studies of potency, the authors demonstrate here that it can help in selectivity issues.  Studies of hERG selectivity in four inhouse classes of chemokine receptor (CCR) antagonists suggest that the selectivity is improved most effectively by structural alterations that increase the lipophilicity-adjusted primary potency, pIC50CCR - LogD.  Fragment-based QSAR anal. is performed using the lipophilicity-adjusted hERG potency, pIC50hERG - LogD, to identify moieties that form nonhydrophobic interactions with the hERG channel.  These moieties, which erode hERG selectivity, can then be avoided.  A novel two-dimensional fragment-based QSAR anal. helps visualizing the lipophilicity-adjusted hERG and CCR potencies within chem. series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1BNQlA8irybVg90H21EOLACvtfcHk0lhC6EXqvzAtmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhslWju78%253D&md5=04596a9552c5cf3b47a3edf9c0bd5498</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm070543k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070543k%26sid%3Dliteratum%253Aachs%26aulast%3DShamovsky%26aufirst%3DI.%26aulast%3DConnolly%26aufirst%3DS.%26aulast%3DDavid%26aufirst%3DL.%26aulast%3DIvanova%26aufirst%3DS.%26aulast%3DNorden%26aufirst%3DB.%26aulast%3DSpringthorpe%26aufirst%3DB.%26aulast%3DUrbahns%26aufirst%3DK.%26atitle%3DOvercoming%2520Undesirable%2520Herg%2520Potency%2520of%2520Chemokine%2520Receptor%2520Antagonists%2520Using%2520Baseline%2520Lipophilicity%2520Relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1162%26epage%3D1178%26doi%3D10.1021%2Fjm070543k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moir, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span> <span> </span><span class="NLM_article-title">Medicinal Chemistry of Herg Optimizations: Highlights and Hang-Ups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5029</span>– <span class="NLM_lpage">5046</span>, <span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+Chemistry+of+Herg+Optimizations%3A+Highlights+and+Hang-Ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lheDRk7hcCtoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520Chemistry%2520of%2520Herg%2520Optimizations%253A%2520Highlights%2520and%2520Hang-Ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Redfern, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlsson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lynch, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKenzie, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palethorpe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegl, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strang, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camm, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, T. G.</span></span> <span> </span><span class="NLM_article-title">Relationships between Preclinical Cardiac Electrophysiology, Clinical QT Interval Prolongation and Torsade De Pointes for a Broad Range of Drugs: Evidence for a Provisional Safety Margin in Drug Development</span>. <i>Cardiovasc. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">45</span>, <span class="refDoi"> DOI: 10.1016/S0008-6363(02)00846-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2FS0008-6363%2802%2900846-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=12667944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2003&pages=32-45&author=W.+S.+Redfernauthor=L.+Carlssonauthor=A.+S.+Davisauthor=W.+G.+Lynchauthor=I.+MacKenzieauthor=S.+Palethorpeauthor=P.+K.+Sieglauthor=I.+Strangauthor=A.+T.+Sullivanauthor=R.+Wallisauthor=A.+J.+Cammauthor=T.+G.+Hammond&title=Relationships+between+Preclinical+Cardiac+Electrophysiology%2C+Clinical+QT+Interval+Prolongation+and+Torsade+De+Pointes+for+a+Broad+Range+of+Drugs%3A+Evidence+for+a+Provisional+Safety+Margin+in+Drug+Development&doi=10.1016%2FS0008-6363%2802%2900846-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development</span></div><div class="casAuthors">Redfern, W. S.; Carlsson, L.; Davis, A. S.; Lynch, W. G.; MacKenzie, I.; Palethorpe, S.; Siegl, P. K. S.; Strang, I.; Sullivan, A. T.; Wallis, R.; Camm, A. J.; Hammond, T. G.</div><div class="citationInfo"><span class="NLM_cas:title">Cardiovascular Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-45</span>CODEN:
                <span class="NLM_cas:coden">CVREAU</span>;
        ISSN:<span class="NLM_cas:issn">0008-6363</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review discussing attempts to det. the relative value of preclin. cardiac electrophysiol. data (in vitro and in vivo) for predicting risk of torsades de pointes (TdP) in clin. use.  Published data on human ether-a-go-go-related gene-encoded voltage-dependent potassium channel (hERG) (or IKr) activity, cardiac action potential duration (at 90% repolarization; APD90), and QT prolongation in dogs were compared against QT effects and reports of TdP in humans for 100 drugs.  These data were set against the free plasma concns. attained during clin. use (effective therapeutic plasma concns.; ETPCunbound).  The drugs were divided into five categories: (1) Class Ia and III antiarrhythmics; (2) withdrawn from market due to TdP; (3) measurable incidence/numerous reports of TdP in humans; (4) isolated reports of TdP in humans; (5) no reports of TdP in humans.  Data from hERG (or IKr) assays in addn. to ETPCunbound data were available for 52 drugs.  For Category 1 drugs, data for hERG/IKr IC50, APD90, QTc in animals and QTc in humans were generally close to or superimposed on the ETPCunbound values.  This relationship was uncoupled in the other categories, with more complex relationships between the data.  In Category 1 (except amiodarone), the ratios between hERG/IKr IC50 and ETPCunbound (max) ranged 0.1-31-fold.  Similar ranges were obtained for drugs in Category 2 (0.31-13-fold) and Category 3 (0.03-35-fold).  A large spread was found for Category 4 drugs (0.13-35,700-fold); this category embraced an assortment of mechanisms ranging from drugs which may well be affecting IKr currents in clin. use (e.g., sparfloxacin) to others such as nifedipine (35,700-fold) where channel block is not involved.  Finally, for the majority of Category 5 drugs there was a >30-fold sepn. between hERG/IKr activity and ETPCunbound values, with the notable exception of verapamil (1.7-fold), which is free from QT prolongation in man; this is probably explained by its multiple interactions with cardiac ion channels.  The dataset confirms the widely held belief that most drugs assocd. with TdP in humans are also assocd. with hERG K+ channel block at concns. close to or superimposed upon the free plasma concns. found in clin. use.  A 30-fold margin between Cmax and hERG IC50 may suffice for drugs currently undergoing clin. evaluation, but for future drug discovery programs, pharmaceutical companies should consider increasing this margin, particularly for drugs aimed at nondebilitating diseases.  However, interactions with multiple cardiac ion channels can either mitigate or exacerbate the prolongation of APD and QT that would ensue from block of IKr currents alone, and delay of repolarization per se is not necessarily torsadogenic.  Clearly, an integrated assessment of in vitro and in vivo data is required in order to predict the torsadogenic risk of a new candidate drug in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkpRDUH0rhyrVg90H21EOLACvtfcHk0lheDRk7hcCtoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXit12gsb8%253D&md5=a236c07febd2e05fe70e61604619bf2e</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2FS0008-6363%2802%2900846-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0008-6363%252802%252900846-5%26sid%3Dliteratum%253Aachs%26aulast%3DRedfern%26aufirst%3DW.%2BS.%26aulast%3DCarlsson%26aufirst%3DL.%26aulast%3DDavis%26aufirst%3DA.%2BS.%26aulast%3DLynch%26aufirst%3DW.%2BG.%26aulast%3DMacKenzie%26aufirst%3DI.%26aulast%3DPalethorpe%26aufirst%3DS.%26aulast%3DSiegl%26aufirst%3DP.%2BK.%26aulast%3DStrang%26aufirst%3DI.%26aulast%3DSullivan%26aufirst%3DA.%2BT.%26aulast%3DWallis%26aufirst%3DR.%26aulast%3DCamm%26aufirst%3DA.%2BJ.%26aulast%3DHammond%26aufirst%3DT.%2BG.%26atitle%3DRelationships%2520between%2520Preclinical%2520Cardiac%2520Electrophysiology%252C%2520Clinical%2520QT%2520Interval%2520Prolongation%2520and%2520Torsade%2520De%2520Pointes%2520for%2520a%2520Broad%2520Range%2520of%2520Drugs%253A%2520Evidence%2520for%2520a%2520Provisional%2520Safety%2520Margin%2520in%2520Drug%2520Development%26jtitle%3DCardiovasc.%2520Res.%26date%3D2003%26volume%3D58%26spage%3D32%26epage%3D45%26doi%3D10.1016%2FS0008-6363%2802%2900846-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jonker, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenna, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leishman, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milligan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonsson, E. N.</span></span> <span> </span><span class="NLM_article-title">A Pharmacokinetic-Pharmacodynamic Model for the Quantitative Prediction of Dofetilide Clinical Qt Prolongation from Human Ether-a-Go-Go-Related Gene Current Inhibition Data</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">572</span>– <span class="NLM_lpage">582</span>, <span class="refDoi"> DOI: 10.1016/j.clpt.2005.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.clpt.2005.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=15961988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlt1Gqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2005&pages=572-582&author=D.+M.+Jonkerauthor=L.+A.+Kennaauthor=D.+Leishmanauthor=R.+Wallisauthor=P.+A.+Milliganauthor=E.+N.+Jonsson&title=A+Pharmacokinetic-Pharmacodynamic+Model+for+the+Quantitative+Prediction+of+Dofetilide+Clinical+Qt+Prolongation+from+Human+Ether-a-Go-Go-Related+Gene+Current+Inhibition+Data&doi=10.1016%2Fj.clpt.2005.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data</span></div><div class="casAuthors">Jonker, Daniel M.; Kenna, Leslie A.; Leishman, Derek; Wallis, Rob; Milligan, Peter A.; Jonsson, E. Niclas</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">572-582</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Background: QT prolongation is an important biomarker of the arrhythmia torsades de pointes and appears to be related mainly to blockade of delayed inward cardiac rectifier potassium currents.  The aim of this study was to quantify the relationship between in vitro human ether-a-go-go-related gene (hERG) potassium channel blockade and the magnitude of QT prolongation in humans for the class III antiarrhythmic dofetilide.  Methods: The in vitro affinity and activity of dofetilide were detd. in recombinant cell cultures expressing the hERG channel, and the QT-prolonging effect of dofetilide was assessed in 5 clin. studies (80 healthy volunteers and 17 patients with ischemic heart disease).  A population pharmacokinetic-pharmacodynamic anal. of the in vitro and in vivo data was performed in NONMEM by use of the operational model of pharmacol. agonism to est. the efficiency of transduction from ion channel binding to Fridericia-cor. QT response.  Results: A 3-compartment pharmacokinetic model with first-order absorption characterized the time course of dofetilide concns.  On the basis of an in vitro potency of 5.13 ng/mL for potassium current inhibition and predicted unbound dofetilide concns., the estd. transducer ratio (τ) of 6.2 suggests that the QT response plateaus before currents are fully blocked.  In our study population, 10% hERG blockade corresponds to a QT prolongation of 20 ms (95% confidence interval, 12-32 ms).  With long-term dofetilide administration, tolerance develops with a half-life of 4.7 days.  Conclusions: The current mechanism-based pharmacokinetic-pharmacodynamic model quantified the relationship between in vitro hERG channel blockade and clin. QT prolongation for dofetilide.  This model may prove valuable for assessing the risk of QT prolongation in humans for other drugs that selectively block the hERG channel on the basis of in vitro assays and pharmacokinetic properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTnqkGXeIQarVg90H21EOLACvtfcHk0ljh35XtDddKRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlt1Gqt7c%253D&md5=85eae08f9ac8076e77040e99b3718a03</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.clpt.2005.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clpt.2005.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DJonker%26aufirst%3DD.%2BM.%26aulast%3DKenna%26aufirst%3DL.%2BA.%26aulast%3DLeishman%26aufirst%3DD.%26aulast%3DWallis%26aufirst%3DR.%26aulast%3DMilligan%26aufirst%3DP.%2BA.%26aulast%3DJonsson%26aufirst%3DE.%2BN.%26atitle%3DA%2520Pharmacokinetic-Pharmacodynamic%2520Model%2520for%2520the%2520Quantitative%2520Prediction%2520of%2520Dofetilide%2520Clinical%2520Qt%2520Prolongation%2520from%2520Human%2520Ether-a-Go-Go-Related%2520Gene%2520Current%2520Inhibition%2520Data%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2005%26volume%3D77%26spage%3D572%26epage%3D582%26doi%3D10.1016%2Fj.clpt.2005.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span> <span> </span><span class="NLM_article-title">Drugs and Valvular Heart Disease</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1056/NEJMp068265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1056%2FNEJMp068265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=17202450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlCitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=6-9&author=B.+L.+Roth&title=Drugs+and+Valvular+Heart+Disease&doi=10.1056%2FNEJMp068265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Drugs and valvular heart disease</span></div><div class="casAuthors">Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6-9</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOaFEwabTP8rVg90H21EOLACvtfcHk0ljh35XtDddKRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlCitQ%253D%253D&md5=e5161a25f1a2596cef68030f0f8a7b61</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1056%2FNEJMp068265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp068265%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DDrugs%2520and%2520Valvular%2520Heart%2520Disease%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D6%26epage%3D9%26doi%3D10.1056%2FNEJMp068265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kheirbek, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ing, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viol, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilbar, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geis, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hano, J. E.</span></span> <span> </span><span class="NLM_article-title">Treatment of Metabolic Alkalosis with Hemofiltration in Patients with Renal Insufficiency</span>. <i>Nephron</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1159/000181691</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1159%2F000181691" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2004&pages=91-92&author=A.+O.+Kheirbekauthor=T.+S.+Ingauthor=G.+W.+Violauthor=R.+M.+Vilbarauthor=V.+K.+Bansalauthor=V.+C.+Gandhiauthor=W.+P.+Geisauthor=J.+E.+Hano&title=Treatment+of+Metabolic+Alkalosis+with+Hemofiltration+in+Patients+with+Renal+Insufficiency&doi=10.1159%2F000181691"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1159%2F000181691&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000181691%26sid%3Dliteratum%253Aachs%26aulast%3DKheirbek%26aufirst%3DA.%2BO.%26aulast%3DIng%26aufirst%3DT.%2BS.%26aulast%3DViol%26aufirst%3DG.%2BW.%26aulast%3DVilbar%26aufirst%3DR.%2BM.%26aulast%3DBansal%26aufirst%3DV.%2BK.%26aulast%3DGandhi%26aufirst%3DV.%2BC.%26aulast%3DGeis%26aufirst%3DW.%2BP.%26aulast%3DHano%26aufirst%3DJ.%2BE.%26atitle%3DTreatment%2520of%2520Metabolic%2520Alkalosis%2520with%2520Hemofiltration%2520in%2520Patients%2520with%2520Renal%2520Insufficiency%26jtitle%3DNephron%26date%3D2004%26volume%3D24%26spage%3D91%26epage%3D92%26doi%3D10.1159%2F000181691" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caccia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conforti, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duchier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garattini, S.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics of Fenfluramine and Norfenfluramine in Volunteers Given D- and Dl-Fenfluramine for 15 Days</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">224</span>, <span class="refDoi"> DOI: 10.1007/BF00547426</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1007%2FBF00547426" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=4076322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADyaL28XksFarsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1985&pages=221-224&author=S.+Cacciaauthor=I.+Confortiauthor=J.+Duchierauthor=S.+Garattini&title=Pharmacokinetics+of+Fenfluramine+and+Norfenfluramine+in+Volunteers+Given+D-+and+Dl-Fenfluramine+for+15+Days&doi=10.1007%2FBF00547426"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics of fenfluramine and norfenfluramine in volunteers given d- and dl-fenfluramine for 15 days</span></div><div class="casAuthors">Caccia, S.; Conforti, I.; Duchier, J.; Garattini, S.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-4</span>CODEN:
                <span class="NLM_cas:coden">EJCPAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    </div><div class="casAbstract">The kinetics of accumulation and elimination d-fenfluramine  [3239-44-9], l-fenfluramine (F)  [37577-24-5], d-norfenfluramine (d-NF)  [19036-73-8], and l-norfenfluramine (l-NF)  [37577-22-3] were studied in healthy volunteers given daily doses of 3 20-mg tablets of dl-fenfluramine  [458-24-2] as the HCl-salt or 2 15-mg capsules of d-F-HCl for 15 days.  Pharmacokinetic parameters measured after repeated doses of dl-F were similar to those obtained with d-F.  Steady-state concns. of all compds. were achieved within 4-8 days.  The predicted mean steady-state concns. of d-F and elimination half-lives calcd. from the results of a previous single dose study were similar to those measured at steady state in this study.  Plasma levels of d-NF were approx. half those of the parent drug and the half-life was almost twice as long.  Steady state concns. both of l-F and l-NF were consistently about 40-50% higher than of the d-isomers; the half-lives of l-isomers were also longer than the d-isomers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjjKkOiVIH7rVg90H21EOLACvtfcHk0ljh35XtDddKRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XksFarsA%253D%253D&md5=0d8a89b4815978c153d9672d260e1116</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1007%2FBF00547426&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF00547426%26sid%3Dliteratum%253Aachs%26aulast%3DCaccia%26aufirst%3DS.%26aulast%3DConforti%26aufirst%3DI.%26aulast%3DDuchier%26aufirst%3DJ.%26aulast%3DGarattini%26aufirst%3DS.%26atitle%3DPharmacokinetics%2520of%2520Fenfluramine%2520and%2520Norfenfluramine%2520in%2520Volunteers%2520Given%2520D-%2520and%2520Dl-Fenfluramine%2520for%252015%2520Days%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D1985%26volume%3D29%26spage%3D221%26epage%3D224%26doi%3D10.1007%2FBF00547426" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frachon, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Gal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leroyer, C.</span></span> <span> </span><span class="NLM_article-title">Benfluorex Withdrawal in France: Still Be Hiding Somewhere in the World?</span>. <i>J. Pharmacol. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">307</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.4103/0976-500X.85942</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.4103%2F0976-500X.85942" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=22025868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BC3MbjvVWktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=307-308&author=I.+Frachonauthor=G.+Le+Galauthor=C.+Hillauthor=C.+Leroyer&title=Benfluorex+Withdrawal+in+France%3A+Still+Be+Hiding+Somewhere+in+the+World%3F&doi=10.4103%2F0976-500X.85942"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Benfluorex withdrawal in France: Still be hiding somewhere in the world?</span></div><div class="casAuthors">Frachon Irene; Le Gal Gregoire; Hill Catherine; Leroyer Christophe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacology & pharmacotherapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQTPw3xVJ6b_BLDWw4HIq2sfW6udTcc2ea0doViTlp0Prntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MbjvVWktw%253D%253D&md5=49d1cda8192f8ff6745036072f890865</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.4103%2F0976-500X.85942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F0976-500X.85942%26sid%3Dliteratum%253Aachs%26aulast%3DFrachon%26aufirst%3DI.%26aulast%3DLe%2BGal%26aufirst%3DG.%26aulast%3DHill%26aufirst%3DC.%26aulast%3DLeroyer%26aufirst%3DC.%26atitle%3DBenfluorex%2520Withdrawal%2520in%2520France%253A%2520Still%2520Be%2520Hiding%2520Somewhere%2520in%2520the%2520World%253F%26jtitle%3DJ.%2520Pharmacol.%2520Pharmacother.%26date%3D2011%26volume%3D2%26spage%3D307%26epage%3D308%26doi%3D10.4103%2F0976-500X.85942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomain, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waldman, S. A.</span></span> <span> </span><span class="NLM_article-title">Antiobesity Pharmacotherapy: New Drugs and Emerging Targets</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">53</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1038/clpt.2013.204</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fclpt.2013.204" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=24105257" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2013&pages=53-66&author=G.+W.+Kimauthor=J.+E.+Linauthor=E.+S.+Blomainauthor=S.+A.+Waldman&title=Antiobesity+Pharmacotherapy%3A+New+Drugs+and+Emerging+Targets&doi=10.1038%2Fclpt.2013.204"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2013.204&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2013.204%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DG.%2BW.%26aulast%3DLin%26aufirst%3DJ.%2BE.%26aulast%3DBlomain%26aufirst%3DE.%2BS.%26aulast%3DWaldman%26aufirst%3DS.%2BA.%26atitle%3DAntiobesity%2520Pharmacotherapy%253A%2520New%2520Drugs%2520and%2520Emerging%2520Targets%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2013%26volume%3D95%26spage%3D53%26epage%3D66%26doi%3D10.1038%2Fclpt.2013.204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, D. J.</span></span> <span> </span><span class="NLM_article-title">Dopamine Agonists: Their Role in the Treatment of Parkinson’s Disease</span>. <i>J. Neurol., Neurosurg. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">685</span>– <span class="NLM_lpage">689</span>, <span class="refDoi"> DOI: 10.1136/jnnp.68.6.685</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1136%2Fjnnp.68.6.685" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10811688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BD3c3ntF2mtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2000&pages=685-689&author=D.+J.+Brooks&title=Dopamine+Agonists%3A+Their+Role+in+the+Treatment+of+Parkinson%E2%80%99s+Disease&doi=10.1136%2Fjnnp.68.6.685"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine agonists: their role in the treatment of Parkinson's disease</span></div><div class="casAuthors">Brooks D J</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurology, neurosurgery, and psychiatry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">685-9</span>
        ISSN:<span class="NLM_cas:issn">0022-3050</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjW5OabTzZ4TQLBVDQn4bCfW6udTcc2ea0doViTlp0Prntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c3ntF2mtA%253D%253D&md5=82168189acbf718f702e5e0ecc697380</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1136%2Fjnnp.68.6.685&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fjnnp.68.6.685%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DD.%2BJ.%26atitle%3DDopamine%2520Agonists%253A%2520Their%2520Role%2520in%2520the%2520Treatment%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Neurol.%252C%2520Neurosurg.%2520Psychiatry%26date%3D2000%26volume%3D68%26spage%3D685%26epage%3D689%26doi%3D10.1136%2Fjnnp.68.6.685" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borovac, J. A.</span></span> <span> </span><span class="NLM_article-title">Side Effects of a Dopamine Agonist Therapy for Parkinson’s Disease: A Mini-Review of Clinical Pharmacology</span>. <i>Yale J. Biol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">37</span>– <span class="NLM_lpage">47</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=27505015" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtlaitbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2016&pages=37-47&author=J.+A.+Borovac&title=Side+Effects+of+a+Dopamine+Agonist+Therapy+for+Parkinson%E2%80%99s+Disease%3A+A+Mini-Review+of+Clinical+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacology</span></div><div class="casAuthors">Borovac, Josip Andjelo</div><div class="citationInfo"><span class="NLM_cas:title">Yale Journal of Biology and Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">37-47</span>CODEN:
                <span class="NLM_cas:coden">YJBMAU</span>;
        ISSN:<span class="NLM_cas:issn">0044-0086</span>.
    
            (<span class="NLM_cas:orgname">Yale Journal of Biology and Medicine</span>)
        </div><div class="casAbstract">Dopamine agonists (DA) are therapeutic agents that are commonly used in the treatment of Parkinson's disease (PD).  They can reduce undesired motor fluctuations and delay the administration of levodopa therapy.  However, this drug family is assocd. with specific side effects that can significantly diminish the quality of life among PD patients.  Some of them impose significant risks for individuals who have a history of cardiovascular diseases, psychosis, and depression, or those older patients who suffer from renal or hepatic insufficiency.  Various pharmacokinetic and pharmacodynamic considerations need to be taken into account when administering DA therapy.  The goal of this review is to provide a comprehensive, up-to-date overview of DA therapeutic modalities for PD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcr2x3aPsDe7Vg90H21EOLACvtfcHk0lhisY0KdLagvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtlaitbo%253D&md5=b0da71799d291c8dc9ce4484c234ad4c</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBorovac%26aufirst%3DJ.%2BA.%26atitle%3DSide%2520Effects%2520of%2520a%2520Dopamine%2520Agonist%2520Therapy%2520for%2520Parkinson%25E2%2580%2599s%2520Disease%253A%2520A%2520Mini-Review%2520of%2520Clinical%2520Pharmacology%26jtitle%3DYale%2520J.%2520Biol.%2520Med.%26date%3D2016%26volume%3D89%26spage%3D37%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jahnichen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertz, H. H.</span></span> <span> </span><span class="NLM_article-title">Agonism at 5-Ht2b Receptors Is Not a Class Effect of the Ergolines</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>513</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2005.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.ejphar.2005.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=15862804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BD2M3ivVaksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=513&publication_year=2005&pages=225-228&author=S.+Jahnichenauthor=R.+Horowskiauthor=H.+H.+Pertz&title=Agonism+at+5-Ht2b+Receptors+Is+Not+a+Class+Effect+of+the+Ergolines&doi=10.1016%2Fj.ejphar.2005.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Agonism at 5-HT2B receptors is not a class effect of the ergolines</span></div><div class="casAuthors">Jahnichen Sven; Horowski Reinhard; Pertz Heinz H</div><div class="citationInfo"><span class="NLM_cas:title">European journal of pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">513</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">225-8</span>
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">Restrictive cardiac valvulopathies observed in Parkinson patients treated with the ergoline dopamine agonist pergolide have recently been associated with the agonist efficacy of the drug at 5-hydroxytryptamine2B (5-HT2B) receptors.  To evaluate whether agonism at 5-HT2B receptors is a phenomenon of the class of the ergolines, we studied 5-HT2B receptor-mediated relaxation in porcine pulmonary arteries to five ergolines which are used as antiparkinsonian drugs.  Pergolide and cabergoline were potent full agonists in this tissue (pEC50 8.42 and 8.72).  Bromocriptine acted as a partial agonist (pEC50 6.86).  Lisuride and terguride, however, failed to relax the arteries but potently antagonized 5-HT-induced relaxation (pKB 10.32 and 8.49).  Thus, agonism at 5-HT2B receptors seems not to be a class effect of the ergolines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjpMe6eCTBV5ggzHGM8X5CfW6udTcc2ebqo2rZuxdiTrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2M3ivVaksg%253D%253D&md5=9ffdbec67605e8e0960d1a94d5d47ecd</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2005.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2005.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DJahnichen%26aufirst%3DS.%26aulast%3DHorowski%26aufirst%3DR.%26aulast%3DPertz%26aufirst%3DH.%2BH.%26atitle%3DAgonism%2520at%25205-Ht2b%2520Receptors%2520Is%2520Not%2520a%2520Class%2520Effect%2520of%2520the%2520Ergolines%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2005%26volume%3D513%26spage%3D225%26epage%3D228%26doi%3D10.1016%2Fj.ejphar.2005.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goudsouzian, N. G.</span></span> <span> </span><span class="NLM_article-title">Rapacuronium and Bronchospasm</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">727</span>– <span class="NLM_lpage">728</span>, <span class="refDoi"> DOI: 10.1097/00000542-200105000-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1097%2F00000542-200105000-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=11388519" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BD3MzhsVKksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2001&pages=727-728&author=N.+G.+Goudsouzian&title=Rapacuronium+and+Bronchospasm&doi=10.1097%2F00000542-200105000-00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Rapacuronium and bronchospasm</span></div><div class="casAuthors">Goudsouzian N G</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">727-8</span>
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJhGoKiK-pxiEJCPKhJPuqfW6udTcc2ebqo2rZuxdiTrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3MzhsVKksQ%253D%253D&md5=0b0beacba1687dd86db09de216bb5367</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1097%2F00000542-200105000-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000542-200105000-00006%26sid%3Dliteratum%253Aachs%26aulast%3DGoudsouzian%26aufirst%3DN.%2BG.%26atitle%3DRapacuronium%2520and%2520Bronchospasm%26jtitle%3DAnesthesiology%26date%3D2001%26volume%3D94%26spage%3D727%26epage%3D728%26doi%3D10.1097%2F00000542-200105000-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jooste, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emala, C. W.</span></span> <span> </span><span class="NLM_article-title">Neuromuscular Blocking Agents’ Differential Bronchoconstrictive Potential in Guinea Pig Airways</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">763</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1097/01.anes.0000264763.48920.c9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1097%2F01.anes.0000264763.48920.c9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=17413914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjvVKit7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2007&pages=763-772&author=E.+Joosteauthor=Y.+Zhangauthor=C.+W.+Emala&title=Neuromuscular+Blocking+Agents%E2%80%99+Differential+Bronchoconstrictive+Potential+in+Guinea+Pig+Airways&doi=10.1097%2F01.anes.0000264763.48920.c9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Neuromuscular blocking agents' differential bronchoconstrictive potential in guinea pig airways</span></div><div class="casAuthors">Jooste, Edmund; Zhang, Yi; Emala, Charles W.</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">763-772</span>CODEN:
                <span class="NLM_cas:coden">ANESAV</span>;
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Neuromuscular blocking agents are designed to antagonize nicotinic cholinergic receptors on skeletal muscle but also antagonize muscarinic receptors.  Several muscle relaxants have the potential to promote bronchoconstriction due to unintended effects exemplified by histamine release of atracurium or mivacurium and detrimental interactions with muscarinic receptors by rapacuronium.  Although interactions of muscle relaxants with muscarinic receptors have been extensively characterized in vitro, limited information is available on their potential interactions with airway tone in vivo.  Changes in pulmonary inflation pressures and heart rates induced by vagal nerve stimulation and i.v. acetylcholine were measured in the absence and presence of increasing doses of gallamine, pancuronium, mivacurium, vecuronium, cisatracurium, rocuronium, or rapacuronium in guinea pigs.  Mivacurium's and rapacuronium's potential of inducing bronchoconstriction by histamine release was also evaluated.  Rapacuronium potentiated both vagal nerve-stimulated and i.v. acetylcholine-induced increases in airway pressures, which were totally blocked by atropine but not pyrilamine.  Vecuronium, rocuronium, mivacurium, and cisatracurium were devoid of significant airway effects.  Mivacurium, at high doses, increased pulmonary inflation pressures, which were attenuated by pyrilamine.  Rapacuronium was unique among muscle relaxants evaluated in that it potentiated both vagal nerve- and i.v. acetylcholine-induced bronchoconstriction with no evidence of histamine release.  The dual detrimental interactions of rapacuronium with muscarinic receptors previously demonstrated in vitro correlate with in vivo muscarinic receptor mechanisms of bronchoconstriction and may account for the profound bronchoconstriction seen with its clin. use.  These findings may establish pharmacol. characteristics to avoid with new muscle relaxants intended for clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiHquLGqJz4LVg90H21EOLACvtfcHk0lghSr_D_JW-9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjvVKit7Y%253D&md5=d614d5c685f5bee7cd75b8ab38302010</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1097%2F01.anes.0000264763.48920.c9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F01.anes.0000264763.48920.c9%26sid%3Dliteratum%253Aachs%26aulast%3DJooste%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DEmala%26aufirst%3DC.%2BW.%26atitle%3DNeuromuscular%2520Blocking%2520Agents%25E2%2580%2599%2520Differential%2520Bronchoconstrictive%2520Potential%2520in%2520Guinea%2520Pig%2520Airways%26jtitle%3DAnesthesiology%26date%3D2007%26volume%3D106%26spage%3D763%26epage%3D772%26doi%3D10.1097%2F01.anes.0000264763.48920.c9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hou, V. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirshman, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emala, C. W.</span></span> <span> </span><span class="NLM_article-title">Neuromuscular Relaxants as Antagonists for M2 and M3 Muscarinic Receptors</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">744</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1097/00000542-199803000-00026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1097%2F00000542-199803000-00026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=9523819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADyaK1cXitFamtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1998&pages=744-750&author=V.+Y.+Houauthor=C.+A.+Hirshmanauthor=C.+W.+Emala&title=Neuromuscular+Relaxants+as+Antagonists+for+M2+and+M3+Muscarinic+Receptors&doi=10.1097%2F00000542-199803000-00026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Neuromuscular relaxants as antagonists for M2 and M3 muscarinic receptors</span></div><div class="casAuthors">Hou, Vivian Y.; Hirshman, Carol A.; Emala, Charles W.</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">744-750</span>CODEN:
                <span class="NLM_cas:coden">ANESAV</span>;
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven Publishers</span>)
        </div><div class="casAbstract">Neuromuscular relaxants such as pancuronium bind to M2 and M3 muscarinic receptors as antagonists.  Blockade of muscarinic receptors in atria of the M2 subtype mediates tachycardia.  In the lung, blockade of M2 receptors on parasympathetic nerves potentiates vagally induced bronchospasm, whereas blockade of M3 receptors on bronchial smooth muscle inhibits bronchospasm.  The current study was designed to quantify the affinity of a series of neuromuscular relaxants for the M2 and M3 muscarinic receptors, which were individually stably transfected in Chinese hamster ovary cell lines.  All muscle relaxants evaluated displaced muscarinic receptor antagonist (3H-QNB3) from muscarinic receptors.  The relative order of potency for the M2 muscarinic receptor (highest to lowest) was pancuronium, gallamine, rocuronium, atracurium, pipecuronium, doxacurium, mivacurium, and succinylcholine.  The relative order of potency for the M3 muscarinic receptor (highest to lowest) was pancuronium, atracurium, pipecuronium, rocuronium, mivacurium, gallamine, succinylcholine, and doxacurium.  All neuromuscular relaxants studied had affinities for the M2 and M3 muscarinic receptor, but only pancuronium and gallamine had affinities within the range of concns. achieved with clin. use.  The high affinities of gallamine and pancuronium for the M2 muscarinic receptor are consistent with a mechanism of M2 receptor blockade in relaxant-induced tachycardia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHOs4wH2oag7Vg90H21EOLACvtfcHk0lghSr_D_JW-9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitFamtL4%253D&md5=91c80c50cec8ddfe7b1ea731b08bce19</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1097%2F00000542-199803000-00026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000542-199803000-00026%26sid%3Dliteratum%253Aachs%26aulast%3DHou%26aufirst%3DV.%2BY.%26aulast%3DHirshman%26aufirst%3DC.%2BA.%26aulast%3DEmala%26aufirst%3DC.%2BW.%26atitle%3DNeuromuscular%2520Relaxants%2520as%2520Antagonists%2520for%2520M2%2520and%2520M3%2520Muscarinic%2520Receptors%26jtitle%3DAnesthesiology%26date%3D1998%26volume%3D88%26spage%3D744%26epage%3D750%26doi%3D10.1097%2F00000542-199803000-00026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jooste, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klafter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirshman, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emala, C. W.</span></span> <span> </span><span class="NLM_article-title">A Mechanism for Rapacuronium-Induced Bronchospasm: M2 Muscarinic Receptor Antagonism</span>. <i>Anesthesiology</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">906</span>– <span class="NLM_lpage">911</span>, <span class="refDoi"> DOI: 10.1097/00000542-200304000-00017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1097%2F00000542-200304000-00017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=12657852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD3sXitlKiu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2003&pages=906-911&author=E.+Joosteauthor=F.+Klafterauthor=C.+A.+Hirshmanauthor=C.+W.+Emala&title=A+Mechanism+for+Rapacuronium-Induced+Bronchospasm%3A+M2+Muscarinic+Receptor+Antagonism&doi=10.1097%2F00000542-200304000-00017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">A Mechanism for Rapacuronium-induced Bronchospasm: M2 Muscarinic Receptor Antagonism</span></div><div class="casAuthors">Jooste, Edmund; Klafter, Farrah; Hirshman, Carol A.; Emala, Charles W.</div><div class="citationInfo"><span class="NLM_cas:title">Anesthesiology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">906-911</span>CODEN:
                <span class="NLM_cas:coden">ANESAV</span>;
        ISSN:<span class="NLM_cas:issn">0003-3022</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A safe and effective ultra-short-acting nondepolarizing neuromuscular blocking agent is required to block nicotinic receptors to facilitate intubation.  Rapacuronium, which sought to fulfill these criteria, was withdrawn from clin. use due to a high incidence of bronchospasm resulting in death.  Understanding the mechanism by which rapacuronium induces fatal bronchospasm is imperative so that newly synthesized neuromuscular blocking agents that share this mechanism will not be introduced clin.  Selective inhibition of M2 muscarinic receptors by muscle relaxants during periods of parasympathetic nerve stimulation (e.g., intubation) can result in the massive release METHODS of acetylcholine to act on unopposed M3 muscarinic receptors in airway smooth muscle, thereby facilitating bronchoconstriction.  Competitive radioligand binding detd. the binding affinities of rapacuronium, vecuronium, cisatracurium, methoctramine (selective M2 antagonist), and 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP; selective M3 antagonist) for M2 and M3 muscarinic receptors.  Rapacuronium competitively displaced 3H-QNB from the M2 muscarinic receptors but not from the M3 muscarinic receptors within clin. relevant concns.  Fifty percent inhibitory concns. (mean ± SE) for rapacuronium were as follows: M2 muscarinic receptor, 5.10±1.5 μm (n = 6); M3 muscarinic receptor, 77.9±11 μm (n = 8).  Cisatracurium and vecuronium competitively displaced 3H-QNB from both M2 and M3 muscarinic receptors but had affinities at greater than clin. achieved concns. for these relaxants.  Rapacuronium in clin. significant doses has a higher affinity for M2 muscarinic receptors as compared with M3 muscarinic receptors.  A potential mechanism by which rapacuronium may potentiate bronchoconstriction is by blockade of M2 muscarinic receptors on prejunctional parasympathetic nerves, leading to increased release of acetylcholine and thereby resulting in M3 muscarinic receptor-mediated airway smooth muscle constriction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAmsOfmK2j97Vg90H21EOLACvtfcHk0lghSr_D_JW-9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXitlKiu74%253D&md5=f29a2c7abdd2d2a7d6383e10814da5a0</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1097%2F00000542-200304000-00017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000542-200304000-00017%26sid%3Dliteratum%253Aachs%26aulast%3DJooste%26aufirst%3DE.%26aulast%3DKlafter%26aufirst%3DF.%26aulast%3DHirshman%26aufirst%3DC.%2BA.%26aulast%3DEmala%26aufirst%3DC.%2BW.%26atitle%3DA%2520Mechanism%2520for%2520Rapacuronium-Induced%2520Bronchospasm%253A%2520M2%2520Muscarinic%2520Receptor%2520Antagonism%26jtitle%3DAnesthesiology%26date%3D2003%26volume%3D98%26spage%3D906%26epage%3D911%26doi%3D10.1097%2F00000542-200304000-00017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dore, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiBello, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapane, K. L.</span></span> <span> </span><span class="NLM_article-title">Telithromycin Use and Spontaneous Reports of Hepatotoxicity</span>. <i>Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">697</span>– <span class="NLM_lpage">703</span>, <span class="refDoi"> DOI: 10.2165/00002018-200730080-00006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.2165%2F00002018-200730080-00006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=17696582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BD2svotVGhtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2007&pages=697-703&author=D.+D.+Doreauthor=J.+R.+DiBelloauthor=K.+L.+Lapane&title=Telithromycin+Use+and+Spontaneous+Reports+of+Hepatotoxicity&doi=10.2165%2F00002018-200730080-00006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Telithromycin use and spontaneous reports of hepatotoxicity</span></div><div class="casAuthors">Dore David D; DiBello Julia R; Lapane Kate L</div><div class="citationInfo"><span class="NLM_cas:title">Drug safety</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">697-703</span>
        ISSN:<span class="NLM_cas:issn">0114-5916</span>.
    </div><div class="casAbstract">BACKGROUND AND OBJECTIVE:  Recent reports have described cases of telithromycin-related hepatotoxicity.  The objective of this study is to quantify the effect of telithromycin use on the risk of hepatotoxicity.  METHODS:  We conducted a spontaneous-report case-control study of hepatotoxicity in telithromycin recipients using reports from the US FDA Adverse Event Reporting System.  Reports from between 1 January 2005 and 30 June 2005 were examined.  Cases included reports of patients with abnormal liver function tests, hepatocellular damage and hepatic impairment, while patients with reported conditions with similar reporting probabilities were considered as controls.  The primary outcome measure of the analysis was the reporting odds ratio (ROR) evaluating the a priori hypothesis that telithromycin use confers an elevated risk of hepatotoxicity relative to other agents.  RESULTS:  A total of 2219 cases and 20,667 controls were identified.  We estimated an ROR for hepatotoxicity associated with telithromycin compared with other agents of 1.82 (95% CI 1.12, 2.96) after controlling for age and gender, approximating an 82% excess risk in users of telithromycin relative to users of other agents.  CONCLUSIONS:  This analysis is the first to specifically quantify the effect of telithromycin on the risk of hepatotoxicity.  Telithromycin use may increase the risk of hepatotoxicity by >80%.  Biases inherent in spontaneous reports include under-reporting of events and differential or time-varying reporting due to enhanced clinician awareness.  Future studies should employ alternative data sources because of the inherent limitations of passive surveillance systems.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSv7TVZm2oNUn6oPH0mYWL1fW6udTcc2eYRbdHlyV29GLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2svotVGhtQ%253D%253D&md5=fc34ce6f1ef8a2db4d4e12334e1fed48</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.2165%2F00002018-200730080-00006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00002018-200730080-00006%26sid%3Dliteratum%253Aachs%26aulast%3DDore%26aufirst%3DD.%2BD.%26aulast%3DDiBello%26aufirst%3DJ.%2BR.%26aulast%3DLapane%26aufirst%3DK.%2BL.%26atitle%3DTelithromycin%2520Use%2520and%2520Spontaneous%2520Reports%2520of%2520Hepatotoxicity%26jtitle%3DDrug%2520Saf.%26date%3D2007%26volume%3D30%26spage%3D697%26epage%3D703%26doi%3D10.2165%2F00002018-200730080-00006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ross, D. B.</span></span> <span> </span><span class="NLM_article-title">The Fda and the Case of Ketek</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">1601</span>– <span class="NLM_lpage">1604</span>, <span class="refDoi"> DOI: 10.1056/NEJMp078032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1056%2FNEJMp078032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=17442902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksFCgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=1601-1604&author=D.+B.+Ross&title=The+Fda+and+the+Case+of+Ketek&doi=10.1056%2FNEJMp078032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Perspective: the FDA and the case of Ketek</span></div><div class="casAuthors">Ross, David B.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1601-1604</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxg3oJZMs06LVg90H21EOLACvtfcHk0li1HIcRhSHRtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksFCgtb4%253D&md5=f077976e1f2d38a66f7730fe4e6fb184</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1056%2FNEJMp078032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMp078032%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DD.%2BB.%26atitle%3DThe%2520Fda%2520and%2520the%2520Case%2520of%2520Ketek%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D1601%26epage%3D1604%26doi%3D10.1056%2FNEJMp078032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, P.</span></span> <span> </span><span class="NLM_article-title">Molecular Characterization of Off-Target Activities of Telithromycin: A Potential Role for Nicotinic Acetylcholine Receptors</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5399</span>– <span class="NLM_lpage">5402</span>, <span class="refDoi"> DOI: 10.1128/AAC.00840-10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1128%2FAAC.00840-10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=20855733" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2msrzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2010&pages=5399-5402&author=D.+Bertrandauthor=S.+Bertrandauthor=E.+Neveuauthor=P.+Fernandes&title=Molecular+Characterization+of+Off-Target+Activities+of+Telithromycin%3A+A+Potential+Role+for+Nicotinic+Acetylcholine+Receptors&doi=10.1128%2FAAC.00840-10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors</span></div><div class="casAuthors">Bertrand, Daniel; Bertrand, Sonia; Neveu, Estelle; Fernandes, Prabhavathi</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5399-5402</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Adverse effects have limited the clin. use of telithromycin.  Preferential inhibition of the nicotinic acetylcholine receptors (nAChR) at the neuromuscular junction (α3β2 and NMJ), the ciliary ganglion of the eye (α3β4 and α7), and the vagus nerve innervating the liver (α7) could account for the exacerbation of myasthenia gravis, the visual disturbance, and the liver failure seen with telithromycin use.  The studies presented here enable the prediction of expected side effects of macrolides in development, such as solithromycin (CEM-101).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0NSdRTqlSyrVg90H21EOLACvtfcHk0li1HIcRhSHRtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2msrzK&md5=5991da1c22328f9ec9abc93c0da200df</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1128%2FAAC.00840-10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00840-10%26sid%3Dliteratum%253Aachs%26aulast%3DBertrand%26aufirst%3DD.%26aulast%3DBertrand%26aufirst%3DS.%26aulast%3DNeveu%26aufirst%3DE.%26aulast%3DFernandes%26aufirst%3DP.%26atitle%3DMolecular%2520Characterization%2520of%2520Off-Target%2520Activities%2520of%2520Telithromycin%253A%2520A%2520Potential%2520Role%2520for%2520Nicotinic%2520Acetylcholine%2520Receptors%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2010%26volume%3D54%26spage%3D5399%26epage%3D5402%26doi%3D10.1128%2FAAC.00840-10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, D.</span></span> <span> </span><span class="NLM_article-title">The Solithromycin Journey-It Is All in the Chemistry</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6420</span>– <span class="NLM_lpage">6428</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.08.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1016%2Fj.bmc.2016.08.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=27595539" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVCgsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=6420-6428&author=P.+Fernandesauthor=E.+Martensauthor=D.+Bertrandauthor=D.+Pereira&title=The+Solithromycin+Journey-It+Is+All+in+the+Chemistry&doi=10.1016%2Fj.bmc.2016.08.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">The solithromycin journey-It is all in the chemistry</span></div><div class="casAuthors">Fernandes, Prabhavathi; Martens, Evan; Bertrand, Daniel; Pereira, David</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6420-6428</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The macrolide class of antibiotics, including the early generation macrolides erythromycin, clarithromycin and azithromycin, have been used broadly for treatment of respiratory tract infections.  An increase of treatment failures of early generation macrolides is due to the upturn in bacterial macrolide resistance to 48% in the US and over 80% in Asian countries and has led to the use of alternate therapies, such as fluoroquinolones.  The safety of the fluoroquinolones is now in question and alternate antibiotics for the outpatient treatment of community acquired bacterial pneumonia are needed.  Telithromycin, approved in 2003, is no longer used owing to serious adverse events, collectively called the 'Ketek effects'.  Telithromycin has a side chain pyridine moiety that blocks nicotinic acetylcholine receptors.  Blockade of these receptors is known exptl. to cause the side effects seen with telithromycin in patients use.  Solithromycin is a new macrolide, the first fluoroketolide, which has been tested successfully in two Phase 3 trials and is undergoing regulatory review at the FDA.  Solithromycin is differentiated from telithromycin chem. and biol. in that its side chain is chem. different and does not significantly block nicotinic acetylcholine receptors.  Solithromycin was well tolerated and effective in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7LdWo7aa8ZrVg90H21EOLACvtfcHk0li1HIcRhSHRtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVCgsrbN&md5=9d19bc32264ad1bb80d19b5d7709f514</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.08.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.08.035%26sid%3Dliteratum%253Aachs%26aulast%3DFernandes%26aufirst%3DP.%26aulast%3DMartens%26aufirst%3DE.%26aulast%3DBertrand%26aufirst%3DD.%26aulast%3DPereira%26aufirst%3DD.%26atitle%3DThe%2520Solithromycin%2520Journey-It%2520Is%2520All%2520in%2520the%2520Chemistry%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D6420%26epage%3D6428%26doi%3D10.1016%2Fj.bmc.2016.08.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Origlia, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenzano, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moretti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domenici, L.</span></span> <span> </span><span class="NLM_article-title">Visual Acuity Is Reduced in Alpha 7 Nicotinic Receptor Knockout Mice</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1211</span>– <span class="NLM_lpage">1218</span>, <span class="refDoi"> DOI: 10.1167/iovs.11-8007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1167%2Fiovs.11-8007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=22281823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38XmslKlt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=1211-1218&author=N.+Origliaauthor=D.+R.+Valenzanoauthor=M.+Morettiauthor=C.+Gottiauthor=L.+Domenici&title=Visual+Acuity+Is+Reduced+in+Alpha+7+Nicotinic+Receptor+Knockout+Mice&doi=10.1167%2Fiovs.11-8007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Visual acuity is reduced in alpha 7 nicotinic receptor knockout mice</span></div><div class="casAuthors">Origlia, Nicola; Valenzano, Dario Riccardo; Moretti, Milena; Gotti, Cecilia; Domenici, Luciano</div><div class="citationInfo"><span class="NLM_cas:title">Investigative Ophthalmology & Visual Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1211-1218</span>CODEN:
                <span class="NLM_cas:coden">IOVSDA</span>;
        ISSN:<span class="NLM_cas:issn">1552-5783</span>.
    
            (<span class="NLM_cas:orgname">Association for Research in Vision and Ophthalmology</span>)
        </div><div class="casAbstract">Purpose: Nicotinic receptors (nAChRs) are part of a heterogeneous family of pentameric ligand-gated ion channels that are widely expressed in the visual system.  The impact of α7 homomeric nAChRs on visual function was investigated using mutant mice lacking the α7 nicotinic receptor subunit.  Methods: The spatial resoln. limit was measured in α7 knockout (α7 KO) and age-matched control mice using three independent methods: an operant behavioral visual task (Prusky maze), cortical visual evoked potentials (VEPs), and the pattern electroretinogram (PERG) evoked by alternating gratings of different spatial frequencies and contrasts.  Results: Visual acuity measured by means of the visual water maze task was significantly decreased in the α7 KO mice and, concordantly, there was a redn. of the cortical spatial resoln. limit measured by VEPs.  However, the PERG was normal in α7 KO mice, compared with control mice.  The use of fluorescently tagged cholera toxin showed that projections from the retina segregate normally in α7 KO mice and, in line with this, the visual cortical responses elicited by stimulating either eye were normally balanced in both visual cortices and showed no retinotopic anomalies.  Conclusions: These findings indicate that the absence of the α7 nicotinic subunit reduces visual acuity.  Because the cortical output has an abnormal spatial resoln. but retinal output is preserved, it can be concluded that the low visual acuity was due to a deficit specifically present in the visual cortex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMRWjl-VN877Vg90H21EOLACvtfcHk0lgc9Eid3jG2Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmslKlt7k%253D&md5=2c6c80ec1fa74695f21a4907e7a8c5e9</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1167%2Fiovs.11-8007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.11-8007%26sid%3Dliteratum%253Aachs%26aulast%3DOriglia%26aufirst%3DN.%26aulast%3DValenzano%26aufirst%3DD.%2BR.%26aulast%3DMoretti%26aufirst%3DM.%26aulast%3DGotti%26aufirst%3DC.%26aulast%3DDomenici%26aufirst%3DL.%26atitle%3DVisual%2520Acuity%2520Is%2520Reduced%2520in%2520Alpha%25207%2520Nicotinic%2520Receptor%2520Knockout%2520Mice%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2012%26volume%3D53%26spage%3D1211%26epage%3D1218%26doi%3D10.1167%2Fiovs.11-8007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summers, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ewart, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nylander, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidaway, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Giezen, J. J.</span></span> <span> </span><span class="NLM_article-title">Characterization of the Adenosine Pharmacology of Ticagrelor Reveals Therapeutically Relevant Inhibition of Equilibrative Nucleoside Transporter 1</span>. <i>J. Cardiovasc. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1177/1074248413511693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1177%2F1074248413511693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=24414167" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnt1artbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=209-219&author=D.+Armstrongauthor=C.+Summersauthor=L.+Ewartauthor=S.+Nylanderauthor=J.+E.+Sidawayauthor=J.+J.+van+Giezen&title=Characterization+of+the+Adenosine+Pharmacology+of+Ticagrelor+Reveals+Therapeutically+Relevant+Inhibition+of+Equilibrative+Nucleoside+Transporter+1&doi=10.1177%2F1074248413511693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter I</span></div><div class="casAuthors">Armstrong, Duncan; Summers, Claire; Ewart, Lorna; Nylander, Sven; Sidaway, James E.; van Giezen, J. J. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cardiovascular Pharmacology and Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-219</span>CODEN:
                <span class="NLM_cas:coden">JCPTFE</span>;
        ISSN:<span class="NLM_cas:issn">1074-2484</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Introduction: Studies have shown that ticagrelor has a further adenosine-mediated mechanism of action in addn. to its potent inhibition of the P2Y12 receptor, which may explain some of ticagrelor's clin. characteristics.  This study aimed to further characterize the adenosine pharmacol. of ticagrelor, its major metabolites, and other P2Y12 receptor antagonists.  Methods: Inhibition of nucleoside transporter-mediated [3H]adenosine uptake by ticagrelor, its major metabolites, and alternative P2Y12 antagonists was examd. in recombinant Madin-Darby canine kidney (MDCK) cells.  The pharmacol. of ticagrelor and its major metabolites at adenosine A1, A2A, A2B, and A3 receptor subtypes was examd. using in vitro radioligand binding and functional assays and ex vivo C-fiber expts. in rat and guinea pig vagus nerves.  Results: Ticagrelor (and less effectively its metabolites) and the main cangrelor metabolite inhibited [3H]adenosine uptake in equilibrative nucleoside transporter (ENT) I-expressing MDCK cells, whereas cangrelor and the active metabolites of prasugrel or clopidogrel had no effect.  No significant inhibitory activity was obsd. in MDCK cells expressing ENT2 or concentrative nucleoside transporters 2/3.  Ticagrelor demonstrated high affinity (inhibition const. [Ki] = 41 nmol/L) for ENT I.  In adenosine receptor-binding expts., ticagrelor and its major circulating metabolite, AR-C124910XX, had low affinity (Ki > 6 μmol/L) for each of the adenosine A1, A2A, and A2B receptors, whereas ticagrelor had a submicromolar (Ki = 190 nmol/L) affinity for the adenosine A3 receptor.  However, in functional assays, at high concns. (10 μmol/L) ticagrelor only partially inhibited 3 mmol/L adenosine-induced depolarizations in the guinea pig and rat vagus nerve prepns. (by 35% and 49%, resp.).  Conclusions: Ticagrelor inhibits cellular adenosine uptake selectively via ENT I inhibition at concns. of clin. relevance.  However, the low-binding affinity and functional inhibition of adenosine receptors obsd. with ticagrelor or its metabolites indicate that they possess a negligible adenosine-like activity at clin. relevant concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuplo327ow5bVg90H21EOLACvtfcHk0lgc9Eid3jG2Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnt1artbc%253D&md5=3994d5d66af983e28a4fa59351e6145c</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1177%2F1074248413511693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1074248413511693%26sid%3Dliteratum%253Aachs%26aulast%3DArmstrong%26aufirst%3DD.%26aulast%3DSummers%26aufirst%3DC.%26aulast%3DEwart%26aufirst%3DL.%26aulast%3DNylander%26aufirst%3DS.%26aulast%3DSidaway%26aufirst%3DJ.%2BE.%26aulast%3Dvan%2BGiezen%26aufirst%3DJ.%2BJ.%26atitle%3DCharacterization%2520of%2520the%2520Adenosine%2520Pharmacology%2520of%2520Ticagrelor%2520Reveals%2520Therapeutically%2520Relevant%2520Inhibition%2520of%2520Equilibrative%2520Nucleoside%2520Transporter%25201%26jtitle%3DJ.%2520Cardiovasc.%2520Pharmacol.%2520Ther.%26date%3D2014%26volume%3D19%26spage%3D209%26epage%3D219%26doi%3D10.1177%2F1074248413511693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
den Berg, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Messaoudi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rongen, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den
Broek, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donders, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riksen, N. P.</span></span> <span> </span><span class="NLM_article-title">Ticagrelor Does Not Inhibit Adenosine Transport at Relevant Concentrations: A Randomized Cross-over Study in Healthy Subjects in Vivo</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0137560</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0137560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1371%2Fjournal.pone.0137560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=26509673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFKmsbjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=T.+N.+van%0Aden+Bergauthor=S.+El+Messaoudiauthor=G.+A.+Rongenauthor=P.+H.+van+den%0ABroekauthor=A.+Bilosauthor=A.+R.+Dondersauthor=M.+E.+Gomesauthor=N.+P.+Riksen&title=Ticagrelor+Does+Not+Inhibit+Adenosine+Transport+at+Relevant+Concentrations%3A+A+Randomized+Cross-over+Study+in+Healthy+Subjects+in+Vivo&doi=10.1371%2Fjournal.pone.0137560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Ticagrelor does not inhibit adenosine transport at relevant concentrations: a randomized cross-over study in healthy subjects in vivo</span></div><div class="casAuthors">van den Berg, T. N. A.; El Messaoudi, S.; Rongen, G. A.; van den Broek, P. H. H.; Bilos, A.; Donders, A. R. T.; Gomes, M. E.; Riksen, N. P.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e0137560/1-e0137560/15</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background and Purpose: In patients with myocardial infarction, ticagrelor reduces cardiovascular and sepsis-related mortality, and can cause dyspnea.  It is suggested that this is caused by adenosine receptor stimulation, because in preclin. studies, ticagrelor blocks the nucleoside transporter and increases cellular ATP release.  We now investigated the effects of ticagrelor on the adenosine system in humans in vivo.  Exptl. Approach: In a double-blinded, placebo-controlled cross-over trial in 14 healthy subjects, we have tested whether ticagrelor (180 mg) affects adenosine- and dipyridamole-induced forearm vasodilation, as surrogates of nucleoside uptake inhibition and adenosine formation, resp.  Also, ex vivo uptake of adenosine and uridine in isolated red blood cells was measured.  Primary endpoint was adenosine-induced vasodilation.  Key Results: Ticagrelor did not affect adenosine- or dipyridamole-induced forearm vasodilation.  Also, ex vivo uptake of adenosine and uridine in isolated red blood cells was not affected by ticagrelor.  In vitro, ticagrelor dose-dependently inhibited nucleoside uptake, but only at supra-physiol. concns.  Conclusion and Implications: In conclusion, at relevant plasma concn., ticagrelor does not affect adenosine transport, nor adenosine formation in healthy subjects.  Therefore, it is unlikely that this mechanism is a relevant pleiotropic effect of ticagrelor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxA-ml-YX0CbVg90H21EOLACvtfcHk0lgc9Eid3jG2Rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFKmsbjP&md5=c91c884cb2118890754e5388fbe2a3ce</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0137560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0137560%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2Bden%2BBerg%26aufirst%3DT.%2BN.%26aulast%3DEl%2BMessaoudi%26aufirst%3DS.%26aulast%3DRongen%26aufirst%3DG.%2BA.%26aulast%3Dvan%2Bden%2BBroek%26aufirst%3DP.%2BH.%26aulast%3DBilos%26aufirst%3DA.%26aulast%3DDonders%26aufirst%3DA.%2BR.%26aulast%3DGomes%26aufirst%3DM.%2BE.%26aulast%3DRiksen%26aufirst%3DN.%2BP.%26atitle%3DTicagrelor%2520Does%2520Not%2520Inhibit%2520Adenosine%2520Transport%2520at%2520Relevant%2520Concentrations%253A%2520A%2520Randomized%2520Cross-over%2520Study%2520in%2520Healthy%2520Subjects%2520in%2520Vivo%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0137560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. U.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology - Foe or Friend?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8955</span>– <span class="NLM_lpage">8971</span>, <span class="refDoi"> DOI: 10.1021/jm400856t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400856t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8955-8971&author=J.+U.+Peters&title=Polypharmacology+-+Foe+or+Friend%3F&doi=10.1021%2Fjm400856t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology - Foe or Friend?</span></div><div class="casAuthors">Peters, Jens-Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8955-8971</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. describes the activity of compds. at multiple targets.  Current research focuses on two aspects of polypharmacol.: (1) unintended polypharmacol. can lead to adverse effects; (2) polypharmacol. across several disease-relevant targets can improve therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse effects.  This perspective reviews these interconnected aspects of polypharmacol.  The first part discusses the relevance of polypharmacol. for the safety of drugs, the mitigation of safety risks, and methods to identify polypharmacol. compds. early in the drug discovery process.  The second part discusses the advantages of polypharmacol. in the treatment of multigenic diseases and infections, and opportunities for drug discovery and drug repurposing.  This perspective aims to provide a balanced view on polypharmacol., which can compromise the safety of drugs, but can also confer superior efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5vnFGPfTnGLVg90H21EOLACvtfcHk0ljOv0Fm2sVPIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1amtrnO&md5=f4aeb6efddd4bfdf4e94656303323cba</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fjm400856t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400856t%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DJ.%2BU.%26atitle%3DPolypharmacology%2520-%2520Foe%2520or%2520Friend%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8955%26epage%3D8971%26doi%3D10.1021%2Fjm400856t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arango, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonnell, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koudriakova, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Los, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span> <span> </span><span class="NLM_article-title">An Orally Available Small-Molecule Inhibitor of C-Met, Pf-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">4408</span>– <span class="NLM_lpage">4417</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-4443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.+P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=S.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+Orally+Available+Small-Molecule+Inhibitor+of+C-Met%2C+Pf-2341066%2C+Exhibits+Cytoreductive+Antitumor+Efficacy+through+Antiproliferative+and+Antiangiogenic+Mechanisms&doi=10.1158%2F0008-5472.CAN-06-4443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0ljOv0Fm2sVPIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520Orally%2520Available%2520Small-Molecule%2520Inhibitor%2520of%2520C-Met%252C%2520Pf-2341066%252C%2520Exhibits%2520Cytoreductive%2520Antitumor%2520Efficacy%2520through%2520Antiproliferative%2520and%2520Antiangiogenic%2520Mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417%26doi%3D10.1158%2F0008-5472.CAN-06-4443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasothan, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, P.</span></span> <span> </span><span class="NLM_article-title">Crizotinib</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">897</span>– <span class="NLM_lpage">898</span>, <span class="refDoi"> DOI: 10.1038/nrd3600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fnrd3600" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=22129984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFGktbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=897-898&author=A.+T.+Shawauthor=U.+Yasothanauthor=P.+Kirkpatrick&title=Crizotinib&doi=10.1038%2Fnrd3600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib</span></div><div class="casAuthors">Shaw, Alice T.; Yasothan, Uma; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">897-898</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In August 2011 crizotinib (Xalkori; Pfizer), a small-mol. kinase inhibitor, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer that is anaplastic lymphoma kinase-pos., as detected by an FDA-approved test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw1A3bWW-DjbVg90H21EOLACvtfcHk0ljOv0Fm2sVPIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFGktbnF&md5=6d2b5ff87f4f61a88929759e79422d99</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fnrd3600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3600%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DYasothan%26aufirst%3DU.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DCrizotinib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D897%26epage%3D898%26doi%3D10.1038%2Fnrd3600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran-Dube, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nambu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pairish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botrous, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grodsky, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padrique, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Timofeevski, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamazaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mroczkowski, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, M. P.</span></span> <span> </span><span class="NLM_article-title">Structure Based Drug Design of Crizotinib (Pf-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (C-Met) Kinase and Anaplastic Lymphoma Kinase (Alk)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6342</span>– <span class="NLM_lpage">6363</span>, <span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dubeauthor=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+Based+Drug+Design+of+Crizotinib+%28Pf-02341066%29%2C+a+Potent+and+Selective+Dual+Inhibitor+of+Mesenchymal-Epithelial+Transition+Factor+%28C-Met%29+Kinase+and+Anaplastic+Lymphoma+Kinase+%28Alk%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0li5IK9qsUZ4Tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520Based%2520Drug%2520Design%2520of%2520Crizotinib%2520%2528Pf-02341066%2529%252C%2520a%2520Potent%2520and%2520Selective%2520Dual%2520Inhibitor%2520of%2520Mesenchymal-Epithelial%2520Transition%2520Factor%2520%2528C-Met%2529%2520Kinase%2520and%2520Anaplastic%2520Lymphoma%2520Kinase%2520%2528Alk%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enomoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurashina, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatanaka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bando, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aburatani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sohara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mano, H.</span></span> <span> </span><span class="NLM_article-title">Identification of the Transforming Eml4-Alk Fusion Gene in Non-Small-Cell Lung Cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1038/nature05945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fnature05945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=17625570" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2007&pages=561-566&author=M.+Sodaauthor=Y.+L.+Choiauthor=M.+Enomotoauthor=S.+Takadaauthor=Y.+Yamashitaauthor=S.+Ishikawaauthor=S.+Fujiwaraauthor=H.+Watanabeauthor=K.+Kurashinaauthor=H.+Hatanakaauthor=M.+Bandoauthor=S.+Ohnoauthor=Y.+Ishikawaauthor=H.+Aburataniauthor=T.+Nikiauthor=Y.+Soharaauthor=Y.+Sugiyamaauthor=H.+Mano&title=Identification+of+the+Transforming+Eml4-Alk+Fusion+Gene+in+Non-Small-Cell+Lung+Cancer&doi=10.1038%2Fnature05945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</span></div><div class="casAuthors">Soda, Manabu; Choi, Young Lim; Enomoto, Munehiro; Takada, Shuji; Yamashita, Yoshihiro; Ishikawa, Shunpei; Fujiwara, Shin-ichiro; Watanabe, Hideki; Kurashina, Kentaro; Hatanaka, Hisashi; Bando, Masashi; Ohno, Shoji; Ishikawa, Yuichi; Aburatani, Hiroyuki; Niki, Toshiro; Sohara, Yasunori; Sugiyama, Yukihiko; Mano, Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue">7153</span>),
    <span class="NLM_cas:pages">561-566</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Improvement in the clin. outcome of lung cancer is likely to be achieved by identification of the mol. events that underlie its pathogenesis.  Here we show that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-assocd. protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.  Mouse 3T3 fibroblasts forced to express this human fusion tyrosine kinase generated transformed foci in culture and s.c. tumors in nude mice.  The EML4-ALK fusion transcript was detected in 6.7% (5 out of 75) of NSCLC patients examd.; these individuals were distinct from those harboring mutations in the epidermal growth factor receptor gene.  Our data demonstrate that a subset of NSCLC patients may express a transforming fusion kinase that is a promising candidate for a therapeutic target as well as for a diagnostic mol. marker in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomhAXuLtrJ6rVg90H21EOLACvtfcHk0li5IK9qsUZ4Tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosVSrtrs%253D&md5=7f567e80814b9ccc87e5bceeebb467a7</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1038%2Fnature05945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05945%26sid%3Dliteratum%253Aachs%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DEnomoto%26aufirst%3DM.%26aulast%3DTakada%26aufirst%3DS.%26aulast%3DYamashita%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DS.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DKurashina%26aufirst%3DK.%26aulast%3DHatanaka%26aufirst%3DH.%26aulast%3DBando%26aufirst%3DM.%26aulast%3DOhno%26aufirst%3DS.%26aulast%3DIshikawa%26aufirst%3DY.%26aulast%3DAburatani%26aufirst%3DH.%26aulast%3DNiki%26aufirst%3DT.%26aulast%3DSohara%26aufirst%3DY.%26aulast%3DSugiyama%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26atitle%3DIdentification%2520of%2520the%2520Transforming%2520Eml4-Alk%2520Fusion%2520Gene%2520in%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DNature%26date%3D2007%26volume%3D448%26spage%3D561%26epage%3D566%26doi%3D10.1038%2Fnature05945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shioda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Classon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maheswaran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulkus, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhlmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greninger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span> <span> </span><span class="NLM_article-title">Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">3389</span>– <span class="NLM_lpage">3395</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-6186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1158%2F0008-5472.CAN-07-6186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=18451166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlSlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=3389-3395&author=U.+McDermottauthor=A.+J.+Iafrateauthor=N.+S.+Grayauthor=T.+Shiodaauthor=M.+Classonauthor=S.+Maheswaranauthor=W.+Zhouauthor=H.+G.+Choiauthor=S.+L.+Smithauthor=L.+Dowellauthor=L.+E.+Ulkusauthor=G.+Kuhlmannauthor=P.+Greningerauthor=J.+G.+Christensenauthor=D.+A.+Haberauthor=J.+Settleman&title=Genomic+Alterations+of+Anaplastic+Lymphoma+Kinase+May+Sensitize+Tumors+to+Anaplastic+Lymphoma+Kinase+Inhibitors&doi=10.1158%2F0008-5472.CAN-07-6186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">McDermott, Ultan; Iafrate, A. John; Gray, Nathanael S.; Shioda, Toshi; Classon, Marie; Maheswaran, Shyamala; Zhou, Wenjun; Choi, Hwan Geun; Smith, Shannon L.; Dowell, Lori; Ulkus, Lindsey E.; Kuhlmann, Georgiana; Greninger, Patricia; Christensen, James G.; Haber, Daniel A.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3389-3395</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Selective kinase inhibitors have had a substantial impact on the field of medical oncol.  Whereas these agents can elicit dramatic clin. responses in some settings, their activity is generally limited to a subset of treated patients whose tumor cells harbor a specific genetic lesion.  We have established an automated platform for examg. the sensitivity to various molecularly targeted inhibitors across a large panel of human tumor-derived cell lines to identify addnl. genotype-correlated responses that may be clin. relevant.  Among the inhibitors tested in a panel of 602 cell lines derived from a variety of human cancers, we found that a selective inhibitor of the anaplastic lymphoma kinase (ALK) potently suppressed growth of a small subset of tumor cells.  This subset included lines derived from anaplastic large cell lymphomas, non-small-cell lung cancers, and neuroblastomas.  ALK is a receptor tyrosine kinase that was first identified as part of a protein fusion derived from a chromosomal translocation detected in the majority of anaplastic large cell lymphoma patients, and has recently been implicated as an oncogene in a small fraction of non-small-cell lung cancers and neuroblastomas.  Significantly, sensitivity in these cell lines was well correlated with specific ALK genomic rearrangements, including chromosomal translocations and gene amplification.  Moreover, in such cell lines, ALK kinase inhibition can lead to potent suppression of downstream survival signaling and an apoptotic response.  These findings suggest that a subset of lung cancers, lymphomas, and neuroblastomas that harbor genomic ALK alterations may be clin. responsive to pharmacol. ALK inhibition. [Cancer Res 2008;68(9):3389-95].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwtwwG7vhYTbVg90H21EOLACvtfcHk0liiDUDLrPXJlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlSlsbg%253D&md5=5168e6ce3ea650df3722dbd4f1aa53ea</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6186%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DShioda%26aufirst%3DT.%26aulast%3DClasson%26aufirst%3DM.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DSmith%26aufirst%3DS.%2BL.%26aulast%3DDowell%26aufirst%3DL.%26aulast%3DUlkus%26aufirst%3DL.%2BE.%26aulast%3DKuhlmann%26aufirst%3DG.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DGenomic%2520Alterations%2520of%2520Anaplastic%2520Lymphoma%2520Kinase%2520May%2520Sensitize%2520Tumors%2520to%2520Anaplastic%2520Lymphoma%2520Kinase%2520Inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D3389%26epage%3D3395%26doi%3D10.1158%2F0008-5472.CAN-07-6186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theodoro, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skokan, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aisner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berge, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terracciano, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cappuzzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Incarbone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roncalli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alloisio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span> <span> </span><span class="NLM_article-title">Identifying and Targeting Ros1 Gene Fusions in Non-Small Cell Lung Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4570</span>– <span class="NLM_lpage">4579</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0550</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1158%2F1078-0432.CCR-12-0550" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=22919003" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ygsLvJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4570-4579&author=K.+D.+Daviesauthor=A.+T.+Leauthor=M.+F.+Theodoroauthor=M.+C.+Skokanauthor=D.+L.+Aisnerauthor=E.+M.+Bergeauthor=L.+M.+Terraccianoauthor=F.+Cappuzzoauthor=M.+Incarboneauthor=M.+Roncalliauthor=M.+Alloisioauthor=A.+Santoroauthor=D.+R.+Camidgeauthor=M.+Varella-Garciaauthor=R.+C.+Doebele&title=Identifying+and+Targeting+Ros1+Gene+Fusions+in+Non-Small+Cell+Lung+Cancer&doi=10.1158%2F1078-0432.CCR-12-0550"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Davies, Kurtis D.; Le, Anh T.; Theodoro, Mariana F.; Skokan, Margaret C.; Aisner, Dara L.; Berge, Eamon M.; Terracciano, Luigi M.; Cappuzzo, Federico; Incarbone, Matteo; Roncalli, Massimo; Alloisio, Marco; Santoro, Armando; Camidge, D. Ross; Varella-Garcia, Marileila; Doebele, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4570-4579</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Oncogenic gene fusions involving the 3' region of ROS1 kinase have been identified in various human cancers.  In this study, we sought to characterize ROS1 fusion genes in non-small cell lung cancer (NSCLC) and establish the fusion proteins as drug targets.  Exptl. Design: An NSCLC tissue microarray (TMA) panel contg. 447 samples was screened for ROS1 rearrangement by FISH.  This assay was also used to screen patients with NSCLC.  In pos. samples, the identity of the fusion partner was detd. through inverse PCR and reverse transcriptase PCR.  In addn., the clin. efficacy of ROS1 inhibition was assessed by treating a ROS1-pos. patient with crizotinib.  The HCC78 cell line, which expresses the SLC34A2-ROS1 fusion, was treated with kinase inhibitors that have activity against ROS1.  The effects of ROS1 inhibition on proliferation, cell-cycle progression, and cell signaling pathways were analyzed by MTS assay, flow cytometry, and Western blotting.  Results: In the TMA panel, 5 of 428 (1.2%) evaluable samples were found to be pos. for ROS1 rearrangement.  In addn., 1 of 48 patients tested pos. for rearrangement, and this patient showed tumor shrinkage upon treatment with crizotinib.  The patient and one TMA sample displayed expression of the recently identified SDC4-ROS1 fusion, whereas two TMA samples expressed the CD74-ROS1 fusion and two others expressed the SLC34A2-ROS1 fusion.  In HCC78 cells, treatment with ROS1 inhibitors was antiproliferative and downregulated signaling pathways that are crit. for growth and survival.  Conclusions: ROS1 inhibition may be an effective treatment strategy for the subset of patients with NSCLC whose tumors express ROS1 fusion genes.  Clin Cancer Res; 18(17); 4570-9. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7gJ6dvuC1ObVg90H21EOLACvtfcHk0liiDUDLrPXJlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ygsLvJ&md5=e515420290d04150e87f8f4c057c64cd</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0550%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DK.%2BD.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DTheodoro%26aufirst%3DM.%2BF.%26aulast%3DSkokan%26aufirst%3DM.%2BC.%26aulast%3DAisner%26aufirst%3DD.%2BL.%26aulast%3DBerge%26aufirst%3DE.%2BM.%26aulast%3DTerracciano%26aufirst%3DL.%2BM.%26aulast%3DCappuzzo%26aufirst%3DF.%26aulast%3DIncarbone%26aufirst%3DM.%26aulast%3DRoncalli%26aufirst%3DM.%26aulast%3DAlloisio%26aufirst%3DM.%26aulast%3DSantoro%26aufirst%3DA.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26atitle%3DIdentifying%2520and%2520Targeting%2520Ros1%2520Gene%2520Fusions%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4570%26epage%3D4579%26doi%3D10.1158%2F1078-0432.CCR-12-0550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Figueiredo-Pontes, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B.</span></span> <span> </span><span class="NLM_article-title">Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in Ros1-Translocated Lung Cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1086</span>– <span class="NLM_lpage">1090</span>, <span class="refDoi"> DOI: 10.1097/JTO.0b013e3182570919</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1097%2FJTO.0b013e3182570919" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=22617245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1aisbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=1086-1090&author=H.+Yasudaauthor=L.+L.+de+Figueiredo-Pontesauthor=S.+Kobayashiauthor=D.+B.+Costa&title=Preclinical+Rationale+for+Use+of+the+Clinically+Available+Multitargeted+Tyrosine+Kinase+Inhibitor+Crizotinib+in+Ros1-Translocated+Lung+Cancer&doi=10.1097%2FJTO.0b013e3182570919"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer</span></div><div class="casAuthors">Yasuda, Hiroyuki; de Figueiredo-Pontes, Lorena L.; Kobayashi, Susumu; Costa, Daniel B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Thoracic Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1086-1090</span>CODEN:
                <span class="NLM_cas:coden">JTOOB7</span>;
        ISSN:<span class="NLM_cas:issn">1556-0864</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Introduction: Most clin. available small-mol. kinase inhibitors are multi-targeted and can inhibit multiple kinases.  Our driving hypothesis was that one of these multi-targeted tyrosine kinase inhibitors (TKIs) would have antiproliferative activity against ROS1 translocated non-small-cell lung cancer (NSCLC).  Methods: We selected NSCLC cell lines-A549 (KRAS G12S), NCI-H3255 (EGFR L858R), NCI-H3122 (EML4-ALK E13;A20), and HCC78 (SLC34A2-ROS1)-to evaluate the antiproliferative effects of submicromolar concns. of the multitargeted TKIs imatinib, sorafenib, erlotinib, and crizotinib.  Results: Imatinib and sorafenib were unable to significantly inhibit proliferation of the aforementioned cell lines.  Erlotinib only inhibited EGFR mutated NCI-H3255, as expected.  Crizotinib displayed dose-dependent inhibition of anaplastic lymphoma kinase translocated NCI-H3122 and also ROS1-translocated HCC78.  The SLC34A2-ROS1 translocated HCC78 cell line had phosphorylated levels of ROS1, AKT, and ERK inhibited by submicromolar doses of crizotinib, and subsequently underwent apoptosis.  Conclusions: The ROS1-translocated HCC78 cell line was sensitive to inhibition by the multitargeted ALK/MET/RON/ROS1 inhibitor crizotinib.  Preclin. data supports the clin. development of crizotinib for ROS1-translocated NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr29dxq_z12VLVg90H21EOLACvtfcHk0liiDUDLrPXJlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1aisbzM&md5=05078de948bc1543886167175cdca4c4</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1097%2FJTO.0b013e3182570919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FJTO.0b013e3182570919%26sid%3Dliteratum%253Aachs%26aulast%3DYasuda%26aufirst%3DH.%26aulast%3Dde%2BFigueiredo-Pontes%26aufirst%3DL.%2BL.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26atitle%3DPreclinical%2520Rationale%2520for%2520Use%2520of%2520the%2520Clinically%2520Available%2520Multitargeted%2520Tyrosine%2520Kinase%2520Inhibitor%2520Crizotinib%2520in%2520Ros1-Translocated%2520Lung%2520Cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2012%26volume%3D7%26spage%3D1086%26epage%3D1090%26doi%3D10.1097%2FJTO.0b013e3182570919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Usari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span> <span> </span><span class="NLM_article-title">Crizotinib in Ros1-Rearranged Advanced Non-Small-Cell Lung Cancer (Nsclc): Updated Results, Including Overall Survival, from Profile 1001</span>. <i>Ann. Oncol</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1121</span>– <span class="NLM_lpage">1126</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdz131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1093%2Fannonc%2Fmdz131" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=30980071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FkvFCmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=1121-1126&author=A.+T.+Shawauthor=G.+J.+Rielyauthor=Y.+J.+Bangauthor=D.+W.+Kimauthor=D.+R.+Camidgeauthor=B.+J.+Solomonauthor=M.+Varella-Garciaauthor=A.+J.+Iafrateauthor=G.+I.+Shapiroauthor=T.+Usariauthor=S.+C.+Wangauthor=K.+D.+Wilnerauthor=J.+W.+Clarkauthor=S.+I.+Ou&title=Crizotinib+in+Ros1-Rearranged+Advanced+Non-Small-Cell+Lung+Cancer+%28Nsclc%29%3A+Updated+Results%2C+Including+Overall+Survival%2C+from+Profile+1001&doi=10.1093%2Fannonc%2Fmdz131"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001</span></div><div class="casAuthors">Shaw A T; Riely G J; Bang Y-J; Kim D-W; Camidge D R; Varella-Garcia M; Solomon B J; Iafrate A J; Clark J W; Shapiro G I; Usari T; Wang S C; Wilner K D; Ou S-H I</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1121-1126</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  In the ongoing phase I PROFILE 1001 study, crizotinib showed antitumor activity in patients with ROS1-rearranged advanced non-small-cell lung cancer (NSCLC).  Here, we present updated antitumor activity, overall survival (OS) and safety data (additional 46.2 months follow-up) for patients with ROS1-rearranged advanced NSCLC from PROFILE 1001.  PATIENTS AND METHODS:  ROS1 status was determined by FISH or reverse transcriptase-polymerase chain reaction.  All patients received crizotinib at a starting dose of 250 mg twice daily.  RESULTS:  Fifty-three patients received crizotinib, with a median duration of treatment of 22.4 months.  At data cut-off, treatment was ongoing in 12 patients (23%).  The objective response rate (ORR) was 72% [95% confidence interval (CI), 58% to 83%], including six confirmed complete responses and 32 confirmed partial responses; 10 patients had stable disease.  Responses were durable (median duration of response 24.7 months; 95% CI, 15.2-45.3).  ORRs were consistent across different patient subgroups.  Median progression-free survival was 19.3 months (95% CI, 15.2-39.1).  A total of 26 deaths (49%) occurred (median follow-up period of 62.6 months), and of the remaining 27 patients (51%), 14 (26%) were in follow-up at data cut-off.  Median OS was 51.4 months (95% CI, 29.3 to not reached) and survival probabilities at 12, 24, 36, and 48 months were 79%, 67%, 53%, and 51%, respectively.  No correlation was observed between OS and specific ROS1 fusion partner.  Treatment-related adverse events (TRAEs) were mainly grade 1 or 2, per CTCAE v3.0.  There were no grade ≥4 TRAEs and no TRAEs associated with permanent discontinuation.  No new safety signals were reported with long-term crizotinib treatment.  CONCLUSIONS:  These findings serve as a new benchmark for OS in ROS1-rearranged advanced NSCLC, and continue to show the clinically meaningful benefit and safety of crizotinib in this molecular subgroup.  TRIAL REGISTRATION NUMBER:  ClinicalTrials.gov identifier NCT00585195.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcToezgxb-wVeFUIs6wFK5xJfW6udTcc2ebxItxxfL_v6Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FkvFCmsg%253D%253D&md5=f11ca150cea3e3be11586eb7db3236ff</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdz131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdz131%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DUsari%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DS.%2BC.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DOu%26aufirst%3DS.%2BI.%26atitle%3DCrizotinib%2520in%2520Ros1-Rearranged%2520Advanced%2520Non-Small-Cell%2520Lung%2520Cancer%2520%2528Nsclc%2529%253A%2520Updated%2520Results%252C%2520Including%2520Overall%2520Survival%252C%2520from%2520Profile%25201001%26jtitle%3DAnn.%2520Oncol%26date%3D2019%26volume%3D30%26spage%3D1121%26epage%3D1126%26doi%3D10.1093%2Fannonc%2Fmdz131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camidge, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salgia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varella-Garcia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephenson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shreeve, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tye, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilner, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iafrate, A. J.</span></span> <span> </span><span class="NLM_article-title">Crizotinib in Ros1-Rearranged Non-Small-Cell Lung Cancer</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>371</i></span>,  <span class="NLM_fpage">1963</span>– <span class="NLM_lpage">1971</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1406766</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1056%2FNEJMoa1406766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=25264305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslGgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=371&publication_year=2014&pages=1963-1971&author=A.+T.+Shawauthor=S.+H.+Ouauthor=Y.+J.+Bangauthor=D.+R.+Camidgeauthor=B.+J.+Solomonauthor=R.+Salgiaauthor=G.+J.+Rielyauthor=M.+Varella-Garciaauthor=G.+I.+Shapiroauthor=D.+B.+Costaauthor=R.+C.+Doebeleauthor=L.+P.+Leauthor=Z.+Zhengauthor=W.+Tanauthor=P.+Stephensonauthor=S.+M.+Shreeveauthor=L.+M.+Tyeauthor=J.+G.+Christensenauthor=K.+D.+Wilnerauthor=J.+W.+Clarkauthor=A.+J.+Iafrate&title=Crizotinib+in+Ros1-Rearranged+Non-Small-Cell+Lung+Cancer&doi=10.1056%2FNEJMoa1406766"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib in ROS1-rearranged non-small-cell lung cancer</span></div><div class="casAuthors">Shaw, Alice T.; Ou, Sai-Hong I.; Bang, Yung-Jue; Camidge, D. Ross; Solomon, Benjamin J.; Salgia, Ravi; Riely, Gregory J.; Varella-Garcia, Marileila; Shapiro, Geoffrey I.; Costa, Daniel B.; Doebele, Robert C.; Le, Long Phi; Zheng, Zongli; Tan, Weiwei; Stephenson, Patricia; Shreeve, S. Martin; Tye, Lesley M.; Christensen, James G.; Wilner, Keith D.; Clark, Jeffrey W.; Iafrate, A. John</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">371</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">1963-1971, 9 pp.</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Chromosomal rearrangements of the gene encoding ROS1 proto-oncogene receptor tyrosine kinase (ROS1) define a distinct mol. subgroup of non-small-cell lung cancers (NSCLCs) that may be susceptible to therapeutic ROS1 kinase inhibition.  Crizotinib is a small-mol. tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK), ROS1, and another proto-oncogene receptor tyrosine kinase, MET.  Methods: We enrolled 50 patients with advanced NSCLC who tested pos. for ROS1 rearrangement in an expansion cohort of the phase 1 study of crizotinib.  Patients were treated with crizotinib at the std. oral dose of 250 mg twice daily and assessed for safety, pharmacokinetics, and response to therapy.  ROS1 fusion partners were identified with the use of next-generation sequencing or reverse-transcriptase-polymerase-chain-reaction assays.  Results: The objective response rate was 72% (95% confidence interval [CI], 58 to 84), with 3 complete responses and 33 partial responses.  The median duration of response was 17.6 mo (95% CI, 14.5 to not reached).  Median progression-free survival was 19.2 mo (95% CI, 14.4 to not reached), with 25 patients (50%) still in follow-up for progression.  Among 30 tumors that were tested, we identified 7 ROS1 fusion partners: 5 known and 2 novel partner genes.  No correlation was obsd. between the type of ROS1 rearrangement and the clin. response to crizotinib.  The safety profile of crizotinib was similar to that seen in patients with ALK-rearranged NSCLC.  Conclusions: In this study, crizotinib showed marked antitumor activity in patients with advanced ROS1-rearranged NSCLC.  ROS1 rearrangement defines a second mol. subgroup of NSCLC for which crizotinib is highly active.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoboSXi9RMETrVg90H21EOLACvtfcHk0lgtckWFotIDWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslGgtQ%253D%253D&md5=10f332ff122809bef11f4a0d8aafd45a</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1406766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1406766%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DLe%26aufirst%3DL.%2BP.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DStephenson%26aufirst%3DP.%26aulast%3DShreeve%26aufirst%3DS.%2BM.%26aulast%3DTye%26aufirst%3DL.%2BM.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DCrizotinib%2520in%2520Ros1-Rearranged%2520Non-Small-Cell%2520Lung%2520Cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2014%26volume%3D371%26spage%3D1963%26epage%3D1971%26doi%3D10.1056%2FNEJMoa1406766" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vladimer, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snijder, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigenzahn, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, K. V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lardeau, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanjiv, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berglund, U. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Fuente, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knobl, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubicek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helleday, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jager, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Superti-Furga, G.</span></span> <span> </span><span class="NLM_article-title">Global Survey of the Immunomodulatory Potential of Common Drugs</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">681</span>– <span class="NLM_lpage">690</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fnchembio.2360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=28437395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvVCltbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&pages=681-690&author=G.+I.+Vladimerauthor=B.+Snijderauthor=N.+Krallauthor=J.+W.+Bigenzahnauthor=K.+V.+M.+Huberauthor=C.+H.+Lardeauauthor=K.+Sanjivauthor=A.+Ringlerauthor=U.+W.+Berglundauthor=M.+Sablerauthor=O.+L.+de+la+Fuenteauthor=P.+Knoblauthor=S.+Kubicekauthor=T.+Helledayauthor=U.+Jagerauthor=G.+Superti-Furga&title=Global+Survey+of+the+Immunomodulatory+Potential+of+Common+Drugs&doi=10.1038%2Fnchembio.2360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Global survey of the immunomodulatory potential of common drugs</span></div><div class="casAuthors">Vladimer, Gregory I.; Snijder, Berend; Krall, Nikolaus; Bigenzahn, Johannes W.; Huber, Kilian V. M.; Lardeau, Charles-Hugues; Sanjiv, Kumar; Ringler, Anna; Berglund, Ulrika Warpman; Sabler, Monika; de la Fuente, Oscar Lopez; Knoebl, Paul; Kubicek, Stefan; Helleday, Thomas; Jaeger, Ulrich; Superti-Furga, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">681-690</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drugs may complement antibody-based therapies in an immune-oncol. setting, yet systematic methods for the identification and characterization of the immunomodulatory properties of these entities are lacking.  We surveyed the immumomodulatory potential of 1,402 small chem. mols., as defined by their ability to alter the cell-cell interactions among peripheral mononuclear leukocytes ex vivo, using automated microscopy and population-wide single-cell image anal.  Unexpectedly, ∼10% of the agents tested affected these cell-cell interactions differentially.  The results accurately recapitulated known immunomodulatory drug classes and revealed several clin. approved drugs that unexpectedly harbor the ability to modulate the immune system, which could potentially contribute to their physiol. mechanism of action.  For instance, the kinase inhibitor crizotinib promoted T cell interactions with monocytes, as well as with cancer cells, through inhibition of the receptor tyrosine kinase MSTR1 and subsequent upregulation of the expression of major histocompatibility complex mols.  The approach offers an attractive platform for the personalized identification and characterization of immunomodulatory therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXf0_7KFGbY7Vg90H21EOLACvtfcHk0lgtckWFotIDWg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvVCltbg%253D&md5=c177974d4daf99d7a40b5c2a73c6504a</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2360%26sid%3Dliteratum%253Aachs%26aulast%3DVladimer%26aufirst%3DG.%2BI.%26aulast%3DSnijder%26aufirst%3DB.%26aulast%3DKrall%26aufirst%3DN.%26aulast%3DBigenzahn%26aufirst%3DJ.%2BW.%26aulast%3DHuber%26aufirst%3DK.%2BV.%2BM.%26aulast%3DLardeau%26aufirst%3DC.%2BH.%26aulast%3DSanjiv%26aufirst%3DK.%26aulast%3DRingler%26aufirst%3DA.%26aulast%3DBerglund%26aufirst%3DU.%2BW.%26aulast%3DSabler%26aufirst%3DM.%26aulast%3Dde%2Bla%2BFuente%26aufirst%3DO.%2BL.%26aulast%3DKnobl%26aufirst%3DP.%26aulast%3DKubicek%26aufirst%3DS.%26aulast%3DHelleday%26aufirst%3DT.%26aulast%3DJager%26aufirst%3DU.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DGlobal%2520Survey%2520of%2520the%2520Immunomodulatory%2520Potential%2520of%2520Common%2520Drugs%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2017%26volume%3D13%26spage%3D681%26epage%3D690%26doi%3D10.1038%2Fnchembio.2360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oleaga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernabini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLamb, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santhanam, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najjar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akanda, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esch, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ouedraogo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotovio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuler, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, J. J.</span></span> <span> </span><span class="NLM_article-title">Multi-Organ Toxicity Demonstration in a Functional Human in Vitro System Composed of Four Organs</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">20030</span>, <span class="refDoi"> DOI: 10.1038/srep20030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fsrep20030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=26837601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFahsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=20030&author=C.+Oleagaauthor=C.+Bernabiniauthor=A.+S.+Smithauthor=B.+Srinivasanauthor=M.+Jacksonauthor=W.+McLambauthor=V.+Plattauthor=R.+Bridgesauthor=Y.+Caiauthor=N.+Santhanamauthor=B.+Berryauthor=S.+Najjarauthor=N.+Akandaauthor=X.+Guoauthor=C.+Martinauthor=G.+Ekmanauthor=M.+B.+Eschauthor=J.+Langerauthor=G.+Ouedraogoauthor=J.+Cotovioauthor=L.+Bretonauthor=M.+L.+Shulerauthor=J.+J.+Hickman&title=Multi-Organ+Toxicity+Demonstration+in+a+Functional+Human+in+Vitro+System+Composed+of+Four+Organs&doi=10.1038%2Fsrep20030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Organ toxicity demonstration in a functional human in vitro system composed of four organs</span></div><div class="casAuthors">Oleaga, Carlota; Bernabini, Catia; Smith, Alec S. T.; Srinivasan, Balaji; Jackson, Max; McLamb, William; Platt, Vivien; Bridges, Richard; Cai, Yunqing; Santhanam, Navaneetha; Berry, Bonnie; Najjar, Sarah; Akanda, Nesar; Guo, Xiufang; Martin, Candace; Ekman, Gail; Esch, Mandy B.; Langer, Jessica; Ouedraogo, Gladys; Cotovio, Jose; Breton, Lionel; Shuler, Michael L.; Hickman, James J.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20030</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We report on a functional human model to evaluate multi-organ toxicity in a 4-organ system under continuous flow conditions in a serum-free defined medium utilizing a pumpless platform for 14 days.  Computer simulations of the platform established flow rates and resultant shear stress within accepted ranges.  Viability of the system was demonstrated for 14 days as well as functional activity of cardiac, muscle, neuronal and liver modules.  The pharmacol. relevance of the integrated modules were evaluated for their response at 7 days to 5 drugs with known side effects after a 48 h drug treatment regime.  The results of all drug treatments were in general agreement with published toxicity results from human and animal data.  The presented phenotypic culture model exhibits a multi-organ toxicity response, representing the next generation of in vitro systems, and constitutes a step towards an in vitro "human-on-a-chip" assay for systemic toxicity screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraQVY4O7h9I7Vg90H21EOLACvtfcHk0lhpGFJj4bELXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFahsLY%253D&md5=3113c7d8206d0748549686f604c52f6c</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1038%2Fsrep20030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep20030%26sid%3Dliteratum%253Aachs%26aulast%3DOleaga%26aufirst%3DC.%26aulast%3DBernabini%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DA.%2BS.%26aulast%3DSrinivasan%26aufirst%3DB.%26aulast%3DJackson%26aufirst%3DM.%26aulast%3DMcLamb%26aufirst%3DW.%26aulast%3DPlatt%26aufirst%3DV.%26aulast%3DBridges%26aufirst%3DR.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DSanthanam%26aufirst%3DN.%26aulast%3DBerry%26aufirst%3DB.%26aulast%3DNajjar%26aufirst%3DS.%26aulast%3DAkanda%26aufirst%3DN.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DMartin%26aufirst%3DC.%26aulast%3DEkman%26aufirst%3DG.%26aulast%3DEsch%26aufirst%3DM.%2BB.%26aulast%3DLanger%26aufirst%3DJ.%26aulast%3DOuedraogo%26aufirst%3DG.%26aulast%3DCotovio%26aufirst%3DJ.%26aulast%3DBreton%26aufirst%3DL.%26aulast%3DShuler%26aufirst%3DM.%2BL.%26aulast%3DHickman%26aufirst%3DJ.%2BJ.%26atitle%3DMulti-Organ%2520Toxicity%2520Demonstration%2520in%2520a%2520Functional%2520Human%2520in%2520Vitro%2520System%2520Composed%2520of%2520Four%2520Organs%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D20030%26doi%3D10.1038%2Fsrep20030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maschmeyer, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorenz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimek, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasenberg, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramme, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambo, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonntag, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marx, U.</span></span> <span> </span><span class="NLM_article-title">A Four-Organ-Chip for Interconnected Long-Term Co-Culture of Human Intestine, Liver, Skin and Kidney Equivalents</span>. <i>Lab Chip</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2688</span>– <span class="NLM_lpage">2699</span>, <span class="refDoi"> DOI: 10.1039/C5LC00392J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1039%2FC5LC00392J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=25996126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2MXot1Wqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=2688-2699&author=I.+Maschmeyerauthor=A.+K.+Lorenzauthor=K.+Schimekauthor=T.+Hasenbergauthor=A.+P.+Rammeauthor=J.+Hubnerauthor=M.+Lindnerauthor=C.+Drewellauthor=S.+Bauerauthor=A.+Thomasauthor=N.+S.+Samboauthor=F.+Sonntagauthor=R.+Lausterauthor=U.+Marx&title=A+Four-Organ-Chip+for+Interconnected+Long-Term+Co-Culture+of+Human+Intestine%2C+Liver%2C+Skin+and+Kidney+Equivalents&doi=10.1039%2FC5LC00392J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents</span></div><div class="casAuthors">Maschmeyer, Ilka; Lorenz, Alexandra K.; Schimek, Katharina; Hasenberg, Tobias; Ramme, Anja P.; Huebner, Juliane; Lindner, Marcus; Drewell, Christopher; Bauer, Sophie; Thomas, Alexander; Sambo, Naomia Sisoli; Sonntag, Frank; Lauster, Roland; Marx, Uwe</div><div class="citationInfo"><span class="NLM_cas:title">Lab on a Chip</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2688-2699</span>CODEN:
                <span class="NLM_cas:coden">LCAHAM</span>;
        ISSN:<span class="NLM_cas:issn">1473-0189</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Systemic absorption and metab. of drugs in the small intestine, metab. by the liver as well as excretion by the kidney are key determinants of efficacy and safety for therapeutic candidates.  However, these systemic responses of applied substances lack in most in vitro assays.  In this study, a microphysiol. system maintaining the functionality of four organs over 28 days in co-culture has been established at a minute but standardized microsystem scale.  Preformed human intestine and skin models have been integrated into the four-organ-chip on std. cell culture inserts at a size 100 000-fold smaller than their human counterpart organs.  A 3D-based spheroid, equiv. to ten liver lobules, mimics liver function.  Finally, a barrier segregating the media flow through the organs from fluids excreted by the kidney has been generated by a polymeric membrane covered by a monolayer of human proximal tubule epithelial cells.  A peristaltic on-chip micropump ensures pulsatile media flow interconnecting the four tissue culture compartments through microfluidic channels.  A second microfluidic circuit ensures drainage of the fluid excreted through the kidney epithelial cell layer.  This four-organ-chip system assures near to physiol. fluid-to-tissue ratios.  In-depth metabolic and gene anal. revealed the establishment of reproducible homeostasis among the co-cultures within two to four days, sustainable over at least 28 days independent of the individual human cell line or tissue donor background used for each organ equiv.  Lastly, 3D imaging two-photon microscopy visualized details of spatiotemporal segregation of the two microfluidic flows by proximal tubule epithelia.  To our knowledge, this study is the first approach to establish a system for in vitro microfluidic ADME profiling and repeated dose systemic toxicity testing of drug candidates over 28 days.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3CptSfAmHS7Vg90H21EOLACvtfcHk0lhpGFJj4bELXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXot1Wqs7w%253D&md5=625936c873db1f9c06adf22e294bbf95</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1039%2FC5LC00392J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5LC00392J%26sid%3Dliteratum%253Aachs%26aulast%3DMaschmeyer%26aufirst%3DI.%26aulast%3DLorenz%26aufirst%3DA.%2BK.%26aulast%3DSchimek%26aufirst%3DK.%26aulast%3DHasenberg%26aufirst%3DT.%26aulast%3DRamme%26aufirst%3DA.%2BP.%26aulast%3DHubner%26aufirst%3DJ.%26aulast%3DLindner%26aufirst%3DM.%26aulast%3DDrewell%26aufirst%3DC.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DSambo%26aufirst%3DN.%2BS.%26aulast%3DSonntag%26aufirst%3DF.%26aulast%3DLauster%26aufirst%3DR.%26aulast%3DMarx%26aufirst%3DU.%26atitle%3DA%2520Four-Organ-Chip%2520for%2520Interconnected%2520Long-Term%2520Co-Culture%2520of%2520Human%2520Intestine%252C%2520Liver%252C%2520Skin%2520and%2520Kidney%2520Equivalents%26jtitle%3DLab%2520Chip%26date%3D2015%26volume%3D15%26spage%3D2688%26epage%3D2699%26doi%3D10.1039%2FC5LC00392J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eriksson, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidock, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamren, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">March, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matcham, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mettetal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicholls, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Platz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snowden, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pangalos, M. N.</span></span> <span> </span><span class="NLM_article-title">Impact of a Five-Dimensional Framework on R&D Productivity at Astrazeneca</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1038/nrd.2017.244</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fnrd.2017.244" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=29348681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1SitL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=167-181&author=P.+Morganauthor=D.+G.+Brownauthor=S.+Lennardauthor=M.+J.+Andertonauthor=J.+C.+Barrettauthor=U.+Erikssonauthor=M.+Fidockauthor=B.+Hamrenauthor=A.+Johnsonauthor=R.+E.+Marchauthor=J.+Matchamauthor=J.+Mettetalauthor=D.+J.+Nichollsauthor=S.+Platzauthor=S.+Reesauthor=M.+A.+Snowdenauthor=M.+N.+Pangalos&title=Impact+of+a+Five-Dimensional+Framework+on+R%26D+Productivity+at+Astrazeneca&doi=10.1038%2Fnrd.2017.244"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of a five-dimensional framework on R&D productivity at AstraZeneca</span></div><div class="casAuthors">Morgan, Paul; Brown, Dean G.; Lennard, Simon; Anderton, Mark J.; Barrett, J. Carl; Eriksson, Ulf; Fidock, Mark; Hamren, Bengt; Johnson, Anthony; March, Ruth E.; Matcham, James; Mettetal, Jerome; Nicholls, David J.; Platz, Stefan; Rees, Steve; Snowden, Michael A.; Pangalos, Menelas N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">167-181</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">In 2011, AstraZeneca embarked on a major revision of its research and development (R&D) strategy with the aim of improving R&D productivity, which was below industry avs. in 2005-2010.  A cornerstone of the revised strategy was to focus decision-making on five tech. determinants (the right target, right tissue, right safety, right patient and right com. potential).  In this article, we describe the progress made using this '5R framework' in the hope that our experience could be useful to other companies tackling R&D productivity issues.  We focus on the evolution of our approach to target validation, hit and lead optimization, pharmacokinetic/pharmacodynamic modeling and drug safety testing, which have helped improve the quality of candidate drug nomination, as well as the development of the right culture, where 'truth seeking' is encouraged by more rigorous and quant. decision-making.  We also discuss where the approach has failed and the lessons learned.  Overall, the continued evolution and application of the 5R framework are beginning to have an impact, with success rates from candidate drug nomination to phase III completion improving from 4% in 2005-2010 to 19% in 2012-2016.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwdx6OlRZpzrVg90H21EOLACvtfcHk0lhpGFJj4bELXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1SitL4%253D&md5=06906e0bc59dc715941998660a514ffe</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2017.244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2017.244%26sid%3Dliteratum%253Aachs%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DBrown%26aufirst%3DD.%2BG.%26aulast%3DLennard%26aufirst%3DS.%26aulast%3DAnderton%26aufirst%3DM.%2BJ.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DEriksson%26aufirst%3DU.%26aulast%3DFidock%26aufirst%3DM.%26aulast%3DHamren%26aufirst%3DB.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DMarch%26aufirst%3DR.%2BE.%26aulast%3DMatcham%26aufirst%3DJ.%26aulast%3DMettetal%26aufirst%3DJ.%26aulast%3DNicholls%26aufirst%3DD.%2BJ.%26aulast%3DPlatz%26aufirst%3DS.%26aulast%3DRees%26aufirst%3DS.%26aulast%3DSnowden%26aufirst%3DM.%2BA.%26aulast%3DPangalos%26aufirst%3DM.%2BN.%26atitle%3DImpact%2520of%2520a%2520Five-Dimensional%2520Framework%2520on%2520R%2526D%2520Productivity%2520at%2520Astrazeneca%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D167%26epage%3D181%26doi%3D10.1038%2Fnrd.2017.244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lounkine, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keiser, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitebread, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikhailov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doak, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cote, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, L.</span></span> <span> </span><span class="NLM_article-title">Large-Scale Prediction and Testing of Drug Activity on Side-Effect Targets</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>486</i></span>,  <span class="NLM_fpage">361</span>– <span class="NLM_lpage">367</span>, <span class="refDoi"> DOI: 10.1038/nature11159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fnature11159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=22722194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFyrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=486&publication_year=2012&pages=361-367&author=E.+Lounkineauthor=M.+J.+Keiserauthor=S.+Whitebreadauthor=D.+Mikhailovauthor=J.+Hamonauthor=J.+L.+Jenkinsauthor=P.+Lavanauthor=E.+Weberauthor=A.+K.+Doakauthor=S.+Coteauthor=B.+K.+Shoichetauthor=L.+Urban&title=Large-Scale+Prediction+and+Testing+of+Drug+Activity+on+Side-Effect+Targets&doi=10.1038%2Fnature11159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Large-scale prediction and testing of drug activity on side-effect targets</span></div><div class="casAuthors">Lounkine, Eugen; Keiser, Michael J.; Whitebread, Steven; Mikhailov, Dmitri; Hamon, Jacques; Jenkins, Jeremy L.; Lavan, Paul; Weber, Eckhard; Doak, Allison K.; Cote, Serge; Shoichet, Brian K.; Urban, Laszlo</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">486</span>
        (<span class="NLM_cas:issue">7403</span>),
    <span class="NLM_cas:pages">361-367</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Discovering the unintended off-targets' that predict adverse drug reactions is daunting by empirical methods alone.  Drugs can act on several protein targets, some of which can be unrelated by conventional mol. metrics, and hundreds of proteins have been implicated in side effects.  Here we use a computational strategy to predict the activity of 656 marketed drugs on 73 unintended side-effect' targets.  Approx. half of the predictions were confirmed, either from proprietary databases unknown to the method or by new exptl. assays.  Affinities for these new off-targets ranged from 1 nM to 30 μM.  To explore relevance, we developed an assocn. metric to prioritize those new off-targets that explained side effects better than any known target of a given drug, creating a drug-target-adverse drug reaction network.  Among these new assocns. was the prediction that the abdominal pain side effect of the synthetic estrogen chlorotrianisene was mediated through its newly discovered inhibition of the enzyme cyclooxygenase-1.  The clin. relevance of this inhibition was borne out in whole human blood platelet aggregation assays.  This approach may have wide application to de-risking toxicol. liabilities in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5sVjfn4mgLLVg90H21EOLACvtfcHk0lgM1MEBE0ga7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFyrtb0%253D&md5=9c133b839d9527818a27a5834e4dfe11</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1038%2Fnature11159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11159%26sid%3Dliteratum%253Aachs%26aulast%3DLounkine%26aufirst%3DE.%26aulast%3DKeiser%26aufirst%3DM.%2BJ.%26aulast%3DWhitebread%26aufirst%3DS.%26aulast%3DMikhailov%26aufirst%3DD.%26aulast%3DHamon%26aufirst%3DJ.%26aulast%3DJenkins%26aufirst%3DJ.%2BL.%26aulast%3DLavan%26aufirst%3DP.%26aulast%3DWeber%26aufirst%3DE.%26aulast%3DDoak%26aufirst%3DA.%2BK.%26aulast%3DCote%26aufirst%3DS.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DUrban%26aufirst%3DL.%26atitle%3DLarge-Scale%2520Prediction%2520and%2520Testing%2520of%2520Drug%2520Activity%2520on%2520Side-Effect%2520Targets%26jtitle%3DNature%26date%3D2012%26volume%3D486%26spage%3D361%26epage%3D367%26doi%3D10.1038%2Fnature11159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chartier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morency, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zylber, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Najmanovich, R. J.</span></span> <span> </span><span class="NLM_article-title">Large-Scale Detection of Drug Off-Targets: Hypotheses for Drug Repurposing and Understanding Side-Effects</span>. <i>BMC Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">18</span>, <span class="refDoi"> DOI: 10.1186/s40360-017-0128-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1186%2Fs40360-017-0128-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=28449705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvVGgt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=18&author=M.+Chartierauthor=L.+P.+Morencyauthor=M.+I.+Zylberauthor=R.+J.+Najmanovich&title=Large-Scale+Detection+of+Drug+Off-Targets%3A+Hypotheses+for+Drug+Repurposing+and+Understanding+Side-Effects&doi=10.1186%2Fs40360-017-0128-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Large-scale detection of drug off-targets: hypotheses for drug repurposing and understanding side-effects</span></div><div class="casAuthors">Chartier, Matthieu; Morency, Louis-Philippe; Zylber, Maria Ines; Najmanovich, Rafael J.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18/1-18/16</span>CODEN:
                <span class="NLM_cas:coden">BPTMAB</span>;
        ISSN:<span class="NLM_cas:issn">2050-6511</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Promiscuity in mol. interactions between small-mols., including drugs, and proteins is widespread.  Such unintended interactions can be exploited to suggest drug repurposing possibilities as well as to identify potential mol. mechanisms responsible for obsd. side-effects.  Methods: We perform a large-scale anal. to detect binding-site mol. interaction field similarities between the binding-sites of the primary target of 400 drugs against a dataset of 14082 cavities within 7895 different proteins representing a non-redundant dataset of all proteins with known structure.  Statistically-significant cases with high levels of similarities represent potential cases where the drugs that bind the original target may in principle bind the suggested off-target.  Such cases are further analyzed with docking simulations to verify if indeed the drug could, in principle, bind the off-target.  Diverse sources of data are integrated to assocd. potential cross-reactivity targets with side-effects.  Results: We observe that promiscuous binding-sites tend to display higher levels of hydrophobic and arom. similarities.  Focusing on the most statistically significant similarities (Z-score ≥ 3.0) and corroborating docking results (RMSD < 2.0 Å), we find 2923 cases involving 140 unique drugs and 1216 unique potential cross-reactivity protein targets.  We highlight a few cases with a potential for drug repurposing (acetazolamide as a chorismate pyruvate lyase inhibitor, raloxifene as a bacterial quorum sensing inhibitor) as well as to explain the side-effects of zanamivir and captopril.  A web-interface permits to explore the detected similarities for each of the 400 binding-sites of the primary drug targets and visualise them for the most statistically significant cases.  Conclusions: The detection of mol. interaction field similarities provide the opportunity to suggest drug repurposing opportunities as well as to identify potential mol. mechanisms responsible for side-effects.  All methods utilized are freely available and can be readily applied to new query binding-sites.  All data is freely available and represents an invaluable source to identify further candidates for repurposing and suggest potential mechanisms responsible for side-effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh2PZMwidAObVg90H21EOLACvtfcHk0lgM1MEBE0ga7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvVGgt7w%253D&md5=86cc822c1993f213623995248eceb62b</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1186%2Fs40360-017-0128-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40360-017-0128-7%26sid%3Dliteratum%253Aachs%26aulast%3DChartier%26aufirst%3DM.%26aulast%3DMorency%26aufirst%3DL.%2BP.%26aulast%3DZylber%26aufirst%3DM.%2BI.%26aulast%3DNajmanovich%26aufirst%3DR.%2BJ.%26atitle%3DLarge-Scale%2520Detection%2520of%2520Drug%2520Off-Targets%253A%2520Hypotheses%2520for%2520Drug%2520Repurposing%2520and%2520Understanding%2520Side-Effects%26jtitle%3DBMC%2520Pharmacol.%2520Toxicol.%26date%3D2017%26volume%3D18%26spage%3D18%26doi%3D10.1186%2Fs40360-017-0128-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cook, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alexander, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">March, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pangalos, M. N.</span></span> <span> </span><span class="NLM_article-title">Lessons Learned from the Fate of Astrazeneca’s Drug Pipeline: A Five-Dimensional Framework</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">431</span>, <span class="refDoi"> DOI: 10.1038/nrd4309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=10.1038%2Fnrd4309" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=24833294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;key=1%3ACAS%3A528%3ADC%252BC2cXotVyqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=419-431&author=D.+Cookauthor=D.+Brownauthor=R.+Alexanderauthor=R.+Marchauthor=P.+Morganauthor=G.+Satterthwaiteauthor=M.+N.+Pangalos&title=Lessons+Learned+from+the+Fate+of+Astrazeneca%E2%80%99s+Drug+Pipeline%3A+A+Five-Dimensional+Framework&doi=10.1038%2Fnrd4309"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework</span></div><div class="casAuthors">Cook, David; Brown, Dearg; Alexander, Robert; March, Ruth; Morgan, Paul; Satterthwaite, Gemma; Pangalos, Menelas N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">419-431</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry.  In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-mol. drug projects from 2005 to 2010.  The anal. allowed us to establish a framework based on the five most important tech. determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right com. potential.  A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these tech. determinants.  AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and anal. here in the hope that it may assist the industry overall in addressing this key challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4yhPFZOUNO7Vg90H21EOLACvtfcHk0lhv_mp-2JLthw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXotVyqtrw%253D&md5=746a86c7223f170f7e6c4f9817760e5b</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1038%2Fnrd4309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4309%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DAlexander%26aufirst%3DR.%26aulast%3DMarch%26aufirst%3DR.%26aulast%3DMorgan%26aufirst%3DP.%26aulast%3DSatterthwaite%26aufirst%3DG.%26aulast%3DPangalos%26aufirst%3DM.%2BN.%26atitle%3DLessons%2520Learned%2520from%2520the%2520Fate%2520of%2520Astrazeneca%25E2%2580%2599s%2520Drug%2520Pipeline%253A%2520A%2520Five-Dimensional%2520Framework%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D419%26epage%3D431%26doi%3D10.1038%2Fnrd4309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i23"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01625">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_04615"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01625?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01625</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Assay descriptions and data and statistical analysis for <a id="rightTab-" class=" internalNav" href="#fig7">Figures <a id="rightTab-" class=" internalNav" href="#fig7">7</a></a>–<a id="rightTab-" class=" internalNav" href="#fig12">12</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01625/suppl_file/jm9b01625_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01625/suppl_file/jm9b01625_si_001.pdf">jm9b01625_si_001.pdf (605.88 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01625&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-12%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01625" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01625" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67992e0d2f653c3a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
